



US010441596B2

(12) **United States Patent**
Pan et al.

(10) **Patent No.:** **US 10,441,596 B2**
(45) **Date of Patent:** ***Oct. 15, 2019**

(54) **METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER**

(71) Applicant: **The University of Chicago**, Chicago, IL (US)

(72) Inventors: **Deng Pan**, Chicago, IL (US); **Masha Kocherginsky**, Chicago, IL (US); **Suzanne D. Conzen**, Park Ridge, IL (US)

(73) Assignee: **The University of Chicago**, Chicago, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 217 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/448,827**

(22) Filed: **Mar. 3, 2017**

(65) **Prior Publication Data**

US 2017/0182066 A1 Jun. 29, 2017

Related U.S. Application Data

(63) Continuation of application No. 14/296,127, filed on Jun. 4, 2014, now Pat. No. 9,623,032, which is a continuation of application No. 14/172,051, filed on Feb. 4, 2014, now Pat. No. 9,149,485, which is a continuation of application No. 13/071,363, filed on Mar. 24, 2011, now Pat. No. 8,710,035.

(60) Provisional application No. 61/317,182, filed on Mar. 24, 2010.

(51) **Int. Cl.**

A61K 31/575 (2006.01)
A61K 31/00 (2006.01)
A61K 45/06 (2006.01)
A61K 31/282 (2006.01)
A61K 31/337 (2006.01)
A61K 31/357 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/7068 (2006.01)
A61K 33/24 (2019.01)
A61K 39/395 (2006.01)
A61N 5/00 (2006.01)
A61J 1/00 (2006.01)
A61K 31/567 (2006.01)
A61K 31/58 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/575** (2013.01); **A61J 1/00** (2013.01); **A61K 31/282** (2013.01); **A61K 31/337** (2013.01); **A61K 31/357** (2013.01); **A61K 31/4745** (2013.01); **A61K 31/567** (2013.01); **A61K 31/58** (2013.01); **A61K 33/24** (2013.01); **A61K 39/395** (2013.01); **A61K 45/06** (2013.01); **A61N 5/00** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 31/575**; **A61K 31/00**

USPC **514/171**; **435/4**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,003,689 B2	8/2011	Veverka
8,658,128 B2 †	2/2014	Altschul
8,710,035 B2	4/2014	Pan et al.
9,114,147 B2 †	8/2015	Altschul
9,149,485 B2	10/2015	Pan et al.
9,623,032 B2	4/2017	Pan et al.
2002/0115613 A1	8/2002	Kumar
2005/0124533 A1	6/2005	Schatzberg et al.
2006/0063748 A1	3/2006	Belanoff
2008/0287419 A1	11/2008	Bruncko et al.
2010/0135956 A1	6/2010	Gant et al.
2014/0315866 A1	10/2014	Pan et al.

FOREIGN PATENT DOCUMENTS

WO 2009064738 A2 5/2009

OTHER PUBLICATIONS

Gura (Science. 1997; 278: 1041-1042).*

Dennis (Nature. Aug. 7, 2006; 442: 739-741).*

Reagan-Shaw et al. (FASEB J, 2007, 22: 659-61).*

Data Sheet: Glucocorticoid Receptor mouse monoclonal antibody NCL-GCR, Novocastra Laboratories Ltd., available at <http://www.ebiotrade.com/buyf/Novocastra/data/hrerp/gcr.pdf>, accessed on Jun. 7, 2011.

Identification of Glucocorticoid Receptor (GR) signatures in primary human breast cancer: Association with relapse-free survival time, poster presented by S.D. Conzen as a short talk, presented at Nuclear Receptors: Signaling, Gene Regulation and Cancer, Keystone Symposia on Molecular and Cellular Biology, Keystone Resort, Keystone, Colorado, Mar. 25, 2010.

Belanoff et al., Selective glucocorticoid receptor {type II} antagonists prevent weight gain caused by olanzapine in rats, Eur. J. Pharmacol., vol. 655, 2011, pp. 117-120.

(Continued)

Primary Examiner — Yan Xiao

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

20 Claims, 12 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**OTHER PUBLICATIONS**

- Belova et al., Glucocorticoid receptor expression in breast cancer associates with older patient age, *Breast Cancer Res Treat*, vol. 116, 2009, pp. 441-447.
- Cho et al., Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes, *Biochemistry*, vol. 44, issue 9, 2005, pp. 3547-3561.
- Clark, Glucocorticoid Receptor Antagonists, *Current Topics in Medicinal Chemistry*, vol. 8, 2008, pp. 813-838.
- Colleoni et al., Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors, *Annals of Oncology*, vol. 11, issue 8, 2000, pp. 1057-1059.
- Desmedt et al., Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series, *Clin Cancer Res.*, vol. 13, 2007, pp. 3207-3214.
- Gaddy et al., Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells, *Clin Cancer Res.*, vol. 10, 2004, pp. 5215-5225.
- Grover et al., The initiation of breast and prostate cancer, *Carcinogenesis*, vol. 23, issue 7, 2002, pp. 1095-1102.
- Hein et al., Click Chemistry, A powerful Tool for Pharmaceutical Sciences, *Pharmaceutical Research*, vol. 25, issue 10, 2008, pp. 2216-2230.
- Henderson et al., Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture, *Cancer Res.*, vol. 48, 1988, pp. 246-253.
- Huang et al., Reversal effect of mifepristone on adriamycin resistance in human breast cancer cell Abstract only line MCF-7/ADM in vitro and in vivo, *J Cent South Univ (Med Sci)*, vol. 35, issue 6, Jun. 2010, pp. 576-583.
- Keen et al., The biology of breast carcinoma, *Cancer*, vol. 97, 3 Supp, 2003, pp. 825-833.
- Kriaucionis et al., The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain, *Science*, vol. 15, 2009, pp. 929-930.
- Loi et al., Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade, *Journal of Clinical Oncology*, vol. 25, 2006, pp. 1239-1246.
- Loi et al., Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen, *BMC Genomics*, vol. 9:239, 2008, 12 pages.
- Lucci et al., Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics, *Int J. Onco.*, vol. 15, 1999, pp. 541-546.
- Ma et al., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma, *J. Immunol*, vol. 171, issue 2, 2003, pp. 608-615.
- Melhem et al., Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues, *Clin. Cancer Res.*, vol. 15, issue 9, 2009, pp. 3196-3204.
- Mikosz et al., Glucocorticoid Receptor-mediated Protection from Apoptosis Is Associated with Induction of the Serine/Threonine Survival Kinase Gene, *sgk-1*, *J. Biol. Chem.*, vol. 276, No. 20, 2001, pp. 16649-16654.
- Minn et al., Genes that mediate breast cancer metastasis to lung, *Nature*, vol. 436(7050), Jul. 28, 2005, pp. 518-524.
- Moran et al., The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells, *Cancer Res.*, vol. 60, issue 4, 2000, pp. 867-872.
- Moses et al., The Growing Applications of Click Chemistry, *Chem Soc Rev* vol. 36, 2007, pp. 1249-1262.
- Pan et al., Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer, *Cancer Research*, vol. 71, Aug. 25, 2011, pp. 6360-6370.
- Pang et al., Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis, *Cancer Biology & Therapy*, vol. 5, Issue 8, 2006, pp. 933-940.
- Peeters et al., Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line, *Ann. NY Acad. Sci.*, vol. 1148, 2008, pp. 536-541.
- Pike et al., Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk, *Epidemiologic Rev.*, vol. 15, issue 1, 1993, pp. 17-35.
- Robinson et al., Octahydrophenanthrene-2, 7-diol Analogues as dissociated Glucocorticoid Receptor Agonists Discovery and Lead Exploration, *J. Med. Chem.*, vol. 52, 2009, pp. 1731-1743.
- Sims et al., The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets—improving meta-analysis and prediction of prognosis, *BMC Medical Genomics*, 1:42, 2008, 14 pages.
- Smith et al., Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue, *Breast Cancer Res.*, vol. 5, issue 1, 2003, pp. R9-R12.
- Smith et al., Progesterone, glucocorticoid, but not estrogen receptor mRNA is altered in breast cancer stroma, *Cancer Lett.*, vol. 255, 2007, pp. 77-84.
- Sorlie et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, *Proc. Natl. Acad. Sci.*, vol. 98, 2001, pp. 10869-10874.
- Sotiriou et al., Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis, *J. Natl. Cancer Inst.*, vol. 98, 2006, pp. 262-272.
- Srinivas et al., Proteomics for cancer biomarker discovery, *Clin. Chem.*, vol. 48, issue 8, 2002, pp. 1160-1169.
- Sui et al., Estrogen Receptor a Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death, *Cancer Res.*, vol. 67, issue 11, 2007, pp. 5337-5344.
- Wang et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, *The Lancet*, vol. 365, No. 9460, Feb. 19, 2005, pp. 671-679.
- Wu et al., Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells, *Mol. Endocrinol.*, vol. 20, issue 10, 2006, pp. 2304-2314.
- Wu et al., Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells, *Cancer Research*, vol. 64, 2004, pp. 1757-1764.
- Wu et al., Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer, *J. Clin. Investigation*, vol. 114, issue 4, 2004, pp. 560-568.
- U.S. Appl. No. 61/317,182, filed Mar. 24, 2010.†
- U.S. Appl. No. 14/451,207; Non-Final Office Action dated Feb. 24, 2016.†
- U.S. Appl. No. 14/451,207; Notice of Withdrawal from Issue under 37 CFR 1.313(b) dated Feb. 4, 2016.†

* cited by examiner

† cited by third party

**Primary human breast ductal epithelium, DCIS (60%)
invasive human cancers (~30-40%) exhibit significant
glucocorticoid receptor expression**




FIG. 1




FIG. 2




FIG. 3

NKI-295 RFS by Signiture




FIG. 4




FIG. 5





FIG. 6



Query = GR alpha
Length=6784

18665 = GR beta

ALIGNMENTS

Query	1	GGCGCCGCCTCCACCCGCTCCCCGCTCGGTCCCGCTCGCTCGCCAGGCCGGGCTGCCCT	60
18665	1	GGCGCCGCCTCCACCCGCTCCCCGCTCGGTCCCGCTCGCTCGCCAGGCCGGGCTGCCCT	60
Query	61	TTCGCGTGTCCGCGCTCTCTTCCCTCCGCCCGCCCTCCCTCCATTTTGCAGACTCGTGTCT	120
18665	61	TTCGCGTGTCCGCGCTCTCTTCCCTCCGCCCGCCCTCCCTCCATTTTGCAGACTCGTGTCT	120
Query	121	TGTGACGGGAGCCCGAGTCACCGCTGCCGTCGGGCACGGATTCTGTGGGTGGAAGGAG	180
18665	121	TGTGACGGGAGCCCGAGTCACCGCTGCCGTCGGGCACGGATTCTGTGGGTGGAAGGAG	180
Query	181	ACGCCGAGCCCGAGCGGCCGAAGCAGCTGGGACCGGGACGGGGACGCGCGCCCGGAAC	240
18665	181	ACGCCGAGCCCGAGCGGCCGAAGCAGCTGGGACCGGGACGGGGACGCGCGCCCGGAAC	240
Query	241	CTCGACCCGCGGAGCCCGCGCGGGCGGAGGGCTGGCTTGTTCAGCTGGGCAATGGGAGA	300
18665	241	CTCGACCCGCGGAGCCCGCGCGGGCGGAGGGCTGGCTTGTTCAGCTGGGCAATGGGAGA	300
Query	301	CTTCTTAAATAGGGGCTCTCCCCCACCCTATGGAGAAAGGGCGGCTGTTTACTTCCCTT	360
18665	301	CTTCTTAAATAGGGGCTCTCCCCCACCCTATGGAGAAAGGGCGGCTGTTTACTTCCCTT	360
Query	361	tttttAGaaaaaaaaaTATATTTCCCTCCTGCTCCTTCTGCGTTTACAAGCTAAGTTGT	420
18665	361	TTTTTAGAAAAAAAAAATATATTTCCCTCCTGCTCCTTCTGCGTTTACAAGCTAAGTTGT	420
Query	421	TTATCTCGGCTGCGCGGGAAGTGCAGACGGTGGCGGGCGAGCGGCTCCTCTGCCAGAGT	480
18665	421	TTATCTCGGCTGCGCGGGAAGTGCAGACGGTGGCGGGCGAGCGGCTCCTCTGCCAGAGT	480
Query	481	TGATATTCAGTATGGACTCCAAAGAATCATTAACCTCTGGTAGAGAAGAAAACCCAGC	540
18665	481	TGATATTCAGTATGGACTCCAAAGAATCATTAACCTCTGGTAGAGAAGAAAACCCAGC	540
Query	541	AGTGTGCTTGCTCAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCTAAGAGGAGGA	600
18665	541	AGTGTGCTTGCTCAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCTAAGAGGAGGA	600
Query	601	GCTACTGTGAAGGTTTCTGCGTCTTACCCTCACTGGCTGTGCTTCTCAATCAGACTCC	660
18665	601	GCTACTGTGAAGGTTTCTGCGTCTTACCCTCACTGGCTGTGCTTCTCAATCAGACTCC	660
Query	661	AAGCAGCGAAGACTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCA	720
18665	661	AAGCAGCGAAGACTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCA	720
Query	721	GATCTGTCCAAAGCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAA	780
18665	721	GATCTGTCCAAAGCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAA	780
Query	781	GTGATGGGAAAAGACCTGGGATTTCCACAGCAGGGCCAAATCAGCCTTTCTCGGGGGAA	840
18665	781	GTGATGGGAAAAGACCTGGGATTTCCACAGCAGGGCCAAATCAGCCTTTCTCGGGGGAA	840
Query	841	ACAGACTTAAAGCTTTTGAAGAAAGCATTGCAAACCTCAATAGGTCGACCACTGTTCCTCA	900
18665	841	ACAGACTTAAAGCTTTTGAAGAAAGCATTGCAAACCTCAATAGGTCGACCACTGTTCCTCA	900

FIG. 7A

Query	901	GAGAACCCCAAGAGTTCAGCATCCACTGCTGTGTCTGCTGCCCCACAGAGAAGGAGTTT	960
18665	901	GAGAACCCCAAGAGTTCAGCATCCACTGCTGTGTCTGCTGCCCCACAGAGAAGGAGTTT	960
Query	961	CCAAAACTCAC'TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACC	1020
18665	961	CCAAAACTCAC'TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACC	1020
Query	1021	AACGGTGGCAATGTGAAAT'TGTATACCACAGACCAGCACCTTTGACATTTTGCAGGAT	1080
18665	1021	AACGGTGGCAATGTGAAAT'TGTATACCACAGACCAGCACCTTTGACATTTTGCAGGAT	1080
Query	1081	TTGGAGTTTTC'TCTGGG'TCCCCAGGTAAAGAGACGAATGAGAGTCC'TTGGAGATCAGAC	1140
18665	1081	TTGGAGTTTTC'TCTGGG'TCCCCAGGTAAAGAGACGAATGAGAGTCC'TTGGAGATCAGAC	1140
Query	1141	CTGT'TGATAGATGAAAAC'TGT'TGCT'TTCTCCTCTGGCGGGAGAAGACGATTCA'TTCCTT	1200
18665	1141	CTGT'TGATAGATGAAAAC'TGT'TGCT'TTCTCCTCTGGCGGGAGAAGACGATTCA'TTCCTT	1200
Query	1201	T'TGGAAGGAAAC'TCGAATGAGGACTGCAAGCCTCTCATTTT'ACCGGACACTAAACCCAAA	1260
18665	1201	T'TGGAAGGAAAC'TCGAATGAGGACTGCAAGCCTCTCATTTT'ACCGGACACTAAACCCAAA	1260
Query	1261	ATTAAGGATAATGGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTG	1320
18665	1261	ATTAAGGATAATGGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTG	1320
Query	1321	AAAACAGAAAAAGAAGAT'TTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAA	1380
18665	1321	AAAACAGAAAAAGAAGAT'TTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAA	1380
Query	1381	CTGGGCACAGTTTACT'GTCAGGCAAGCTTTCCTGGAGCAAATATAAATGGTAATAAAATG	1440
18665	1381	CTGGGCACAGTTTACT'GTCAGGCAAGCTTTCCTGGAGCAAATATAAATGGTAATAAAATG	1440
Query	1441	TCTGCCATTTCT'GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATG	1500
18665	1441	TCTGCCATTTCT'GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATG	1500
Query	1501	AATACAGCATCCCT'TTCTCAACAGCAGGATCAGAAGCCTATTTTAAATGTCATTCCACCA	1560
18665	1501	AATACAGCATCCCT'TTCTCAACAGCAGGATCAGAAGCCTATTTTAAATGTCATTCCACCA	1560
Query	1561	AT'TCCCGT'TGGT'TCCGAAAAT'TGGAATAGGTGCCAAGGATCTGGAGATGACAAC'TTGACT'	1620
18665	1561	AT'TCCCGT'TGGT'TCCGAAAAT'TGGAATAGGTGCCAAGGATCTGGAGATGACAAC'TTGACT'	1620
Query	1621	TCTCT'GGGGACTCT'GAACT'TCCCTGGTTCGAACAGT'TTTTCTAATGGCTATTCAAGCCCC	1680
18665	1621	TCTCT'GGGGACTCT'GAACT'TCCCTGGTTCGAACAGT'TTTTCTAATGGCTATTCAAGCCCC	1680
Query	1681	AGCAT'GAGACCAGATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCA	1740
18665	1681	AGCAT'GAGACCAGATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCA	1740
Query	1741	CCTCCCAAAC'TCTGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTA	1800
18665	1741	CCTCCCAAAC'TCTGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTA	1800
Query	1801	ACTTGTGGAAGCTGTAAAGTTTCTTCAAAGAGCAGTGAAGGACAGCACAAATTACCTA	1860
18665	1801	ACTTGTGGAAGCTGTAAAGTTTCTTCAAAGAGCAGTGAAGGACAGCACAAATTACCTA	1860
Query	1861	TGTGCT'GGAAGGAATGATTGCATCATCGATAAAAATTCGAAGAAAAAATGCCAGCATGC	1920
18665	1861	TGTGCT'GGAAGGAATGATTGCATCATCGATAAAAATTCGAAGAAAAAATGCCAGCATGC	1920
Query	1921	CGCTATCGAAAATGTCTTCAGGCTGGAATGAACCTGGAAGCTCGaaaaacaagaaaaaa	1980
18665	1921	CGCTATCGAAAATGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAA	1980
Query	1981	ataaaaGGAATTCAGCAGGCCACTACAGGAGTCTCACAGAAGAACCTCTGAAAATCCTGGT	2040
18665	1981	ATAAAGGAATTCAGCAGGCCACTACAGGAGTCTCACAGAAGAACCTCTGAAAATCCTGGT	2040
Query	2041	AACAAAACAATAGT'TCCTGCAACGTTACCACAAC'TACCCCT'ACCCCTGGT'GT'CAC'TGT'G	2100
18665	2041	AACAAAACAATAGT'TCCTGCAACGTTACCACAAC'TACCCCT'ACCCCTGGT'GT'CAC'TGT'G	2100
Query	2101	GAGGT'TATTGAACCTGAAGT'GTTATATGCAGGATATGATAGCTCTGT'TCCAGACTCAACT	2160
18665	2101	GAGGT'TATTGAACCTGAAGT'GTTATATGCAGGATATGATAGCTCTGT'TCCAGACTCAACT	2160

FIG. 7B

Query	2161	TGGAGGATCATGACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGA	2220
18665	2161	TGGAGGATCATGACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGA	2220
Query	2221	TGGGCAAAGGCAATACCAGGTTTCAGGAACCTTACACCTGGATGACCAAATGACCCTACTG	2280
18665	2221	TGGGCAAAGGCAATACCAGGTTTCAGGAACCTTACACCTGGATGACCAAATGACCCTACTG	2280
Query	2281	CAGTACTCCTGGATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCA	2340
18665	2281	CAGTACTCCTGGATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCA	2340
Query	2341	AGTGCAAACCTGCTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTA	2400
18665	2341	AGTGCAAACCTGCTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTA	2400
Query	2401	CCCTGCATGTACGACCAATGTAACACATGCTGTATGTTTCTCTGAGTTACACAGGCTT	2460
18665	2401	CCCTGCATGTACGACCAATGTAACACATGCTGTATGTTTCTCTGAGTTACACAGGCTT	2460
Query	2461	CAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCT	2520
18665	2461	CAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCT	2520
Query	2521	AAGGACGGTCTGAAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAG	2580
18665	2521	AAGGACGGTCTGAAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAG	2580
Query	2581	CTAGGAAAAGCCATTTGTCAAGAGGGAAGGAACTCCAGCCAGAACTGGCAGCGGTTTAT	2640
18665	2581	CTAGGAAAAGCCATTTGTCAAGAGGGAAGGAACTCCAGCCAGAACTGGCAGCGGTTTAT	2640
Query	2641	CAACTGACAAAACCTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACATA	2700
18665	2641	CAACTGACAAAACCTCTTGGATTCTATGCATGAA	2673
Query	2701	TTCCAAACATTTTGGATAAGACCATGAGTATTGAATTCCTCCGAGATGTTAGCTGAAATC	2760
Query	2761	ATCACCAATCAGATACCAAAATATTCAAATGGAAATATCAAAAACTTCTGTTTCATCAA	2820
Query	2821	AAGTGACTGCCTTAATAAGAAATGGTTGCCTTAAAGAAAGTCGAATTAATAGCTTTTATTG	2880
Query	2881	TATAAACTATCAGTTTGTCTGTAGAGgttttgttgttttatttttattgttttcatct	2940
Query	2941	gttgttttgttttAAATACGCACTACATGTGGTTTATAGAGGGCCAAGACTTGGCAACAG	3000
Query	3001	AAGCAGTTGAGTCGTCATCACTTTTCAGTGATGGGAGAGTAGATGGTGAATTTATTAGT	3060
Query	3061	TAATATATCCCAGAAATTAGAAACCTTAATATGTGGACGTAATCTCCACAGTCAAAGAAG	3120
Query	3121	GATGGCACCTAAACCACCAGTGCCCAAAGTCTGTGTGATGAACTTTCTCTTCATACTttt	3180
Query	3181	tttCACAGTTGGCTGGATGAAATTTCTAGACTTTCTGTGGTGTATcccccccTGTAT	3240
Query	3241	AGTTAGGATAGCATTTTGTGATTATGCATGGAAACCTGaaaaaaAGTTTACAAGTGATA	3300
Query	3301	TCAGAAAAGGGAAGTTGTGCCTTTTATAGCTATTACTGTCTGGTTTAAACAATTTCTTT	3360
Query	3361	ATATTTAGTGAACACGCTTGCTCATTTTCTTTACATAATTTTTATTCAGTTATTTGT	3420
Query	3421	ACAGCTGTTTAAAGATGGGCAGCTAGTTCGTAGCTTTCCCAAATAAACTCTAAACATTAAT	3480
Query	3481	CAATCATCTGTGTGAAAATGGGTGGTGTCTTCTAACCTGATGGCACTTAGCTATCAGAAG	3540
Query	3541	ACCACAAAAATGACTCAAATCTCCAGTATTCTTGTGCaAAAAAAAAAAAAAAAAGCTCA	3600
Query	3601	TATTTTGTATAATCTGCTTCAGTGGAGAATTATAATAGGTGTGCAAAATTAACAGTCCTA	3660
Query	3661	ACTGGTATAGAGCACCTAGTCCAGTGACCTGCTGGGTAAACTGTGGAATGATGGTTGCAAA	3720
Query	3721	AGACTAATTTAAAAAATAACTACCAAGAGGCCCTGTCTGTACCTAACGCCCTATTTTGTG	3780

FIG. 7C

Query	3781	AAATGGCTATATGGCAAGAAAGCTGGTAAACTATTTGTCTTTCAGGACCTTTTGAAGTAGT	3840
Query	3841	TTGTATAAAGTTTGTGATTCCAGATAACCAGCTGTAAACACAGCTGAGAGACT	3900
Query	3901	TTTAAATCAGACAAAGTAATTCCTCTCACTAAACTTTACCCAAAACTAAATCTCTAATAT	3960
Query	3961	GGCAAAAAATGGCTAGACACCCATTTTCACATTCCCATCTGTCACCAATTTGGTTAATCTTTT	4020
Query	4021	CCTGATGGTACAGGAAAGCTCAGCTACTGATTTTTGTGATTTAGAACTGTATGTCAGACA	4080
Query	4081	TCCAATGTTTGTAAAACCTACACATCCCTAATGTGTGCCATAGAGTTTAACACAAGTCCTGT	4140
Query	4141	GAAATTTCTTTCACCTGTTGAAAATTATTTTAAACAAAAATAGAAGCTGTAGTAGCCCCTTTCTG	4200
Query	4201	TGTCACCTTTACCAACTTTCTGTAAACTCAAACTTAACATATTTACTAAGCCACAAGAA	4260
Query	4261	ATTTGATTTCTATTTCAAGGTGGCCAAATTATTTGTGTAATAGAAAACGTAAAATCTAATA	4320
Query	4321	TTAAAAATATGGAACTTCTAatataatattttatatttagttatagtttcagatatatatca	4380
Query	4381	tatTGGTATTCACCTAATCTGGGAAGGGAAGGGCTACTGCAGCTTTACATGCAATTTATTA	4440
Query	4441	AAATGATTTGTAAAATAGCTTGTATAGTGTAAAATAAGAATGATTTTTTAGATGAGATTGTT	4500
Query	4501	TTATCATGACATGTTATATATTTTTTTGTAGGGGTCAAAGAAATGCTGATGGATAACCTAT	4560
Query	4561	ATGATTTTATAGTTTGTACATGCATTTCATACAGGCAGCGATGGTCTCAGAAACCAAACAGT	4620
Query	4621	TTGCTCTAGGGGAAGAGGGAGATGGAGACTGGTCCTGTGTGCAGTGAAGGTTGCTGAGGC	4680
Query	4681	TCTGACCCAGTGAGATTACAGAGGAAGTTATCCTCTGCCTCCCATTCTGACCACCTTCT	4740
Query	4741	CATTTCCAACAGTGAGTCTGTGACGCGAGGTTTAGTTTACTCAATCTCCCCCTGCACTAAA	4800
Query	4801	GTATGTAAAGTATGTAAACAGGAGACAGGAAGGTGGTGCTTACATCCTTAAAGGCACCAT	4860
Query	4861	CTAATAGCGGGTTACTTTTACATACAGCCCTCCCCCAGCAGTTGAATGACAACAGAAGCT	4920
Query	4921	TCAGAAGTTTGGCAATAGTTTGCATAGAGGTACCAGCAATATGTAAATAGTGCAGAACTCT	4980
Query	4981	CATAGGTTGCCAATAATACACTAATTCCTTTCTATCCTACAACAAGAGTTTATTTCCAAA	5040
Query	5041	TAAAATGAGGACATgtttttgttttctttgaatgctttttgaatggtattttgttattttc	5100
Query	5101	agtatttttgagaaatttatttAATAaaaaaaCAATCATTTGCTTTTTTGAATGCTCTCTAA	5160
Query	5161	AAGGGAATGTAAATATTTTAAGATGGTGTGTAACCCGGCTGGATAAAATTTTGGTGCCTA	5220
Query	5221	GAAAACCTGCTTGAATATTCCTTATCAATGACAGTGTAAAGTTTCAAAAAGAGCTTCTAAAA	5280
Query	5281	CGTAGATTATCATTCCTTTTATAGAATGTTATGTGGTTAAAACCAGAAAGCACATCTCACA	5340
18665	2674	AATGTTATGTGGTTAAAACCAGAAAGCACATCTCACA	2710
Query	5341	CATTAATCTGATTTTCATCCCAACAATCTTGGCGCTCAAAAAATAGAACTCAATGAGAAA	5400
18665	2711	CATTAATCTGATTTTCATCCCAACAATCTTGGCGCTCAAAAAATAGAACTCAATGAGAAA	2770
Query	5401	AAGAAGATTATGTGCACTTCGTTGTCAATAATAAGTCAACTGATGCTCATCGACAACATAT	5460
18665	2771	AAGAAGATTATGTGCACTTCGTTGTCAATAATAAGTCAACTGATGCTCATCGACAACATAT	2830
Query	5461	AGGAGGCTTTTTCATTTAAATGGGAAAAGAAGCTGTGCCCTTTTJAGGATACGTGGGGGAAA	5520
18665	2831	AGGAGGCTTTTTCATTTAAATGGGAAAAGAAGCTGTGCCCTTTTJAGGATACGTGGGGGAAA	2890
Query	5521	GAAAGTCATCTTAATTAATGTTTAAATGTGGATTTAAGTGCTATATGGTGGTGCTGTTTGA	5580

FIG. 7D

18665	2891	GAAAGTCATCTTAATTATGTTTAAATTGTGGATTTAAGTGCATATATGGTGGTGCTGTTTGA	2950
Query	5581	AAGCAGATTTATTTCCCTATGTATGTGTATCTGGCCATCCCAACCCAAACTGTTGAAGTT	5640
18665	2951	AAGCAGATTTATTTCCCTATGTATGTGTATCTGGCCATCCCAACCCAAACTGTTGAAGTT	3010
Query	5641	TGTAGTAACTTCAGTGAGAGTTGGTTACTCACAAACAAATCCTGAAAAGTATTTTTAGTGT	5700
18665	3011	TGTAGTAACTTCAGTGAGAGTTGGTTACTCACAAACAAATCCTGAAAAGTATTTTTAGTGT	3070
Query	5701	TTGTAGGTATTTCTGTGGGATACTATACAAGCAGAACTGAGGCACCTTAGGACATAACACTT	5760
18665	3071	TTGTAGGTATTTCTGTGGGATACTATACAAGCAGAACTGAGGCACCTTAGGACATAACACTT	3130
Query	5761	TTGGGGTATATATATCCAAATGCCTAAAACATATGGGAGGAAACCTTGGCCACCCCAAAG	5820
18665	3131	TTGGGGTATATATATCCAAATGCCTAAAACATATGGGAGGAAACCTTGGCCACCCCAAAG	3190
Query	5821	GAAACTAACATGATTTGTGTCTATGAAGTGCTGGATAATTAGCATGGGATGAGCTCTGG	5880
18665	3191	GAAACTAACATGATTTGTGTCTATGAAGTGCTGGATAATTAGCATGGGATGAGCTCTGG	3250
Query	5881	GCAATGCCATGAAGCAAAGCCACGCTCCCTTCAGAATTCAGAGGCAGGGAGCAATTCAGT	5940
18665	3251	GCAATGCCATGAAGCAAAGCCACGCTCCCTTCAGAATTCAGAGGCAGGGAGCAATTCAGT	3310
Query	5941	TTACCTTAAGTCTCATAAATTTAGTTCCCTTTTAAAAACCCTGAAAACFACATCACCATG	6000
18665	3311	TTACCTTAAGTCTCATAAATTTAGTTCCCTTTTAAAAACCCTGAAAACFACATCACCATG	3370
Query	6001	GAATGAAAAATATTTGTTATACAATACATTTGATCTGTCAAACCTCCAGAACCATGGTAGCC	6060
18665	3371	GAATGAAAAATATTTGTTATACAATACATTTGATCTGTCAAACCTCCAGAACCATGGTAGCC	3430
Query	6061	TTCACTGAGATTTCCATCTTGGCTGGTCACTCCCTGACTGTAGCTGTAGGTGAATgtgtt	6120
18665	3431	TTCACTGAGATTTCCATCTTGGCTGGTCACTCCCTGACTGTAGCTGTAGGTGAATGTGTT	3490
Query	6121	tttgt	6180
18665	3491	TTTTGT	3550
Query	6181	TTAAACCCCTTTGGGTGGAGTTTCGTAATTTCCCAGACTATTTTCAAGCAACCTGGTCCAC	6240
18665	3551	TTAAACCCCTTTGGGTGGAGTTTCGTAATTTCCCAGACTATTTTCAAGCAACCTGGTCCAC	3610
Query	6241	CCAGGATTAGTGACCAGGTTTTCAGGAAAGGATTTGCTTCTCTCTAGAAAATGTCFGAAA	6300
18665	3611	CCAGGATTAGTGACCAGGTTTTCAGGAAAGGATTTGCTTCTCTCTAGAAAATGTCFGAAA	3670
Query	6301	GGATTTTATTTTCTGATGAAAGGCTGTATGAAAATACCCTCCTCAAATAACTTGCCTAAC	6360
18665	3671	GGATTTTATTTTCTGATGAAAGGCTGTATGAAAATACCCTCCTCAAATAACTTGCCTAAC	3730
Query	6361	TACATATAGATTCAGTGCTGTCATATTTCTATTTTGTATATTAATGCTATATAATGGGG	6420
18665	3731	TACATATAGATTCAGTGCTGTCATATTTCTATTTTGTATATTAATGCTATATAATGGGG	3790
Query	6421	ACAAAATCTATATTTATACGTGTATGGCATTTAAGAAGCTTTTTCATTTATTTTATCA	6480
18665	3791	ACAAAATCTATATTTATACGTGTATGGCATTTAAGAAGCTTTTTCATTTATTTTATCA	3850
Query	6481	CAGTAATTTTAAAAATGTGTAAAAATTTAAACCAGTGACTCCGTGTTAAAAATAAAAGTTG	6540
18665	3851	CAGTAATTTTAAAAATGTGTAAAAATTTAAACCAGTGACTCCGTGTTAAAAATAAAAGTTG	3910
Query	6541	TAGTTTTTTTATTCATGCTGAATAATAATCTGTAGTTAAAAAGTGTCTTTTACCTA	6600
18665	3911	TAGTTTTTTTATTCATGCTGAATAATAATCTGTAGTTAAAAAGTGTCTTTTACCTA	3970
Query	6601	CGCAGTGAAAATGTCAGACTGTAAAACCTTGTGTGGAAATGTTTAACTTTTATTTTTCAT	6660
18665	3971	CGCAGTGAAAATGTCAGACTGTAAAACCTTGTGTGGAAATGTTTAACTTTTATTTTTCAT	4030
Query	6661	TTAAATTTGCTGTCTCTGGTATTTACCAAACACACATTTGTACCGAATTGGCAGTAAATGT	6720
18665	4031	TTAAATTTGCTGTCTCTGGTATTTACCAAACACACATTTGTACCGAATTGGCAGTAAATGT	4090
Query	6721	TAGCCATTTTACAGCAATGCCAAATATGGAGAAACATCATAAATAAAAAAATCTGCTTTTC	6780
18665	4091	TAGCCATTTTACAGCAATGCCAAATATGGAGAAACATCATAAATAAAAAAATCTGCTTTTC	4150
Query	6781	ATTA 6784	

FIG. 7E

18665 4151 ATTA 4154

FIG. 7F




FIG. 8




FIG. 9

1

METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 14/296,127, filed Jun. 4, 2014, which is a Continuation of U.S. application Ser. No. 14/172,051, filed Feb. 4, 2014, which is a Continuation of U.S. application Ser. No. 13/071,363, filed Mar. 24, 2011, which claims priority to U.S. Provisional Application No. 61/317,182, filed on Mar. 24, 2010, which is hereby incorporated by reference.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with government support under CA089208 awarded by the National Institutes of Health. The government has certain rights in the invention.

REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON AN ASCII TEXT FILE

The Sequence Listing written in file "SeqListing096487-1040478.TXT", created on Mar. 2, 2017, 231,303 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference in its entirety for all purposes.

BACKGROUND OF THE INVENTION

I. Field of the Invention

Embodiments of this invention are directed generally to biology and medicine. In certain aspects methods involve determining the prognosis for a breast cancer patient. In other embodiments, there are methods and compositions for treating a breast cancer patient with a glucocorticoid antagonist.

II. Background

There are over 1 million cases of breast cancer per year on a global basis, of which around 0.5 million are in the US, 40,000 are in the UK and nearly 2,000 in Ireland. It is the leading cause of cancer deaths among women (Keen and Davidson, 2003). Although the overall incidence of the disease is increasing within the western world, wider screening and improved treatments have led to a gradual decline in the fatality rate of about 1% per year since 1991. Inheritance of susceptibility genes, such as BRCA1 and BRCA2, account for only 5% of breast cancer cases and the factors responsible for the other 95% remain obscure (Grover and Martin, 2002). In the absence of a strategy to reduce causative agents of breast cancer, early detection remains the best approach to reducing the mortality rate of this disease. It is widely held that breast cancer initiates as the pre-malignant stage of atypical ductal hyperplasia (ADH), progresses into the pre-invasive stage of ductal carcinoma in situ (DCIS), and culminates in the potentially lethal stage of invasive ductal carcinoma (IDC). This linear model of breast cancer progression has been the rationale for the use of detection methods such as mammography in the hope of diagnosing and treating breast cancer at earlier clinical stages (Ma et al., 2003).

2

As more molecular information is being collated, diseases such as breast cancer are being sub-divided according to genetic signatures linked to patient outcome, providing valuable information for the clinician. Emerging novel technologies in molecular medicine have already demonstrated their power in discriminating between disease sub-types that are not recognizable by traditional pathological criteria (Sorlie et al., 2001) and in identifying specific genetic events involved in cancer progression (Srinivas et al., 2002).

Endocrine therapy is a popular mode of treatment for all stages of breast cancer. A majority of breast cancers belong to the type in which growth is stimulated by the female sex hormones, estrogens and progesterone. Therefore some of the therapies are based on depriving the tumor of the hormone-induced growth stimulus. Some of the current modes of endocrine treatments include blockade of the estrogen receptor with an antiestrogen, e.g. tamoxifen; hormonal ablation by surgery (oophorectomy, adrenalectomy or hypophysectomy), radiotherapy or medically by administration of a luteinizing hormone-releasing hormone analogue (LH-RHa), e.g., goserelin; suppression of estrogen synthesis with aromatase inhibitors, e.g., anastrozole; pharmacological doses of estrogens and progestagens, e.g., megestrol acetate.

Despite recent advances, the challenge of cancer treatment, including breast cancer therapy remains. Progress is limited with respect to the development of specific treatment regimens to clinically distinct tumor types, and to personalize tumor treatment in order to maximize outcome and efficiency. Moreover, a number of patients exhibit chemotherapy resistance.

Mere classification of breast cancers into a few subgroups characterized by low to absent gene expression of the estrogen receptor (ER) alone may not reflect the cellular and molecular heterogeneity of breast cancer, and may not allow the design of treatment strategies maximizing patient response. Once a patient is diagnosed with cancer, such as breast or ovarian cancer, or an individual wants predisposition analysis, there is a strong need for methods that allow the physician to predict the expected course of disease, including the likelihood of cancer recurrence, long-term survival of the patient, and the like, and accordingly select an appropriate treatment option that is effective.

SUMMARY OF THE INVENTION

Embodiments concern methods, compositions, and apparatuses related to assessing, prognosing, and/or treating breast cancer patients. It concerns using information related to glucocorticoid receptor (GR) activity and/or expression in conjunction with information related to estrogen receptor (ER) activity or expression to identify patients with the least favorable prognosis based on current standards of care for breast cancer. Patients with relatively low levels of estrogen receptor expression and relatively high levels of glucocorticoid expression fall into a group of breast cancer patients with the least favorable prognosis (i.e., mortality rate).

Accordingly, methods concern evaluating a patient with breast cancer. Embodiments include evaluating a biological sample from a patient; evaluating breast cancer cells from a patient; evaluating a biological sample from a breast cancer patient; assessing a breast cancer patient; testing a breast cancer sample or biopsy; testing a breast tumor; prognosing a breast cancer patient; treating a breast cancer patient, particularly a patient with a particular profile related to ER and GR; determining a treatment for a breast cancer patient; altering a treatment plan for a breast cancer patient; report-

ing prognosis of a breast cancer patient; determining a prognosis score for a breast cancer patient; generating a prognosis score for a breast cancer patient; assessing the risk of mortality of a breast cancer patient generally or within a certain time frame, such as 150 months from end of cancer treatment; generating an ER and GR expression profile for a breast cancer patient; comparing a patient's ER and GR expression profile to a standardized profile; and/or, determining a breast cancer patient has a poor prognosis based on the patient's ER and GR status.

Embodiments also cover apparatuses, kits, and computer readable medium and systems for assessing the level or activity of ER and/or GR in a patient's breast cancer sample and determining a prognosis; and/or treating the patient accordingly. It is specifically contemplated that a breast cancer patient is a human. Accordingly, in human patients, ER refers to an estrogen receptor in a human and GR refers to a glucocorticoid receptor in a human.

Some embodiments include generating an expression profile for glucocorticoid receptor, which means obtaining the level of expression of GR directly or indirectly by measuring or assaying activity or expression. Methods include directly measuring or assaying the level of expression or activity refers to measuring or assaying a sample to determine the level of GR expression (protein or transcript) in the cell. Indirectly obtaining the level of expression includes measuring or assaying expression or activity of a gene or protein that correlates with GR expression or activity. In some embodiments, the level of GR expression can be indirectly obtained by measuring or assaying expression of a GR-responsive gene, which refers to a gene whose expression is affected in a dose-dependent manner by GR expression or activity. Expression refers to either protein expression or RNA (transcript) expression. Methods may involve either type of expression and a variety of assays are well known to those of skill in the art. For example, quantitative PCR may be performed to obtain RNA expression levels. The Affymetrix chip used in the Examples also provides information regarding RNA expression levels. Alternatively, reagents to detect protein expression levels may be employed in embodiments. Methods may involve probes, primers, and/or antibodies that are specific to GR or ER in order to assess expression levels.

In some embodiments, the activity level of GR is measured by assaying the level of GR expression. In additional embodiments, GR expression is GR transcript expression. In other embodiments, GR expression is GR protein expression. As discussed above, in some embodiments, the activity level of GR is measured by assaying the expression level of one or more GR-responsive genes. A GR-responsive gene may be one or more of the following: MCL1, SAP30, DUSP1, SGK1, SMARCA2, PTGDS, TNFRSF9, SFN, LAPTM5, GPSM2, SORT1, DPT, NRP1, ACSL5, BIRC3, NNMT, IGFBP6, PLXNC1, SLC46A3, C14orf139, PIAS1, IDH2, SERPINF1, ERBB2, PECAM1, LBH, ST3GAL5, IL1R1, BIN1, WIPF1, TFPI, FN1, FAM134A, NRIP1, RAC2, SPP1, PHF15, BTN3A2, SESN1, MAP3K5, DPYSL2, SEMA4D, STOM, or MAOA.

In some embodiments, there is a step of assaying or measuring the activity level of glucocorticoid receptor (GR) in a biological sample from the patient containing breast cancer cells. As discussed above, the activity level of GR can be obtained directly or indirectly. It is specifically contemplated that levels of glucocorticoid activity or expression refers to activity or expression of GR α , GR β , or both. Unless specifically stated otherwise, the terms "glucocorticoid receptor" or "GR" refer to both forms. Embodiments

discussed with respect to glucocorticoid receptor or GR may also be implemented solely with GR α or solely with GR β .

Methods may also include obtaining a level of estrogen receptor (ER) expression in breast cancer cells from the patient. The level can be obtained by obtaining the results of an assay that measured the level of ER expression. In some embodiments, the level is obtained by measuring or assaying the level of ER expression.

In some embodiments, the level of estrogen receptor expression in breast cancer cells from patient is obtained by measuring the level of estrogen receptor expression from the biological sample from the patient. In other embodiments, the level is obtained by receiving qualitative and/or quantitative data regarding the level.

In some embodiments, methods include identifying the patient as having or not having a risk factor for cancer recurrence based on the levels of ER and GR expression. Methods may involve categorizing the patient as ER+ or ER- based the level of estrogen receptor expression and a predetermined threshold value for ER expression. The term "ER+" refers to a classification of ER expression that indicates the patient expresses estrogen receptor in breast cancer cells at or above a certain level. The term "ER-" refers to a classification of ER expression that indicates the patient expresses estrogen receptor at a relatively low level in breast cancer cells, meaning at or below a certain level. In embodiments of the invention, that certain level or a predetermined threshold value is at, below, or above 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percentile, or any range derivable therein.

Methods may involve measuring the activity level of glucocorticoid receptor in a biological sample from the patient containing breast cancer cells and measuring the expression level of estrogen receptor in the biological sample.

In certain embodiments, the predetermined threshold value for ER expression identifies a patient as ER+ if the patient's ER expression level is in the 25th percentile or greater compared to a normalized sample. This means the patient may be designated as having a level of ER expression that is at or above 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percentile, or any range derivable therein. It is contemplated that in some cases, a patient may be designated as ER+ if the patient's ER expression level is at or above 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range derivable therein. The patient may also be referred to as having a normal or high ER expression level. The higher the percentile, the higher the relative expression level.

In embodiments, methods may also involve categorizing the patient as GR+ or GR- based on a predetermined threshold value for GR activity. In some cases, a predetermined threshold value for GR activity is dependent on whether the patient is categorized as ER+ or ER-. Embodi-

ments may involve a predetermined threshold value for GR activity that identifies a patient as GR+ if the patient is ER- and GR activity level is in the 65th percentile or greater compared to a normalized sample. It is contemplated that in some cases, a patient may be designated as GR+ if the patient's GR expression level is at or above 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range derivable therein. The threshold value may or may not be dependent on ER expression levels or status. In some embodiments, the threshold value depends on whether the patient is ER- or not. The higher the percentile, the higher the relative expression level.

Methods may involve the use of a normalized sample or control that is based on one or more breast cancer samples that are not from the patient being tested.

In some embodiments, methods involve calculating a prognosis score for the patient based on the levels of ER and/or GR expression. Methods may alternatively or additionally involve reporting a prognosis score or report the levels of ER and/or GR expression. The score or report may contain or reflect raw data regarding expression levels or it may reflect a categorization of the expression levels obtained. A score could indicate the risk factor for mortality, recurrence, and/or both. The score could be a number within a numeric scale in which one end of the scale is most favorable and the other end is the least favorable with respect to a prognosis for breast cancer.

In certain embodiments, methods may involve identifying the patient as having a poor prognosis if the patient is determined to have a glucocorticoid receptor activity level at or above a certain threshold level and a level of estrogen receptor that is at or below a second threshold level. In each case, the threshold levels are specific for each of GR and ER. In certain embodiments, it is contemplated that a GR level in the 65th percentile or above based on breast cancer patients whose are in the 35th percentile or below is indicative of a poor prognosis. In some embodiments, patients with a poor prognosis include a population of breast cancer patients that numbers approximately 10% or less.

Methods also include identifying the patient as having a poor prognosis if the patient is determined to have i) an activity level of glucocorticoid receptor that is higher than the activity level of glucocorticoid receptor in normalized control sample and ii) a expression level of estrogen receptor expression that is lower than the expression level of estrogen receptor in a normalized control sample. Consequently, methods of the invention include prognosing a breast cancer patient. In some cases, a patient is identified as having a relatively good prognosis.

Other embodiments include methods of treating a patient for breast cancer comprising: treating the patient for breast cancer after a biological sample from the patient containing breast cancer cells is analyzed for i) the activity level of glucocorticoid receptor and ii) the expression level of estrogen receptor. A patient may be treated with a different treatment protocol than the patient would have been treated with if the patient's biological sample had not been analyzed. In some embodiments, the patient is categorized as ER- and GR+ based on the activity level of the glucocorticoid receptor and the expression level of estrogen receptor. In some cases, the patient is treated with a more aggressive therapy than the patient would have been treated with if the

patient had not been categorized as ER- and GR+. The term "more aggressive" refers to a treatment regimen that may include more drugs or drugs with more severe side effects and/or it may include an increased dosage or increased frequency of drugs. It may also include radiation or a combination of therapies. In some cases, the therapy includes one or more chemotherapeutics and/or biologics. In some embodiments, the patient is treated with a therapy comprising an anti-angiogenic agent. In additional embodiments, the therapy further comprises a chemotherapeutic agent in addition to the anti-angiogenic agent. Embodiments also include administering a glucocorticoid receptor antagonist and/or tyrosine kinase inhibitor.

Embodiments may also include where the patient is treated with more than one type of cancer therapy. This may be after the patient is determined to have a particular prognosis or after the status of the patient's GR and ER expression profile is known. In some embodiments, certain treatments are provided to an ER-/GR+ breast cancer patient who might have otherwise been treated with a less aggressive treatment for breast cancer. In some embodiments, a patient is treated with at least two of the following: radiation, chemotherapy, or a biologic. In particular embodiments, the patient may be treated with a kinase inhibitor and/or anti-angiogenic agent.

Methods may also involve obtaining a biological sample comprising breast cancer cells from the patient and categorizing the patient as i) GR+ or GR- based on the level of glucocorticoid activity assayed in the sample and compared to a predetermined threshold value for GR activity; and ii) ER+ or ER- based on the level of estrogen receptor expression assayed in the sample and compared to a predetermined threshold value for ER expression.

Any method may also include treating the patient for breast cancer, which may include directly administering or providing a cancer therapy. In some embodiments, a practitioner or doctor may prescribe a cancer therapy that the patient administers to herself.

To achieve these methods, a doctor, medical practitioner, or their staff may retrieve a biological sample from a patient for evaluation. The sample may be a biopsy, such as a breast tissue or tumor biopsy. The sample may be analyzed by the practitioner or their staff, or it may be sent to an outside or independent laboratory. The medical practitioner may be cognizant of whether the test is providing information regarding the patient's level of GR and/or ER expression or activity, or the medical practitioner may be aware only that the test indicates directly or indirectly that the test reflects that the patient has a particular prognosis or can be given a particular prognosis score. Furthermore, the practitioner may know the patient's ER or GR status, such as ER+ or ER-, or GR+ or GR-. Alternatively, she may be aware only that the test or assay indicates the patient has a poor prognosis, or the worst prognosis.

Embodiments also concern kits to determine glucocorticoid receptor status in breast cancer cells comprising: (a) one or more reagents for determining expression levels of NR3C1 in a biological sample; and (b) an algorithm and software encoding the algorithm for calculating a risk factor index from the expression of NR3C1 in a sample and the estrogen receptor status of the breast cancer cells to determine a prognosis or a prognosis score. Kits may also include one or more reagents for determining expression levels of ESR1 in the biological sample to provide estrogen receptor status.

Other embodiments include a computer readable medium having software modules for performing a method compris-

ing the acts of: (a) comparing glucocorticoid receptor data obtained from a patient's breast cancer sample with a reference; and (b) providing an assessment of glucocorticoid receptor status to a physician for use in determining an appropriate therapeutic regimen for a patient. In further embodiments, the computer readable medium further comprises a software module for assessing estrogen receptor status of the patient's breast cancer sample.

Computer systems are also included. In some embodiments, they have a processor, memory, external data storage, input/output mechanisms, a display, for assessing glucocorticoid receptor activity, comprising: (a) a database; (b) logic mechanisms in the computer generating for the database a GR-responsive gene expression reference; and (c) a comparing mechanism in the computer for comparing the GR-responsive gene expression reference to expression data from a patient sample using a comparison model to determine a GR gene expression profile of the sample.

Other embodiments include an internet accessible portal for providing biological information constructed and arranged to execute a computer-implemented method for providing: (a) a comparison of gene expression data of one or more GR-responsive genes in a patient sample with a calculated reporter index; and (b) providing an assessment of GR activity or expression to a physician for use in determining an appropriate therapeutic regime for a patient.

In addition to compiling, collecting and/or processing data related to GR status, methods, media and systems may also include the same embodiments with respect to data related to ER status. Such aspects may be instead of or in addition to the aspects related to GR status or data.

Embodiments also include methods of killing breast cancer cells comprising administering to a breast cancer patient an effective amount of a combination of anti-cancer compounds, wherein the anticancer compounds comprise a glucocorticoid receptor antagonist and a chemotherapeutic.

In other embodiments, there are methods for treating breast cancer in a patient comprising administering to the patient an effective amount of glucocorticoid receptor antagonist and a chemotherapeutic.

In further embodiments, methods are provided for treating chemotherapy-insensitive breast cancer cells comprising administering to a breast cancer patient an effective amount of a glucocorticoid receptor antagonist followed by chemotherapy.

Other methods include methods for treating breast cancer in a patient comprising: a) administering radiation or at least a first chemotherapeutic to the patient; b) subsequently administering an effective amount of a glucocorticoid receptor antagonist to the patient; and, c) administering radiation again or at least a second chemotherapeutic to the patient after the glucocorticoid receptor antagonist is administered to the patient.

In some embodiments, there are methods for treating breast cancer in a patient comprising: a) administering an effective amount of a glucocorticoid receptor antagonist to the patient, wherein the patient expresses detectable levels of GR prior to administration of the GR antagonist; b) then administering an effective amount of radiation or at least one chemotherapeutic.

It is contemplated that in methods described herein, breast cancer cells may undergo apoptosis following treatment set forth herein. Moreover, in some embodiments, the combination of a glucocorticoid receptor antagonist and an anti-cancer agent or compound induces more apoptosis than treatment with just the anticancer treatment alone. In other

methods, it is specifically contemplated to exclude treatment with a synthetic glucocorticoid, such as dexamethasone.

Glucocorticoid receptor antagonists are known to those of skill in the art. It refers to a compound or substance that that does not provoke a biological response itself upon binding to the glucocorticoid receptor, but blocks or dampens agonist-mediated responses. Examples include, but are not limited to, beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mifepristone, mometasone, and triamcinolone. In additional embodiments, the glucocorticoid receptor antagonist has undetectable level or a lower level of activity as a progesterone receptor antagonist. In certain embodiments, the glucocorticoid receptor antagonist has greater than 10-fold, 50-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 1000-fold lower binding activity (or any range derivable therein) for another hormone receptor compared to its binding activity for glucocorticoid receptor. In specific embodiments the hormone receptor is estrogen receptor or progesterone receptor.

In some embodiments, a patient had been previously treated with an anti-cancer therapy, such as radiation, chemotherapy, or immunotherapy (or a combination or multiple therapies thereof). In certain embodiments, a first anti-cancer therapy prior to therapy with glucocorticoid receptor antagonist was last administered more than two weeks prior to the glucocorticoid receptor antagonist or its combination with a second anti-cancer therapy. In certain embodiments, this first anti-cancer therapy that does not include a glucocorticoid receptor antagonist was last administered to the breast cancer patient at least 7, 8, 9, 10, 11, 12, 13, 14 days, and/or 1, 2, 3, 4, or 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months prior to treatment with a glucocorticoid receptor antagonist. Treatment methods may be applied to breast cancer or breast cancer cells that are chemo-resistant or breast cancer cells that are not chemo-sensitive. Moreover, treatment may be applied to breast cancer or to breast cancer cells that were previously administered a first apoptosis inducing agent, but were resistant to apoptosis.

In some embodiments, the breast cancer cells are determined to be resistant to apoptosis. In additional embodiments, the breast cancer or the breast cancer cells are determined not to be chemo-sensitive or are determined to be chemo-resistant. This determination may be based on the results of a genetic test or based on information obtained from an assessment of a tumor or the breast cancer after treatment with a first anti-cancer therapy. In specific embodiments, the first anti-cancer therapy is a chemotherapeutic, Herceptin®, radiation, a combination of chemotherapeutics, or a combination of one or more chemotherapeutic agents and Herceptin®.

In additional embodiments, the breast cancer cells express a detectable level of glucocorticoid receptor or its transcript. In some embodiments, the patient is determined to have breast cancer cells that express a detectable level of glucocorticoid receptor or its transcript. This may be determined directly or indirectly.

It is contemplated that breast cancer cells may be treated with a glucocorticoid receptor antagonist regardless of estrogen receptor status. Therefore, breast cancer cells may be estrogen receptor-negative (ER-) or estrogen receptor-positive (ER+), accordingly to a standardized and industry accepted test for ER status. In certain embodiments, the breast cancer cells do not express any detectable levels of ER; in other embodiments, ER expression is detectable in the breast cancer cells.

It is contemplated that breast cancer cells may be treated with a glucocorticoid receptor antagonist depending on or

regardless of progesterone receptor status. Therefore, breast cancer cells may be progesterone receptor-negative (PR-) or progesterone receptor-positive (PR+), accordingly to a standardized and industry accepted test for ER status. In certain embodiments, the breast cancer cells do not express any detectable levels of PR; in other embodiments, PR expression is detectable in the breast cancer cells.

Methods involve treating breast cancer, particularly a chemo-resistant breast cancer, with a combination of therapies that includes a glucocorticoid receptor antagonist and an anticancer therapy that induces apoptosis (together they may be referred to as a combination of anti-cancer agents or compounds), such as a chemotherapeutic. In some embodiments, the chemotherapeutic is capecitabine, carboplatin, cyclophosphamide (Cytoxan), daunorubicin, docetaxel (Taxotere), doxorubicin (Adriamycin), epirubicin (Ellence), fluorouracil (also called 5-fluorouracil or 5-FU), gemcitabine, eribulin, ixabepilone, methotrexate, mitomycin C, mitoxantrone, paclitaxel (Taxol), thiotepa, vincristine, or vinorelbin, or a combination of these agents. In other embodiments, therapy with a glucocorticoid receptor antagonist is combined Herceptin®, radiation, chemotherapeutic(s) and radiation, a combination of chemotherapeutics, or a combination of one or more chemotherapeutic agents and Herceptin®.

It is contemplated that in some embodiments of the combination therapy the glucocorticoid receptor antagonist is administered within 5, 10, 30, 45, 60 minutes, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and/or 1, 2, 3, 4, 5, 6, 7 days, or any combination thereof within administration of at least one or the combination of the anti-cancer agents or compounds. In specific embodiments, the glucocorticoid receptor antagonist is administered within 2 hours, 12 hours or 24 hours of administration of a anticancer agent or compound (or a combination of such agents or compounds).

It is specifically contemplated that treatment may continue or be repeated. In some embodiments, once treated with the combination of a glucocorticoid receptor antagonist and at least one anticancer agent or compound, all or part of the treatment may be repeated alone or in combination with a different anticancer agent or compound.

In certain embodiments, the glucocorticoid receptor antagonist is administered prior to as the other agent or therapy included in the combination therapy. In certain embodiments, the glucocorticoid receptor antagonist is administered 5, 10, 30, 45, 60 minutes, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and/or 1, 2, 3, 4, 5, 6, 7 days, or any combination thereof prior to administration of at least one or the combination of the anti-cancer agents or compounds. It is specifically contemplated that in some embodiments, the glucocorticoid receptor antagonist is given prior to administration of the anticancer agent or compound but that the glucocorticoid receptor antagonist is also given concurrently with or after administration of the initial or a subsequent dose of the anticancer agent or compound. As discussed throughout, the anticancer agent or compound may be in a combination of such agents or compounds. In certain embodiments, the glucocorticoid receptor antagonist is administered up to three days prior to administering the anticancer agent or compound.

Additionally or alternatively, the glucocorticoid receptor antagonist is administered after administration of the other agent or therapy included in the combination therapy. In certain embodiments, the glucocorticoid receptor antagonist is administered 5, 10, 30, 45, 60 minutes, and/or 1, 2, 3, 4,

5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and/or 1, 2, 3, 4, 5, 6, 7 days, or any combination thereof after administration of at least one or the combination of the anti-cancer agents or compounds. It is specifically contemplated that in some embodiments, the glucocorticoid receptor antagonist is given after administration of the anticancer agent or compound; such administration may be repeated. As discussed throughout, the anticancer agent or compound may be in a combination of such agents or compounds. In certain embodiments, the glucocorticoid receptor antagonist is administered up to three days after administering the anticancer agent or compound.

In certain embodiments, the breast cancer is an unresectable breast cancer. In further embodiments, the breast cancer is inflammatory breast cancer.

It is specifically contemplated that in some methods, dexamethasone has not been administered to the patient within 24 hours of administration of the glucocorticoid receptor antagonist.

Compositions are contemplated to include a glucocorticoid receptor antagonist and any other anticancer compound discussed herein, such a Herceptin or one or more chemotherapeutic compounds. In some embodiments, the composition is in a pharmaceutically acceptable formulation.

Use of the one or more compositions may be employed based on methods described herein. Other embodiments are discussed throughout this application. Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa. The embodiments in the Example section are understood to be embodiments that are applicable to all aspects of the technology described herein.

“Cancer prognosis” generally refers to a forecast or prediction of the probable course or outcome of the cancer. As used herein, cancer prognosis includes the forecast or prediction of any one or more of the following: duration of survival of a patient susceptible to or diagnosed with a cancer, duration of recurrence-free survival, duration of progression free survival of a patient susceptible to or diagnosed with a cancer, response rate in a group of patients susceptible to or diagnosed with a cancer, and/or duration of response in a patient or a group of patients susceptible to or diagnosed with a cancer.

In certain aspects, prognosis is an estimation of the likelihood of metastasis free survival of said patient over a predetermined period of time, e.g., over a period of 5 years.

In further aspects, prognosis is an estimation of the likelihood of death of disease of said patient over a predetermined period of time, e.g., over a period of 5 years.

The term “recurrence” refers to the detection of breast cancer in form of metastatic spread of tumor cells, local recurrence, contralateral recurrence or recurrence of breast cancer at any site of the body of the patient after breast cancer had been substantially undetectable or responsive to treatments.

As used herein, “prognostic for cancer” means providing a forecast or prediction of the probable course or outcome of the cancer. In some embodiments, “prognostic for cancer” comprises providing the forecast or prediction of (prognostic for) any one or more of the following: duration of survival of a patient susceptible to or diagnosed with a cancer, duration of recurrence-free survival, duration of progression free survival of a patient susceptible to or diagnosed with a cancer, response rate in a group of patients susceptible to or

diagnosed with a cancer, and/or duration of response in a patient or a group of patients susceptible to or diagnosed with a cancer.

By “gene” is meant any polynucleotide sequence or portion thereof with a functional role in encoding or transcribing a protein or regulating other gene expression. The gene may consist of all the nucleic acids responsible for encoding a functional protein or only a portion of the nucleic acids responsible for encoding or expressing a protein. The polynucleotide sequence may contain a genetic abnormality within exons, introns, initiation or termination regions, promoter sequences, other regulatory sequences or unique adjacent regions to the gene.

As used herein, “treatment” or “therapy” is an approach for obtaining beneficial or desired clinical results. This includes: reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and/or stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and/or stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder, shrinking the size of the tumor, decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of patients.

The term “therapeutically effective amount” refers to an amount of the drug that may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy in vivo can, for example, be measured by assessing the duration of survival, time to disease progression (TTP), the response rates (RR), duration of response, and/or quality of life.

The terms “overexpress”, “overexpression”, “overexpressed”, “up-regulate”, or “up-regulated” interchangeably refer to a biomarker that is transcribed or translated at a detectably greater level, usually in a cancer cell, in comparison to a non-cancer cell or cancer cell that is not associated with the worst or poorest prognosis. The term includes overexpression due to transcription, post transcriptional processing, translation, post-translational processing, cellular localization, and/or RNA and protein stability, as compared to a non-cancer cell or cancer cell that is not associated with the worst or poorest prognosis. Overexpression can be detected using conventional techniques for detecting mRNA (i.e., RT-PCR, PCR, hybridization) or proteins (i.e., ELISA, immunohistochemical techniques, mass spectroscopy). Overexpression can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more in comparison to a normal cell or cancer cell that is not associated with the worst or poorest prognosis. In certain instances, overexpression is 1-fold, 2-fold, 3-fold, 4-fold 5, 6, 7, 8, 9, 10, or 15-fold or more higher levels of transcription or translation in comparison to a non-cancer cell or cancer cell that is not associated with the worst or poorest prognosis.

“Biological sample” includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include breast cancer tissues, cultured cells, e.g., primary cultures, explants, and

transformed cells. A biological sample is typically obtained from a mammal, such as a primate, e.g., human.

A “biopsy” refers to the process of removing a tissue sample for diagnostic or prognostic evaluation, and to the tissue specimen itself. Any biopsy technique known in the art can be applied to the diagnostic and prognostic methods of the present invention. The biopsy technique applied will depend on the tissue type to be evaluated (e.g., breast), the size and type of the tumor, among other factors. Representative biopsy techniques include, but are not limited to, excisional biopsy, incisional biopsy, needle biopsy, and surgical biopsy. An “excisional biopsy” refers to the removal of an entire tumor mass with a small margin of normal tissue surrounding it. An “incisional biopsy” refers to the removal of a wedge of tissue that includes a cross-sectional diameter of the tumor. A diagnosis or prognosis made by endoscopy or fluoroscopy can require a “core-needle biopsy”, or a “fine-needle aspiration biopsy” which generally obtains a suspension of cells from within a target tissue. Biopsy techniques are discussed, for example, in Harrison’s Principles of Internal Medicine, 2005. Obtaining a biopsy includes both direct and indirect methods, including obtaining the biopsy from the patient or obtaining the biopsy sample after it is removed from the patient.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” It is also contemplated that anything listed using the term “or” may also be specifically excluded.

As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

13

FIG. 1. Primary human breast ductal epithelium, DCIS (60%) in vasive human cancers (*30-40%) exhibit significant glucocorticoid receptor expression.

FIG. 2. Unsupervised cluster analysis identifies GR target gene signature (Sig+) vs Sig- tumors (n=68 genes) A GR-regulated gene expression set from MCF10A-Myc (ER-/GR+) cells treated +/- Dex from 30 m-24 h was used to perform a two dimensional unsupervised clustering analysis on the NKI-295 early breast cancer gene expression data set (n=2034 starting genes). GR-regulated genes (n=68) that separate these tumors into two groups (GRsig+=Red and GRsig-=Green) are shown in rows while each column represents a patient. Several EMT genes (e.g. Snail) and known anti-apoptotic genes are included.

FIG. 3. NR3C1 expression correlates with GR signature gene expression. The GRsig+ vs. GRsig- tumor designations correlate with higher NR3C1 vs. lower expression, respectively. For ESR1+ tumors (orange) the $P < 0.00001$ and for ESR1- tumors (green) $p = 0.7$ (t test). Error bars are +/-SD.

FIG. 4. RFS of GR gene expression signature. The GR signature predicts a differential prognosis for ESR1+ patients and ESR1- pts with respect to GR-signature expression. ESR1-/GR+ signature patients have the worst prognosis.

FIG. 5. Meta-analysis of NR3C1 expression and RFS.

FIG. 6. Common genes differentially expressed in ESR1- and NR3C1+/- tumors, ChIP-seq and gene expression in Dex-treated MCF10A-Myc cells.

FIG. 7A-F. Schematic of glucocorticoid receptor (GR) isoforms. GR alpha=SEQ ID NO:47; GR beta=SEQ ID NO:48

FIG. 8. Administration of mifepristone increases MDA-MB-231 tumor susceptibility to paclitaxel treatment in vivo.

FIG. 9. Mifepristone pretreatment increases tamoxifen-resistant MCF-7 (T-R-MCF-7), but not parental MCF-7 cell susceptibility to paclitaxel in vitro.

DETAILED DESCRIPTION OF THE INVENTION

Glucocorticoid receptor (GR) activation initiates a potent cell survival signal in ER-breast cancer models. However, GR activity has not been previously examined in primary human breast cancers. Because anti-apoptotic signaling is believed to be an important determinant of breast cancer viability and relapse, the inventors contemplate that early stage primary human breast cancer demonstrates a correlation between high GR (NR3C1) and GR-mediated gene expression and cancer recurrence.

The Dutch NKI 295 data set was examined and the inventors determined that a gene expression signature of 68 GR-regulated genes (based on in vitro data) could cluster patients into different groups with differential outcome. In addition, it was found that GR-mediated gene expression correlated with NR3C1 expression levels. The inventors examined NR3C1 tumor expression in a much larger meta-dataset and again found that ER-/GR (NR3C1)+ patients did the worst. Moreover, key cell survival genes identified as GR gene targets from ChIP-seq experiments were differentially expressed.

I. Hormone Receptor Status of Breast Cancer

Intracellular receptors (IRs) form a class of structurally-related genetic regulators scientists have named "ligand dependent transcription factors" (R. M. Evans, Science, 240:889, 1988). Steroid receptors are a recognized subset of the IRs, including androgen receptor (AR), progesterone

14

receptor (PR), estrogen receptor (ER), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). Regulation of a gene by such factors requires both the IR itself and a corresponding ligand, which has the ability to selectively bind to the IR in a way that affects gene transcription.

Naturally occurring as well as synthetic steroidal glucocorticoids (e.g., cortisol, cortisone, prednisolone, dexamethasone) have been widely used for over fifty years for the treatment of acute and chronic inflammatory and immune disorders. In particular, glucocorticoids have been prescribed for the treatment of rheumatoid arthritis, osteoarthritis, rheumatic fever, asthma, allergic rhinitis, systemic lupus erythematosus, chronic obstructive pulmonary disease, Crohn's disease, inflammatory bowel disease, and ulcerative colitis. However, the use of glucocorticoids is often associated with severe and sometimes irreversible side effects such as bone loss/osteoporosis, hyperglycemia, diabetes mellitus, hypertension, glaucoma, muscle atrophy, Cushing's syndrome, and psychosis.

Glucocorticoids exert their pharmacological effects by regulating gene transcription after the formation of a complex with the glucocorticoid receptor (GR). GR-glucocorticoid complex affects gene transcription by translocating to the nucleus after binding of the glucocorticoid where it acts as a dimer in binding to DNA glucocorticoid hormone response elements (GREs) in the promoter regions of particular genes. The GR-glucocorticoid/GRE complex then, in turn, activates (transactivation) or inhibits transcription of proximally located genes. Conversely, the GR-glucocorticoid complex may negatively regulate gene transcription by a process that does not involve binding to DNA. In this process, termed transrepression, following binding of the glucocorticoid, the complexed GR enters the nucleus where it acts as a monomer to directly interact (via protein-protein interaction) with other transcription factors, repressing their ability to induce gene transcription and thus protein expression.

Estrogen, mediated through the estrogen receptor (ER), plays a major role in regulating the growth and differentiation of normal breast epithelium (Pike et al. Epidemiologic Reviews (1993) 15(1):17-35; Henderson et al. Cancer Res. (1988) 48:246-253). It stimulates cell proliferation and regulates the expression of other genes, including the progesterone receptor (PgR). PgR then mediates the mitogenic effect of progesterone, further stimulating proliferation (Pike et al., 1993; Henderson et al., 1988). The molecular differences between estrogen receptor ("ER") negative and ER positive tumors are significant in light of clinical observations which indicate that the nature and biological behavior of ER positive and ER negative tumors are distinct even in the absence of hormonal therapy. For example, ER negative cancers tend to recur sooner and show a different rate of recurrence in distant organ sites compared to ER positive tumors. Clinical observations and molecular profiling data suggest that tumors not expressing both ER and PgR represent a different clinical entity in terms of chemotherapy responsiveness. (Colleoni et al., Annals of Oncology 11(8): 1057 (2000)). Thus, ER negative and ER positive breast cancers are two distinct disease entities rather than phenotypic variations of the same disease.

Relatively increased expression of these genes in primary ER-negative human breast tumors is associated with high GR expression and with an earlier relapse in ER-negative breast cancer patients (described herein). Activation of the glucocorticoid receptor (GR) in epithelial cells has been shown to initiate an anti-apoptotic (i.e., cell survival) signaling pathway that prevents breast (Wu et al, 2004) and

ovarian cancer (Melhem et al, 2009) cell death in vitro and in vivo (Pang et al, 2006). Blocking or antagonizing GR activation with a GR antagonist such as mifepristone reverses cell survival signaling pathways initiated by the GR (Moran et al., 2000). Other GR antagonists (e.g., dexamethasone oxetanone) also reverse GR-mediated cell survival and potentiate apoptosis in response to cell stressors such as growth factor withdrawal (Mikosz et al, 2001). The mechanism(s) whereby GR activation protects from cell death includes the transcriptional upregulation of genes encoding anti-apoptotic proteins such as SGK1, MKP1, MCL1, and BIRC3. However, experiments with a glucocorticoid receptor antagonist, RU486, in conjunction with dexamethasone did not increase the number of apoptotic cells induced by paclitaxel, compared to paclitaxel alone (Wu et al., 2004).

II. Biomarkers and Evaluating Levels of Biomarkers

Biomarkers for prognosing human breast cancer patients have been identified. They include estrogen receptor (ER) in combination with the activity of the glucocorticoid receptor (GR) activity. It is contemplated that these biomarkers may be evaluated based on their gene products. In some embodiments, the gene product is the RNA transcript. In other embodiments, the gene product is the protein expressed by the RNA transcript. In still another embodiment is the evaluation of surrogate genes or gene targets of ER, GR, or ER and GR.

In certain aspects a meta-analysis of expression or activity can be performed. In statistics, a meta-analysis combines the results of several studies that address a set of related research hypotheses. This is normally done by identification of a common measure of effect size, which is modeled using a form of meta-regression. Generally, three types of models can be distinguished in the literature on meta-analysis: simple regression, fixed effects meta-regression and random effects meta-regression. Resulting overall averages when controlling for study characteristics can be considered meta-effect sizes, which are more powerful estimates of the true effect size than those derived in a single study under a given single set of assumptions and conditions. A meta-gene expression value, in this context, is to be understood as being the median of the normalized expression of a marker gene or activity. Normalization of the expression of a marker gene is preferably achieved by dividing the expression level of the individual marker gene to be normalized by the respective individual median expression of this marker genes, wherein said median expression is preferably calculated from multiple measurements of the respective gene in a sufficiently large cohort of test individuals. The test cohort preferably comprises at least 3, 10, 100, 200, 1000 individuals or more including all values and ranges thereof. Dataset-specific bias can be removed or minimized allowing multiple datasets to be combined for meta-analyses (See Sims et al. BMC Medical Genomics (1:42), 1-14, 2008, which is incorporated herein by reference in its entirety).

The calculation of a meta-gene expression value is performed by: (i) determining the gene expression value of at least two, preferably more genes (ii) "normalizing" the gene expression value of each individual gene by dividing the expression value with a coefficient which is approximately the median expression value of the respective gene in a representative breast cancer cohort (iii) calculating the median of the group of normalized gene expression values.

A gene shall be understood to be specifically expressed in a certain cell type if the expression level of said gene in said cell type is at least 2-fold, 5-fold, 10-fold, 100-fold, 1000-fold, or 10000-fold higher than in a reference cell type, or in

a mixture of reference cell types. Reference cell types include non-cancerous breast tissue cells or a heterogenous population of breast cancers.

In certain algorithms a suitable threshold level is first determined for a marker gene. The suitable threshold level can be determined from measurements of the marker gene expression in multiple individuals from a test cohort. The median expression of the marker gene in said multiple expression measurements is taken as the suitable threshold value.

Comparison of multiple marker genes with a threshold level can be performed as follows:

1. The individual marker genes are compared to their respective threshold levels.

2. The number of marker genes, the expression level of which is above their respective threshold level, is determined.

3. If a marker genes is expressed above its respective threshold level, then the expression level of the marker gene is taken to be "above the threshold level".

"A sufficiently large number", in this context, means preferably 30%, 50%, 80%, 90%, or 95% of the marker genes used.

In certain aspects, the determination of expression levels is on a gene chip, such as an Affymetrix™ gene chip.

In another aspect, the determination of expression levels is done by kinetic real time PCR.

In certain aspects, the methods can relate to a system for performing such methods, the system comprising (a) apparatus or device for storing data on the ER or nodal status of the patient; (b) apparatus or device for determining the expression level of at least one marker gene or activity; (c) apparatus or device for comparing the expression level of the first marker gene or activity with a predetermined first threshold value; (d) apparatus or device for determining the expression level of at least one second marker gene or activity; and (e) computing apparatus or device programmed to provide a unfavorable or poor prognosis if the data indicates a negative ER status and an increased or decreased expression level of said first marker gene or activity (e.g., GR expression or activity) with the predetermined first threshold value and, alternatively, the expression level of said second marker gene is above or below a predetermined second threshold level.

The person skilled in the art readily appreciates that an unfavorable or poor prognosis can be given if the expression level of the first marker gene with the predetermined first threshold value indicates a tumor that is likely to recur or not respond well to standard therapies.

The expression patterns can also be compared by using one or more ratios between the expression levels of different breast cancer biomarkers. Other suitable measures or indicators can also be employed for assessing the relationship or difference between different expression patterns.

The GR nucleic acid and protein sequences are provided in GenBank accession number AY436590. The ER nucleic acid and protein sequences are provided in GenBank accession number NG_008493. The content of all of these GenBank Accession numbers is specifically incorporated herein by reference as of the filing date of this application.

The following biomarkers are provided for implementation with embodiments discussed herein. All of them designate nucleic acid sequences for the particular gene identifier. Nucleic acid sequences related to these gene designation can be found in the Genbank sequence databases. Additional biomarkers include the MCL1, SAP30, DUSP1, SGK1, SMARCA2, PTGDS, TNFRSF9, SFN,

LAPTM5, GPSM2, SORT1, DPT, NRP1, ACSL5, BIRC3, NNMT, IGFBP6, PLXNC1, SLC46A3, C14orf139, PIAS1, IDH2, SERPINF1, ERBB2, PECAM1, LBH, ST3GAL5, IL1R1, BIN1, WIPF1, TFPI, FN1, FAM134A, NRIP1, RAC2, SPP1, PHF15, BTN3A2, SESN1, MAP3K5, DPYSL2, SEMA4D, STOM, and MAOA genes.

One or more of the biomarkers can be used to prognose a human patient with breast cancer. The expression pattern of these biomarkers in breast cancer cells may be used to evaluate a patient to determine whether they are likely to respond to standard chemotherapy, likely not to respond to standard chemotherapy, or likely to relapse after standard chemotherapy.

The expression levels of breast cancer biomarkers can be compared to reference expression levels using various methods. These reference levels can be determined using expression levels of a reference based on all breast cancer patients or all breast cancer patients determined to be ER+ and/or ER-. Alternatively, it can be based on an internal reference such as a gene that is expressed in all cells. In some embodiments, the reference is a gene expressed in breast cancer cells at a higher level than any biomarker. Any comparison can be performed using the fold change or the absolute difference between the expression levels to be compared. One or more breast cancer biomarkers can be used in the comparison. It is contemplated that 1, 2, 3, 4, 5, 6, 7, 8, and/or 9 biomarkers may be compared to each other and/or to a reference that is internal or external. A person of ordinary skill in the art would know how to do such comparisons.

Comparisons or results from comparisons may reveal or be expressed as x-fold increase or decrease in expression relative to a standard or relative to another biomarker or relative to the same biomarker but in a different class of prognosis. In some embodiments, patients with a poor prognosis have a relatively high level of expression (over-expression) or relatively low level of expression (under-expression) when compared to patients with a better or favorable prognosis, or vice versa.

Fold increases or decreases may be, be at least, or be at most 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-, 85-, 90-, 95-, 100- or more, or any range derivable therein. Alternatively, differences in expression may be expressed as a percent decrease or increase, such as at least or at most 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900, 1000% difference, or any range derivable therein.

Other ways to express relative expression levels are by normalized or relative numbers such as 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, or any range derivable therein.

Algorithms, such as the weighted voting programs, can be used to facilitate the evaluation of biomarker levels. In addition, other clinical evidence can be combined with the biomarker-based test to reduce the risk of false evaluations. Other cytogenetic evaluations may be considered in some embodiments of the invention.

Any biological sample from the patient that contains breast cancer cells may be used to evaluate the expression pattern of any biomarker discussed herein. In some embodiments, a biological sample from a breast tumor is used. Evaluation of the sample may involve, though it need not involve, panning (enriching) for cancer cells or isolating the cancer cells.

A. Nucleic Acids

Screening methods based on differentially expressed gene products are well known in the art. In accordance with one aspect of the present invention, the differential expression patterns of breast cancer biomarkers can be determined by measuring the levels of RNA transcripts of these genes, or genes whose expression is modulated by the these genes, in the patient's breast cancer cells. Suitable methods for this purpose include, but are not limited to, RT-PCR, Northern Blot, in situ hybridization, Southern Blot, slot-blotting, nuclease protection assay and oligonucleotide arrays.

In certain aspects, RNA isolated from breast cancer cells can be amplified to cDNA or cRNA before detection and/or quantitation. The isolated RNA can be either total RNA or mRNA. The RNA amplification can be specific or non-specific. Suitable amplification methods include, but are not limited to, reverse transcriptase PCR, isothermal amplification, ligase chain reaction, and Qbeta replicase. The amplified nucleic acid products can be detected and/or quantitated through hybridization to labeled probes. In some embodiments, detection may involve fluorescence resonance energy transfer (FRET) or some other kind of quantum dots.

Amplification primers or hybridization probes for a breast cancer biomarker can be prepared from the gene sequence or obtained through commercial sources, such as Affymatrix. In certain embodiments the gene sequence is identical or complementary to at least 8 contiguous nucleotides of the coding sequence.

Sequences suitable for making probes/primers for the detection of their corresponding breast cancer biomarkers include those that are identical or complementary to all or part of genes or SEQ ID NOs described herein. These sequences are all nucleic acid sequences of breast cancer biomarkers.

The use of a probe or primer of between 13 and 100 nucleotides, preferably between 17 and 100 nucleotides in length, or in some aspects of the invention up to 1-2 kilobases or more in length, allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over contiguous stretches greater than 20 bases in length are generally preferred, to increase stability and/or selectivity of the hybrid molecules obtained. One will generally prefer to design nucleic acid molecules for hybridization having one or more complementary sequences of 20 to 30 nucleotides, or even longer where desired. Such fragments may be readily prepared, for example, by directly synthesizing the fragment by chemical means or by introducing selected sequences into recombinant vectors for recombinant production.

In one embodiment, each probe/primer comprises at least 15 nucleotides. For instance, each probe can comprise at least or at most 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400 or more nucleotides (or any range derivable therein). They may have these lengths and have a sequence that is identical or complementary to a gene or SEQ ID NO described herein. Preferably, each probe/primer has relatively high sequence complexity and does not have any ambiguous residue (undetermined "n" residues). The probes/primers preferably can hybridize to the target gene, including its RNA transcripts, under stringent or

highly stringent conditions. In some embodiments, because each of the biomarkers has more than one human sequence, it is contemplated that probes and primers may be designed for use with each one of these sequences. For example, inosine is a nucleotide frequently used in probes or primers to hybridize to more than one sequence. It is contemplated that probes or primers may have inosine or other design implementations that accommodate recognition of more than one human sequence for a particular biomarker.

For applications requiring high selectivity, one will typically desire to employ relatively high stringency conditions to form the hybrids. For example, relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50° C. to about 70° C. Such high stringency conditions tolerate little, if any, mismatch between the probe or primers and the template or target strand and would be particularly suitable for isolating specific genes or for detecting specific mRNA transcripts. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide.

In another embodiment, the probes/primers for a gene are selected from regions which significantly diverge from the sequences of other genes. Such regions can be determined by checking the probe/primer sequences against a human genome sequence database, such as the Entrez database at the NCBI. One algorithm suitable for this purpose is the BLAST algorithm. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length *W* in the query sequence, which either match or satisfy some positive-valued threshold score *T* when aligned with a word of the same length in a database sequence. *T* is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence to increase the cumulative alignment score. Cumulative scores are calculated using, for nucleotide sequences, the parameters *M* (reward score for a pair of matching residues; always >0) and *N* (penalty score for mismatching residues; always <0). The BLAST algorithm parameters *W*, *T*, and *X* determine the sensitivity and speed of the alignment. These parameters can be adjusted for different purposes, as appreciated by one of ordinary skill in the art.

In one embodiment, quantitative RT-PCR (such as TaqMan, ABI) is used for detecting and comparing the levels of RNA transcripts in breast cancer samples. Quantitative RT-PCR involves reverse transcription (RT) of RNA to cDNA followed by relative quantitative PCR (RT-PCR). The concentration of the target DNA in the linear portion of the PCR process is proportional to the starting concentration of the target before the PCR was begun. By determining the concentration of the PCR products of the target DNA in PCR reactions that have completed the same number of cycles and are in their linear ranges, it is possible to determine the relative concentrations of the specific target sequence in the original DNA mixture. If the DNA mixtures are cDNAs synthesized from RNAs isolated from different tissues or cells, the relative abundances of the specific mRNA from which the target sequence was derived may be determined for the respective tissues or cells. This direct proportionality between the concentration of the PCR products and the relative mRNA abundances is true in the linear range portion of the PCR reaction. The final concentration of the target DNA in the plateau portion of the curve is determined by the availability of reagents in the reaction mix and is indepen-

dent of the original concentration of target DNA. Therefore, the sampling and quantifying of the amplified PCR products preferably are carried out when the PCR reactions are in the linear portion of their curves. In addition, relative concentrations of the amplifiable cDNAs preferably are normalized to some independent standard, which may be based on either internally existing RNA species or externally introduced RNA species. The abundance of a particular mRNA species may also be determined relative to the average abundance of all mRNA species in the sample.

In one embodiment, the PCR amplification utilizes one or more internal PCR standards. The internal standard may be an abundant housekeeping gene in the cell or it can specifically be GAPDH, GUSB and β -2 microglobulin. These standards may be used to normalize expression levels so that the expression levels of different gene products can be compared directly. A person of ordinary skill in the art would know how to use an internal standard to normalize expression levels.

A problem inherent in clinical samples is that they are of variable quantity and/or quality. This problem can be overcome if the RT-PCR is performed as a relative quantitative RT-PCR with an internal standard in which the internal standard is an amplifiable cDNA fragment that is similar or larger than the target cDNA fragment and in which the abundance of the mRNA encoding the internal standard is roughly 5-100 fold higher than the mRNA encoding the target. This assay measures relative abundance, not absolute abundance of the respective mRNA species.

In another embodiment, the relative quantitative RT-PCR uses an external standard protocol. Under this protocol, the PCR products are sampled in the linear portion of their amplification curves. The number of PCR cycles that are optimal for sampling can be empirically determined for each target cDNA fragment. In addition, the reverse transcriptase products of each RNA population isolated from the various samples can be normalized for equal concentrations of amplifiable cDNAs.

Nucleic acid arrays can also be used to detect and compare the differential expression patterns of breast cancer biomarkers in breast cancer cells. The probes suitable for detecting the corresponding breast cancer biomarkers can be stably attached to known discrete regions on a solid substrate. As used herein, a probe is "stably attached" to a discrete region if the probe maintains its position relative to the discrete region during the hybridization and the subsequent washes. Construction of nucleic acid arrays is well known in the art. Suitable substrates for making polynucleotide arrays include, but are not limited to, membranes, films, plastics and quartz wafers.

A nucleic acid array of the present invention can comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more different polynucleotide probes, which may hybridize to different and/or the same biomarkers. Multiple probes for the same gene can be used on a single nucleic acid array. Probes for other disease genes can also be included in the nucleic acid array. The probe density on the array can be in any range. In some embodiments, the density may be 50, 100, 200, 300, 400, 500 or more probes/cm².

Specifically contemplated by the present inventors are chip-based nucleic acid technologies such as those described by Hacia et al. (1996) and Shoemaker et al. (1996). Briefly, these techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as

high density arrays and screen these molecules on the basis of hybridization (see also, Pease et al., 1994; and Fodor et al., 1991). It is contemplated that this technology may be used in conjunction with evaluating the expression level of one or more breast cancer biomarkers with respect to diagnostic, prognostic, and treatment methods of the invention.

The present invention may involve the use of arrays or data generated from an array. Data may be readily available. Moreover, an array may be prepared in order to generate data that may then be used in correlation studies.

An array generally refers to ordered macroarrays or microarrays of nucleic acid molecules (probes) that are fully or nearly complementary or identical to a plurality of mRNA molecules or cDNA molecules and that are positioned on a support material in a spatially separated organization. Macroarrays are typically sheets of nitrocellulose or nylon upon which probes have been spotted. Microarrays position the nucleic acid probes more densely such that up to 10,000 nucleic acid molecules can be fit into a region typically 1 to 4 square centimeters. Microarrays can be fabricated by spotting nucleic acid molecules, e.g., genes, oligonucleotides, etc., onto substrates or fabricating oligonucleotide sequences in situ on a substrate. Spotted or fabricated nucleic acid molecules can be applied in a high density matrix pattern of up to about 30 non-identical nucleic acid molecules per square centimeter or higher, e.g. up to about 100 or even 1000 per square centimeter. Microarrays typically use coated glass as the solid support, in contrast to those of the nitrocellulose-based material of filter arrays. By having an ordered array of complementing nucleic acid samples, the position of each sample can be tracked and linked to the original sample. A variety of different array devices in which a plurality of distinct nucleic acid probes are stably associated with the surface of a solid support are known to those of skill in the art. Useful substrates for arrays include nylon, glass and silicon. Such arrays may vary in a number of different ways, including average probe length, sequence or types of probes, nature of bond between the probe and the array surface, e.g. covalent or non-covalent, and the like. The labeling and screening methods of the present invention and the arrays are not limited in its utility with respect to any parameter except that the probes detect expression levels; consequently, methods and compositions may be used with a variety of different types of genes.

Representative methods and apparatus for preparing a microarray have been described, for example, in U.S. Pat. Nos. 5,143,854; 5,202,231; 5,242,974; 5,288,644; 5,324,633; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,432,049; 5,436,327; 5,445,934; 5,468,613; 5,470,710; 5,472,672; 5,492,806; 5,525,464; 5,503,980; 5,510,270; 5,525,464; 5,527,681; 5,529,756; 5,532,128; 5,545,531; 5,547,839; 5,554,501; 5,556,752; 5,561,071; 5,571,639; 5,580,726; 5,580,732; 5,593,839; 5,599,695; 5,599,672; 5,610,287; 5,624,711; 5,631,134; 5,639,603; 5,654,413; 5,658,734; 5,661,028; 5,665,547; 5,667,972; 5,695,940; 5,700,637; 5,744,305; 5,800,992; 5,807,522; 5,830,645; 5,837,196; 5,871,928; 5,847,219; 5,876,932; 5,919,626; 6,004,755; 6,087,102; 6,368,799; 6,383,749; 6,617,112; 6,638,717; 6,720,138, as well as WO 93/17126; WO 95/11995; WO 95/21265; WO 95/21944; WO 95/35505; WO 96/31622; WO 97/10365; WO 97/27317; WO 99/35505; WO 09923256; WO 09936760; WO0138580; WO 0168255; WO 03020898; WO 03040410; WO 03053586; WO 03087297; WO 03091426; WO03100012; WO 04020085; WO 04027093; EP 373 203; EP 785 280; EP 799 897 and UK 8 803 000; the disclosures of which are all herein incorporated by reference.

It is contemplated that the arrays can be high density arrays, such that they contain 100 or more different probes. It is contemplated that they may contain 1000, 16,000, 65,000, 250,000 or 1,000,000 or more different probes. The probes can be directed to targets in one or more different organisms. The oligonucleotide probes range from 5 to 50, 5 to 45, 10 to 40, or 15 to 40 nucleotides in length in some embodiments. In certain embodiments, the oligonucleotide probes are 20 to 25 nucleotides in length.

The location and sequence of each different probe sequence in the array are generally known. Moreover, the large number of different probes can occupy a relatively small area providing a high density array having a probe density of generally greater than about 60, 100, 600, 1000, 5,000, 10,000, 40,000, 100,000, or 400,000 different oligonucleotide probes per cm². The surface area of the array can be about or less than about 1, 1.6, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm².

Moreover, a person of ordinary skill in the art could readily analyze data generated using an array. Such protocols include information found in WO 9743450; WO 03023058; WO 03022421; WO 03029485; WO 03067217; WO 03066906; WO 03076928; WO 03093810; WO 03100448A1, all of which are specifically incorporated by reference.

In one embodiment, nuclease protection assays are used to quantify RNAs derived from the breast cancer samples. There are many different versions of nuclease protection assays known to those practiced in the art. The common characteristic that these nuclease protection assays have is that they involve hybridization of an antisense nucleic acid with the RNA to be quantified. The resulting hybrid double-stranded molecule is then digested with a nuclease that digests single-stranded nucleic acids more efficiently than double-stranded molecules. The amount of antisense nucleic acid that survives digestion is a measure of the amount of the target RNA species to be quantified. An example of a nuclease protection assay that is commercially available is the RNase protection assay manufactured by Ambion, Inc. (Austin, Tex.).

B. Proteins and Polypeptides

In other embodiments, the differential expression patterns of breast cancer biomarkers can be determined by measuring the levels of polypeptides encoded by these genes in breast cancer cells. Methods suitable for this purpose include, but are not limited to, immunoassays such as ELISA, RIA, FACS, dot blot, Western Blot, immunohistochemistry, and antibody-based radioimaging. Protocols for carrying out these immunoassays are well known in the art. Other methods such as 2-dimensional SDS-polyacrylamide gel electrophoresis can also be used. These procedures may be used to recognize any of the polypeptides encoded by the breast cancer biomarker genes described herein.

One example of a method suitable for detecting the levels of target proteins in peripheral blood samples is ELISA. In an exemplifying ELISA, antibodies capable of binding to the target proteins encoded by one or more breast cancer biomarker genes are immobilized onto a selected surface exhibiting protein affinity, such as wells in a polystyrene or polyvinylchloride microtiter plate. Then, breast cancer cell samples to be tested are added to the wells. After binding and washing to remove non-specifically bound immunocomplexes, the bound antigen(s) can be detected. Detection can be achieved by the addition of a second antibody which is specific for the target proteins and is linked to a detectable label. Detection may also be achieved by the addition of a second antibody, followed by the addition of a third antibody

that has binding affinity for the second antibody, with the third antibody being linked to a detectable label. Before being added to the microtiter plate, cells in the peripheral blood samples can be lysed using various methods known in the art. Proper extraction procedures can be used to separate the target proteins from potentially interfering substances.

In another ELISA embodiment, the breast cancer cell samples containing the target proteins are immobilized onto the well surface and then contacted with the antibodies of the invention. After binding and washing to remove non-specifically bound immunocomplexes, the bound antigen is detected. Where the initial antibodies are linked to a detectable label, the immunocomplexes can be detected directly. The immunocomplexes can also be detected using a second antibody that has binding affinity for the first antibody, with the second antibody being linked to a detectable label.

Another typical ELISA involves the use of antibody competition in the detection. In this ELISA, the target proteins are immobilized on the well surface. The labeled antibodies are added to the well, allowed to bind to the target proteins, and detected by means of their labels. The amount of the target proteins in an unknown sample is then determined by mixing the sample with the labeled antibodies before or during incubation with coated wells. The presence of the target proteins in the unknown sample acts to reduce the amount of antibody available for binding to the well and thus reduces the ultimate signal.

Different ELISA formats can have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immunocomplexes. For instance, in coating a plate with either antigen or antibody, the wells of the plate can be incubated with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate are then washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test samples. Examples of these nonspecific proteins include bovine serum albumin (BSA), casein and solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.

In ELISAs, a secondary or tertiary detection means can also be used. After binding of a protein or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the control and/or clinical or biological sample to be tested under conditions effective to allow immunocomplex (antigen/antibody) formation. These conditions may include, for example, diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween and incubating the antibodies and antigens at room temperature for about 1 to 4 hours or at 49° C. overnight. Detection of the immunocomplex then requires a labeled secondary binding ligand or antibody, or a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand.

After all of the incubation steps in an ELISA, the contacted surface can be washed so as to remove non-complexed material. For instance, the surface may be washed with a solution such as PBS/Tween, or borate buffer. Following the formation of specific immunocomplexes between the test sample and the originally bound material, and subsequent washing, the occurrence of the amount of immunocomplexes can be determined.

To provide a detecting means, the second or third antibody can have an associated label to allow detection. In one embodiment, the label is an enzyme that generates color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one may contact and incubate the first or second immunocomplex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immunocomplex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween).

After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azido-di-(3-ethyl)-benzthiazoline-6-sulfonic acid (ABTS) and hydrogen peroxide, in the case of peroxidase as the enzyme label. Quantitation can be achieved by measuring the degree of color generation, e.g., using a spectrophotometer.

Another suitable method is RIA (radioimmunoassay). An example of RIA is based on the competition between radio-labeled-polypeptides and unlabeled polypeptides for binding to a limited quantity of antibodies. Suitable radiolabels include, but are not limited to, I^{125} . In one embodiment, a fixed concentration of I^{125} -labeled polypeptide is incubated with a series of dilution of an antibody specific to the polypeptide. When the unlabeled polypeptide is added to the system, the amount of the I^{125} -polypeptide that binds to the antibody is decreased. A standard curve can therefore be constructed to represent the amount of antibody-bound I^{125} -polypeptide as a function of the concentration of the unlabeled polypeptide. From this standard curve, the concentration of the polypeptide in unknown samples can be determined. Various protocols for conducting RIA to measure the levels of polypeptides in breast cancer cell samples are well known in the art.

Suitable antibodies for this invention include, but are not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, single chain antibodies, Fab fragments, and fragments produced by a Fab expression library.

Antibodies can be labeled with one or more detectable moieties to allow for detection of antibody-antigen complexes. The detectable moieties can include compositions detectable by spectroscopic, enzymatic, photochemical, biochemical, bioelectronic, immunochemical, electrical, optical or chemical means. The detectable moieties include, but are not limited to, radioisotopes, chemiluminescent compounds, labeled binding proteins, heavy metal atoms, spectroscopic markers such as fluorescent markers and dyes, magnetic labels, linked enzymes, mass spectrometry tags, spin labels, electron transfer donors and acceptors, and the like.

Protein array technology is discussed in detail in Pandey and Mann (2000) and MacBeath and Schreiber (2000), each of which is herein specifically incorporated by reference. These arrays typically contain thousands of different proteins or antibodies spotted onto glass slides or immobilized in tiny wells and allow one to examine the biochemical activities and binding profiles of a large number of proteins at once. To examine protein interactions with such an array, a labeled protein is incubated with each of the target proteins immobilized on the slide, and then one determines which of the many proteins the labeled molecule binds. In certain embodiments such technology can be used to quantitate a number of proteins in a sample, such as a breast cancer biomarker proteins.

The basic construction of protein chips has some similarities to DNA chips, such as the use of a glass or plastic surface dotted with an array of molecules. These molecules can be DNA or antibodies that are designed to capture proteins. Defined quantities of proteins are immobilized on each spot, while retaining some activity of the protein. With fluorescent markers or other methods of detection revealing the spots that have captured these proteins, protein microarrays are being used as powerful tools in high-throughput proteomics and drug discovery.

The earliest and best-known protein chip is the ProteinChip by Ciphergen Biosystems Inc. (Fremont, Calif.). The ProteinChip is based on the surface-enhanced laser desorption and ionization (SELDI) process. Known proteins are analyzed using functional assays that are on the chip. For example, chip surfaces can contain enzymes, receptor proteins, or antibodies that enable researchers to conduct protein-protein interaction studies, ligand binding studies, or immunoassays. With state-of-the-art ion optic and laser optic technologies, the ProteinChip system detects proteins ranging from small peptides of less than 1000 Da up to proteins of 300 kDa and calculates the mass based on time-of-flight (TOF).

The ProteinChip biomarker system is the first protein biochip-based system that enables biomarker pattern recognition analysis to be done. This system allows researchers to address important clinical questions by investigating the proteome from a range of crude clinical samples (i.e., laser capture microdissected cells, biopsies, tissue, urine, and serum). The system also utilizes biomarker pattern software that automates pattern recognition-based statistical analysis methods to correlate protein expression patterns from clinical samples with disease phenotypes.

In other aspects, the levels of polypeptides in samples can be determined by detecting the biological activities associated with the polypeptides. If a biological function/activity of a polypeptide is known, suitable in vitro bioassays can be designed to evaluate the biological function/activity, thereby determining the amount of the polypeptide in the sample.

III. Breast Cancer Therapy

Certain embodiments are directed to methods of treating breast cancer based on GR status of the breast cancer tissue. In some embodiments, the hormone receptor status is determined based on the expression of a hormone receptor such as the estrogen receptor (ER) in combination with the glucocorticoid receptor (GR).

In certain aspects, the hormone receptor status is high for GR and may also be low for one or more other hormone receptors such as the estrogen receptor. An individual having an elevated GR and low ER is likely to have a poor prognosis. In the event of a poor prognosis the physician may pursue a more aggressive therapy for those patients. In some embodiments, the method comprises identifying a breast cancer patient based on a hormone receptor status of patients having tumor tissue with elevated levels of GR expression.

In certain aspects, there may be provided methods for treating a subject determined to have cancer and with a predetermined expression profile of one or more biomarkers disclosed herein.

In a further aspect, biomarkers and related systems that can establish a prognosis of cancer patients in this invention can be used to identify patients who may get benefit of conventional single or combined modality therapy. In the same way, the invention can identify those patients who do

not get much benefit from such conventional single or combined modality therapy and can offer them alternative treatment(s).

In certain aspects of the present invention, conventional cancer therapy may be applied to a subject wherein the subject is identified or reported as having a good prognosis based on the assessment of the biomarkers as disclosed. On the other hand, at least an alternative cancer therapy may be prescribed, as used alone or in combination with conventional cancer therapy, if a poor prognosis is determined by the disclosed methods, systems, or kits.

Embodiments concern a glucocorticoid receptor antagonist. In some embodiments, the glucocorticoid receptor antagonist is a selective glucocorticoid receptor antagonist, as set forth in Clark, 2008, which is hereby incorporated by reference. In other embodiments, the glucocorticoid receptor antagonist is a non-selective glucocorticoid receptor antagonist, such as mifepristone. In certain embodiments, the glucocorticoid receptor antagonist is steroidal. In other embodiments, the glucocorticoid receptor antagonist is non-steroidal. A glucocorticoid receptor antagonist includes those in the following classes of chemical compounds: octahydrophenanthrenes, spirocyclic dihydropyridines, triphenylmethanes and diaryl ethers, chromenes, dibenzyl anilines, dihydroisoquinolines, pyrimidinediones, azadecalins, and aryl pyrazolo azadecalins, and which are described in more detail in Clark, 2008, which is hereby incorporated by reference. Some embodiments of steroidal antagonists from Clark, 2008 are: RU-486, RU-43044, 11-monoaryl and 11,21 bisaryl steroids (including 11 β -substituted steroids), 10 β -substituted steroids, 11 β -aryl conjugates of mifepristone, and phosphorous-containing mifepristone analogs. Further embodiments of nonsteroidal antagonists from Clark, 2008 are: octahydrophenanthrenes, spirocyclic dihydropyridines, triphenylmethanes and diaryl ethers, chromenes, dibenzyl anilines, dihydroquinolines, pyrimidinediones, azadecalins, aryl pyrazolo azadecalins (including 8a-benzyl isoquinolones, N-substituted derivatives, bridgehead alcohol and ethers, bridgehead amines). Additional specific examples include, but are not limited to the following specific antagonists: beclometasone, betametasone, budesonide, ciclesonide, flunisolide, fluticasone, mifepristone, mometasone, and triamcinolone. Other examples include those described and/or depicted in U.S. Patent Application Publication 2010/0135956, which is hereby incorporated by reference. Even further examples include ORG-34517 (Merck), RU-43044, dexamethasone mesylate (Dex-Mes), dexamethasone oxetanone (Dex-Ox), deoxycorticosterone (DOC) (Peeters et al., 2008, which is hereby incorporated by reference in its entirety and Cho et al. 2005, which is hereby incorporated by reference in its entirety). In additional embodiments the glucocorticoid receptor antagonist may be CORT 0113083 or CORT 00112716, which are described in Belanoff et al. (2011), which is hereby incorporated by reference. It is specifically contemplated that one or more of the antagonists discussed herein or in the incorporated references may be excluded in embodiments of the invention. It is also contemplated that in some embodiments, more than one glucocorticoid receptor antagonist is employed, while in other embodiments, only one is employed as part of the therapeutic method (though it may be administered multiple times). It is contemplated that the second one may be administered concurrently with the first one or they may be administered at different times.

Conventional cancer therapies include one or more selected from the group of chemical or radiation based treatments and surgery. Chemotherapies include, for

example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dacarbazine, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabine, navelbine, farnesyl-protein transferase inhibitors, transplatin, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.

Suitable therapeutic agents include, for example, vinca alkaloids, agents that disrupt microtubule formation (such as colchicines and its derivatives), anti-angiogenic agents, therapeutic antibodies, EGFR targeting agents, tyrosine kinase targeting agent (such as tyrosine kinase inhibitors), serine kinase targeting agents, transitional metal complexes, proteasome inhibitors, antimetabolites (such as nucleoside analogs), alkylating agents, platinum-based agents, anthracycline antibiotics, topoisomerase inhibitors, macrolides, therapeutic antibodies, retinoids (such as all-trans retinoic acids or a derivatives thereof); geldanamycin or a derivative thereof (such as 17-AAG), and other standard chemotherapeutic agents well recognized in the art.

Certain chemotherapeutics are well known for use against breast cancer. These breast cancer chemotherapeutics are capecitabine, carboplatin, cyclophosphamide (Cytosan), daunorubicin, docetaxel (Taxotere), doxorubicin (Adriamycin), epirubicin (Ellence), fluorouracil (also called 5-fluorouracil or 5-FU), gemcitabine, eribulin, ixabepilone, methotrexate, mitomycin C, mitoxantrone, paclitaxel (Taxol), thiotepa, vincristine, vinorelbine.

In some embodiments, the chemotherapeutic agent is any of (and in some embodiments selected from the group consisting of) adriamycin, colchicine, cyclophosphamide, actinomycin, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, mitoxantrone, fluorouracil, carboplatin, carmustine (BCNU), methyl-CCNU, cisplatin, etoposide, interferons, camptothecin and derivatives thereof, phenesterine, taxanes and derivatives thereof (e.g., paclitaxel and derivatives thereof, taxotere and derivatives thereof, and the like), topotecan, vinblastine, vincristine, tamoxifen, pipsulfan, nab-5404, nab-5800, nab-5801, Irinotecan, HKP, Ortataxel, gemcitabine, Herceptin®, vinorelbine, capecitabine, Gleevec®, Alimta®, Avastin®, Velcade®, Tarceva®, Neulasta®, Lapatinib, STI-571, ZD1839, Iressa® (gefitinib), SH268, genistein, CEP2563, SU6668, SU11248, EMD121974, and Sorafenib.

In some embodiments, the chemotherapeutic agent is a composition comprising nanoparticles comprising a thio-colchicine derivative and a carrier protein (such as albumin).

In further embodiments a combination of chemotherapeutic agents is administered to breast cancer cells. The chemotherapeutic agents may be administered serially (within minutes, hours, or days of each other) or in parallel; they also may be administered to the patient in a pre-mixed single composition. The composition may or may not contain a glucocorticoid receptor antagonist. Combinations of breast cancer therapeutics include, but are not limited to the following: AT (Adriamycin and Taxotere), AC±T: (Adriamycin and Cytosan, with or without Taxol or Taxotere), CMF (Cytosan, methotrexate, and fluorouracil), CEF (Cytosan, Ellence, and fluorouracil), FAC (fluorouracil, Adriamycin, and Cytosan), CAF (Cytosan, Adriamycin, and fluorouracil) (the FAC and CAF regimens use the same medicines but use different doses and frequencies), TAC (Taxotere, Adriamycin, and Cytosan), and GET (Gemzar, Ellence, and Taxol). In some embodiments trastuzumab (Herceptin®) is administered to a breast cancer patient with

a glucocorticoid receptor antagonist, which may be with or without a chemotherapeutic or a combination of chemotherapeutics.

Various combinations with a glucocorticoid receptor antagonist and an anticancer agent or compound (or a combination of such agents and/or compounds) may be employed, for example glucocorticoid receptor antagonist is "A" and the anticancer agent or compound (or a combination of such agents and/or compounds) given as part of an anticancer therapy regime, is "B".

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B B/A/B/B B/B/B/A
B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B
A/A/A/B B/A/A/A A/B/A/A A/A/B/A

Administration of the therapeutic compounds or agents to a patient will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the therapy. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the described therapy.

The term "a serine/threonine kinase inhibitor", as used herein, relates to a compound which inhibits serine/threonine kinases. An example of a target of a serine/threonine kinase inhibitor includes, but is not limited to, dsRNA-dependent protein kinase (PKR). Examples of indirect targets of a serine/threonine kinase inhibitor include, but are not limited to, MCP-1, NF-kappaB, eIF2alpha, COX2, RANTES, IL8, CYP2A5, IGF-1, CYP2B1, CYP2B2, CYP2H1, ALAS-1, HIF-1, erythropoietin and/or CYP1A1. An example of a serine/threonine kinase inhibitor includes, but is not limited to, Sorafenib and 2-aminopurine, also known as 1H-purin-2-amine(9CI). Sorafenib is marketed as NEXAVAR.

The term "an angiogenesis inhibitor", as used herein, relates to a compound which targets, decreases or inhibits the production of new blood vessels. Targets of an angiogenesis inhibitor include, but are not limited to, methionine aminopeptidase-2 (MetAP-2), macrophage inflammatory protein-1 (MIP-1a), CCL5, TGF-beta., lipoxigenase, cyclooxygenase, and topoisomerase. Indirect targets of an angiogenesis inhibitor include, but are not limited to, p21, p53, CDK2 and collagen synthesis. Examples of an angiogenesis inhibitor include, but are not limited to, Fumagillin, which is known as 2,4,6,8-decatetraenedioic acid, mono[3R, 4S,5S,6R]-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)oxi-ranyl]-1-oxaspiro[2.5]oct-6-yl]ester, (2E,4E, 6E,8E)-(9CI); Shikonin, which is also known as 1,4-naphthalenedione, 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-(9CI); Tranilast, which is also known as benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-(9CI); ursolic acid; suramin; thalidomide and lenalidomide, and marketed as REVLIMID.

Radiation therapy that cause DNA damage and have been used extensively include what are commonly known as gamma-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and

depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic construct and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.

Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative and palliative surgery. Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and/or alternative therapies.

Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed. Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs' surgery). It is further contemplated that the present invention may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.

Laser therapy is the use of high-intensity light to destroy tumor cells. Laser therapy affects the cells only in the treated area. Laser therapy may be used to destroy cancerous tissue and relieve a blockage in the esophagus when the cancer cannot be removed by surgery. The relief of a blockage can help to reduce symptoms, especially swallowing problems.

Photodynamic therapy (PDT), a type of laser therapy, involves the use of drugs that are absorbed by cancer cells; when exposed to a special light, the drugs become active and destroy the cancer cells. PDT may be used to relieve symptoms of esophageal cancer such as difficulty swallowing.

Upon excision of part of all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well. A patient may be administered a single compound or a combination of compounds described herein in an amount that is, is at least, or is at most 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 mg/kg (or any range derivable therein). A patient may be administered a single compound or a combination of compounds described herein in an amount that is, is at least, or is at most 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350,

360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500 mg/kg/day (or any range derivable therein).

Alternative cancer therapy include any cancer therapy other than surgery, chemotherapy and radiation therapy in the present invention, such as immunotherapy, gene therapy, hormonal therapy or a combination thereof. Subjects identified with poor prognosis using the present methods may not have favorable response to conventional treatment(s) alone and may be prescribed or administered one or more alternative cancer therapy per se or in combination with one or more conventional treatments.

For example, the alternative cancer therapy may be a targeted therapy. The targeted therapy may be an anti-EGFR treatment. In one embodiment of the method of the invention, the anti-EGFR agent used is a tyrosine kinase inhibitor. Examples of suitable tyrosine kinase inhibitors are the quinazoline derivatives described in WO 96/33980, in particular gefitinib (Iressa). Other examples include quinazoline derivatives described in WO 96/30347, in particular erlotinib (Tarceva), dual EGFR/HER2 tyrosine kinase inhibitors, such as lapatinib, or pan-Erb inhibitors. In a preferred embodiment of the method or use of the invention, the anti-EGFR agent is an antibody capable of binding to EGFR, i.e. an anti-EGFR antibody.

In a further embodiment, the anti-EGFR antibody is an intact antibody, i.e. a full-length antibody rather than a fragment. An anti-EGFR antibody used in the method of the present invention may have any suitable affinity and/or avidity for one or more epitopes contained at least partially in EGFR. Preferably, the antibody used binds to human EGFR with an equilibrium dissociation constant (K_D) of 10^{-8} M or less, more preferably 10^{-10} M or less.

Particularly antibodies for use in the present invention include zalutumumab (2F8), cetuximab (Erbix), nimotuzumab (h-R3), panitumumab (ABX-EGF), and matuzumab (EMD72000), or a variant antibody of any of these, or an antibody which is able to compete with any of these, such as an antibody recognizing the same epitope as any of these. Competition may be determined by any suitable technique. In one embodiment, competition is determined by an ELISA assay. Often competition is marked by a significantly greater relative inhibition than 5% as determined by ELISA analysis.

Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

Gene therapy is the insertion of polynucleotides, including DNA or RNA, into an individual's cells and tissues to treat a disease. Antisense therapy is also a form of gene therapy in the present invention. A therapeutic polynucleotide may be administered before, after, or at the same time of a first cancer therapy. Delivery of a vector encoding a variety of proteins is encompassed within the invention. For example, cellular expression of the exogenous tumor sup-

pressor oncogenes would exert their function to inhibit excessive cellular proliferation, such as p53, p16 and C-CAM.

Additional agents to be used to improve the therapeutic efficacy of treatment include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers. Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine analogs; or MIP-1, MIP-1beta, MCP-1, RANTES, and other chemokines. It is further contemplated that the upregulation of cell surface receptors or their ligands such as Fas/Fas ligand, DR4 or DR5/TRAIL would potentiate the apoptotic inducing abilities of the present invention by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increases in intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with the present invention to improve the anti-hyperproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the present invention to improve the treatment efficacy.

Hormonal therapy may also be used in the present invention or in combination with any other cancer therapy previously described. The use of hormones may be employed in the treatment of certain cancers such as breast, prostate, ovarian, or cervical cancer to lower the level or block the effects of certain hormones such as testosterone or estrogen. This treatment is often used in combination with at least one other cancer therapy as a treatment option or to reduce the risk of metastases.

II. Kits

Certain aspects of the present invention also encompass kits for performing the diagnostic and prognostic methods of the invention. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise any one or more of the following materials: enzymes, reaction tubes, buffers, detergent, primers, probes, antibodies. In a preferred embodiment, these kits allow a practitioner to obtain samples of neoplastic cells in blood, tears, semen, saliva, urine, tissue, serum, stool, sputum, cerebrospinal fluid and supernatant from cell lysate. In another preferred embodiment these kits include the needed apparatus for performing RNA extraction, RT-PCR, and gel electrophoresis. Instructions for performing the assays can also be included in the kits.

In a particular aspect, these kits may comprise a plurality of agents for assessing the differential expression of a plurality of biomarkers, for example, GR and/or ER, wherein the kit is housed in a container. The kits may further comprise instructions for using the kit for assessing expression, means for converting the expression data into expression values and/or means for analyzing the expression values to generate prognosis. The agents in the kit for measuring biomarker expression may comprise a plurality of PCR probes and/or primers for qRT-PCR and/or a plurality of antibody or fragments thereof for assessing expression of

the biomarkers. In another embodiment, the agents in the kit for measuring biomarker expression may comprise an array of polynucleotides complementary to the mRNAs of the biomarkers of the invention. Possible means for converting the expression data into expression values and for analyzing the expression values to generate scores that predict survival or prognosis may be also included.

Kits may comprise a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container may hold a composition which includes a probe that is useful for prognostic or non-prognostic applications, such as described above. The label on the container may indicate that the composition is used for a specific prognostic or non-prognostic application, and may also indicate directions for either in vivo or in vitro use, such as those described above. The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

Example 1

Tumor Biomarker Status

A. Results

The glucocorticoid receptor (GR) is highly expressed in the myoepithelium of the normal human breast and in a subset of both ERalpha-positive and negative human breast cancers. In vitro and in vivo experiments suggest that activation of the GR in ER- pre-malignant breast epithelial and cancer cells triggers cell survival pathways under stress conditions (e.g. chemotherapy) that usually induce apoptosis. The inventors examined the association between NR3C1 gene expression and GR target gene expression in human ER- breast cancers and found that ER- breast cancers with high NR3C1 expression also express GR target genes associated with EMT and anti-apoptotic signaling, and that those ER- patients with high NR3C1 gene expression have a significantly worse outcome than NR3C1-low patients. Interestingly, the high NR3C1 gene expression in the ER+ (ESR1-high) subset of patients suggests a slight better outcome, implying a crosstalk between the ER and the GR that is absent in ER- tumors.

Using a global approach of gene expression studies merged with data from GR ChIP-sequencing in ER- pre-malignant breast cells (MCF10A-Myc), the inventors have identified direct GR target genes are significantly associated with cell survival signaling pathways. Interestingly, a meta-

analysis of the high NR3C1-expressing ER- tumors reveals that many genes identified by ChIP-sequencing/gene expression analysis are indeed differentially expressed in high versus low NR3C1-primary breast cancers. These results suggest that GR expression may be a functional biomarker in ER- breast cancer.

TABLE 1

Clinical studies used for meta-analysis		
GEO ID	# of pts	Reference
GSE9195	77	Loi S, et al
GSE7390	189	Desmedt C, et al
GSE6532	212	Loi S, et al
GSE2603	73	Minn A J, et al
GSE2990	183	Sotiriou C, et al
GSE2034	280	Wang Y X, et al
TOTAL	1206	

TABLE 2

Differentially expressed genes with concordant expression by all three methods (33/44 genes)			
Gene expression after Dex-treatment in MCF10A-Myc	Gene expression in NR3C1 + vs. - tumors	GR-binding within distance to TSS after Dex-treatment in MCF10A-Myc	Genes
Up	Up	10 kb 10-100 kb	DUSP1, SGK1, SMARCA2, PTGDS, MCL1, DPYSL2, STOM, LAPTM5, NNMT, SERPINF1, NRIP1, WIPF1, BIN1, IL1R1, ST3GAL5, SEMA4D, MAP3K5, SMARCA2, DPT, BIRC3, PTGDS, PHF15, MAOA, TFPI, SLC46A3, PIAS1, ACSL5, SESN1, C14orf139, LBH
Down	Down	10 kb 10-100 kb	NONE SFN, SPP1, ERBB2
Overlapping genes with NKI-295 gene signature			DUSP1, DPT, NNMT, SERPINF1, IL1R1, FN1, DPYSL2

B. Materials and Methods

Cell Culture and Glucocorticoid Treatment:

MCF10A-Myc cells were cultured in a 1:1 mixture of DMEM and Hams/F12 medium supplemented with 10% fetal bovine serum, hydrocortisone (0.5 µg/ml), EGF (10 ng/ml), insulin (5 ng/ml) and 100 U/ml penicillin/streptomycin were also added. The cells were then starved for three days of all growth factors and treated with dexamethasone (10-6M) and ethanol of the same volume as a control.

Microarray Gene Expression: MCF10A-Myc Cells:

Time course (0.5 h, 2 h, 4 h and 24 h) microarray data were obtained using Affymetrix gene arrays (HG-U133A) (Wu et al., 2006). Genes that were induced or repressed ≥ 1.5 fold-change were considered to be regulated.

GR ChIP-Seq Experiment and Analysis for MCF10A-Myc Cells:

Cells were collected for the ChIP assay following 1 hour of Dex (10-6M) or EtOH treatment. The ChIP assay was done basically following Millipore's ChIP Assay Kit instructions. The DNA input (1%) was also sequenced using Illumina's Solexa Sequencer. Short-tag reads (36 bp) were mapped to the Human Genome (UCSC, hg18) by using Maq aligner. GR-binding peaks were called by using MACS software. Known SGK1 and GILZ promoter GR binding-regions (GBRs) were used as positive controls to determine the FDR threshold for retrieving significant GBRs.

Human Primary Breast Cancer Analysis:

1) Data Collection: All the clinical data and raw CEL files (all Affymetrix HU-133A and HU-133+2) were obtained from GEO (see Table 1). Low quality arrays were removed by AffyPLM. Arrays were normalized by using RMA and then centered by mean within each study and pooled together. 2) Determination of ESR1 and NR3C1 positivity: Expression data of tumors with known ER IHC status were analyzed using ROC analysis. The Youden Index of the best ESR1 probe's ROC curve was used as the cut-off point to separate ESR1+ and ESR1- tumors. Due to the lack of tumors with both GR IHC and NR3C1 gene expression information, we were unable to use ROC analysis to determine the NR3C1 cutoff. Therefore, based on published and our unpublished GR IHC data, we used the percentiles of NR3C1 gene expression levels that correspond to the observed proportion of GR+ patients. 3) Clustering: Un-supervised clustering was performed by Cluster using Pearson correlation distance and complete-linkage method.

Heat-maps were plotted by Treeview. 4) Statistical analysis: Relapse-free survival (RFS) Kaplan-Meier plot and log-rank test were done by using R's "survival" package. Microarray SAM analysis was performed by using R's "siggenes" package.

Tumor Assessment.

pAUC areas were calculated for all the probes on the chip by setting $p=0.2$ (meaning can separate at least 80% patients) for tumors with known ER status ($n=1000$). A probe was then selected that has biggest pAUC area, which is the ESR1 probe 205225_at. So, this probe is the best one that can separate ER IHC + versus -. Using the 205225_at probe, the Youden Index of its ROC curve was calculated, that is the max (sensitivity+specificity-1) as the cut-off value for ESR1+ and -. The range of ESR1 expression after normalization was $[-5.223868-3.944120]$. The Youden Index, i.e. the cut-off is -1.257434 . In the $n=1000$, training set, $n=773 > -1.257434$ (ESR1+), and $n=227 \leq -1.257434$ (ESR1-) or i.e. 77.3% quantile.

This cut-off was applied to the entire dataset, $n=898$ (ESR+), $n=308$ (ESR-). In addition to the method, the ACTUAL Log 2 value cutoff is needed for ESR1 positivity in normalized meta-dataset, as well as the range of ESR1 values encountered following batched mean normalization. If in one study, samples are obtained from different hospitals, they were normalized separately. So, to be precisely accurate, the normalization is done within the samples from the same source.

35

The ESR1 probe ID from Affymetrix is 205225_at.
 The NR3C1 probe ID from Affymetrix is 216321_s_at
 The range for NR3C1 probe (216321_s_at) is [-3.145456 to 2.158716] for the entire data set. For ESR1+, the range is [-3.009359 2.158716] and for ESR1-, the range is [-3.145456 1.917823] Thus, the cut-off for ESR1+, is 0.172189, 55.98% quantile (or about 44% NR3C1+ percentage) and the cut-off for ESR1-, is 0.47332, 82.51% quantile (or about 17.5% NR3C1+ percentage). All the cut-off are log 2 values.

The cutoffs used are the best cut-off that can separate patients with a $p < 0.01$. If the p-value is loosened to 0.05, the range can be widened.

For ESR1+ patients, NR3C1+ patients can be from about 35% to 60% (about 44% is the best). For ESR1- patients, NR3C1+ patients can be from about 30% to 15% (about 17.5% is the best)

Example 2

Mifepristone Pretreatment Enhances Paclitaxel Anti-Tumor Effectiveness in Models of Human Breast Cancer

Xenografted ER-/PR-/HER2- (GR+) MDA-MB-231 human breast cancer cells (1×10^7 cells in 50 μ l of PBS) were injected into the mammary fat pad of female Severe Combined Immunodeficient Mice (SCID) mice and allowed to grow until reaching approximately 100 mm³. Mice were then injected intraperitoneally with either both vehicles,

36

paclitaxel (10 mg/kg)+the mifepristone vehicle, or the combination of mifepristone (15 mg/kg) administered two hours prior to paclitaxel (10 mg/kg) for five successive days. The longest (L) and shortest (S) diameters of the tumors were measured bi-weekly with electronic calipers and tumor volume was calculated using the formula for an ellipsoid sphere: volume= $S^2 \times L \times 0.52$. Mifepristone pretreatment significantly decreased tumor volume over time ($P=0.013$) compared to treatment with paclitaxel alone (FIG. 8).

Example 3

Mifepristone Pretreatment Increases Tamoxifen-Resistant MCF-7 (T-R-MCF-7), but not Parental MCF-7 Cell Susceptibility to Paclitaxel In Vitro

Parental MCF-7 (ER+/PR+/GR+) and T-R MCF-7 (ER+/PR+/GR+) cells were treated with the appropriate vehicle (ethanol for mifepristone and castor oil/saline for paclitaxel), paclitaxel alone (10^{-6} M), and paclitaxel/mifepristone (10^{-6} M). Apoptosis was measured using FITC conjugated-anti-Annexin V antibody labeling followed FACS analysis to determine the percentage of the total cell population undergoing apoptosis after 20 hours of treatment. Mean $\pm$ SE is shown. Significantly more apoptosis ($P=0.028$) was observed in the T-R MCF-7 cells when treated with mifepristone/paclitaxel compared to paclitaxel alone (FIG. 9). No difference was seen in the parental MCF-7 cells.

Sequence Listing

NR3C1 GenBank AY436590-127687 bp, incorporated herein by reference
 ESR1 GenBank NG_008493-419779 bp, incorporated herein by reference

NR3C1 mRNA

SEQ ID NO: 1

TTTTTAGAAAAAAAAATATATTTCCCTCCTGCTCCTTCTGCGTTCACAAGCTAAGTTGTTATCTCGGC
 TGC GCGGGAAGTTCGCGAGCGTGGCGGCGAGCGGCTCCTCTGCCAGAGTTGATATTTCACTGATGGACTC
 CAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCAGCAGTGTGCTTGCTCAGGAGAGGGGAGATGTG
 ATGGACTTCTATAAAACCTAAGAGGAGGAGCTACTGTGAAGGTTTCTGCGTCTTCAACCTCACTGGCTG
 TCGCTTCTCAATCAGACTCCAAGCAGCGAAGACTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGC
 GCAGCAGCCAGATCTGTCCAAAGCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAA
 GTGATGGGAAATGACCTGGGATTCCACAGCAGGGCCAAATCAGCCTTCTCCTCGGGGAAACAGACTTAA
 AGCTTTTGGAAGAAAGCATTGCAACCTCAATAGTTCGACCAAGTGTTCAGAGAACCCCAAGAGTTCAGC
 ATCCACTGCTGTGCTGCTGCCCCACAGAGAAGGAGTTTCCAAAACCTCACTCTGATGTATCTTCAGAA
 CAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAATGTGAAATTGTATACCAGACCAAAGCA
 CCTTTGACATTTTGCAAGATTTGGAGTTTCTTCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTG
 GAGATCAGACCTGTTGATAGATGAAAACCTGTTGCTTCTCCTCTGGCGGAGAGACGATTCATTCCTT
 TTGGAAGGAACTCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATA
 ATGGAGATCTGGTTTGTCAAGCCCCAGTAATGTAACACTGCCCAAGTAAACAGAAAAGAAGATTT
 CATCGAAGTCTGCACCCCTGGGGTAATTAAGCAAGAGAACTGGGCACAGTTTACTGTCAAGGCAAGCTTT
 CCTGGAGCAATATAATTGGTAATAAAATGTCTGCCATTTCTGTTTCATGGTGTGAGTACCTCTGGAGGAC
 AGATGTACCACTATGACATGAATACAGCATCCCTTCTCAACAGCAGGATCAGAAGCCTATTTTAAATGT
 CATTCCACCAATTCCTGTTGGTTCGGAATTTGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACT

Sequence Listing

TCTCTGGGGACTCTGAACTTCCTGGTCGAACAGTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGAC
CAGATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACACAGGACCACCTCCCAAACCTGCCTGGT
GTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACCTGTGGAAGCTGTAAAGTTTCTTCAA
AGAGCAGTGGAAGGACAGCACAAATTACCTATGTGCTGGAAGGAATGATTGCATCATCGATAAAATTCGAA
GAAAAAACTGCCAGCATGCCGCTATCGAAAATGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAAC
AAAGAAAAAATAAAGGAATTCAGCAGGCCACTACAGGAGTCTCACAGAAACCTCTGAAAATCCTGGT
AACAAAACAATAGTTTCCTGCAACGTTACCACAACACACCCCTACCCCTGGTGTCACTGTTGGAGGTTATTG
AACCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATGACTACGCT
CAACATGTTAGGAGGGCGCAAGTATTGCAGCAGTGAAATGGGCAAAGGCAATACCAGGTTTCAGGAAC
TTACACCTGGATGACCAATGACCCCTACTGCAGTACTCCTGGATGTTTCTTATGGCATTGTCTCTGGGGT
GGAGATCATATAGACAATCAAGTGCAAACCTGCTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAG
AATGACTCTACCCCTGCATGTACGACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTT
CAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTTCAGTTCCTAAGGACGGTC
TGAAGAGCCAAGAGCTATTGTATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAA
GAGGGAAGGAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAACCTCTTGATTCTATGCAT
GAAGTGGTTGAAAATCTCCTTAACATATTGCTTCCAAACATTTTGGATAAGACCATGAGTATTGAATTCC
CCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAATATTCAAATGGAATATCAAAAACTTCT
GTTTCATCAAAAGTGACTGCCTTAATAAGAATGGTTGCCTTAAAGAAAGTCGAATTAATAGCTTTTATTG
TATAAACTATCAGTTTGTCTGTAGAGGTTTTGTTGTTTTATTTTTATGTTTTCATCTGTTGTTTTGT
TTTAAATACGCACTACATGTGGTTTTATAGAGGGCCAAGACTTGGCAACAGAAGCAGTTGAGTCGCATCA
CTTTTCAGTGATGGGAGAGTAGATGGTGAAATTTATTAGTTAATATATCCCAGAAATTAGAAACCTTAAT
ATGTGGACGTAATCTCCACAGTCAAAGAAGGATGGCACCTAAACCACAGTGCCCAAAGTCTGTGTGATG
AACTTTCTCTTCATACTTTTTTTCACAGTTGGCTGGATGAAATTTCTAGACTTTCTGTTGGTGTATCCC
CCCCCTGTATAGTTAGGATAGCATTTTGTATTATGCATGGAAACCTGAAAAAAGTTTACAAGTGTAT
ATCAGAAAAGGGAAGTTGTGCTTTTATAGCTATTACTGTCTGGTTTTAACAAATTCCTTTATATTTAGT
GAACTACGCTTGCTCATTTTTTCTTACATAATTTTTTATTCAAGTTATTGTACAGCTGTTTAAGATGGGC
AGCTAGTTCGTAGCTTTCCCAAATAAATCTAAACATTAATCAATCATCTGTGTGAAAATGGGTTGGTGC
TTCTAACCTGATGGCACTTAGCTATCAGAAGACCACAAAATTGACTCAAATCTCCAGTATTCTGTCAA
AAAAAAGGCTCATATTTTGTATATATCTGCTTCAGTGGAGAATTATATAGGTTGTGCAAT
TAACAGTCCTAACTGGTATAGACACCTAGTCCAGTGACCTGCTGGGTAACTGTGGATGATGGTTGCAA
AAGACTAATTTAAAAAATAACTACCAAGAGGCCCTGTCTGTACCTAACGCCCTATTTTGTCAATGGCTAT
ATGGCAAGAAAGCTGGTAACTATTGTCTTTTTCAGGACCTTTTGAAGTAGTTTGTATAAATCTTAAAAAG
TTGTGATTCAGATAACCAGCTGTAAACAGCTGAGAGACTTTTAAATCAGACAAAGTAATTCCTCTCACT
AACTTTTACCCAAAACTAAATCTCTAATATGGCAAAATGGCTAGACACCATTTTCACATTCCCATCT
GTCACCAATTGGTTAATCTTTCTGATGGTACAGGAAAGCTCAGCTACTGATTTTGTGATTAGAACTG
TATGTATGTCAGACATCCATGTTTGTAAACTACACATCCCTAATGTGTGCCATAGAGTTTAACACAAGT
CCTGTGAATTTCTTCACTGTTGAAAATTATTTTAAACAAAATAGAAGCTGTAGTAGCCCTTTCTGTGTGC
ACCTTACCAACTTTCTGTAACTCAAACTTAACATATTTACTAAGCCACAAGAAATTTGATTTCTATTCT
AAGGTGGCCAAATATTGTGTAATAGAAAAGTGAATCTAATATTTAAATATGGAACCTCTAATATA

-continued

Sequence Listing

TTTTTATATTTAGTTATAGTTTCAGATATATATCATATTGGTATTCACTAATCTGGGAAGGGAAGGGCTA
 CTGCAGCTTTACATGCAATTTATTAAGATGATTGTAAATAGCTTGTATAGTGTAATAAAGAAATGATT
 TTAGATGAGATTGTTTTATCATGACATGTTATATATTTTTTTGTAGGGGTCAAAGAAATGCTGATGGATAA
 CCTATATGATTTATAGTTTGTACATGCATTCATACAGGCAGCGATGGTCTCAGAAACCAAACAGTTTGCT
 CTAGGGGAAGAGGGAGATGGAGACTGGTCCTGTGTGCAGTGAAGGTTGCTGAGGCTCTGACCCAGTGAGA
 TTACAGAGGAAGTTATCCTCTGCCTCCCATTCCTGACCACCCTTCTCATTCCAACAGTGAGTCTGTGAGCG
 CAGGTTTAGTTTACTCAATCTCCCTTGCACTAAAGTATGTAAAGTATGTAAACAGGAGACAGGAAGGTG
 GTGCTTACATCCTTAAAGGCACCATCTAATAGCGGGTTACTTTACATACAGCCCTCCCCAGCAGTTGA
 ATGACAACAGAAGCTTCAGAAGTTTGGCAATAGTTTGCATAGAGGTACCAGCAATATGTAATAGTGCAG
 AATCTCATAGGTTGCCAATAATACACTAATTCCTTTCTATCCTACAACAAGAGTTTATTTCCAAATAAAA
 TGAGGACATGTTTTGTTTTCTTTGAATGCTTTTGAATGTTATTGTTATTTTTCAGTATTTTGGAGAAA
 TTATTTAATAAAAAAAACAATCATTGCTTTTTG

ESR1 Mrna (partial)

SEQ ID NO: 2

AGGAGCTGGC GGAGGGCGTT CGTCCTGGGA CTGCACTTGC TCCCGTCGGG TCGCCCGGCT
 TCACCGGACC CGCAGGCTCC CGGGGCAGGG CCGGGGCCAG AGCTCGCGTG TCGGCGGGAC
 ATGCGCTGCG TCGCCTCTAA CCTCGGCTG TGCTCTTTTT CCAGGTGGCC CGCCGGTTTC
 TGAGCCTTCT GCCCTGCGGG GACACGGTCT GCACCCTGCC CGCGGCCACG GACCATGACC
 ATGACCCCTCC ACACCAAAGC ATCTGGGATG GCCCTACTGC ATCAGATCCA AGGGAACGAG
 CTGGAGCCCC TGAACCGTCC GCAGCTCAAG ATCCCCCTGG AGCGGCCCTT GGGCGAGGTG
 TACCTGGACA GCAGCAAGCC CGCCGTGTAC AACTACCCCG AGGGCGCCGC CTACGAGTTC
 AACGCCGCGG CCGCCGCCAA CGCGCAGGTC TACGGTCAGA CCGGCCTCCC CTACGGCCCC
 GGGTCTGAGG CTGCGGCGTT CGGCTCCAAC GGCTTGGGGG GTTTCCCCC ACTCAACAGC
 GTGTCTCCGA GCCCGCTGAT GCTACTGCAC CCGCCGCCGC AGCTGTGCGC TTTCTGCGAG
 CCCCACGGCC AGCAGGTGCC CTACTACCTG GAGAACGAGC CCAGCGGCTA CACGGTGCGC
 GAGGCCGGCC CGCCGGCATT CTACAGGCCA AATTCAGATA ATCGACGCCA GGGTGGCAGA
 GAAAGATTGG CCAGTACCAA TGACAAGGGA AGTATGGCTA TGGAATCTGC CAAGGAGACT
 CGCTACTGTG CAGTGTGCAA TGACTATGCT TCAGGCTACC ATTATGGAGT CTGGTCTGT
 GAGGGCTGCA AGGCCTTCTT CAAGAGAAGT ATTCAAGGAC ATAACGACTA TATGTGTCCA
 GCCACCAACC AGTGACCCAT TGATAAAAAC AGGAGGAAGA GCTGCCAGGC CTGCCGGCTC
 CGCAAATGCT ACGAAGTGGG AATGATGAAA GGTGGGATAC GAAAAGACCG AAGAGGAGGG
 AGAATGTTGA AACACAAGCG CCAGAGAGAT GATGGGGAGG GCAGGGGTGA AGTGGGGTCT
 GCTGGAGACA TGAGAGCTGC CAACCTTTGG CCAAGCCCGC TCATGATCAA ACGCTCTAAG
 AAGAACAGCC TGGCCTTGTC CCTGACGGCC GACCAGATGG TCAGTGCCTT GTTGATGCT
 GAGCCCCCA TACTCTATTC CGAGTATGAT CCTACCAGAC CTTTCAGTGA AGCTTCGATG
 ATGGGCTTAC TGACCAACCT GGCAGACAGG GAGCTGGTTC ACATGATCAA CTGGGCGAAG
 AGGGTGCCAG GCTTTGTGGA TTTGACCTC CATGATCAGG TCCACCTTCT AGAATGTGCC
 TGGCTAGAGA TCCTGATGAT TGGTCTCGTC TGGCGCTCCA TGAGCACCC AGGGAAGCTA
 CTGTTTGCTC CTAACCTGCT CTTGGACAGG AACCAGGGAA AATGTGTAGA GGGCATGGTG

-continued

Sequence Listing

GAGATCTTCG ACATGCTGCT GGCTACATCA TCTCGGTTCC GCATGATGAA TCTGCAGGGA
 GAGGAGTTTG TGTGCCTCAA ATCTATTATT TTGCTTAATT CTGGAGTGTA CACATTTCTG
 TCCAGCACCC TGAAGTCTCT GGAAGAGAAG GACCATATCC ACCGAGTCCT GGACAAGATC
 ACAGACACTT TGATCCACCT GATGGCCAAG GCAGGCCTGA CCCTGCAGCA GCAGCACCAG
 CGGCTGGCCC AGTCCTCTCT CATCCTCTCC CACATCAGGC ACATGAGTAA CAAAGGCATG
 GAGCATCTGT ACAGCATGAA GTGCAAGAAC GTGGTGCCCC TCTATGACCT GCTGCTGGAG
 ATGCTGGACG CCCACCGCCT ACATGCGCCC ACTAGCCGTG GAGGGGCATC CGTGGAGGAG
 ACGGACCAAA GCCACTTGGC CACTGCGGGC TCTACTTCAT CGCATTCCCT GCAAAAGTAT
 TACATCACGG GGGAGGCAGA GGGTTTCCCT GCCACGGTCT GAGAGCTCCC TGGCTCCCAC
 ACGGTTCCAGA TAATCCCTGC TGCATTTTAC CCTCATCATG CACCACTTTA GCCAAATTCT
 GTCTCTTGCA TACACTCCGG CATGCATCCA ACACCAATGG CTTTCTAGAT GAGTGGCCAT
 TCATTTGCTT GCTCAGTTCT TAGTGGCACA TCTTCTGTCT TCTGTTGGGA ACAGCCAAAG
 GGATTCCAAG GCTAAATCTT TGTAACAGCT CTCTTTCCCC CTTGCTATGT TACTAAGCGT
 GAGGATTCCC GTAGCTCTTC ACAGCTGAAC TCAGTCTATG GGTGGGGCT CAGATAACTC
 TGTGCATTTA AGCTACTTGT AGAGACCCAG GCCTGGAGAG TAGACATTTT GCCTCTGATA
 AGCACTTTTT AAATGGCTCT AAGAATAAGC CACAGCAAAG AATTAAAGT GGCTCCTTTA
 ATTGGTGACT TGGAGAAAGC TAGGTCAAGG GTTTATTATA GCACCTCTT GTATTCTAT
 GGCAATGCAT CCTTTTATGA AAGTGGTACA CCTTAAAGCT TTTATATGAC TGTAGCAGAG
 TATCTGGTGA TTGTCAATTC ATTCCCCTA TAGGAATACA AGGGGCACAC AGGGAAGGCA
 GATCCCCTAG TTGGCAAGAC TATTTTAACT TGATACTG CAGATTGAGA TGTGCTGAAA
 GCTCTGCCTC TGGCTTTCCG GTCATGGGTT CCAGTTAATT CATGCCTCCC ATGGACCTAT
 GGAGAGCAGC AAGTTGATCT TAGTTAAGTC TCCCCTATATG AGGGATAAGT TCCTGATTTT
 TGTTTTTATT TTTGTGTTAC AAAAGAAAGC CCTCCCTCCC TGAACCTGCA GTAAGGTCAG
 CTTCAGGACC TGTTCAGTG GGCACGTAC TTGGATCTTC CCGCGTGTG TGTGCCTTAC
 ACAGGGGTGA ACTGTTCACT GTGGTGATGC ATGATGAGGG TAAATGGTAG TTGAAAGGAG
 CAGGGGCCCT GGTGTTGCAT TTAGCCCTGG GGCATGGAGC TGAACAGTAC TTGTGCAGGA
 TTGTTGTGGC TACTAGAGAA CAAGAGGGAA AGTAGGGCAG AACTGGATA CAGTTCTGAG
 GCACAGCCAG ACTTGCTCAG GGTGGCCCTG CCACAGGCTG CAGCTACCTA GGAACATTCC
 TTGCAGACCC CGCATTGCCC TTTGGGGGTG CCCTGGGATC CCTGGGGTAG TCCAGCTCTT
 CTTCATTTCC CAGCGTGCC CTGGTTGGAA GAAGCAGCTG TCACAGCTGC TGTAGACAGC
 TGTGTTCCCTA CAATTGGCCC AGCACCCCTG GGCACGGGAG AAGGGTGGGG ACCGTTGCTG
 TCACTACTCA GGCTGACTGG GGCCTGGTCA GATTACGTAT GCCCTTGGTG GTTTAGAGAT
 AATCCAAAT CAGGGTTTGG TTTGGGAAG AAAATCCTCC CCCTTCCTCC CCCGCCCCGT
 TCCCTACCGC CTCCACTCCT GCCAGCTCAT TTCCTTCAAT TTCCTTTGAC CTATAGGCTA
 AAAAAAGAAAG GCTCATTCCA GCCACAGGCG AGCCTTCCTT GGGCCTTTGC TTCTCTAGCA
 CAATTATGGG TTACTTCCTT TTTCTTAACA AAAAGAATG TTTGATTTC TCTGGGTGAC
 CTTATTGTCT GTAATTGAAA CCCTATTGAG AGGTGATGTC TGTGTTAGCC AATGACCCAG
 GTGAGCTGCT CGGGCTTCTC TTGGTATGTC TTGTTGGAA AAGTGGATTT CATTCAATTC
 TGATTGTCCA GTTAAGTGAT CACCAAGGA CTGAGAATCT GGGAGGGCAA AAAAAAAAAA

-continued

Sequence Listing

AAAGTTTTTA TGTGCACTTA AATTTGGGGA CAATTTTATG TATCTGTGTT AAGGATATGT
 TTAAGAACAT AATTCTTTTG TTGCTGTTG TTAAAGAAGC ACCTTAGTTT GTTAAAGAAG
 CACCTTATAT AGTATAATAT ATATTTTTTT GAAATTACAT TGCTTGTTTA TCAGACAATT
 GAATGTAGTA ATTCTGTCTT GGATTTAATT TGA CTGGGTT AACATGCAA AACCAAGGAA
 AAATATTTAG TTTTTTTTTT TTTTTTTGTA TACTTTTCAA GCTACCTGT CATGTATACA
 GTCATTTATG CCTAAAGCCT GGTGATTATT CATTAAATG AAGATCACAT TTCATATCAA
 CTTTGTATC CACAGTAGAC AAAATAGCAC TAATCCAGAT GCCTATTGTT GGATACTGAA
 TGACAGACAA TCTTATGTAG CAAAGATTAT GCCTGAAAAG GAAAATTATT CAGGGCAGCT
 AATTTTGCTT TTACCAAAT ATCAGTAGTA ATATTTTTTG ACAGTAGCTA ATGGGTCAGT
 GGGTCTTTT TAATGTTTAT ACTTAGATTT TCTTTTAAA AAATTAAAT AAAACAAAA
 AAAATTTCTA GGACTAGACG ATGTAATACC AGCTAAAGCC AAACAATTAT ACAGTGAAG
 GTTTTACATT ATTCATCCAA TGTGTTTCTA TTCATGTTAA GATACTACTA CATTTGAAGT
 GGGCAGAGAA CATCAGATGA TTGAAATGTT CGCCCAGGGG TCTCCAGCAA CTTTGAAAT
 CTCTTTGTAT TTTTACTTGA AGTGCCACTA ATGGACAGCA GATATTTTCT GGCTGATGTT
 GGTATTGGGT GTAGGAACAT GATTTAAAA AAAACTCTTG CCTCTGCTTT CCCCCACTCT
 GAGGCAAGTT AAAATGTAAA AGATGTGATT TATCTGGGG GCTCAGGTAT GGTGGGAAG
 TGATTTCAGG AATCTGGGA ATGGCAAATA TATTAAGAAG AGTATTGAAA GTATTTGGAG
 GAAAATGGTT AATCTGGGT GTGCACCAGG GTTCAGTAGA GTCCACTTCT GCCCTGGAGA
 CCACAAATCA ACTAGCTCCA TTTACAGCCA TTTCTAAAT GGCAGCTTCA GTTCTAGAGA
 AGAAAGAACA ACATCAGCAG TAAAGTCCAT GGAATAGCTA GTGGTCTGTG TTTCTTTTCG
 CCATTGCCTA GCTTGCCGTA ATGATTCTAT AATGCCATCA TGCAGCAATT ATGAGAGGCT
 AGGTCATCCA AAGAGAAGAC CCTATCAATG TAGGTTGCAA AATCTAACC CTAAGGAAGT
 GCAGTCTTTG ATTTGATTTC CTTAGTAACC TTGCAGATAT GTTTAACCA GCCATAGCCC
 ATGCCTTTTG AGGGCTGAAC AATAAGGGA CTTACTGATA ATTTACTTTT GATCACATTA
 AGGTGTTCTC ACCTTGAAAT CTTATACACT GAAATGGCCA TTGATTTAGG CCACTGGCTT
 AGAGTACTCC TTCCCTGCA TGACACTGAT TACAAATACT TTCCTATTCA TACTTTCCAA
 TTATGAGATG GACTGTGGGT ACTGGGAGTG ATCACTAACA CCATAGTAAT GTCTAATATT
 CACAGGCAGA TCTGCTTGGG GAAGCTAGTT ATGTGAAAGG CAAATAGAGT CATACAGTAG
 CTCAAAAGGC AACCATAATT CTCTTTGGTG CAGGTCTTGG GAGCGTGATC TAGATTACAC
 TGCACCATT CCAAGTTAAT CCCCTGAAAA CTTACTCTCA ACTGGAGCAA ATGAACCTTG
 GTCCCAAATA TCCATCTTTT CAGTAGCGTT AATTATGCTC TGTTTCCAAC TGCATTTCCT
 TTCCAATTGA ATTAAGTGT GGCCTCGTTT TTAGTCATT AAAATTGTTT TCTAAGTAAT
 TGCTGCCTCT ATTATGGCAC TTCAATTTTG CACTGTCTTT TGAGATTCAA GAAAAATTC
 TATTCTTTTT TTGTCATCCA ATTGTGCTG AACTTTTAAA ATATGTAAAT GCTGCCATGT
 TCCAAACCCA TCGTCAGTGT GTGTGTTTAG AGCTGTGCAC CCTAGAAACA ACATATTGTC
 CCATGAGCAG GTGCTGAGA CACAGACCCC TTTGCATTCA CAGAGAGGTC ATTGGTTATA
 GAGACTTGAA TTAATAAGTG ACATTATGCC AGTTTCTGTT CTCTCACAGG TGATAACAA
 TGCTTTTTGT GCACTACATA CTCTTCAGTG TAGAGCTCTT GTTTTATGGG AAAAGGCTCA

Sequence Listing

AATGCCAAAT TGTGTTTGAT GGATTAATAT GCCCTTTTGC CGATGCATAC TATTACTGAT

GTGACTCGGT TTTGTCGCAG CTTTGCTTTG TTTAATGAAA CACACTTGTA AACCTCTTTT

GCACCTTGAA AAAGAATCCA GCGGGATGCT CGAGCACCTG TAAACAATTT TCTCAACCTA

SEQ ID NO: 3-46

MCL1, SAP30, DUSP1, SGK1, SMARCA2, PTGDS, TNFRSF9, SFN, LAPTMS, GPSM2, SORT1, DPT, NR1P1, ACSL5, BIRC3, NNMT, IGFBP6, PLXNC1, SLC46A3, C14orf139, PIAS1, IDH2, SERPINF1, ERBB2, PECAM1, LBH, ST3GAL5, IL1R1, BIN1, WIPF1, TFPI, FN1, FAM134A, NR1P1, RAC2, SPP1, PHF15, BTN3A2, SESN1, MAP3K5, DPYSL2, SEMA4D, STOM, and MAOA gene.

SEQ ID NO: 47

GR alpha.

SEQ ID NO: 48

GR beta.

SEQ ID NO: 49

NRR3C1 mRNA (complete)

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Pat. No. 5,143,854

U.S. Pat. No. 5,202,231

U.S. Pat. No. 5,242,974

U.S. Pat. No. 5,288,644

U.S. Pat. No. 5,324,633

U.S. Pat. No. 5,384,261

U.S. Pat. No. 5,405,783

U.S. Pat. No. 5,412,087

U.S. Pat. No. 5,424,186

U.S. Pat. No. 5,429,807

U.S. Pat. No. 5,432,049

U.S. Pat. No. 5,436,327

U.S. Pat. No. 5,445,934

U.S. Pat. No. 5,468,613

U.S. Pat. No. 5,470,710

U.S. Pat. No. 5,472,672

U.S. Pat. No. 5,492,806

U.S. Pat. No. 5,503,980

U.S. Pat. No. 5,510,270

U.S. Pat. No. 5,525,464

U.S. Pat. No. 5,525,464

U.S. Pat. No. 5,527,681

U.S. Pat. No. 5,529,756

U.S. Pat. No. 5,532,128

U.S. Pat. No. 5,545,531

U.S. Pat. No. 5,547,839

U.S. Pat. No. 5,554,501

U.S. Pat. No. 5,556,752

U.S. Pat. No. 5,561,071

U.S. Pat. No. 5,571,639

U.S. Pat. No. 5,580,726

U.S. Pat. No. 5,580,732

U.S. Pat. No. 5,593,839

U.S. Pat. No. 5,599,672

U.S. Pat. No. 5,599,695

U.S. Pat. No. 5,610,287

25 U.S. Pat. No. 5,624,711

U.S. Pat. No. 5,631,134

U.S. Pat. No. 5,639,603

U.S. Pat. No. 5,654,413

30 U.S. Pat. No. 5,658,734

U.S. Pat. No. 5,661,028

U.S. Pat. No. 5,665,547

U.S. Pat. No. 5,667,972

U.S. Pat. No. 5,695,940

35 U.S. Pat. No. 5,700,637

U.S. Pat. No. 5,744,305

U.S. Pat. No. 5,800,992

U.S. Pat. No. 5,807,522

U.S. Pat. No. 5,830,645

40 U.S. Pat. No. 5,837,196

U.S. Pat. No. 5,847,219

U.S. Pat. No. 5,871,928

U.S. Pat. No. 5,876,932

U.S. Pat. No. 5,919,626

45 U.S. Pat. No. 6,004,755

U.S. Pat. No. 6,087,102

U.S. Pat. No. 6,368,799

U.S. Pat. No. 6,383,749

U.S. Pat. No. 6,617,112

50 U.S. Pat. No. 6,638,717

U.S. Pat. No. 6,720,138

U.S. Patent Publn. 2010/0135956

Belanoff et al., *Eur. J. Pharmacol.*, 655(1-3):117-20, 2011.

Cho et al. *Biochemistry*, 44(9):3547-61, 2005.

55 Clark, *Curr. Top. Med. Chem.* 8(9):813-838, 2008.

Colleoni et al., *Annals of Oncology*, 11(8):1057, 2000.

European Appln. EP 373 203

European Appln. EP 785 280

European Appln. EP 799 897

60 Evans, *Science*, 240:889, 1988.

Fodor et al., *Science*, 251:767-777, 1991.

Grover and Martin, *Carcinogenesis*, 23(7):1095-102, 2002.

Hacia et al., *Nature Genet.*, 14:441-449, 1996.

Harrison's Principles of Internal Medicine, Kasper et al.

65 (Eds.), 16th Ed., Chapter 70, 2005.

Henderson et al. *Cancer Res.*, 48:246-253, 1988.

Keen and Davidson, *Cancer*, 97(3 Suppl):825-33, 2003.

Ma et al., *J. Immunol.*, 171(2):608-615, 2003.
 MacBeath and Schreiber, *Science*, 289(5485):1760-3, 2000.
 Melhem et al, *Clin. Cancer Res.*, 15(9):3196-204, 2009.
 Mikosz et al., *J. Biol. Chem.*, 276:16649-54, 2001.
 Moran et al., *Cancer Res.*, 60:867-872, 2000.
 Pandey and Mann, *Nature*, 405(6788):837-46, 2000.
 Pang and Conzen, *Cancer Biol. Ther. Cancer Biol. Ther.*,
 5(8):933-40, 2006.
 PCT Appln. WO 01/68255
 PCT Appln. WO 03/020898
 PCT Appln. WO 03/022421
 PCT Appln. WO 03/023058
 PCT Appln. WO 03/029485
 PCT Appln. WO 03/040410
 PCT Appln. WO 03/053586
 PCT Appln. WO 03/066906
 PCT Appln. WO 03/067217
 PCT Appln. WO 03/076928
 PCT Appln. WO 03/087297
 PCT Appln. WO 03/091426
 PCT Appln. WO 03/093810
 PCT Appln. WO 03/100448A1
 PCT Appln. WO 04/020085
 PCT Appln. WO 04/027093
 PCT Appln. WO 09/923256
 PCT Appln. WO 09/936760

PCT Appln. WO 93/17126
 PCT Appln. WO 95/11995
 PCT Appln. WO 95/21265
 PCT Appln. WO 95/21944
 5 PCT Appln. WO 95/35505
 PCT Appln. WO 96/30347
 PCT Appln. WO 96/31622
 PCT Appln. WO 96/33980
 PCT Appln. WO 97/10365
 10 PCT Appln. WO 97/27317
 PCT Appln. WO 97/43450
 PCT Appln. WO 99/35505
 PCT Appln. WO 01/38580
 PCT Appln. WO 03/100012
 15 Pease et al., *Proc. Natl. Acad. Sci. USA*, 91:5022-5026,
 1994.
 Peeters et al., *Ann. NY Acad. Sci.*, 1148:536-41, 2008.
 Pike et al., *Epidemiologic Rev.*, 15(1):17-35, 1993.
 Shoemaker et al., *Nature Genetics*, 14:450-456, 1996.
 20 Sims et al. *BMC Medical Genomics*, 1(42):1-14, 2008.
 Sorlie et al., *Proc. Natl. Acad. Sci. USA*, 98:10869-10874.,
 2001.
 Srinivas et al., *Clin. Chem.*, 48(8):1160-9, 2002.
 UK Appln. 8 803 000
 25 Wu et al., *Cancer Res.*, 64:1757-64, 2004.
 Wu et al., *J. Clin. Invest.*, 114:560-568, 2004.
 Wu et al., *Mol Endocrinol.*, 2006

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 49

<210> SEQ ID NO 1

<211> LENGTH: 4794

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: nuclear receptor subfamily 3, group C, member 1
 (NR3C1), glucocorticoid receptor cDNA

<400> SEQUENCE: 1

```

tttttagaaa aaaaaaatat atttcctcc tgctcctct gcgttcacaa gctaagttgt      60
ttatctcggc tgccggcgga actgcggacg gtggcgggcg agcggctcct ctgccagagt      120
tgatattcac tgatggactc caaagaatca ttaactcctg gtagagaaga aaacccacgc      180
agtgtgcttg ctcaggagag gggagatgtg atggacttct ataaaacct aagaggagga      240
gctactgtga aggtttctgc gtcttcaccc tcaactggctg tcgcttctca atcagactcc      300
aagcagcgaa gacttttggt tgattttcca aaaggctcag taagcaatgc gcagcagcca      360
gatctgtcca aagcagtttc actctcaatg ggactgtata tgggagagac agaaacaaaa      420
gtgatgggaa atgacctggg attcccacag cagggccaaa tcagcctttc ctcgggggaa      480
acagacttaa agcttttgga agaaagcatt gcaaacctca ataggtcgac cagtgttcca      540
gagaacccca agagttcagc atccactgct gtgtctgctg ccccccacaga gaaggagttt      600
ccaaaaactc actctgatgt atcttcagaa cagcaacatt tgaagggcc aactggcacc      660
aacggtggca atgtgaaatt gtataccaca gaccaaagca cctttgacat tttgcaggat      720
ttggagtttt cttctgggtc cccaggtaaa gagacgaatg agagtccttg gagatcagac      780
ctgttgatag atgaaaactg tttgctttct cctctggcgg gagaagacga ttcattcctt      840
ttggaaggaa actcgaatga ggaactgaag cctctcattt taccggacac taaacccaaa      900
attaaggata atggagatct ggttttgtca agcccagta atgtaacact gccccaagtg      960

```

-continued

aaaacagaaa	aagaagat	tttcatcgaactc	tgccaccctg	gggtaattaa	gcaagagaaa	1020								
ctgggcacag	tttactgtca	ggcaagcttt	cctggagcaa	atataattgg	taataaaatg	1080								
tctgccat	tttctcatgg	tgtgagtacc	tctggaggac	agatgtacca	ctatgacatg	1140								
aatacagcat	ccctttctca	acagcaggat	cagaagccta	tttttaatgt	cattccacca	1200								
attcccg	ttgtccgaaa	ttggaatagg	tgccaaggat	ctggagatga	caacttgact	1260								
tctctgggga	ctctgaa	ctctgggtcga	acagttttt	ctaattggcta	ttcaagcccc	1320								
agcatgagac	cagatgtaag	ctctcctcca	tccagctcct	caacagcaac	aacaggacca	1380								
cctcccaaac	tctgcctgg	gtgctctgat	gaagcttcag	gatgtcatta	tggagtctta	1440								
acttg	tggtgaa	gctgtaa	agt	tttcttcaaa	agagcagtgg	aaggacagca	caattaccta	1500						
tg	tgctggaa	ggaatgattg	catcatcgat	aaaattcgaa	gaaaaaactg	cccagcatgc	1560							
cgctatc	gaa	aatgtcttca	ggctggaatg	aacctggaag	ctcgaaaaac	aaagaaaaaa	1620							
ataaaagg	gaa	ttcagcaggc	cactacagga	gtctcacaag	aaacctctga	aaatcctgg	1680							
aacaaaa	caa	tagttcctgc	aacgttacca	caactcacc	ctacctgg	gtcactgtt	1740							
gaggttatt	g	aacctgaagt	gttatatgca	ggatatgata	gctctgttcc	agactcaact	1800							
tggaggat	ca	tgactacgct	caacatg	tgaggggcggc	aagtgattgc	agcagtga	1860							
tgggcaa	agg	caataccagg	tttcaggaa	ttacacctgg	atgaccaa	atgacctactg	1920							
cagtactc	ct	ggatgtttct	tatggcattt	gctctgggg	ggagatcata	tagacaatca	1980							
agtgcaaa	acc	tgctgtgttt	tgctcctgat	ctgattatta	atgagcagag	aatgactcta	2040							
ccctgcat	gt	acgaccaatg	taaacacatg	ctgtatgttt	cctctgagtt	acacaggctt	2100							
cagg	tatctt	atgaagagta	tctctgtatg	aaaaccttac	tgcttctctc	ttcagttcct	2160							
aaggac	gg	gtc	agaagagcca	agagctattt	gatgaaatta	gaatgaccta	catcaaagag	2220						
ctaggaaa	ag	ccattgtcaa	gagggaa	gga	aactccagcc	agaactggca	gcggttttat	2280						
caactgac	aa	aactcctgga	ttctatgcat	gaagtgggtg	aaaatctcct	taactattgc	2340							
ttccaa	acat	ttttggataa	gacctgag	attgaattcc	ccgagatgtt	agctgaaatc	2400							
atcacca	atc	agataccaaa	atattcaaat	ggaaatatca	aaaaacttct	gtttcatcaa	2460							
aagt	gactgc	cttaataaga	atgggtgcct	taaagaaagt	cgaattaata	gcttttattg	2520							
tataaa	ctat	cagtttgtcc	tgtagagg	ttgtgtgttt	attttttatt	gttttcatct	2580							
gtt	gtttt	gt	tttaaatac	g	cactacatgt	ggtttataga	gggccaagac	ttggcaacag	2640					
aagcag	ttga	gtcgtcatca	cttttcag	tg	gggagag	agatgg	tgaa	atttattag	2700					
taatata	tcc	cagaaattag	aaacctta	at	gtggacgt	aatctccaca	gtcaaaga	ag	2760					
gat	ggcacct	aaaccaccag	tgcccaa	agt	ctgtgtgatg	aactttctct	tcatactttt	2820						
tttcacag	tt	ggctggatga	aattttctag	actttctgtt	gggttatccc	ccccctgta	2880							
tag	ttaggat	agcattttt	gtt	atgtatgcat	ggaaacctga	aaaaaagt	ttt	acaagtgtat	2940					
atcagaaa	ag	ggaagtgtg	ccttttatag	ctattactgt	ctggttttaa	caatttcctt	3000							
tata	tttagt	gaactacgct	tgctcatttt	ttcttacata	attttttatt	caagttattg	3060							
tacagct	gtt	taagatgggc	agctagt	tcg	tagctttccc	aaataaactc	taaacattaa	3120						
tcaat	catct	gtgtgaaaat	gggttggtgc	ttctaacctg	atggcactta	gctatcagaa	3180							
gaccacaaaa	attgactcaa	atctccagta	ttcttg	tgcaa	aaaaaaaaa	aaaaaagctc	3240							
atatttt	tgta	tatatctgct	tcag	tg	ggaga	attatata	agg	ttgtgcaaat	taacag	tcct	3300			
aact	gg	tata	gagcac	tag	tccag	tgacc	tgctgg	gttaa	actgtg	gatg	atgg	ttg	caa	3360

-continued

```

aagactaatt taaaaaataa ctaccaagag gccctgtctg tacctaacgc cctatTTTTg 3420
caatggctat atggcaagaa agctggtaaa ctatttTctt ttcaggacct tttgaagtag 3480
tttgTataac ttcttaaaag ttgtgattcc agataaccag ctgtaacaca gctgagagac 3540
ttttaatcag acaaagtaat tcctctcact aaactttacc caaaaactaa atctctaata 3600
tgggaaaaat ggctagacac ccattttcac attcccatct gtcaccaatt ggTtaatctt 3660
tcctgatggT acaggaaagc tcagctactg atttttTgta tttagaactg tatgtatgtc 3720
agacatccat gtttGtaaaa ctacacatcc ctaatgtgtg ccatagagtt taacacaagt 3780
cctgtgaatt tcctcactgt tgaaaattat tttaacaaa atagaagctg tagtagccct 3840
ttctgtgtgc accttaccaa ctttctgtaa actcaaaact taacatattt actaagccac 3900
aagaaatttg atttctattc aaggtggcca aattatttgt gtaatagaaa actgaaaatc 3960
taataTtaaa aatatggaac ttctaataata tttttatatt tagttatagt ttcagatata 4020
tatcatattg gtattcacta atctgggaag ggaagggcta ctgcagcttt acatgcaatt 4080
tattaaaatg attgTaaaat agcttTgata gtgTaaaata agaatgattt ttagatgaga 4140
ttgttttatc atgacatgtt atatatTTTT tgtaggggtc aaagaaatgc tgatggataa 4200
cctatatgat ttatagtTtg tacatgcatt catacaggca gcatgggtct cagaaaccaa 4260
acagtttTgt ctaggggaag agggagatgg agactggTcc tgtgtgcagt gaaggtTgtc 4320
gaggctctga cccagtgaga ttacagagga agttatcctc tgcctcccat tctgaccacc 4380
cttctcatc caacagtgag tctgtcagcg caggtttagt ttactcaatc tccccttgca 4440
ctaaagtatg taaagtatgt aaacaggaga caggaaggTg gtgcttacat ccttaaaggc 4500
accatctaata agcgggttac ttccacatac agccctcccc cagcagttga atgacaacag 4560
aagcttcaga agtttggcaa tagtttgcT agaggTacca gcaatatgta aatagtgcag 4620
aatctcatag gttccaata atacactaat tcctttctat cctacaacaa gagtttattt 4680
ccaaataaaa tgaggacatg tttttgtttt ctttgaatgc tttttgaatg ttatttgTta 4740
ttttcagtat tttggagaaa ttatttaata aaaaaacaa tcatttgctt ttTg 4794

```

<210> SEQ ID NO 2

<211> LENGTH: 6300

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: nuclear receptor subfamily 3, group A, member
1, transcript variant 4 (NR3A1), estrogen receptor
(ESR1, ER, ESR, ESRA, ESTR) cDNA (partial)

<400> SEQUENCE: 2

```

aggagctggc ggagggcggt cgtcctggga ctgcacttgc tcccgTcggg tcgcccggt 60
tcaccggacc cgcaggctcc cggggcaggg ccggggccag agctcgcgtg tcggcgggac 120
atgcgctgcg tcgcctctaa cctcgggctg tgcTcttttt ccaggTggcc cgcgggtttc 180
tgagccttct gccTgcggg gacacggTct gcaacctgcc cgcggccacg gacctgacc 240
atgacctcc acaccaaagc atctgggatg gccctactgc atcagatcca agggaacgag 300
ctggagcccc tgaacctgcc gcagctcaag atccccctgg agcgccccct gggcgaggtg 360
tacctggaca gcagcaagcc cgcctgttac aactaccccg agggcgccgc ctacgagttc 420
aacgcgcggc ccgcgcgcaa cgcgcaggTc tacggTcaga ccggcctccc ctacggcccc 480
gggtctgagg ctgcggcggt cggtccaaac ggcctggggg gtttcccccc actcaacagc 540

```

-continued

gtgtctccga	gcccgtgat	gctactgcac	ccgccgccgc	agctgtcgcc	tttctgcag	600
ccccacggcc	agcaggtgcc	ctactacctg	gagaacgagc	ccagcggcta	cacggtgccg	660
gaggccggcc	cgccggcatt	ctacaggcca	aattcagata	atcgacgcca	gggtggcaga	720
gaaagattgg	ccagtaccaa	tgacaaggga	agtatggcta	tggaatctgc	caaggagact	780
cgctactgtg	cagtgtgcaa	tgactatgct	tcaggctacc	attatggagt	ctggtcctgt	840
gagggtctga	aggccttctt	caagagaagt	attcaaggac	ataacgacta	tatgtgtcca	900
gccaccaacc	agtgcaccat	tgataaaaac	aggaggaaga	gctgccaggc	ctgccggctc	960
cgcaaatgct	acgaagtggg	aatgatgaaa	ggtgggtatac	gaaaagaccg	aagaggaggg	1020
agaatgttga	aacacaagcg	ccagagagat	gatggggagg	gcaggggtga	agtgggtctt	1080
gctggagaca	tgagagtgc	caacctttgg	ccaagccgc	tcgatgata	acgtcttaag	1140
aagaacagcc	tggccttgtc	cctgacggcc	gaccagatgg	tcagtgcctt	gttggatgct	1200
gagcccccca	tactctatct	cgagtatgat	cctaccagac	ccttcagtga	agcttcgatg	1260
atgggcttac	tgaccaacct	ggcagacagg	gagctggttc	acatgatcaa	ctgggcgaag	1320
aggggtgccg	gctttgtgga	tttgacctc	catgatcagg	tccacctctt	agaatgtgcc	1380
tggctagaga	tcctgatgat	tgtctctgtc	tggcgtccca	tggagacccc	agggaagcta	1440
ctgtttgtct	ctaacttgc	cttgacagg	aaccagggaa	aatgtgtaga	gggcattggtg	1500
gagatctctg	acatgctgct	ggctacatca	tctcggttcc	gcagtatgaa	tctgcaggga	1560
gaggagtgtg	tgtgcctcaa	atctattatt	ttgcttaatt	ctggagtgtg	cacatttctg	1620
tccagcacc	tgaagtctct	ggaagagaag	gaccatatcc	accgagtcct	ggacaagatc	1680
acagacactt	tgatccacct	gatggccaag	gcaggcctga	ccctgcagca	gcagcaccag	1740
cggctggccc	agctcctcct	catcctctcc	cacatcaggc	acatgagtaa	caaaggcatg	1800
gagcatctgt	acagcatgaa	gtgcaagaac	gtggtgcccc	tctatgacct	gctgctggag	1860
atgctggacg	cccaccgcct	acatgcgccc	actagccgtg	gaggggcata	cgtggaggag	1920
acggacacaa	gccacttggc	cactgcgggc	tctacttcat	cgcattcctt	gcaaaagtat	1980
tacatcacgg	gggaggcaga	gggtttccct	gccacggtct	gagagctccc	tggtccccc	2040
acggttcaga	taatccctgc	tgcattttac	cctcatcatg	caccacttta	gcaaaattct	2100
gtctcctgca	tacactccgg	catgcatcca	acaccaatgg	ctttctagat	gagtggccat	2160
tcatttgctt	gctcagttct	tagtggcaca	tcttctgtct	tctgttggga	acagccaaag	2220
ggattccaag	gctaatactt	tgtaacagct	ctctttcccc	cttgctatgt	tactaagcgt	2280
gaggattccc	gtagctcttc	acagctgaac	tcagtctatg	ggttgggggt	cagataactc	2340
tgtgcattta	agctacttgt	agagaccag	gcctggagag	tagacatttt	gcctctgata	2400
agcacttttt	aaatggctct	aagaataagc	cacagcaaa	aatttaaagt	ggctccttta	2460
attggtgact	tggagaaagc	taggtcaagg	gtttattata	gcacctctct	gtattcctat	2520
ggcaatgcat	ccttttatga	aagtgtgaca	ccttaaagct	tttatatgac	tgtagcagag	2580
tatctggtga	ttgtcaattc	attcccccta	taggaataca	aggggcacac	agggaaggca	2640
gatccccctag	ttggcaagac	tatttttaact	tgatacactg	cagattcaga	tgtgctgaaa	2700
gctctgcctc	tggctttccg	gtcatgggtt	ccagttaatt	catgcctccc	atggacctat	2760
ggagagcagc	aagttgatct	tagttaagtc	tccttatatg	agggataagt	tcctgatttt	2820
tgtttttatt	tttgtgttac	aaaagaaagc	cctccctccc	tgaacttgca	gtaaggtcag	2880
cttcaggacc	tgttcagtg	ggcactgtac	ttggatcttc	ccggcgtgtg	tgtgccttac	2940

-continued

acaggggtga	actgttcact	gtggtgatgc	atgatgaggg	taaatggtag	ttgaaaggag	3000
caggggccct	ggtgttgcac	ttagccctgg	ggcatggagc	tgaacagtac	ttgtgcagga	3060
ttgttgtggc	tactagagaa	caagagggaa	agtagggcag	aaactggata	cagttctgag	3120
gcacagccag	acttgcctag	ggtggccctg	ccacaggctg	cagctaccta	ggaacattcc	3180
ttgcagaccc	cgcattgccc	tttgggggtg	ccctgggatc	cctggggtag	tccagctctt	3240
cttcatttcc	cagcgtggcc	ctgggttgaa	gaagcagctg	tcacagctgc	tgtagacagc	3300
tgtgttccta	caattggccc	agcaccctgg	ggcacgggag	aaggggtggg	accgttgctg	3360
tcactactca	ggctgactgg	ggcctgggca	gattacgtat	gcccttggtg	gtttagagat	3420
aatccaaat	cagggtttgg	tttggggaag	aaaatcctcc	cccttctctc	cccgccccgt	3480
tcctaccgc	ctccactcct	gccagctcat	ttccttcaat	ttcctttgac	ctataggcta	3540
aaaaagaaag	gctcattcca	gccacagggc	agccttcctc	gggcctttgc	ttctctagca	3600
caattatggg	ttacttccct	tttcttaaca	aaaaagaatg	tttgatttcc	tctgggtgac	3660
cttattgtct	gtaattgaaa	cctatttgag	agggtgatgc	tgtgttagcc	aatgaccag	3720
gtgagctgct	cgggcttctc	ttggtatgct	ttgtttgaa	aagtggattt	cattcatttc	3780
tgattgtcca	gttaagtgat	caccaagga	ctgagaatct	gggagggcaa	aaaaaaaaa	3840
aaagttttta	tgtgcactta	aatttgggga	caattttatg	tatctgtgtt	aaggatatgt	3900
ttaagaacat	aattcttttg	ttgctgtttg	tttaagaagc	accttagttt	gtttaagaag	3960
caccttatat	agtataatat	atattttttt	gaaattacat	tgcttgttta	tcagacaatt	4020
gaatgtagta	attctgttct	ggatttaatt	tgactgggtt	aacatgcaaa	aaccaaggaa	4080
aaataattag	tttttttttt	tttttttgta	tacttttcaa	gctaccttgt	catgtatata	4140
gtcatttatg	cctaagccct	ggtgattatt	cattttaaag	aagatcacat	ttcatatcaa	4200
cttttgtatc	cacagtagac	aaaatagcac	taatccagat	gcctattggt	ggatactgaa	4260
tgacagacaa	tcttatgtag	caaagattat	gcctgaaaag	gaaaattatt	cagggcagct	4320
aattttgctt	ttacccaaat	atcagtagta	atattttttg	acagtagcta	atgggtcagt	4380
gggttctttt	taatgtttat	acttagattt	tcttttaaaa	aaattaaaa	aaaacaaaa	4440
aaaatttcta	ggactagacg	atgtaatacc	agctaaagcc	aaacaattat	acagtgggaag	4500
gtttttacatt	attcatccaa	tgtgtttcta	ttcatgttaa	gatactacta	catttgaaag	4560
gggcagagaa	catcagatga	ttgaaatggt	cgcacagggg	tctccagcaa	ctttggaaat	4620
ctctttgtat	ttttacttga	agtgcacta	atggacagca	gatattttct	ggctgatgtt	4680
ggtattgggt	gtaggaacat	gatttaaaaa	aaaactcttg	cctctgcttt	ccccactct	4740
gaggcaagtt	aaaatgtaaa	agatgtgatt	tatctggggg	gctcaggtat	ggtgggggaag	4800
tggattcagg	aatctgggga	atggcaaata	tattaagaag	agtattgaaa	gtatttgag	4860
gaaaatgggt	aattctgggt	gtgcaccagg	gttcagtaga	gtccacttct	gccctggaga	4920
ccacaaatca	actagctcca	tttacagcca	tttctaaaat	ggcagcttca	gttctagaga	4980
agaaagaaca	acatcagcag	taaagtccat	ggaatagcta	gtggtctgtg	tttcttttcg	5040
ccattgccta	gcttgccgta	atgattctat	aatgccatca	tcagcaatt	atgagaggct	5100
aggatcatcca	aagagaagac	cctatcaatg	taggttgcaa	aatctaacc	ctaagggaag	5160
gcagtccttg	atttgatttc	cctagtaacc	ttgcagatat	gtttaaccaa	gccatagccc	5220
atgccttttg	agggctgaac	aaataaggga	cttactgata	atttactttt	gatcacatta	5280

-continued

```

agggtgttctc accttgaaat cttatacact gaaatggcca ttgatttagg ccactggcct 5340
agagtactcc tccccctgca tgacactgat tacaataact ttccatttca tactttccaa 5400
ttatgagatg gactgtgggt actgggagtg atcactaaca ccatagtaat gtctaataat 5460
cacaggcaga tctgcttggg gaagctagtt atgtgaaagg caaatagagt catacagtag 5520
ctcaaaaggc aaccataatt ctctttgggt caggtcttgg gagcgtgatc tagattacac 5580
tgcaccattc ccaagttaat cccctgaaaa cttactctca actggagcaa atgaactttg 5640
gtcccaaata tccatctttt cagtagcgtt aattatgctc tgtttccaac tgcatttcct 5700
ttccaattga attaaagtgt ggctcgttt ttagtcattt aaaattgttt tctaagtaat 5760
tgctgcctct attatggcac ttcaattttg cactgtcttt tgagattcaa gaaaaatttc 5820
tattcttttt tttgcatcca attgtgctg aacttttaaa atatgtaaat gctgccatgt 5880
tccaaaccca tcgtcagtggt gtgtgttttag agctgtgcac cctagaaaca acatattgtc 5940
ccatgagcag gtgcctgaga cacagacccc ttgcatcca cagagaggtc attggttata 6000
gagacttgaa ttaataagtg acattatgcc agtttctgtt ctctcacagg tgataaaca 6060
tgctttttgt gcactacata ctcttcagtg tagagctctt gttttatggg aaaaggctca 6120
aatgccaaat tgtgtttgat ggattaatat gcccttttgc cgatgcatac tattactgat 6180
gtgactcggg tttgtcgcag ctttgctttg tttaatgaaa cacacttgta aacctctttt 6240
gcactttgaa aaagaatcca gcgggatgct cgagcacctg taaacaattt tctcaaccta 6300

```

<210> SEQ ID NO 3

<211> LENGTH: 4107

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: MCL1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 3

```

gcgcaacccct cgggaagctg cggccctttt ccccttttat gggaatactt tttttaaaaa 60
aaaagagttc gctggcgcca ccccgtagga ctggcgccc taaaaccgtg ataaaggagc 120
tgctcgccac ttctcacttc cgcttccttc cagtaaggag tcggggtctt cccagtttt 180
ctcagccagg cggcgggggc gactggcaat gtttggcctc aaaagaaacg cggtaatcgg 240
actcaacctc tactgtgggg gggccggcct gggggccggc agcggcgggc ccaccgccc 300
gggagggcga cttttggcta cgagaagga ggcctcgcc cggcgagaga tagggggagg 360
ggagggcggc gcggtgatg gcggaagcgc cggcgcaagc ccccggtcca cctcacgcc 420
agactcccg agggctcgcg ggcgcggcc cattggcgcc gaggtcccg acgtcacgc 480
gaccccgcg aggctgcttt tcttcgcgc caccgcgcgc gcggcgccgc ttgaggagat 540
ggaagccccg gccgctgacg ccatcatgtc gccgaagag gagctggacg ggtacgagcc 600
ggagcctctc ggggaagcgc cggtgtcct gccgctgctg gagttggtcg gggaaatctgg 660
taataacacc agtacggacg ggtcactacc ctgcacgccc ccgccagcag aggaggagga 720
ggacgagttg taccggcagt cgctggagat tatctctcgg taccttcggg agcaggccac 780
cggcgccaag gacacaaagc caatgggcag gtctggggcc accagcagga aggcgctgga 840
gaccttacga cgggttgggg atggcgtgca gcgcaaccac gagacggcct tccaaggcat 900
gcttcggaag ctggacatca aaaacgaaga cgatgtgaaa tcgttgtctc gagtgtgat 960
ccatgttttc agcgacggcg taacaaactg gggcaggatt gtgactctca tttcttttgg 1020
tgcttttgtg gctaaacact tgaagacct aaaccaagaa agctgcatcg aaccattagc 1080

```

-continued

agaaagtatc acagacgttc tcgtaaggac aaaacgggac tggctagtta aacaaagagg	1140
ctgggatggg tttgtggagt tcttccatgt agaggaccta gaagggtggca tcaggaatgt	1200
gctgctggct tttgcaggtg ttgctggagt aggagctggg ttggcatatc taataagata	1260
gccttactgt aagtgcataa gttgactttt aaccaaccac caccaccacc aaaaccagtt	1320
tatgcagttg gactccaagc tgtaacttcc tagagttgca ccctagcaac ctagccagaa	1380
aagcaagtgg caagaggatt atggctaaca agaataaata catgggaaga gtgctcccca	1440
ttgattgaag agtcactgtc tgaagaagc aaagttcagt ttcagcaaca aacaaacttt	1500
gtttgggaag ctatggagga ggacttttag atttagtgaa gatggtaggg tggaagact	1560
taatttcctt gttgagaaca ggaagtggc cagtagccag gcaagtcata gaattgatta	1620
ccgcgcgaat tcattaatct actgtagtgt taagagaagc actaagaatg ccagtgcct	1680
gtgtaaaagt tacaagtaat agaactatga ctgtaagcct cagtactgta caagggaagc	1740
ttttcctctc tctaattagc tttcccagta tacttcttag aaagtccaag tggtcaggac	1800
ttttatacct gttatacttt ggcttggtt ccatgattct tactttatta gctagttta	1860
tcaccaataa tacttgacgg aaggctcagt aattagttat gaatatggat atcctcaatt	1920
cttaagacag cttgtaaatg tatttgtaaa aattgtatat atttttacag aaagtctatt	1980
tctttgaaac gaagggaagta tcgaatttac attagttttt ttcataccct tttgaacttt	2040
gcaacttccg taattaggaa cctgtttctt acagcttttc tatgctaaac tttgttctgt	2100
tcagttctag agtgatatac gaacgaattg atgtgtaact gtatgcagac tggttgtagt	2160
ggaacaaatc tgataactat gcagggttaa attttcttat ctgattttgg taagtattcc	2220
ttagataggt ttttcttga aaacctggga ttgagagggt gatgaatgga aattctttca	2280
cttcattata tgcaagtttt caataattag gtctaagtg agttttaagg ttactgatga	2340
cttacaataa atgggctctg attgggcaat actcatttga gttccttcca tttgacctaa	2400
tttaactggg gaaatttaaa gtgaattcat gggctcatct ttaaagcttt tactaaaaga	2460
ttttcagctg aatggaactc attagctgtg tgcataataa aagatcacat cagggtggatg	2520
gagagacatt tgatcccttg tttgcttaat aaattataaa atgatggctt ggaaaagcag	2580
gctagtctaa ccatgggtgct attattaggc ttgcttgta cacacacagg tctaagccta	2640
gtatgtcaat aaagcaataa cttactgttt tgtttctatt aatgattccc aaaccttggt	2700
gcaagttttt gcattggcat ctttggtatt cagtcttgat gtttgttcta tcagacttaa	2760
ccttttattt cctgtccttc cttgaaattg ctgattgttc tgctccctct acagatattt	2820
atatcaattc ctacagcttt ccctgccat ccctgaactc tttctagccc ttttagattt	2880
tggcactgtg aaacccctgc tggaaacctg agtgacctc cctccccacc aagagtcac	2940
agacctttca tctttcacga acttgatcct gttagcagggt ggtaatacca tgggtgctgt	3000
gacactaaca gtcattgaga ggtgggagga agtccctttt ccttggaactg gtatcttttc	3060
aactattgtt ttatcctgtc tttgggggca atgtgtcaaa agtccctca ggaattttca	3120
gaggaaagaa cattttatga ggctttctct aaagtttctt ttgtatagga gtatgctcac	3180
ttaaatttac agaaagaggt gagctgtgtt aaacctcaga gtttaaaagc tactgataaa	3240
ctgaagaaag tgtctatatt ggaactaggg tcatttgaaa gcttcagctc cggaacatga	3300
cctttagtct gtggactcca tttaaaaata ggtatgaata agatgactaa gaatgtaatg	3360
gggaagaact gccctgcctg cccatctcag agccataagg tcatctttgc tagagctatt	3420

-continued

```

tttacctatg tatttatcgt tcttgatcat aagccgctta tttatatcat gtatctctaa 3480
ggacctaaaa gcactttatg tagtttttaa ttaatcttaa gatctgggta cggtaactaa 3540
aaaagcctgt ctgccaaatc cagtggaaac aagtgcatag atgtgaattg gtttttaggg 3600
gccccacttc ccaattcatt aggtatgact gtggaaatac agacaaggat cttagtgtat 3660
atthttgggct tggggcagtg agggcttagg acaccccaag tggtttggga aaggaggagg 3720
ggagtgggtg gttttatagg ggaggaggag gcaggtggtc taagtgtga ctggctacgt 3780
agttcgggca aatcctccaa aagggaagg gaggatttgc ttagaaggat ggcgctccca 3840
gtgactactt tttgacttct gtttgtctta cgcttctctc agggaaaaac atgcagtcct 3900
ctagtgtttc atgtacattc tgtggggggt gaacaccttg gttctgggta aacagctgta 3960
cttttgatag ctgtgccagg aagggttagg accaactaca aattaatgtt ggttgtcaaa 4020
tgtagtgtgt ttccctaact tctgtttttt cctgagaaaa aaaaataaat cttttattca 4080
aatacaggga aaaaaaaaaa aaaaaaa 4107

```

```

<210> SEQ ID NO 4
<211> LENGTH: 1126
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: SAP30 glucocorticoid receptor-responsive gene
<400> SEQUENCE: 4

```

```

tccccatgtg acagtgagcg gggtecccg tccaggagac gctcgagtct gcgtcccggc 60
cctcagcact gtccactgtt tcggtgccag cagagaccag caggcccggg acagttggtg 120
tttgcccggt cgcgtgtcta acttggtgtg cagagtgaat tgccgctgcc ggagcggaga 180
gaggcggagc ggccaggaga gaggggattt ctgtcagcgc cggcctcggg agctcggaga 240
catgaacggc ttcacgcctg acgagatgag ccgcggcggg gatgcggccg ccgcagtggc 300
cgcagtggtc gctgcccgcg ccgcgcgcgc ctcggcgggg aacgggaccg gcgcggggcac 360
cggggctgag gtgcggggcg cgggggcggt ctacagcggt gggcccccg gggcgggcgg 420
gccgggcccc gggcaactgt gctgcctgcg ggaggtgggt gagcgggtgcg gccgggcggc 480
aggcaacgcc agcttcagca agaggatcca gaagagcatc tcccagaaga aggtgaagat 540
cgagctggat aagagcgcaa ggcatcttta catatgtgat tatcataaaa acttaattca 600
gagtgttcga aacagaagaa agagaaaagg gagtgatgat gatggagggtg attcacctgt 660
tcaagatatt gataccccag aggttgattt ataccaatta caagtaaata cacttaggag 720
atacaaaaaga cacttcaagc taccaaccag accaggactt aataaagcac aacttggtga 780
gatagttggt tgccacttta ggtctattcc agtgaatgaa aaagacacct taacatattt 840
catctactca gtgaagaatg acaagaacaa atcagatctc aaggttgata gtggtgttca 900
ctaggagacg tggaattgag actaataact tggatgttaa cactgtttac tgttttttca 960
catgtagaaa tgttctttgt gtattttttc tacagaggat tttctctgat tttattttct 1020
ttgtttctga ctctaataat tagttggaaa ctcatataaa atgagctttc cttaaataaa 1080
tctattttta ataaagggtt ttactattaa aaaaaaaaaa aaaaaa 1126

```

```

<210> SEQ ID NO 5
<211> LENGTH: 2040
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: DUSP1 glucocorticoid receptor-responsive gene

```

-continued

<400> SEQUENCE: 5

```

tcgctgcgaa ggacatttgg gctgtgtgtg cgacgcgggt cggaggggca gtcgggggaa    60
ccgcgaagaa gccgaggagc ccggagcccc gcgtgacgct cctctctcag tccaaaagcg    120
gcttttgggt cggcgcagag agaccggggg gtctagcttt tcctcgaaaa gcgccgccct    180
gcccttgccc ccgagaacag acaaagagca ccgcagggcc gatcacgctg ggggcgctga    240
ggccggccat ggtcatggaa gtgggcaccc tggacgctgg aggcctgcgg gcgctgctgg    300
gggagcgagc ggcgcaatgc ctgctgctgg actgccgctc cttcttcgct ttcaacgccg    360
gccacatcgc cggctctgtc aacgtgcgct tcagcaccat cgtgcggcgc cgggccaagg    420
gcgccatggg cctggagcac atcgtgccca acgccgagct ccgcggccgc ctgctggccg    480
gcgcctacca cgccgtggtg ttgctggacg agcgacgcgc cgccctggac ggcgccaagc    540
gcgacggcac cctggccctg gcggccggcg cgctctgccg cgaggcgcgc gccgcgcaag    600
tcttcttctc caaaggagga tacgaagcgt ttctggcttc ctgcccggag ctgtgcagca    660
aacagtgcac ccccatgggg ctcagccttc cctgagtag tagcgtccct gacagcgcgg    720
aatctgggtg cagttcctgc agtaccacac tctacgatca gggtagggcg gtggaaatcc    780
tgccctttct gtacctgggc agtgcgtagc acgcttcccg caaggacatg ctggatgcct    840
tgggcatcac tgccctgac aacgtctcag ccaattgtcc caaccatttt gagggtaact    900
accagtacaa gagcatccct gtggaggaca accacaaggc agacatcagc tcctggttca    960
acgaggccat tgacttcata gactccatca agaattgctg aggaagggtg tttgtccact   1020
gccaggcagg catttcccg tcagccacca tctgccttgc ttaccttatg aggactaatc   1080
gagtcaagct ggacgaggcc tttgagtttg tgaagcagag gcgaagcatc atctctccca   1140
acttcagctt catgggccag ctgctgcagt ttgagtccca ggtgctggct ccgcactggt   1200
cggcagaggc tgggagcccc gccatggctg tgctcgaccg aggcacctcc accaccaccg   1260
tgttcaactt ccccgctctc atccctgtcc actccacgaa cagtgcgctg agctaccttc   1320
agagcccatc tacgacctct ccagctgct gaaaggccac gggagggtgag gctcttcaca   1380
tcccattggg actccatgct ccttgagagg agaaatgcaa taactctggg aggggctcga   1440
gagggtggtt ccttatttat ttaacttcac ccgagttcct ctgggtttct aagcagttat   1500
ggtgatgact tagcgtcaag acatttgcgt aactcagcac attcgggacc aatatatagt   1560
gggtacatca agtccatctg acaaaatggg gcagaagaga aaggactcag tgtgtgatcc   1620
ggtttctttt tgctcgcccc tgttttttgt agaattctct catgcttgac atacctacca   1680
gtattattcc cgacgacaca tatacatatg agaataatcc ttattttatt ttgtgtaggt   1740
gtctgccttc acaaatgtca ttgtctactc ctagaagaac caaatacctc aatttttgtt   1800
tttgagtact gtactatcct gtaaataat cttaagcagg tttgttttca gcactgatgg   1860
aaaataccag tgttgggttt ttttttagtt gccaacagtt gtatgtttgc tgattattta   1920
tgacctgaaa taatatatct cttcttctaa gaagacattt tgttacataa ggatgacttt   1980
tttatacaat ggaataaatt atggcatttc tattgaaatt tcaaaaaaaaa aaaaaaaaaa   2040

```

<210> SEQ ID NO 6

<211> LENGTH: 3208

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: SGK1 glucocorticoid receptor-responsive gene

-continued

<400> SEQUENCE: 6

agatattcat gaacogttgc ttcttccagc ctogccttct cgctccctct gcctttcttg	60
cgctgttctc cctccctccc tctggcttct gctctttctt actccttctc tcagctgctt	120
aactacagct cccactggaa cttgcacaat caaaaacaac tctcctctct caagccgcct	180
ccaggagcgc atcacctgga gaagagcgac tcgctccccc cgccggccgc ggaagagcag	240
ccaggtagct gggggcgagg aggcgtaccc ttctcccgct cggttaagagc cacagcatct	300
ccccggagat tggccgtatc ccaccgtccg gccccagggt tcctgcagcg gtgatgcata	360
tgtttcggag caatgatgga aggagaaaag ccgctgtcgg tggcaactga aagtggggag	420
aggttgctgc agtagctggt gctgcagaat gcgcgagtga agaactgagc cccgctagat	480
tctccatccc gctcagctct cattaactgt ctgcaggagg taaaccgggg aaacagatat	540
gcactaacca ggcgggtgcc aacctggatc tataactgtg aattccccc ggtggaaaat	600
ggtaaacaaa gacatgaatg gattcccagt caagaaatgc tcagccttcc aattttttaa	660
gaagcgggta cgaagggtga tcaagagccc aatggctcagt gtggacaagc atcagagtcc	720
cagcctgaag tacaccggtc cctccatggt gcacatccct ccaggggagc cagacttcga	780
gtcttctctg tgtcaaacat gctgggtga acatgcttcc caaagagggg ttctccctca	840
ggagaacgag tcattgttcat gggaaactca atctgggtgt gaagtgagag agccatgtaa	900
tcattgccaac atcctgacca agcccgatcc aagaaccttc tggactaatg atgatccagc	960
tttcatgaag cagaggagga tgggtctgaa cgactttatt cagaagattg ccaataactc	1020
ctatgcatgc aaacaccctg aagttcagtc catcttgaag atctcccaac ctgaggagcc	1080
tgagcttatg aatgccaacc cttctcctcc accaagtctc tctcagaaa tcaaccttgg	1140
cccgtcgtcc aatcctcatg ctaaaccttc tgactttcac ttcttgaaag tgatcggaag	1200
gggcagtttt ggaaagggtc ttctagcaag acacaaggca gaagaagtgt tctatgcagt	1260
caaagtttta cagaagaaag caatcctgaa aaagaagagc gagaagcata ttatgtcgga	1320
gcggaatggt ctgttgaaag atgtgaagca ccccttctct gtgggccttc acttctcttt	1380
ccagactgct gacaaattgt actttgtcct agactacatt aatgggtggag agttgttcta	1440
ccatctccag agggaaagct gcttctctga accacgggct cgtttctatg ctgctgaaat	1500
agccagtgcc ttgggctacc tgcattcact gaacatcggt tatagagact taaaaccaga	1560
gaatatattg ctagattcac agggacacat tgtccttact gacttcggac tctgcaagga	1620
gaacattgaa cacaacagca caacatccac cttctgtggc acgcccaggt atctcgacc	1680
tgagggtgct cataagcagc cttatgacag gactgtggac tgggtgtgct tgggagctgt	1740
cttgtagtag atgctgtatg gcctgcggcc tttttatagc cgaaacacag ctgaaatgta	1800
cgacaacatt ctgaacaagc ctctccagct gaaaccaaatt attacaaatt ccgcaagaca	1860
cctctggag ggcctcctgc agaaggacag gacaaagcgg ctccggggcca aggatgactt	1920
catggagatt aagagtcagc tcttcttctc cttaattaac tgggatgac tcattaataa	1980
gaagattact ccccttttta acccaaatgt gagtggggcc aacgacctac ggcactttga	2040
ccccgagttt accgaagagc ctgtccccc aaaccattggc aagtcacctg acagcgtcct	2100
cgtcacagcc agcgtcaagg aagctgccga ggcttttcta ggcttttctt atgcgcctcc	2160
cacggactct ttctctgaa cctgttagg gcttggtttt aaaggatttt atgtgtgttt	2220
ccgaatgttt tagttagcct tttggtggag ccgccagctg acaggacatc ttacaagaga	2280
atttgcacat ctctggaagc ttagcaatct tattgcacac tggtcgtgg aagctttttg	2340

-continued

```

aagagcacat tctcctcagt gagctcatga ggttttcatt tttattcttc cttccaacgt 2400
ggtgctatct ctgaaacgag cgtagagtg ccgccttaga cggaggcagg agtttcgtta 2460
gaaagcggac gctgttctaa aaaagggtctc ctgcagatct gtctgggctg tgatgacgaa 2520
tattatgaaa tgtgcctttt ctgaagagat tgtgttagct ccaaagcttt tctatcgca 2580
gtgtttcagt tctttatttt cccttggtga tatgctgtgt gaaccgtcgt gtgagtgtgg 2640
tatgcctgat cacagatgga ttttggtata agcatcaatg tgacactgc aggacactac 2700
aacgtgggac attgtttgtt tcttcatat ttggaagata aatttatgtg tagacttttt 2760
tgtaagatac ggtaataaac taaaatttat tgaaatggc ttgcaatgac tcgtattcag 2820
atgcttaag aaagcattgc tgcacaaat atttctatt ttagaaagg tttttatgga 2880
ccaatgcccc agtgtcagt cagagcgtt ggtgtttttc attgtttaa atgtcacctg 2940
taaaatgggc attatttatg ttttttttt tgcattcctg ataattgtat gtattgtata 3000
aagaacgtct gtacattggg ttataacact agtatattta aacttacagg cttatttgta 3060
atgtaaacca ccattttaat gtactgtaat taacatggtt ataatacgta caatccttc 3120
ctcatcccat cacacaactt tttttgtgtg tgataaactg attttggtt gcaataaaac 3180
cttgaaaaat atttacctat aaaaaaaa 3208

```

```

<210> SEQ ID NO 7
<211> LENGTH: 5758
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: SMARCA2 glucocorticoid receptor-responsive gene
<400> SEQUENCE: 7

```

```

tttctgtact ctgggtgact cagagaggga agagattcag ccagcacact cctcgcgagc 60
aagcattact ctactgactg gcagagacag gagaggtaga tgtccacgcc cacagaccct 120
ggtgcgatgc cccaccaggg gccttcgccg gggcctgggc cttcccctgg gccaatctt 180
gggcctagtc caggaccagg accatcccca ggttcctgcc acagcatgat ggggccaagt 240
cctggacctc caagtgtctc ccatcctatg ccgacgatgg ggtccacaga cttcccacag 300
gaaggcatgc atcaaatgca taagcccatc gatggtatgc atgacaaggg gattgtagaa 360
gacatccatt gtggatccat gaagggcact ggtatgcgac cacctacccc aggcattggc 420
cctcccaga gtccaatgga tcaacacagc caaggttata tgtcaccaca cccatctcca 480
ttaggagccc cagagcacgt ctccagccct atgtctggag gaggcccaac tccacctcag 540
atgccaccaa gccagccggg ggccctcctc ccaggtgac cgcaggccat gagccagccc 600
aacagaggtc cctcaccttt cagtctgtc cagctgcac agcttcgagc tcagatttta 660
gcttataaaa tgctggcccc aggccagccc ctccccgaaa cgctgcagct tgcagtccag 720
gggaaaagga cgttgctctg cttgcagcaa caacagcagc agcaacagca gcagcagcag 780
cagcagcagc agcagcagca gcagcaacag cagccgcagc agcagccgcc gcaaccacag 840
acgcagcaac aacagcagcc ggcccttgtt aactacaaca gaccatctgg ccggggggcg 900
gagctgagcg gcccagcagc ccgcagagaag ctgccgggtc ccgcgcccgg cggccggccc 960
tcgcccgcgc ccccgccagc cgcgcagccg ccgcggggcg cagtgcgccg gccctcagtg 1020
ccgcagccgg ccccggggca gccctcgcgc gtcctccagc tgcagcagaa gcagagccgc 1080
atcagcccca tccagaaacc gcaaggcctg gaccccggtg aaattctgca agagcgggaa 1140

```

-continued

tacagacttc	aggccccgat	agctcatagg	atacaagaac	tggaaaatct	gcttggtctc	1200
ttgccaccag	atttaagaac	caaagcaacc	gtggaactaa	aagcacttcg	gttactcaat	1260
ttccagcgtc	agctgagaca	ggaggtgggtg	gcctgcctgc	gcagggacac	gacctggag	1320
acggctctca	actccaaagc	atacaaacgg	agcaagcgcc	agactctgag	agaagctcgc	1380
atgaccgaga	agctggagaa	gcagcagaag	attgagcagg	agaggaaacg	ccgtcagaaa	1440
caccaggaat	acctgaacag	tattttgcaa	catgcaaaag	attttaagga	atatcatcgg	1500
tctgtggccg	gaaagatcca	gaagctctcc	aaagcagtgg	caacttggca	tgccaacact	1560
gaaagagagc	agaagaagga	gacagagcgg	attgaaaagg	agagaatgcg	gcgactgatg	1620
gctgaagatg	aggagggtta	tagaaaactg	attgatcaaa	agaaagacag	gcgttttagct	1680
taccttttgc	agcagaccga	tgagtatgta	gccaatctga	ccaatctggt	ttgggagcac	1740
aagcaagccc	aggcagccaa	agagaagaag	aagaggagga	ggaggaagaa	gaaggctgag	1800
gagaatgcag	agggtgggga	gtctgccctg	ggaccggatg	gagagcccat	agatgagagc	1860
agccagatga	gtgacctccc	tgtcaaagtg	actcacacag	aaaccggcaa	ggttctgttc	1920
ggaccagaag	cacccaaagc	aagtcagctg	gacgcctggc	tggaaatgaa	tcctggttat	1980
gaagttgccc	ctagatctga	cagtgaagag	agtgattctg	attatgagga	agaggatgag	2040
gaagaagagt	ccagtaggca	ggaaaccgaa	gagaaaatac	tcctggatcc	aaatagcgaa	2100
gaagtttctg	agaaggatgc	taagcagatc	attgagacag	ctaagcaaga	cgtggatgat	2160
gaatacacga	tgcagtacag	tgccaggggc	tcccagtcct	actacaccgt	ggctcatgcc	2220
atctcggaga	gggtggagaa	acagctctgcc	ctcctaatta	atgggaccct	aaagcattac	2280
cagctccagg	gcctggaatg	gatgggttcc	ctgtataata	acaacttgaa	cggaatctta	2340
gccgatgaaa	tggggcttgg	aaagaccata	cagaccattg	cactcatcac	ttatctgatg	2400
gagcacaaaa	gactcaatgg	cccctatctc	atcattgttc	cccttcgcac	tctatctaac	2460
tggacatatg	aatttgacaa	atgggctcct	tctgtgggtg	agattttctta	caagggtact	2520
cctgccatgc	gtcgtctcct	tgtccccccag	ctacggagtg	gcaaattcaa	tgtcctcttg	2580
actacttatg	agtatattat	aaaagacaag	cacattcttg	caaagattcg	gtggaaatac	2640
atgatagtgg	acgaaggcca	ccgaatgaag	aatcaccact	gcaagctgac	tcaggctctg	2700
aacactcact	atgtggcccc	cagaaggatc	ctcttgactg	ggaccccgcg	gcagaataag	2760
ctccctgaac	tctgggccct	cctcaacttc	ctcctcccaa	caatttttaa	gagctgcagc	2820
acatttgaac	aatgggtcaa	tgtcccatct	gccatgactg	gtgaaagggg	ggacttaaat	2880
gaagaagaaa	ctatatgtat	catcaggcgt	ctacataagg	tggttaagacc	atttttacta	2940
aggagactga	agaaagaagt	tgaatcccag	cttcccgaaa	aagtggaata	tgtgatcaag	3000
tgtgacatgt	cagctctgca	gaagattctg	tatcgccata	tgcaagccaa	ggggatcctt	3060
ctcacagatg	gttctgagaa	agataagaag	gggaaaggag	gtgctaagac	acttatgaac	3120
actattatgc	agttgagaaa	aatctgcaac	cacccatata	tgtttcagca	cattgaggaa	3180
tcctttgctg	aacacctagg	ctattcaaat	ggggtcacat	atggggctga	actgtatcgg	3240
gcctcaggga	agtttgagct	gcttgatcgt	attctgccaa	aattgagagc	gactaatcac	3300
cgagtgcctg	ttttctgcca	gatgacatct	ctcatgacca	tcattggagga	ttattttgct	3360
tttcggaaact	tcctttacct	acgccttgat	ggcaccacca	agttctgaaga	tcgtgctgct	3420
ttgctgaaga	aattcaatga	acctggatcc	cagtatttca	ttttcttgct	gagcacaaga	3480
gctggtggcc	tgggcttaaa	tcttcaggca	gctgatacag	tggtcatctt	tgacagcgac	3540

-continued

tggaatcctc atcaggatct gcaggcccaa gaccgagctc accgcatcgg gcagcagaac	3600
gaggteccggg tactgagget ctgtaccgtg aacagcgtgg aggaaaagat cctcgcggcc	3660
gcaaaataca agctgaacgt ggatcagaaa gtgatccagg cgggcatgtt tgaccaaag	3720
tcttcaagcc acgagcggag ggcattcctg caggccatct tggagcatga ggaggaaaat	3780
gaggaagaag atgaagtacc ggacgatgag actctgaacc aaatgattgc tcgacgagaa	3840
gaagaatttg acctttttat gcggatggac atggaccggc ggagggaaga tgcccgaac	3900
ccgaaacgga agccccgttt aatggaggag gatgagctgc cctcctggat cattaaggat	3960
gacgctgaag tagaaaggct cacctgtgaa gaagaggagg agaaaatatt tgggaggggg	4020
tccccccagc gccgtgacgt ggactacagt gacgccctca cggagaagca gtggctaagg	4080
gccatcgaag acgccaatth ggaggaaatg gaagaggagac tacggcttaa gaagcgaana	4140
agacgaagaa atgtggataa agatcctgca aaagaagatg tggaaaaagc taagaagaga	4200
agaggccgcc ctccccgtga gaaactgtca ccaaatcccc ccaactgac aaagcagatg	4260
aacgctatca tcgatactgt gataaactac aaagataggt gtaacgtgga gaagggtccc	4320
agtaattctc agttggaaat agaaggaaac agttcagggc gacagctcag tgaagtcttc	4380
attcagttac cttcaaggaa agaattacca gaatactatg aattaattag gaagccagt	4440
gatttcaaaa aaataaaggaa aaggattcgt aatcataagt accggagcct aggcgacctg	4500
gagaaggatg tcattgcttct ctgtcacaac gctcagacgt tcaacctgga gggatcccag	4560
atctatgaag actccatcgt cttacagtca gtgtttaaga gtgcccggca gaaaattgcc	4620
aaagaggag agagtggagg tgaagcaat gaagaggagg aagagggaaga tgaagaagag	4680
tcagagtcag agggcaaatc agtcaagggt aaaattaagc tcaataaaaa agatgacaaa	4740
ggccgggaca aagggaagg caagaaaagg ccaaatcgag gaaaagccaa acctgtagt	4800
agcgattttg acagcgatga ggagcaggat gaacgtgaac agtcagaagg aagtgggacg	4860
gatgatgagt gatcagtatg gacctttttc cttggtagaa ctgaattcct tcctccctg	4920
tctcatttct acccagtgag ttcatttgtc atataggcac tgggtgtgtt ctatatcatc	4980
atcgtctata aactagcttt aggatagtgc cagacaaaca tatgatatac tgggtgtaaaa	5040
aacacacaca tacacaaata tttgtaacat attgtgacca aatgggcctc aaagattcag	5100
attgaaacaa acaaaaagct tttgatggaa aatatgtggg tggatagtat atttctatg	5160
gtgggtctaa tttggtaacg gtttgattgt gcttggtttt atcacctgtt cagatgagaa	5220
gatttttgtc tttttagtca ctgataacca ggagaagcca ttaaaagcca ctggttattt	5280
tatttttcat caggcaatth tcgaggtttt tatttggtcg gtattgtttt tttacactgt	5340
ggtacatata agcaacttta ataggtgata aatgtacagt agttagattt cactgcata	5400
tacatttttc cattttatgc tctatgatct gaacaaaagc tttttgaatt gtataagatt	5460
tatgtctact gtaaacattg cttaattttt ttgctcttga tttaaaaaa agttttgttg	5520
aaagcgctat tgaatattgc aatctatata gtgtattgga tggcttcttt tgtcacctg	5580
atctcctatg ttaccaatgt gtatcgtctc cttctcccta aagtgtactt aatctttgct	5640
ttctttgcac aatgtctttg gttgcaagtc ataagcctga ggcaataaaa attccagtaa	5700
tttcgaagaa tgtggtgttg gtgctttcct aataaagaaa taatttagct tgacaaaa	5758

<210> SEQ ID NO 8

<211> LENGTH: 837

<212> TYPE: DNA

-continued

```

<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: PTGDS glucocorticoid receptor-responsive gene

<400> SEQUENCE: 8
gctcctctctg cacacctccc tcgctctccc acaccactgg caccaggccc cggacacccg      60
ctctgctgca ggagaatggc tactcatcac acgctgtgga tgggactggc cctgctgggg      120
gtgctggggc acctgcaggc agcaccggag gccagggtct cgtgcagcc caacttcag      180
caggacaagt tcctggggcg ctggttcagc gcgggcctcg cctccaactc gagctggctc      240
cgggagaaga aggcggcggt gtccatgtgc aagtctgtgg tggccctgc cacggatggt      300
ggcctcaacc tgacctccac ctctctcagg aaaaaccagt gtgagacccg aacctgctg      360
ctgcagcccg cggggtcctt cggtcctac agctaccgga gtccccactg gggcagcacc      420
tactcctgtg cagtgggtga gaccgactac gaccagtacg cgctgctgta cagccagggc      480
agcaaggggc ctggcgagga ctctcgcatg gccacctctt acagccgaac ccagaccccc      540
agggctgagt taaaggagaa attcaccgcc ttctgcaagg cccagggtt cacagaggat      600
accattgtct tcctgcccc aaccgataag tgcatacagg aacaatagga ctcccaggg      660
ctgaagctgg gateccggcc agccagggtga cccccacgct ctggatgtct ctgctctgtt      720
ccttccccga gccctgccc cggtccccc ccaaagcaac cctgccact caggcttcat      780
cctgcacaat aaactccgga agcaagtcag taaaaaaaa aaaaaaaaa aaaaaaa      837

<210> SEQ ID NO 9
<211> LENGTH: 6001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: TNFRSF9 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 9
caaggaggga tcccacagat gtcacaggc tgtcacagag ctgtggtggg aatttcccat      60
gagaccccg ccttggtgta gtcaccgcac tcctgtgttt gacctgaagt cctctcgagc      120
tgcagaagcc tgaagaccaa ggagtggaaa gttctccggc agccctgaga tctcaagagt      180
gacatttgtg agaccagcta atttgattaa aattctcttg gaatcagctt tgctagtatc      240
atacctgtgc cagatttcat catgggaaac agctgttaca acatagtagc cactctgttg      300
ctggtcctca actttgagag gacaagatca ttgcaggatc cttgtagtaa ctgccagct      360
ggtacattct gtgataataa caggaatcag atttgcagtc cctgtcctcc aaatagtttc      420
tccagcgcag gtggacaaag gacctgtgac atatgcaggc agtgtaaagg tgttttcagg      480
accaggaagg agtgttcctc caccagcaat gcagagtgtg actgcactcc agggtttcac      540
tgcctggggg caggatgcag catgtgtgaa caggattgta aacaaggtea agaactgaca      600
aaaaaagggt gtaaagactg ttgctttggg acatttaacg atcagaaacg tggcactctg      660
cgaccctgga caaactgttc ttggatgga aagtctgtgc ttgtgaatgg gacgaaggag      720
agggacgtgg tctgtggacc atctccagcc gacctctctc cgggagcacc ctctgtgacc      780
ccgctgccc ctgcgagaga gccaggacac tctccgcaga tcatctcctt ctttcttgcg      840
ctgacgtcga ctgcgttgc ctctctgctg ttcttctca cgctccgttt ctctgttgtt      900
aaacggggca gaaagaaact cctgtatata ttcaaacac catttatgag accagtacaa      960
actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt      1020
gaactgtgaa atggaagtca atagggtgtg tgggactttc ttgaaaagaa gcaaggaaat      1080

```

-continued

atgagtcac	cgtatcaca	gctttcaaaa	gcaagaacac	catcctacat	aatacccagg	1140
attccccca	cacacgttct	tttctaaatg	ccaatgagtt	ggcctttaa	aatgcaccac	1200
ttttttttt	tttttgacag	ggtctcactc	tgtcacccag	gctggagtg	agtggcacca	1260
ccatggctct	ctgcagcctt	gacctctggg	agctcaagtg	atcctcctgc	ctcagtctcc	1320
tgagtagctg	gaactacaag	gaagggccac	cacacctgac	taactttttt	gttttttgtt	1380
tggtaaagat	ggcatttcac	catgtgtgac	aggctgggtc	caaactccta	ggttcacttt	1440
ggcctcccaa	agtgtctggg	ttacagacat	gaactgccag	gcccggccaa	aataatgcac	1500
cacttttaac	agaacagaca	gatgaggaca	gagctggtga	taaaaaaaaa	aaaaaaaaag	1560
cattttctag	ataccactta	acaggtttga	gctagttttt	tgaaatcca	aagaaaatta	1620
tagtttaaat	tcaattacat	agtccagtgg	tccaactata	attataatca	aaatcaatgc	1680
aggtttgtt	tttgggtgta	atatgacata	tgacaataag	ccacgaggtg	cagtaagtac	1740
ccgactaaag	tttccgtggg	tctgtcatg	taacacgaca	tgctccaccg	tcagggggga	1800
gtatgagcag	agtgcctgag	tttaggggtca	aggacaaaa	acctcaggcc	tgagggaagt	1860
tttgaaaga	gttcaagtgt	ctgtatatcc	tatggtcttc	tccatctca	cacctctgc	1920
ctttgtcctg	ctccctttta	agccagggtta	cattctaaaa	attcttaact	tttaacataa	1980
tattttatatac	caaagccaat	aaatgaactg	catatgatag	gtatgaagta	cagtgaagaa	2040
attaacacct	gtgagctcat	tgtcctacca	cagcactaga	gtgggggccg	ccaaactccc	2100
atggccaaac	ctggtgcacc	atttgccctt	gtttgtctgt	tggtttgctt	gagacagtct	2160
tgtctgttg	cccaggttg	aatggagtg	ctattcacag	gcacaatcat	agcacacttt	2220
agccttaaac	tcttgggtc	aagtgatcca	cccgcctcag	tctcccaagt	agctgggatt	2280
acaggtgcaa	acctggcatg	cctgccattg	tttggttat	gatctaagga	tagcttttta	2340
aattttatct	attttatttt	tttttgagac	agtgtctcac	tctgtctccc	aggctggagt	2400
acagtgttac	aatcttggt	caccgcctcc	cagtttcaag	tgatctccct	gcctcagcct	2460
cctaagtagc	tgggactaca	ggtatgtgcc	accacgcctg	gctaattttt	atatttttag	2520
tagagacggg	gtttcaccat	gttgtccagg	ctgggtctca	actcctgacc	tcaggtgac	2580
tgccacctc	tgcctcccaa	agtgtctggg	ttacaggcat	gagccaccat	gcctggccat	2640
ttcttacact	tttgatgac	atgcctattg	caagcttgcg	tgcctctgtc	ccatgttatt	2700
ttactctggg	atttaggtg	agggagcagc	ttctatttgg	aacattggcc	atcgcatggc	2760
aaatgggtat	ctgtcacttc	tgtcctatt	tagttgggtc	tactataacc	tttagagcaa	2820
atcctgcagc	caagccaggc	atcaataggg	cagaaaagta	tattctgtaa	ataggggtga	2880
ggagaagata	tttctgaaca	atagtctact	gcagtaccaa	attgcttttc	aaagtggctg	2940
ttctaagtga	ctcccgctcag	tcatataagt	gtcatgtaag	tatccattg	atccacatcc	3000
ttgctaccct	ctggtactat	cagggtgccct	taattttgcc	aagccagtgg	gtatagaatg	3060
agatctcact	gtggtcttag	tttgcatgtg	cttggttact	gatgagcacc	ttgtcaaata	3120
tttatatacc	atttgtgttt	atttttttaa	ataaaatgct	tgtcatgct	tttttgccca	3180
tttgcaaaaa	aacttggggc	cgggtgcagt	ggctcatgcc	tgtagtccca	gctctttggg	3240
aggccaaggt	gggcagatcg	cttgagccca	ggagtctgag	accagccttg	gcaacatggc	3300
gaaaccctgt	ctttacaaaa	aatacaaaaa	ttagccgggt	gtggtggtgt	gcacctgaag	3360
tcccagctac	tcagtaggtt	cgctttgagc	ctgggaggca	gaggttgtag	tgagctggga	3420

-continued

ccgcatcact	acacttcagc	ctgggcaaca	gagaaaaacc	ttttctcaga	aacaaacaaa	3480
cccaaatgtg	gttgtttgtc	ctgattccta	aaaggtcttt	atgtattcta	gataataatc	3540
tttggtcagt	tatatgtgtt	aaaaaatatc	ttctttgtgg	ccaggcacgg	tagctcacac	3600
ctgtaatccc	agcactttgc	ggggctgagg	tgggtggatc	atctgaggtc	aagagttcaa	3660
gatcagcctg	gccaacacag	tgaaccccca	tctctactaa	acatgtacaa	aacttagctg	3720
ggtatggtgg	cgggtgcctg	taaccccgag	tgctccagag	gctgtggcag	aagaatcgct	3780
tgaacccagg	aggcagaggt	tgacgcgagc	caagattgtg	ccattgcact	ccagactggg	3840
tgacaagagt	gaaattctgc	ctatctatct	atctatctat	ctatctatct	atatatatat	3900
atatatatcc	tttgaatatt	atttttccct	ttttaaaatt	ttttataaaa	ttctttttta	3960
tttttatatt	tagcagaggt	gaggtttctg	aggtttcatt	atgttgccca	ggctggtctt	4020
gaactcctga	gctcaagtga	tcctcccacc	tcagccttcc	aaagtgtctg	aattgcagac	4080
atgagccacc	gcgcccctcc	tgtttttctc	taattaatgg	tgtctttctt	tgtctttctg	4140
gtaataagca	aaaagttctt	catttgattt	ggttaaattt	ataactgttt	tctcatatgg	4200
ttaacatttt	ttcttgccctg	gctaaagaaa	tccttttctg	cccaatacta	taaagaggtt	4260
tgcccacatt	ttattccaaa	agttttaagt	tttgtcttcc	atcttgaagt	ctaagtatc	4320
aggaactggc	ttttgtgctt	gttgggaggt	agtgatccaa	ttccatgtct	tgcatgtagg	4380
taaccactgg	tccttgccgc	atgtattcaa	tacgtcgtct	ttctcctgcg	ggtctgcaat	4440
ctcacctacc	atccatcaag	tttccatagg	gccatgggtc	tgtttctggg	ctcccgttcc	4500
tgttccattg	tcaatttgtc	tatcctgtgc	cagtatcaca	ctgtgtttat	tacaatagct	4560
ttgtaacagc	tctcgatatc	cggtaggaca	tctccctcca	ccttcttttt	ctacttcaga	4620
agtgtcttag	ctaggtcagg	cacgggtggc	cacgcctgta	atcccagcac	tttgggaggc	4680
cgacgcggat	ggatcacctg	aggtcaggag	ttttgagaca	gcctggccaa	catggtgaaa	4740
ccccatctct	actaaaaaat	acaaaaatta	gtcaggcatg	gtggcatgtg	cctgtaatcc	4800
cagctatttg	ggaggctgag	gccggagaat	tgcttgaacc	cggggggcgg	aggttgacgt	4860
gagccgagat	cgtaccattg	cactccagcc	tgggtgacag	agcgaaactc	tgtctcagga	4920
aaaaaaagaa	aagagatgtc	ttggttattc	ttggttcttt	attattcaat	ataaatttta	4980
gaagctgaat	ttgaaaagat	ttggattgga	atttcattaa	atctacaggt	caatttaggg	5040
agagttgata	attttacaga	attgagtcac	ctgggtgtcc	aataagaata	agagaacaat	5100
tattggctgt	acaattcttg	ccaaatagta	ggcaaagcaa	agcttaggaa	gtatactggt	5160
gccatttcag	gaacaaagct	aggtgcgaat	atttttgtct	ttctgaatca	tgatgctgta	5220
agttctaaag	tgattttctcc	tcttggtctt	ggacacatgg	tgtttaatta	cctactgctg	5280
actatccaca	aacagaaaga	gactggtcac	gccccacagg	gttggggtat	ccaagataat	5340
ggagcgaggc	tctcatgtgt	cctaggttac	acaccgaaaa	tccacagtct	attctgtgaa	5400
gaaaggaggc	tatgtttatg	atacagactg	tgatattttt	atcatagcct	attctgggat	5460
catgtgcaaa	agctataaat	gaaaaacaca	ggaacttggc	atgtgagtca	ttgctcccc	5520
taaatgacaa	ttaataagga	aggaacattg	agacagaata	aaatgatccc	cttctggggt	5580
taatttagaa	agtcccataa	ttaggtttta	tagaaaaaaa	tgtaaatctc	tatgattaaa	5640
aataaattag	cacatttagg	gatacacaaa	ttataaatca	ttttctaaat	gctaaaaaca	5700
agctcaggtt	tttttcagaa	gaaagtttta	attttttttc	tttagtgga	gatatactc	5760
tgacggaaa	ttttgatgtg	agggggcgat	gactataaag	tgggcactct	ccccacagg	5820

-continued

```

aagatgtttc catctgtggg tgagaggtgc ccaccgcagc tagggcaggt tacatgtgcc 5880
ctgtgtgtgg taggacttgg agagtgatct ttatcaacgt ttttatttaa aagactatct 5940
aataaaacac aaaactatga tgttcacagg aaaaaaagaa taagaaaaaa agaaaaaaa 6000
a 6001

```

```

<210> SEQ ID NO 10
<211> LENGTH: 1336
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: SFN glucocorticoid receptor-responsive gene

```

```

<400> SEQUENCE: 10

```

```

gagagacaca gagtccggca ttggtcccag gcagcagtta gcccgccgcc cgctgtgtg 60
tccccagagc catggagaga gccagtctga tccagaaggc caagctggca gagcaggccg 120
aacgctatga ggacatggca gccttcatga aaggcgccgt ggagaagggc gaggagctct 180
cctgcgaaga gcgaacctg ctctcagtag cctataagaa cgtgggtggc ggccagaggg 240
ctgcctggag ggtgctgtcc agtattgagc agaaaagcaa cgaggagggc tcggaggaga 300
aggggccccg ggtgctgtg taccgggaga aggtggagac tgagctccag ggcgtgtgct 360
acaccgtgct gggcctgctg gacagccacc tcatcaagga ggccggggac gccgagagcc 420
gggtcttcta cctgaagatg aagggtgact actaccgcta cctggccgag gtggccaccg 480
gtgacgacaa gaagcgcac attgactcag cccggtcagc ctaccaggag gccatggaca 540
tcagcaagaa ggagatgccg cccaccaacc ccatccgctt gggcctggcc ctgaactttt 600
ccgtcttcca ctacgagatc gccaacagcc ccgaggaggc catctctctg gccaagacca 660
ctttcgacga ggccatggct gatctgcaca ccctcagcga ggactcctac aaagacagca 720
ccctcatcat gcagctgctg cgagacaacc tgacactgtg gacggccgac aacgcggggg 780
aagagggggg cgaggctccc caggagcccc agagctgagt gttgccgcc accgcccgc 840
cctgccccct ccagtccccc accctgccga gaggactagt atggggtggg aggccccacc 900
cttctccccct aggcgctggt cttgctccaa agggctccgt ggagagggac tggcagagct 960
gaggccacct ggggtgggg atcccaactct tcttgagct gttgagcga cctaaccact 1020
ggtcatgccc ccaccctgc tctccgccc cgttctctcc cgaccccagg accaggtac 1080
ttctccctc ctcttgctc cctctgccc ctgctgctc tgatcgtagg aattgaggag 1140
tgtccgcct tgtggctgag aactggacag tggcaggggc tggagatggg tgtgtgtgtg 1200
tgtgtgtgtg tgtgtgtgtg tgtgctgctg cggcagtgca agaccgagat tgagggaaag 1260
catgtctgct ggggtgtgacc atgtttctc tcaataaagt tcccctgtga cactcaaaaa 1320
aaaaaaaaa aaaaaa 1336

```

```

<210> SEQ ID NO 11
<211> LENGTH: 2240
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: LAPTM5 glucocorticoid receptor-responsive gene

```

```

<400> SEQUENCE: 11

```

```

ggagggcagc cagcagcttc cccttctctg cctgctcca ggcaccaggc tctttccct 60
tcagtgtctc agaggagggg acggcagcac catggacccc cgcttgctca ctgtccgcca 120

```

-continued

gacctgctgc tgettcaatg tccgcatcgc aaccaccgcc ctggccatct accatgtgat	180
catgagcgtc ttgttggtca tcgagcactc agtagagggt gcccatggca aggcgtcctg	240
caagctctcc cagatgggct acctcaggat cgctgacctg atctccagct tectgctcat	300
cacctgctgc ttcacatca gctgagcct actgatcggc gtagtcaaga accgggagaa	360
gtacctgctg ccttctctgt ccttgcaaat catggactat ctctgtgccc tgctcaccct	420
gctgggctcc tacattgagc tgcccgccta cctcaagttg gcctcccgga gccgtgctag	480
ctcctccaag tccccctga tgacgtgca gctgctggac ttctgctga gcatcctgac	540
cctctgcagc tcctacatgg aagtgtccac ctatctcaac ttcaagtcca tgaaccacat	600
gaattacctc ccagccagg aggatatgcc tcataaccag ttcacatcaaga tgatgatcat	660
cttttccatc gccttcatca ctgtccttat cttcaaggtc tacatgttca agtgcgtgtg	720
gcggtgctac agattgatca agtgcatgaa ctcggtggag gagaagagaa actccaagat	780
gtccagaag gtggtctgc cgtcctacga ggaagccctg tctttgccat cgaagacccc	840
agaggggggc ccagcaccac ccccatctc agaggtgtga ccctgccag gccccagccc	900
cagtgcctgg aggggtggag ctgcctcata atctgctttt ttgctttggt ggcccctgtg	960
gcctgggtgg gccctccgc cctccctgg caggacaatc tgettgtgct tccctcgtg	1020
gcctgctcct cctgcagggc ctgtgagctg ctcaaacctg ggtcaacgct ttaggctgag	1080
tcactcctcg ggtctctcca taattcagcc caacaatgct tggtttattt caatcagctc	1140
tgacacttgt ttagacgatt ggccattcta aagttggtga gtttgtcaag caactatcga	1200
cttgatcagt tcagccaagc aactgacaaa tcaaaaaccc acttgtcagt tcagtaaaat	1260
aatttggtca aacaacagtc tattgcattg atttataaat agttgtcagt tcacatagca	1320
atttaataca gtaatcatta attagttacc ccttatatat aaatatatgt aatcaatttc	1380
ttcaaatagc ttgcttacat gataatcaat tagccaacca tgagtcattt agaatagtga	1440
taaatagaat acacagaata gtgatgaaat tcaattttaa aaatcacgtt agcctccaaa	1500
ccatttaatt caaatgaacc catcaactgg atgccaaactc tggcgaatgt aggacctctg	1560
agtggctgta taattgttaa ttcaaatgaa attcatttaa acagttgaca aactgtcatt	1620
caacaattag ctccaggaaa taacagttat ttcatacaaa aacagtcctt tcaaacacac	1680
aattgttctg ctgaagagtt gtcacatca atccaatgct cactatttca gttgctctgt	1740
ggtcagtgtg gctgcataac agtggattcc atgaaaggag tcattttagt gatgagctgc	1800
cagtcatttc ccaggccagg ctgtcgtctg ccatcattc agtcgattca gtcataggcg	1860
aatctgttct gcccgaggct tgtggtcaag caaaaattca gccctgaaat caggcacatc	1920
tgttcgttgg actaaaccca caggtagtt cagtcaaagc aggcaacccc cttgtgggca	1980
ctgaccctgc cactggggtc atggcggttg tggcagctgg ggagggttgg ccccaacagc	2040
cctctgtgct ctgcttccct gtgtgtcggg gtccctccagg gagctgacct agaggtggag	2100
gccacggagg cagggtctct ggggactgtc ggggggtaca gagggagaag gctctgcaag	2160
agctccctgg caataccccc ttgtgtaatt gctttgtgtg cgacaggagg gaagtttcaa	2220
taaagcagca acaagcttct	2240

<210> SEQ ID NO 12

<211> LENGTH: 3039

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: GPSM2 glucocorticoid receptor-responsive gene

-continued

<400> SEQUENCE: 12

```

aggcgcagag gagggcgggtg ttgagaccgg cggagcggcg ggacccttag gtggcggagg      60
gacgctccgg gaaagcgagg ggcgctacga gctctggccc acgtgacctg ccgggggcg      120
gagcaggggg cgcccgggcc tctgcggtg cccctgcctt ggggaggggc cgtgaccacc      180
cgtctgtcgc ccgaggcggc cgccgctgca ccttcaccgc gtacccgga cccgcccgc      240
cgcgggagaa atgttgctga agtgctgtg aaagggccag agatgcaagg atttgggata      300
cattttgaac ctttaagctg tctgacattg acctccttc attattaata aagaagaatc      360
aggagcttag gatgtattaa caccaactca ttaatatact aaccggacaa tgttctacaa      420
acaattctac attgtaaagg actggattgg caaaaataa aataatttta ttttattcag      480
cttataatat gactcgatgg aggaaaattt gataagcatg agagaagacc attcttttca      540
tgttcgttac agaatggaag cttcttgct agagctggcc ttggaagggg aacgtctatg      600
taaatacagg gactgccgcg ctggcggtgc attctttgaa gctgcagtgc aagttggaac      660
tgaagaccta aaacactta gcgctattta cagccagttg ggcaatgctt atttctattt      720
gcatgattat gccaaagcat tagaatatca ccatcatgat ttaacccttg caaggactat      780
tggagaccag ctgggggaag cgaagctag tggtaatctg ggaaacacct taaaagtctt      840
tgggaatttt gacgaagcca tagtttgttg tcagcgacac ctagatattt ccagagagct      900
taatgacaag gtgggagaag caagagcact ttacaatctt gggaatgtgt atcatgccaa      960
agggaaaagt tttggttgc ctgggtccca ggatgtagga gaatttccag aagaagtga      1020
agatgctctg caggcagcgc tggattttta tgaggaaaac ctatcattag tgactgcttt      1080
gggtgaccga gcgcacaaag gacgtgcctt tggaaatctt ggaaacacac attacctcct      1140
tggcaacttc agggatgcag ttatagctca tgagcagcgt ctcttattg caaaagaatt      1200
tggagataaa gcagctgaaa gaagagcata tagcaacctt ggaaatgcat atatatttct      1260
tggatgaattt gaaactgcct cggaatacta caagaagaca ctactgttgg ccgacagct      1320
taaagaccga gctgtagaag cacagtcttg ttacagtctt ggaaatacat atactttact      1380
tcaagactat gaaaaggcca ttgattatca tctgaagcac ttagcaattg ctcaagagct      1440
gaatgataga attggtgaag gaagagcatg ttggagctta ggaaatgcat acacagcact      1500
aggaaatcat gatcaagcaa tgcattttgc tgaaaagcac ttggaaattt caagagaggt      1560
tggggataaa agtgggtgaac taacagcacg acttaatctc tcagaccttc aaatggttct      1620
tggctctgagc tacagcacia ataactccat aatgtctgaa aatactgaaa ttgatagcag      1680
tttgaaatgg gtacgcccc agttgggacg ccggcatagt atggaaaata tggaacttat      1740
gaagttaaca ccagaaaagg tacagaactg gaacagtga atctctgcta agcaaaaacc      1800
tcttattgcc aaaccttctg caaagctact ctttgtcaac agactgaagg ggaaaaata      1860
caaaacgaat tcctccacta aagttctcca agatgccagt aattctattg accaccgaat      1920
tccaaattct cagaggaaaa tcagtgcaga tactattgga gatgaagggt tctttgactt      1980
attaagccga tttcaaagca ataggatgga tgatcagaga tgttgcttac aagaaaagaa      2040
ctgccataca gcttcaacaa caactcttc cactccccct aaaatgatgc taaaaacatc      2100
atctgttcct gtggtatccc ccaacacgga tgagttttta gatcttcttg ccagctcaca      2160
gagtcgccgt ctggatgacc agagggctag ttacagtaat ttgccagggc ttcgtctaac      2220
acaaaacagc cagtcggtac ttgcccacct gatgactaat gacaacaaag aggctgatga      2280

```

-continued

```

agatttcttt gacatccttg taaaatgtca aggatccaga ttagatgatc aaagatgtgc 2340
tccaccacct gctaccacaa aggggtccgac agtaccagat gaagactttt tcagccttat 2400
tttacggtcc cagggaaaga gaatggatga acagagagtt cttttacaaa gagatcaaaa 2460
cagagacact gactttgggc taaaggactt ttgcaaaaat aatgctttgt tggagttaa 2520
aaattcaggg aaaaaatcgg cagaccatta gttactatgg atttattttt ttccctttca 2580
aacacggtaa ggaacaatc tattactttt ttccttaaaa ggagaattta tagcactgta 2640
atacagctta aaatattttt agaatgatgt aaatagttaa ccttcagtag tctattaagg 2700
cattaatact tctctggaca tgcgcgtttg aggggtggagg ggtcctgtaa ggtgcttcat 2760
cgtctgtgat tactgcttgg gatgtgttct ttggcagctt gtgagattac ttacctagt 2820
gtttataaag taggaagtta agtgaatcat agattagaat ttaatactct tatggaaata 2880
atTTTTtaac atcctaattg acaatggcgt ttttttatac ataaccatgg atgtagtggg 2940
aaacaatggt gtttggtaaa aataatgtac ttgatcaatg taaaaaagta tataaaatag 3000
tcttactaaa aatctagggt ttttttctc ccaaaaaaa 3039

```

<210> SEQ ID NO 13

<211> LENGTH: 7018

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: SORT1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 13

```

ggcgggcgcg cggggcgcca ggtgtcggcg tcggcggcat tcggcggcga tggagcggcc 60
ctggggagct gcggacggcc tctcgcgtcg gccccatggc ctcggcctcc tcctcctcct 120
gcagctgctg ccgccgtoga cctcagcca ggaccggctg gacgcgcgcg cgcgcgcgcg 180
tgccgcgctg ccgcgctggg ctggcccatc cggggtgagc tgggggctgc gggcggccgc 240
agccgggggc gcgtttcccc gcggcgcccg ttggcgtcgc agcgcgcgcg gcgaggacga 300
ggagtgcggc cgggtccggg acttcgtcgc caagctggcc aacaacacgc accagcatgt 360
gtttgatgat ctcagaggct cagtatcctt gtccctgggt ggagatagca ctggggctcat 420
tctagtcttg actaccttcc atgtaccact ggtaattatg acttttggac agtccaagct 480
atatcgaagt gaggattatg ggaagaactt taaggatatt acagatctca tcaataaac 540
ctttattcgg actgaatttg gcatggctat tggtcctgag aactctggaa aggtggtgtt 600
aacagcagag gtgtctggag gaagtcgtgg aggaagaatc ttcagatcat cagattttgc 660
gaagaatttt gtgcaaacag atctcccttt tcatcctctc actcagatga tgtatagccc 720
tcagaattct gattatcttt tagctctcag cactgaaaat ggctgtggg tgtccaagaa 780
ttttggggga aaatgggaag aaatccacaa agcagtatgt ttggccaaat ggggatcaga 840
caacaccatc ttctttacaa cctatgcaaa tggctcctgc aaagctgacc ttggggctct 900
ggaattatgg agaacttcag acttgggaaa aagcttcaaa actattgggt tgaaaatcta 960
ctcatttggg cttgggggac gtttcctttt tgcctctgtg atggctgata aggataccac 1020
aagaaggatc cacgtttcaa cagatcaagg ggacacatgg agcatggccc agctccctc 1080
cgtgggacag gaacagtctt attctattct ggcagcaaat gatgacatgg tattcatgca 1140
tgtagatgaa cctggagaca ctgggttttg cacaatcttt acctcagatg atcgaggcat 1200
tgtctattcc aagtcttttg accgacatct ctacactacc acaggcggag agacggactt 1260
taccaacgtg acctccctcc gcggcgtcta cataacaagc gtgctctccg aagataattc 1320

```

-continued

tatccagacc atgatcactt ttgaccaagg aggaaggtgg acgcacctga ggaagcctga	1380
aaacagtga tgtgatgcta cagcaaaaa caagaatgag tgcagccttc atattcatgc	1440
ttcctacagc atctcccaga aactgaatgt tccaatggcc ccactctcag agccgaatgc	1500
cgtaggcatt gtcattgttc atggtagcgt gggggatgcc atctcagtga tggttccaga	1560
tgtgtacatc tcagatgatg ggggttactc ctggacaaa atgctggaag gaccccacta	1620
ttacaccatc ctggattctg gaggcacat tgtggccatt gagcacagca gccgtcctat	1680
caatgtgatt aagttctcca cagacgaagg tcaatgctgg caaacctaca cgttcaccag	1740
ggaccccac tatttcactg gcctagcttc agaacctgga gctaggctcca tgaatatcag	1800
catttggggc ttcacagaat ctttctcgac cagccagtg gtctcctaca ccattgattt	1860
taaagatata cttgaaagga actgtgaaga gaaggactat accatatggc tggcacactc	1920
cacagaccct gaagattatg aagatggctg cattttgggc taaaaaac agtttctgcg	1980
gctacgcaag tcatccgtgt gtcagaatgg tcgagactat gttgtgacca agcagccctc	2040
catctgcctc tgttccctgg aggactttct ctgtgatatt ggctactacc gtccagaaaa	2100
tgactccaag tgtgtggaac agccagaact gaagggccac gacctggagt ttgtctgta	2160
cggaagagaa gaacacctaa caacaaatgg gtaccggaaa attccagggg acaaatgcc	2220
gggtggggta aatccagttc gagaagtaaa agacttgaaa aagaaatgca caagcaactt	2280
tttgagtcgc gaaaaacaga attccaagtc aaattctgtt ccaattatcc tggccatcgt	2340
gggattgatg ctggttcacag tcgtagcagg agtgctcatt gtgaagaaat atgtctgtgg	2400
gggaagggtc ctggtgcacg gatactctgt gctgcagcag catgcagagg ccaatgggtg	2460
ggatgggtgt gatgctttgg acacagcctc ccacactaat aaaagtgggt atcatgatga	2520
ctcagatgag gacctcttgg aatagctctt cagaggagct ggacccagca tggatgggtg	2580
aaccacagta cctcttacac tcctgtgtgc tccaacttca ggaaataaat tcccattgc	2640
gagggaccca gctctgtttc tgctgcttcc atcaaagcca aaaggacct cactaaagaa	2700
atgcaggggt ggggtgggga accctgagca cttttttaca attggctctg agaaaaagg	2760
agacatttta aattctttaa cttcttattt ctcttctgt ctctttgcaa agtatgggt	2820
tttttgtttt tgttttttaa gggaaacgaa atggaattcg aagggacctt ttcactaacc	2880
ccacttctgt gtgttctgca tggcgctgc cccagggcat ctgccaaact cagtatcagc	2940
tctcacagtg tacttggtac catccctggg ctctgctggc gagacgaaac agctgtagag	3000
atgaaaacag gctgcagagg ctggcacagc ctggcggct tttctccatc tggggacagt	3060
cctactccaa gaacactgca caccagctcc tcacacagat cccacttact cttttttttt	3120
ttttcagaga ccacagacca cagtgatatt tcttttccct tgtttaatta ggcaataccc	3180
ttgttaattg ccctttggca actaaactaa ccatgtgctt cccacacagt acatcaggaa	3240
aacttacagg gcaatatttt taacttgggg caggaagaag ggagcagcag agaattgact	3300
agatatagca cctattaaaa gagaactctt gcttcttctg agatttttca agctgtgctt	3360
tgtgtgtgtg ccagtagact tacgcaagga cagggtacaa acttagctgg aagtctgcc	3420
aggctgaatg atctcttccc tagagttgat tgtcgggtac acagtgtgaa cccccgaaga	3480
cggaacctca cagtcttcca tgttcccttc ttaactgtcg tgtggctcgt tgctaaatca	3540
tgacaatggc tgctatctg ctgcttctta ggttgctgtt gtacatggaa ccaggactag	3600
agatttttct agatttatag acttaaaaa ttagaatttt attaccaggc tttccttctc	3660

-continued

accccttttt tctgactttg ccaagtaatt tgttgacacg aaaattttgg aggaaccaat	3720
tgaaaacaca cttccagtct agatgatgct ttgtgtgata cattaagttc ttatttttga	3780
ttaaaagaag ttttccattht gatactttct taaattaaat aaattataga atgtagttgg	3840
gtggattttg ggggtggccat atagtaatgg aaagctgcaa taattagttt taatacagct	3900
tgaatatttg ctatatagaa atatagtatg gaaagttttt ggtcttaatg tagctactgt	3960
gcggtgcaca gtttctccca atgattatga ctgggacatt ctttggtaga taccatttgc	4020
tactagttha ttttgtggct agaaagtcag ttttgtgtgt tttttttttt ttttatttga	4080
agtgcctaat taactttagt cagaatgtga gcagatggct aagttctctc ctcccagaa	4140
tggattaaca gctgcgtgga aagtggggga gagagtggat ggagactttt agagatgtta	4200
aaactgcagt agaataaat gagtcaggga gcttcagtta gaaaataaag ttgaggcagt	4260
ttttgtgaag ataatatggt tagggctgga gtgcactagt ctttttgctt attcattttg	4320
catggtttta aaattaaaaa taattccgaa gatacaccag ctccaaaatg aaaacgtcag	4380
cctctgcccc accctccctc ctgcccgaag tgaatttggc actcagaaaa gaactgttta	4440
taccactcac ctttctccca gcactgtctc actgtgggca gatgcaccaa tacatggtaa	4500
tcctcttact cattttaaga cgtaggaaac tcaatattct tctctaacca tatacgaatg	4560
ggctcttcgc ttttaaatgat atctgggatt tctgtggaac ttggcaaat ttcagagcac	4620
cttcactcac ataatgtcat ttgaacctca caatgttctt gggatggagt cagttgttca	4680
gggtccccgt gtgtgtgata agcagtgtgt gctggctgtc ttcagaactc ttggaaatct	4740
ttacacatgc gagtgctaac cactttgagc aaggctgcct tctttagatg gacttgcgtg	4800
tctttatgac agggatcagt ggcatttgtt tcttagcagt atttagcacc tttttgccac	4860
cttggtgaac agaaaattgt attttcctgt ctttcatggc tgaaaacaaa agtaatggga	4920
attttaaata cgtttgcaga aactgcccct cccctcattg agggtcactg ctcaagagtg	4980
caggagtgga ctctccactg atgggtctcc ctccccatcc tggtttccac cccgggctgg	5040
ctagctctgt tggtttgaag actgacagcc agcctggctc attctcatta ttggctagt	5100
agctttcttt atcaacctgc tcaactcaca atgtgtgccc tcagccagag agtaagaaag	5160
cccaaatctg ttacagcttc taaaaaaata gatttctaatt ttgtctact catgttagga	5220
gcattatctt tgaaggtaaa acatagtgtg tcattgtgta aactcccagg cttgatgtag	5280
cagaagagat catttctgga ggcttcagca atggaattta gcattataag agagattgga	5340
caaaccagtc caaagtggc cgagttctta aatccaggta gggaaactcac tcttcttct	5400
tctctggacc taattgggca ttgggcttta gtgagaccac agaccaggcc cgtctctct	5460
gtaggctttt aattcaatgg caactctatt tcaagaata aaagccttg gagagttgcg	5520
gcagttctgg gggcgggctc aggagagtcc atagatcagc cgtaactgga acgtagaatc	5580
tacgtctgcc tctgaatgga ctccccacct cctctctctt gctctgatgc ttgctctgg	5640
gcctctccat gccaagggtg gtctttctac cttgacaggc tggtaatgtg ctggccacct	5700
ccagctctg catcgagtct gtaaacaga gctggttctc atggccttcg tcacgatacc	5760
aggatacga ggggagccca gggccatcca taccacccc agggtaacgg ggctggcctg	5820
gcattagtca ttatttagtt tccaggccaa ccatccagat agagattccc tctttcttt	5880
gagcagtgtc ctcaagagct ccgtgcctgt ccacaatgac ctagagtga tctgctcat	5940
tgtagtgta gcccctcgcc cctatattca tccaggatac ttggaagtgc taaaatagga	6000
agggattcgg ctttcaactt tgctaccatc ttccctgaag caggaaaatg aacatggact	6060

-continued

taaatgttct	ttgaaaaaac	caaagtttta	agatttgctg	tgtgatgaag	tgacagggag	6120
ggccggagtc	agcagggtgc	agactttctg	ttctgtctgc	catgggtttg	tccagctcag	6180
gtagctctag	gagcaccatc	ctgccctagc	agagcccagg	ccttgccctc	atgaagcatc	6240
attgaaatag	caggagcatg	ttgatttctt	ggttaggttg	cattataata	acaagagtca	6300
gaacattaat	tcgaaacaac	ttgcagtatg	catttcttca	caccagtaca	ttcttaagtg	6360
tacttgttta	taaggaataa	cataaactaa	tctgtacctt	tatatatatg	tgtgtgtaca	6420
tataacata	tataaactgt	atagtgtaca	tggtaatgat	ttattgctat	gccccagatc	6480
cttaatgtag	ttctcctcct	ccgcatgcc	tcagccacaa	gcgggtgact	gactgttccc	6540
tgatgatttg	gccccacctc	tgtgtttgga	cctctaggga	ggagggtttt	ggtcatactc	6600
tccttatcct	cgtgcacaga	aatgctcagg	gtccccatgt	gcctgttggt	cagccctctc	6660
tcttgttccc	tttctgagca	tgtggtcctt	ccccaggctg	tgggacagct	gccttcccac	6720
gaaagtgtaa	agcagtatta	agatcattac	tgcatgtgcc	ctaaaaaccc	aagttttcta	6780
ttcccttagg	acagaaaatt	gcagtgtgagg	tgggataatc	gagtttcagt	gaccacgctc	6840
agttacacat	taaagccaga	ccccatgata	aaattccaca	aaatggaaat	aaaactcaaa	6900
tttcttttagc	attgtgtaaa	taaatctgaa	tgtgtttaac	tttgactagg	taattttctg	6960
tatatattgga	atatattgggt	taaaaataaa	acagactgga	ctttgttacc	tgacctac	7018

<210> SEQ ID NO 14

<211> LENGTH: 1749

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: DPT glucocorticoid receptor-responsive gene

<400> SEQUENCE: 14

gtgacattgt	ttgcaaaat	cccaggcagc	atggacctca	gtcttctctg	ggtacttctg	60
cccctagtc	ccatggcctg	gggccagtat	ggcgattatg	gataccata	ccagcagtat	120
catgactaca	gcgatgatgg	gtgggtgaat	ttgaaccggc	aaggcttcag	ctaccagtgt	180
ccccaggggc	aggtgatagt	ggccgtgagg	agcatcttca	gcaagaagga	aggttctgac	240
agacaatgga	actacgcctg	catgcccacg	ccacagagcc	tcggggaacc	cacggagtgc	300
tggtgggagg	agatcaacag	ggctggcatg	gaatggtacc	agacgtgctc	caacaatggg	360
ctggtggcag	gattccagag	ccgctacttc	gagtcagtgc	tggatcgggg	gtggcagttt	420
tactgttgtc	gctacagcaa	gaggtgcca	tattcctgct	ggctaacaac	agaatatcca	480
ggtcactatg	gtgaggaaat	ggacatgatt	tcctacaatt	atgattacta	tatccgagga	540
gcaacaacca	ctttctctgc	agtggaaagg	gatcgccagt	ggaagttcat	aatgtgccgg	600
atgactgaat	acgactgtga	atttgcaaat	gttttagattt	gccacatacc	aaatctgggt	660
gaaaggaaag	gggccgggga	caggaggggtg	tccacatatg	ttaacatcag	ttggatctcc	720
tatagaagtt	tctgctgctc	tctttccttc	tcctgagct	ggtaactgca	atgccaactt	780
cctgggcctt	tctgactagt	atcacacttc	taataaaatc	cacaattaaa	ccatgtttct	840
cacttttcac	atgtttcata	gcaactgctt	tatatgactg	atgatggctt	ccttgcacac	900
cacatataca	gtgcgcatgc	ttacagccgg	gcttctggag	caccagctgc	agcctggcta	960
ctgcttttta	ctgcagaatg	aactgcaagt	tcagcatagt	ggaggggaga	ggcagaactg	1020
gaggagaggt	gcagtgaagg	ttctctacag	ctaagcctgt	ttgaatgata	cgtaggttcc	1080

-continued

```

ccacccaaaag cagcgtttct gccctgaggg acatcttccc actcccctgc tccacatgag 1140
ccatgcatgc ttagcaatcc aagtgcagag ctctttgctc caggagtgcg gagactggga 1200
ggtgaaatgg ggaaatggaa gggtttgag gcagagctga aaacagggtt ggaaggattt 1260
cctgaattag aagacaaaac ttagcatacc cagtaaggaa aatgagtgcg ggggcccagg 1320
gaaccctga ggatcactct caaatgagat taaaaacaag gaagcagaga atggtcagag 1380
aatgggattc agattgggaa ctgtgggga tgagagtgc caggttgaac tgggaagtgc 1440
aaaaaggagt ttgagtcact ggcacctaga agcctgccc cgattcctag gaaggctggc 1500
agacacctg gaaccctggg gagctactgg caaactctcc tggattgggc ctgatttttt 1560
tggtgggaaa ggtgcctcg gggatcaact ttccttctgt gtgtggctca ggagttcttc 1620
tgcagagatg gcgctatctt tcctctctct gtgatgtcct gctcccaacc atttgactc 1680
ttcattacaa aagaaataaa aatattaacg ttcactatgc tgaaaataaa aaaaaaaaaa 1740
aaaaaaaaa                                     1749

```

<210> SEQ ID NO 15

<211> LENGTH: 2478

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: NRP1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 15

```

gcagttggg aaactctct gtctcccgt catcttttca ttgctgttc cctccttcc 60
cgcagacacc cggacctccc ctgggcgcca gctccgccc tccaacgggt ccagaaacaa 120
gccggatttt tttttttct tcctggaaat tggttttgg gtgtgttgc ctacctccct 180
cctccccctc cccccacag ccccccccg gcctttttt tttttttt ttttttgag 240
acatggcccg ggcagtggct cctggaagag gaacaagtgt gggaaaagg agaggaagcc 300
ggagctaaat gacaggatgc aggcgacttg agacacaaa agagaagcgt tcctctcgga 360
tccaggcatt gcctcgtgc tttctttct ccaagacggg ctgaggattg tacagctcta 420
ggcggagtgc gggctcttc gatcgcttag attctctct ttgctgcatt tccccccacg 480
tcctcgttct ccgcgctcg cctgcccacc cggagaagg agaatggaga gggggctgcc 540
gctctctgc gccgtgctg cctcgtctc cgcctcgcc ggcgctttc gcaacgataa 600
atgtggcgat actataaaaa ttgaaagccc cgggtacct acatctcctg gttatcctca 660
ttcttatcac ccaagtgaat aatgcgaat gctgattcag gctccggacc cataccagag 720
aattatgac aacttcaacc ctacttcga ttggaggac agagactgca agtatgacta 780
cgtggaagtc ttcgatggag aaaatgaaa tggacattt aggggaaagt tctgtggaaa 840
gatagcccct cctcctgtg tgtcttcagg gccatttct tttatcaaat ttgtctctga 900
ctacgaaaca catgggtcag gattttccat acgttatgaa attttcaaga gaggtcctga 960
atgttcccag aactacacaa cacctagtgg agtgataaag tccccggat tccctgaaaa 1020
atatcccaac agccttgaat gcacttatat tgtctttgcg ccaagatgt cagagattat 1080
cctggaattt gaaagctttg acctggagcc tgactcaaat cctccagggg ggatgttctg 1140
tcgctacgac cggctagaaa tctgggatgg attccctgat gttggccctc acattgggag 1200
ttactgtgga cagaaaacac caggtcgaat ccgactctca tcgggcatc tctccatggt 1260
tttttacacc gacagcgcga tagcaaaaga aggtttctca gcaactaca gtgtcttgca 1320
gagcagtgtc tcagaagatt tcaaatgtat ggaagctctg ggcattggaat caggagaaat 1380

```

-continued

tcattctgac cagatcacag cttcttccca gtatagcacc aactggtctg cagagcgctc	1440
ccgcctgaac taccctgaga atgggtggac tcccggagag gattcctacc gagagtggat	1500
acaggtagac ttgggccttc tgcgctttgt cacggctgtc gggacacagg gcgccatttc	1560
aaaagaaacc aagaagaaat attatgtcaa gacttacaag atcgacgtta gctccaacgg	1620
ggaagactgg atcaccataa aagaagggaa caaacctgtt ctctttcagg gaaacaccaa	1680
ccccacagat gttgtggttg cagtattccc caaaccactg ataactcgat ttgtccgaat	1740
caagcctgca acttgggaaa ctggcatatc tatgagattt gaagtatacg gttgcaagat	1800
aacagattat ccttgctctg gaatgttggg tatggtgtct ggacttattt ctgactccca	1860
gatcacatca tccaaccaag gggacagaaa ctggatgcct gaaaacatcc gcctggtaac	1920
cagtcgctct ggctgggcac ttcccccgc acctcattcc tacatcaatg agtggctcca	1980
aatagacctg ggggaggaga agatcgtgag gggcatcatc attcagggtg ggaagcaccg	2040
agagaacaag gtgttcatga ggaagttcaa gatcgggtac agcaacaacg gctcggactg	2100
gaagatgata atggatgaca gcaaacgcaa ggcgaagtct tttgaggga acaacaacta	2160
tgatacacct gagctgcgga cttttccagc tctctccacg cgattcatca ggatctaccc	2220
cgagagagcc actcatggcg gactggggct cagaatggag ctgctgggct gtgaagtgga	2280
agcccttaca gctggaccga ccactcccaa cgggaacttg gtggatgaat gtgatgacga	2340
ccaggccaac tgccacagtg gaacaggtga tgacttccag ctcacaggtg gcaccactgt	2400
gctggccaca gaaaagccca cggtcataga cagcaccata caatcaggta tcaaataaaa	2460
tacgaaatgt gacagatt	2478

<210> SEQ ID NO 16
 <211> LENGTH: 3372
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: ACSL5 glucocorticoid receptor-responsive gene
 <400> SEQUENCE: 16

taaaaccagg aagtgaagtc ccgagcacg ttagaaagcc tgacatggcc tgactcggga	60
cagctcagag cagggcagaa ctggggacac tctgggccgg ccttctgcct gcatggacgc	120
tctgaagcca ccctgtctct ggaggaaaca cgagcgaggg aagaaggaca gggactcgtg	180
tggcaggaag aactcagagc cgggaagccc ccattcacta gaagcactga gagatgcggc	240
cccctcgcag ggtctgaatt tcctgtgtct gttcacaaag atgcttttta tctttaactt	300
tttgttttcc ccacttccga ccccgcggtt gatctgcac ctgacatttg gagctgccat	360
cttcttgtgg ctgatcacca gaacctcaacc cgtcttacct cttcttgacc tgaacaatca	420
gtctgtggga attgagggag gagcacggaa gggggtttcc cagaagaaca atgacctaac	480
aagttgctgc ttctcagatg ccaagactat gtatgaggtt ttccaaagag gactcgtgt	540
gtctgacaat gggccctgct tgggatatag aaaaccaaac cagccctaca gatggctatc	600
ttacaaacag gtgtctgata gagcagagta cctgggttcc tgtctcttgc ataaaggtta	660
taaatcatca ccagaccagt ttgtcggcat ctttgetcag aataggccag agtggatcat	720
ctccgaattg gcttgttaca cgtactctat ggtagctgta cctctgtatg acaccttggg	780
accagaagcc atcgtaata ttgtcaacaa ggctgatata gccatgggtga tctgtgacac	840
accccaaaag gcattggtgc tgataggga tgtagagaaa ggcttcaccc cgagcctgaa	900

-continued

ggtgatcatc	cttatggacc	cctttgatga	tgacctgaag	caaagagggg	agaagagtgg	960
aattgagatc	ttatccctat	atgatgctga	gaacctaggc	aaagagcact	tcagaaaacc	1020
tgtgcctcct	agcccagaag	acctgagcgt	catctgcttc	accagtggga	ccacaggtga	1080
cccaaagga	gccatgataa	cccatcaaaa	tattgtttca	aatgetgctg	cctttctcaa	1140
atgtgtggag	catgcttatg	agcccactcc	tgatgatgtg	gccatatect	acctccctct	1200
ggctcatatg	tttgagagga	ttgtacaggc	tgttgtgtac	agctgtggag	ccagagttag	1260
attcttccaa	ggggatattc	ggttgctggc	tgacgacatg	aagactttga	agcccacatt	1320
gtttcccgcg	gtgcctcgac	tccttaacag	gatctacgat	aaggtacaaa	atgaggccaa	1380
gacacccttg	aagaagttct	tgttgaagct	ggctgtttcc	agtaaatcca	aagagcttca	1440
aaagggtatc	atcaggcatg	atagtttctg	ggacaagctc	atctttgcaa	agatccagga	1500
cagctggggc	ggaaggggtc	gtgtaattgt	cactggagct	gccccatgt	ccacttcagt	1560
catgacattc	ttccgggcag	caatgggatg	tcaggtgtat	gaagcttatg	gtcaaacaga	1620
atgcacaggt	ggctgtacat	ttacattacc	tggggactgg	acatcaggtc	acgttggggg	1680
gccccggct	tgcaattacg	tgaagctgga	agatgtggct	gacatgaact	actttacagt	1740
gaataatgaa	ggagaggtct	gcataagggg	tacaaacgtg	ttcaaaggat	acctgaagga	1800
ccctgagaag	acacaggaag	ccctggacag	tgatggctgg	cttcacacag	gagacattgg	1860
tcgctggctc	ccgaatggaa	ctctgaagat	catcgaccgt	aaaaagaaca	ttttcaagct	1920
ggcccaagga	gaatacattg	caccagagaa	gatagaaaat	atctacaaca	ggagtcaacc	1980
agtgttacaa	atttttgtac	acggggagag	cttacgggtc	tccttagtag	gagtgggtgg	2040
tcctgacaca	gatgtacttc	cctcatttgc	agccaagctt	ggggtgaagg	gctcctttga	2100
ggaactgtgc	caaaaaccaag	ttgtaaggga	agccatttta	gaagacttgc	agaaaattgg	2160
gaaagaaagt	ggccttaaaa	cttttgaaca	ggtcaaagcc	atttttcttc	atccagagcc	2220
attttccatt	gaaaatgggc	tcttgacacc	aacattgaaa	gcaaagcgag	gagagctttc	2280
caaatacttt	cggacccaaa	ttgacagcct	gtatgagcac	atccaggatt	aggataaggt	2340
acttaagtac	ctgccggccc	actgtgcact	gcttgtgaga	aaatggatta	aaaactattc	2400
ttacatttgt	tttgcccttc	ctcctatttt	tttttaacct	gttaaaactct	aaagccatag	2460
cttttgtttt	atattgagac	atataatgtg	taaacttagt	tcccaaataa	atcaatctcg	2520
tctttcccat	cttcgatgtt	gctaataatta	aggcttcagg	gctaacttta	tcaacatgcc	2580
tgtcttcaag	atcccagttt	atgttctgtg	tccttctcca	tgattttcaa	ccttaatact	2640
attagtaacc	acaagtccaa	gggtcaaagg	gacctctctg	gccttcttct	ttgttttgtg	2700
ataaacataa	cttgccaaca	gtctctatgc	ttatttacat	cttctactgt	tcaaaactaag	2760
agatttttaa	attctgaaaa	actgcttaca	attcatgttt	tctagccact	ccacaaacca	2820
ctaaaatttt	agtttttagcc	tatcactcat	gtcaatcata	tctatgagac	aaatgtctcc	2880
gatgctcttc	tgcgtaaatt	aaattgtgta	ctgaagggaa	aagtttgatc	ataccaaaaca	2940
tttctaaac	tctctagtta	gatatctgac	ttgggagtat	taaaaattgg	gtctatgaca	3000
tattgtccaa	aaggaatgct	gttcttaaaag	cattattttac	agtaggaact	ggggagttaa	3060
tctgttcctc	acagtttgct	gctgagctgg	aagctgtggg	ggaaggagtt	gacaggtggg	3120
cccagtgaa	ttttccagta	aatgaagcaa	gcactgaata	aaaacctctc	gaactgggaa	3180
caaagatcta	caggcaagca	agatgcccac	acaacaggct	tattttctgt	gaaggaaacca	3240
actgatctcc	cccacccttg	gatttagagtt	cctgctctac	cttaccacaca	gataaacacat	3300

-continued

```

gtgtgtttcta cttgtaaatg taaagtcttt aaaataaaact attacagata cttaaaaaaa 3360
aaaaaaaaaa aa 3372

```

```

<210> SEQ ID NO 17
<211> LENGTH: 5243
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BICR3 glucocorticoid receptor-responsive gene

```

```

<400> SEQUENCE: 17

```

```

agcgtgagac tcgcgccctc cggcacggaa aaggccaggc gacagggtgc gcttgaaaag 60
actgggcttg tccttgctgg tgcattcgctc gtcggcctct gggcagcagg ttacaaaagg 120
aggaaaacga cttcttctag attttttttt cagtcttctc tataaatcaa aacatctcaa 180
aatggagacc taaaatcctt aaagggactt agtctaattc cgggaggtag tttgtgcat 240
gggtaaacaa attaagtatt aactgggtgt ttactatcca aagaatgcta attttataaa 300
catgatcgag ttatataagg tataccataa tgagtttgat tttgaatttg atttgtggaa 360
ataaaggaaa agtgattcta gctggggcat attgttaaag catttttttc agagttggcc 420
aggcagtcct ctactggcac attctcccat tatgtagaat agaaatagta cctgtgtttg 480
ggaaagattt taaaatgagt gacagttatt tggaacaaag agctaataat caatccactg 540
caaattaaag aaacatgcag atgaaagttt tgacacatta aaatacttct acagtgacaa 600
agaaaaatca agaacaaagc tttttgatat gtgcaacaaa tttagaggaa gtaaaaagat 660
aatgtgatg attggtcaag aaattatcca gttatttaca aggccactga tattttaaac 720
gtccaaaagt ttgtttaaat gggctgttac cgctgagaat gatgaggatg agaattgatg 780
ttgaagggtt catttttagg aatgaagaaa cttagaaat taatataaag acagtgatga 840
atacaagaaa gatttttata acaatgtgta aaatttttgg ccagggaag gaattattgaa 900
gttagataca attacttacc tttgaggga ataattgttg gtaatgagat gtgatgtttc 960
tcctgccacc tggaacaaa gcattgaagt ctgcagtga aaagcccaac gtctgtgaga 1020
tcagggaac catgcttgca aaccactggt aaaaaaaaa aaaaaaaa aaaaaagcca 1080
cagtgacttg cttattggtc attgctagta ttatcgactc agaacctctt tactaatggc 1140
tagtaaatca taattgagaa attctgaatt ttgacaaggt ctctgctgtt gaaatggtaa 1200
atttattatt tttttgtca tgataaatc tgggtcaagg tatgctatcc atgaaataat 1260
ttctgaccaa aactaaattg atgcaatttg attatccatc ttagcctaca gatggcatct 1320
ggtaactttt gactgtttta aaaaataaat ccactatcag agtagatttg atgttggtct 1380
cagaaacatt tagaaaaaca aaagttcaaa aatgttttca ggaggtgata agttgaataa 1440
ctctacaatg ttagttcttt gagggggaca aaaaatttaa aatctttgaa aggtcttatt 1500
ttacagccat atctaaatta tcttaagaaa atttttaaca aagggaatga aatatatct 1560
atgattctgt tttccaaaa gtaacctgaa tatagcaatg aagttcagtt ttgttattgg 1620
tagtttgggc agagtctctt tttgcagcac ctgttgctta ccataattac agaggacatt 1680
tccatgttct agccaagtat actattagaa taaaaaaact taacattgag ttgcttcaac 1740
agcatgaaac tgagtccaaa agaccaaatg aacaaacaca ttaatctctg attatttatt 1800
ttaaatagaa tatttaattg tgtaagatct aatagatca ttatactaa gcaatcatat 1860
tcctgatgat ctatgggaaa taactattat ttaattaata ttgaaaccag gttttaagat 1920

```

-continued

gtggttagcca	gtcctgttac	tagtaaatct	ctttatttgg	agagaaattt	tagattgttt	1980
tgttctcctt	attagaagga	ttgtagaaag	aaaaaatga	ctaattggag	aaaaattggg	2040
gatatatcat	atttactga	attcaaaatg	tcttcagttg	taaatcttac	cattatttta	2100
cgtacctcta	agaaataaaa	gtgcttctaa	ttaaaatatg	atgtcattaa	ttatgaaata	2160
cttcttgata	acagaagttt	taaaatagcc	atcttagaat	cagtgaata	tggtaatgta	2220
ttattttcct	cctttgagtt	aggctcttg	cttttttttc	ctggccacta	aatttcacaa	2280
tttccaaaaa	gcaaaataaa	catattctga	atatttttgc	tgtgaaacac	ttgacagcag	2340
agctttccac	catgaaaaga	agcttcatga	gtcacacatt	acatctttgg	gttgattgaa	2400
tgccactgaa	acattctagt	agcctggaga	agttgacct	cctgtggaga	tgccctccat	2460
taaatggcat	cctgatggct	taatacacat	cactcttctg	tgaagggttt	taattttcaa	2520
cacagcttac	tctgtagcat	catgtttaca	ttgtatgtat	aaagattata	caaagggtgca	2580
attgtgtatt	tcttccttaa	aatgtatcag	tataggattt	agaatctcca	tgttgaaact	2640
ctaaatgcat	agaaataaaa	ataataaaaa	atttttcatt	ttggcttttc	agcctagtat	2700
taaaactgat	aaaagcaaag	ccatgcacaa	aactacctcc	ctagagaaag	gctagtcctt	2760
tttcttcccc	attcatttca	ttatgaacat	agtagaaaac	agcatattct	tatcaaattt	2820
gatgaaaagc	gccaacacgt	ttgaactgaa	atcgcacttg	tcatgtgaac	tgtaccgaat	2880
gtctacgtat	tccacttttc	ctgctggggt	tctgtctcca	gaaaggagtc	ttgctcgtgc	2940
tggtttctat	tacactgggt	tgaatgacaa	ggtcaaattc	ttctgttggt	gctgtatgct	3000
ggataactgg	aaaagaggag	acagtcctac	tgaaaagcat	aaaaagtgt	atcctagctg	3060
cagattcgtt	cagagtctaa	attccgttaa	caacttgga	gctacctctc	agcctacttt	3120
tccttcttca	gtaacaaatt	ccacacactc	attacttccg	ggtacagaaa	acagtggata	3180
tttccgtggc	tcttattcaa	actctccatc	aatccctgta	aactccagag	caaatcaaga	3240
tttttctgcc	ttgatgagaa	gttcctacca	ctgtgcaatg	aataacgaaa	atgccagatt	3300
acttactttt	cagacatggc	cattgacttt	tctgtcgcca	acagatctgg	caaaagcagg	3360
cttttactac	ataggacctg	gagacagagt	ggcttgcttt	gcctgtgggt	gaaaattgag	3420
caattgggaa	ccgaaggata	atgctatgtc	agaacacctg	agacattttc	ccaaatgccc	3480
atttatagaa	aatcagcttc	aagacacttc	aagatacaca	gtttctaata	tgagcatgca	3540
gacacatgca	gcccgcctta	aaacattctt	taactggccc	tctagtgttc	tagttaatcc	3600
tgagcagctt	gcaagtgcgg	gtttttatta	tgtgggtaac	agtgatgatg	tcaaatgctt	3660
ttgctgtgat	gggtggactca	gggtgtggga	atctggagat	gatccatggg	ttcaacatgc	3720
caagtgggtt	ccaagggtgt	agtacttgat	agaattaaa	ggacaggagt	tcacccgtca	3780
agttcaagcc	agttaccctc	atctacttga	acagctgcta	tccacatcag	acagcccagg	3840
agatgaaaaa	gcagagtcac	caattatcca	ttttgaacct	ggagaagacc	attcagaaga	3900
tgcaatcatg	atgaatactc	ctgtgattaa	tgctgccgtg	gaaatgggct	ttagtagaag	3960
cctggtaaaa	cagacagttc	agagaaaaat	cctagcaact	ggagagaatt	atagactagt	4020
caatgatctt	gtgttagact	tactcaatgc	agaagatgaa	ataaggggaag	aggagagaga	4080
aagagcaact	gaggaaaaag	aatcaaatga	tttattatta	atccggaaga	atagaatggc	4140
actttttcaa	catttgactt	gtgtaattcc	aatcctggat	agtctactaa	ctgccggaat	4200
tattaatgaa	caagaacatg	atgttattaa	acagaagaca	cagacgtctt	tacaagcaag	4260
agaactgatt	gatacgattt	tagtaaaagg	aaatattgca	gccactgtat	tcagaaactc	4320

-continued

```

tctgcaagaa gctgaagctg tggtatatga gcattttatt gtgcaacagg acataaaata 4380
tattcccaca gaagatgttt cagatctacc agtgaagaa caattgcgga gactacaaga 4440
agaaagaaca tgtaaagtgt gtatggacaa agaagtgtcc atagtgttta ttccttgtagg 4500
tcacttagta gtatgcaaag attgtgctcc ttctttaaga aagtgtccta tttgtaggag 4560
tacaatcaag ggtacagttc gtacatttct ttcattgaaga agaaccacaaa catcgtctaa 4620
actttagaat taattttatta aatgtattat aactttaact tttatcctaa tttgggtttcc 4680
ttaaaatttt tattttttta caactcaaaa aacattgttt tgtgtaacat atttatatat 4740
gtatctaaac catatgaaca tatatttttt agaaactaag agaatgatag gcttttggtc 4800
ttatgaacga aaaagaggta gcactacaaa cacaatattc aatcaaaatt tcagcattat 4860
tgaaattgta agtgaagtaa aacttaagat atttgagtta acctttaaga attttaaata 4920
ttttggcatt gtactaatac cggaacatg aagccaggtg tgggtgtagt tgcctgtagt 4980
cccaggctga ggcaagagaa ttacttgagc ccaggagttt gaatccatcc tgggcagcat 5040
actgagaccc tgcctttaaa aacaaacaga acaaaaacaa aacaccaggg acacatttct 5100
ctgtcttttt tgatcagtggt cctatacatc gaaggtgtgc atatatgttg aatgacattt 5160
tagggacatg gtgtttttat aaagaattct gtgagaaaaa atttaataaa gcaacaaaaa 5220
ttactcttaa aaaaaaaaaa aaa 5243

```

<210> SEQ ID NO 18

<211> LENGTH: 1579

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: NNMT glucocorticoid receptor-responsive gene

<400> SEQUENCE: 18

```

gaggagggtc ttgccagaca ctgggtcatg gcagtggctg gtgaagctgc agttgcctag 60
ggcagggatg gagagagagt ctgggcatga ggagagggtc tcgggatgtt tggctggact 120
agattttaca gaaagcctta tccaggcttt taaaattact ctttcagac ttcatctgag 180
actccttctt cagccaacat tccttagccc tgaatacatt tcctatcctc atctttccct 240
tctttttttt cctttctttt acatgtttta atttaaacca ttcttcgtga ccccttttct 300
tgggagattc atggcaagaa cgagaagaat gatggtgctt gttaggggat gtcctgtctc 360
tctgaacttt ggggtcctat gcattaaata attttcctga cgagctcaag tgcctcctct 420
ggtctacaat ccctggcggc tggcctcat cccttgggca agcattgcac acagctcatg 480
gccctccctc taccataccc tccacccccg ttgccttaag ctccctctc cggaatttc 540
atcatttctc agaacagcca gaacatttgt ggtctatttc tctgttagtg tttaaccaac 600
catctgttct aaaagaaggg ctgaactgat ggaaggaatg ctgttagcct gagactcagg 660
aagacaactt ctgcagggc actccctggc ttctggagga aagagaagga gggcagtgct 720
ccagtgttac agaagtgaga cataatggaa tcaggttcca cctccaagga cacctatcta 780
agccatttta accctcggga ttacctagaa aaatattaca agtttggttc taggcactct 840
gcagaaagcc agattcttaa gcacctctg aaaaatcttt tcaagatatt ctgcctagac 900
ggtgtgaagg gagacctgct gattgacatc ggctctggcc cactatcta tcagctcctc 960
tctgcttggt aatcctttta ggagatcgtc gtcactgact actcagacca gaacctgcag 1020
gagctggaga agtggctgaa gaaagagcca gaggcctttg actgggtccc agtggtgacc 1080

```

-continued

tatgtgtgtg atcttgaagg gaacagagtc aagggtccag agaaggagga gaagttgaga	1140
caggcggtca agcagggtgct gaagtgtgat gtgactcaga gccagccact gggggccgctc	1200
cccttaccoc cggtgactg cgtgctcagc aactgtgtc tggatgccgc ctgccagac	1260
ctccccacct actgcagggc gctcaggaac ctgcgcagcc tactgaagcc agggggcttc	1320
ctggtgatca tggatgcgct caagagcagc tactacatga ttggtgagca gaagtctctc	1380
agcctccccc tgggccggga ggcagtagag gctgctgtga aagaggctgg ctacacaatc	1440
gaatggtttg aggtgatctc gcaaagtatt tcttccacca tggccaacaa cgaaggactt	1500
ttctccctgg tggcgaggaa gctgagcaga cccctgtgat gcctgtgacc tcaattaaag	1560
caattccttt gacctgtca	1579

<210> SEQ ID NO 19
 <211> LENGTH: 980
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: IGFBP6 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 19

gcgcgccgcg gcagcagctg cgtgcgact gctctggaag gagaggacgg ggcacaaacc	60
ctgacctga cccccacag gctgctgcca ccgctgctgc tgctgctagc tctgctgctc	120
gctgccagcc caggaggcgc cttggcgcgg tgcccaggt gcgggcaagg ggtgcaggcg	180
ggttctccag ggggctcgct ggaggaggag gatgggggt cgccagccga gggctgcgcg	240
gaagctgagg gctgtctcag gagggagggg caggagtgcg gggctctacac ccctaactgc	300
gccccaggac tgcagtcca tccgcccaag gacgacgagg cgctttgcg ggcgctgctg	360
ctcgcccgag gccgctgct tccggccgc gcgcctgctg ttgcagagga gaatcctaag	420
gagagtaaac cccaagcagg cactgcccgc ccacaggatg tgaaccgcag agaccaacag	480
aggaatccag gcacctctac cagccctcc cagcccaatt ctgcgggtgt ccaagacact	540
gagatgggccc catgccgtag acatctggac tcagtgtgc agcaactcca gactgaggtc	600
taccgagggg ctcaaacact ctacgtgcc aattgtgacc atcgaggctt ctaccggaag	660
cggcagtgcc gctcctccca ggggcagcgc cgaggctcct gctggtgtgt ggatcggatg	720
ggcaagtccc tgccagggtc tccagatggc aatggaagct cctcctgcc cactgggagt	780
agcggctaaa gctgggggat agaggggctg cagggccact ggaaggaaaca tggagctgtc	840
atcactcaac aaaaaaccga ggcctcaat ccacctcag gcccccccc atgggcccct	900
caccgctggt tggaaagagt gttggtgtg gctggggtgt caataaagct gtgcttgggg	960
tcgctgaaaa aaaaaaaaaa	980

<210> SEQ ID NO 20
 <211> LENGTH: 7346
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: PLXNC1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 20

gcgaggagga aacggtgccg gagcgcgag ggcttgctgc cgccaccgcc gctgcacagg	60
ctgcgggagc gagectgcc gcgcgcgcc tcccgtctct ccttctggg cgagctgcgg	120
ggatggggcg gccgcgggag cccgagcgc gcaggaacc gccgcgcgc ccgcccggt	180
ctccgttgcc gcgcgctga gccgcgctc ccgcgcgcgc cctgccccg gggcgcccc	240

-continued

cccagcccca	tggaggtctc	cggaggaag	gcgcgcgcgc	gccccccgcg	ccccgcagcg	300
ccactgcccc	tgtctgccta	tctgttgga	ctggcggctc	cggcccgggg	cgcggaacgag	360
cccggtgtggc	ggtcggagca	agccatcgga	gccatcgcg	cgagccagga	ggacggcgctg	420
tttgtggcga	gcggcagctg	cctggaccag	ctggactaca	gcctggagca	cagcctctcg	480
cgctgtacc	gggaccaagc	gggcaactgc	acagagccgg	tctcgctggc	gccccccgcg	540
cggccccggc	cggggagcag	cttcagcaag	ctgctgctgc	cctaccgcga	gggggcgggcc	600
ggcctcgggg	ggctgctgct	caccggctgg	accttcgacc	ggggcgccctg	cgaggtgcgg	660
cccctgggca	acctgagccg	caactccctg	cgcaacggca	cggaggtggg	gtcgtgccac	720
cgcgagggct	cgacggccgg	cgtggtgtac	cgcgcgggcc	ggaacaaccg	ctggtacctg	780
gggtggtggc	ccacctacgt	gctgctgag	cggagagcgg	cgagccgctg	caaccccgcg	840
gcacccgacc	acgacacggc	catcgcgctc	aaggacacgg	aggggcgcg	cctggccacg	900
caggagctgg	ggcgccctca	gctgtgcgag	ggcgcgggca	gcctgcactt	cgtggacgcc	960
tttctctgga	acggcagcat	ctacttcccc	tactaccctc	acaactacac	gagcggcgct	1020
gccaccggct	ggcccagcat	ggcgcgcatc	gcgcagagca	cggaggtgct	gttccagggc	1080
caggcatccc	tcgactcgcg	ccacggccac	cccgcggccc	gccgcctgct	cctctcctcc	1140
agcctagtgg	aggccctgga	cgtctggggc	ggagtgttca	gcgcggccgc	tggagagggc	1200
caggagcggc	gctccccac	caccacggcg	ctctgcctct	tcagaatgag	tgagatccag	1260
gcgcgcgcca	agagggctcag	ctgggacttc	aagacggccg	agagccactg	caaagaaggg	1320
gatcaacctg	aaagagtcca	accaatcgca	tcatctacct	tgatccattc	cgacctgaca	1380
tccgtttatg	gcaccgtggg	aatgaacagg	actgttttat	tcttggggac	tggagatggc	1440
cagttactta	aggttattct	tggtgagaat	ttgacttcaa	attgtccaga	ggttatctat	1500
gaaattaaag	aagagacacc	tgtttttctac	aaactcgttc	ctgatcctgt	gaagaatatc	1560
tacatttatc	taacagctgg	gaaagagggtg	aggagaattc	gtgttgcaaa	ctgcaataaa	1620
cataaatcct	gttcggagtg	tttaacagcc	acagaccctc	actgcggttg	gtgccattcg	1680
ctacaaagg	gcacttttca	aggagattgt	gtacattcag	agaacttaga	aaactggctg	1740
gatatttcgt	ctggagcaaa	aaagtgcct	aaaattcaga	taattcgaag	cagtaaagaa	1800
aagactacag	tgactatggg	gggaagcttc	tctccaagac	actcaaagtg	catggtgaag	1860
aatgtggact	ctagcagggg	gctctgccag	aataaaaagtc	agcccaaccg	gacctgcacc	1920
tgtagcatcc	caaccagagc	aacctacaaa	gatgtttcag	ttgtcaacgt	gatgttctcc	1980
ttcggttctt	ggaatttatc	agacagattc	aactttacca	actgctcatc	attaaaagaa	2040
tgccagcat	gcgtagaaac	tggctgcgcg	tgggttaaaa	gtgcaagaag	gtgtatccac	2100
cccttcacag	cttgcgaccc	ttctgattat	gagagaaacc	aggaacagtg	tccagtggct	2160
gtcgagaaga	catcaggagg	aggaagaccc	aaggagaaca	aggggaacag	aaccaaccag	2220
gctttacagg	tctttctacat	taagtccatt	gagccacaga	aagtatcgac	attagggaaa	2280
agcaacgtga	tagtaacggg	agcaaaacttt	acccgggcat	cgaacatcac	aatgatcctg	2340
aaaggaacca	gtacctgtga	taaggatgtg	atacaggtta	gccatgtgct	aaatgacacc	2400
cacatgaaat	tctctcttcc	atcaagccgg	aaagaaatga	aggatgtgtg	tatccagttt	2460
gatggtggga	actgctcttc	tgtgggatcc	ttatcctaca	ttgctctgcc	acattgttcc	2520
cttatatttc	ctgctaccac	ctggatcagt	ggtggtcaaa	atataaccat	gatgggcaga	2580

-continued

aattttgatg taattgacaa cttaatcatt tcacatgaat taaaaggaaa cataaatgtc	2640
tctgaatatt gtgtggcgac ttactgcggt tttttagccc ccagttttaa gagttcaaaa	2700
gtgcgcacga atgtcactgt gaagctgaga gtacaagaca cctacttgga ttgtggaacc	2760
ctgcagtatc gggaggaccc cagattcacg gggatcggg tggaatccga ggtggacaca	2820
gaactggaag tgaatttca aaaagaaaat gacaacttca acatttccaa aaaagacatt	2880
gaaattactc tcttccatgg ggaattggg caattaaatt gcagttttga aaatattact	2940
agaaatcaag atcttaccac catcctttgc aaaattaaag gcatcaagac tgcaagcacc	3000
attgccaact cttctaagaa agttcgggtc aagctgggaa acctggagct ctacgtcgag	3060
caggagtcat ttccttccac atgggtatgt ctgattgtgc tccctgtctt gctagtgtt	3120
gtcatttttg cgcccggtgg ggtgaccagg cacaaatcga aggagctgag tcgcaaacag	3180
agtcaacaac tagaattgct ggaagcggag ctccggaaag agatacgtga cggctttgct	3240
gagctgcaga tggataaatt ggatgtggt gatagttttg gaactgttcc ctcccttgac	3300
tacaaacatt ttgctctgag aactttcttc cctgagtcag gtggtctcac ccacatcttc	3360
actgaagata tgcataacag agacgccaac gacaagaatg aaagtctcac agctttggat	3420
gccctaactc gtaataaaag ctttcttggt actgtcatcc acaccttga aaagcagaag	3480
aacttttctg tgaaggacag gtgtctgttt gcctccttcc taaccattgc actgcaaacc	3540
aagctggtct acctgaccag catcctagag gtgctgacca gggacttgat ggaacagtgt	3600
agtaacatgc agccgaaact catgctgaga cgcacggagt ccgtcttga aaaactctc	3660
acaaactgga tgtccgtctg cctttctgga tttctccggg agactgtcgg agagcccttc	3720
tatttgctgg tgacgactct gaaccagaaa attaacaagg gtcccgtgga tgtaactact	3780
tgcaaaagccc tgtacacact taatgaagac tggctgttgt ggcaggttcc ggaattcagt	3840
actgtggcat taaacgtcgt ctttgaaaa atcccggaaa acgagagtgc agatgtctgt	3900
cggaatatct cagtcaatgt tctcgactgt gacaccattg gccaaagcaa agaaaagatt	3960
ttccaagcat tcttaagcaa aaatggctct ccttatggac ttcagcttaa tgaaattggt	4020
cttgagcttc aaatgggcac acgacagaaa gaacttctgg acatcgacag ttcctccgtg	4080
attcttgaag atggaatcac caagctaaac accattggcc actatgagat atcaaatgga	4140
tccactataa aagctcttaa gaagatagca aattttactt cagatgtgga gtactcgat	4200
gaccactgcc atttgatttt accagattcg gaagcattcc aagatgtgca aggaaagaga	4260
catcgaggga agcacaagtt caaagtaaaa gaaatgtatc tgacaaagct gctgtcgacc	4320
aaggtggcaa ttcattctgt gcttgaaaa ctttttagaa gcatttggag tttacccaac	4380
agcagagctc catttgctat aaaatacttt ttgtactttt tggacgcccc ggctgaaaac	4440
aaaaaaatca cagatcctga cgtcgtacat atttgaaaa caaacagcct tcctcttcgc	4500
ttctgggtga acatcctgaa gaacctcag ttgtctttg acattaagaa gacaccacat	4560
atagacggct gttgtcagt gattgcccag gcattcatgg atgcattttc tctcacagag	4620
cagcaactag ggaagggaag accaactaat aagcttctct atgccaagga tatcccaacc	4680
tacaaagaag aagtaaaatc ttattacaaa gcaatcaggg atttgctcc attgtcatcc	4740
tcagaaatgg aagaattttt aactcaggaa tctaagaaac atgaaaatga atttaatgaa	4800
gaagtggcct tgacagaaat ttacaaatac atcgtaaaat attttgatga gattctaaat	4860
aaactagaaa gagaacgagg gctggaagaa gctcagaaac aactcttgca tgtaaaagtc	4920
ttatttgatg aaaagaagaa atgcaagtgg atgtaagcac tctggggcct ggcttaactc	4980

-continued

ggcaaagttc	ttcagacgac	ttgggagcaa	aatggctgct	tgagctactc	tgtgtcgtaa	5040
at ttgttgtt	tgcacatagg	ttccactttg	ggcactgtct	ttttaagaga	ccaaggcaca	5100
tgcacagctt	ttagaaagca	taccaaccct	tgtgcctgtg	tgtataccgt	gggaaccctt	5160
ctgtaaatag	agttgaagtg	gttgttgcaa	acagcctcct	tgtttacaga	gaatacaagg	5220
ccagtaagcg	aatgtcagta	ttgtaactac	agtctccact	taagcacaat	gatataagtg	5280
gttttgtttg	aaaactacag	ctatgtagca	cttgtgtctc	actgcacctc	tgcatgttaa	5340
agggatactg	ccagtgtctc	aaacaaaatg	tgaaatgagt	catttggaag	caagggtggg	5400
gtgttagggc	aacctcgagg	atttgcagca	ttgaaacttt	ccccagtagt	tcttggaagaa	5460
gctgaccgca	gaatttggtg	gtgtacactt	agcattttgt	agtggtgtgt	tgtgtttaa	5520
ccaaaaacta	acagtgttgc	aacattgttg	aaagggtctg	tgtttttcag	tggtcatcaa	5580
ctgcactcca	tcaaaactac	ctccatttca	ccaaggagct	ctaaagtaag	gagagtgggc	5640
tttattttaa	tgaacagcat	tttaaccaga	tactttgtcc	taatgtatgt	tccttttctt	5700
catctgtttt	ttcatactaa	atgtatttga	tagtggacat	gttggatatt	atacaaaaaa	5760
atcattaatt	catttctgtt	ccaaaacctt	tgatcagaac	gatctgtgga	agagtaactc	5820
catttctata	tgagtgtgtg	tctccttgct	ttagatttct	gggtgaacct	gtgggttatga	5880
atacttgtgt	gtgattttaa	aaaaaaaaaga	tacattttac	atttcacga	attgctgttc	5940
acactggagt	attatatata	aatatatata	tttgaggccc	aaggcctgaa	aaatattagt	6000
atacaacttg	gtatcttagt	cttactatgt	actttttgaa	agtattcctc	gcaggagaaa	6060
gaatttaaaa	taccattttt	attcatgcct	ttctttttaa	agaattctct	atccagttat	6120
actgtagtct	ttttagtgtc	gattttttta	ttcctgaatt	tttgcgtctc	atgaccagtt	6180
ttaataccac	tgtgttttcc	ttctatttaa	ccagaagaag	taaacagcat	aattggcaac	6240
tcttgagctt	ttcttgtggc	aggcaccttt	tacccttggg	gctccaaatc	ccccatctag	6300
gaaagaaaat	tttttcaagt	caaataacat	tgatcacata	ttccttgaaa	tcatttacca	6360
acactgtatg	gagcattagg	atttaaatat	gaatttgtct	taaaggcaat	tcctttttgc	6420
ttctgtatta	tctggaaaag	catgagagag	gtgacacctc	aacaaactga	tcagagaaaa	6480
taagcagtta	ctaccctgat	aggcaccttc	ccaatcctgt	tgcttttgac	cattgtctgt	6540
ccaacggaca	cacctcaaac	aaacaaaact	accaaataga	tgacagatca	gaataaagg	6600
gagaggtctg	gtccccattg	aaggctgcta	cagtcttcaa	agaggtgaag	gagttcataa	6660
gagaacaaca	gtaggaaaagt	tgagagccaa	gggtaggaga	gttgcccaa	agacttcccc	6720
tactacttta	gggtactgaa	aactcaagg	atcagctaca	gctttatcta	agtatttact	6780
aaatgctaca	tgagggtgtc	cctgtccagc	tttctggcac	atgagtcctg	tgtggagagt	6840
tacctcctct	tccagggact	gtgctgttgg	gaactttggg	caagtcactt	acctctttgt	6900
gcctcaattt	ctgtataata	tttctaagct	acctcactga	gggtggtatga	agattcacta	6960
atgtatgtag	cgtgtttgtc	aatcctccag	tgaagagcac	tatctagatc	acattttgga	7020
tcacattagc	caaatgcagt	aaatggccaa	attagatgtg	tgctgaagac	aatcagtcac	7080
tggtgtctata	ttaaacagca	accagagcaa	caaatggcaa	acaatttcta	ttttcaagtt	7140
tctttgcata	tttttttggg	gcaaaacctt	ttataaactt	ttttttctaa	cactagtgtc	7200
tacagcagca	ttcaaaaaaa	ttctgttacc	ttttctgtat	taggatttaa	agtcattttc	7260
ttattgtata	cctgattgaa	gctgttcttg	gagatgaatg	ttttaaatgt	ctatatccaa	7320

-continued

```

aaaataaaca ttttgatgta actgtg 7346

<210> SEQ ID NO 21
<211> LENGTH: 2828
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: SLC46A3 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 21

agaacagtga cagcgccgcg gcagccgacc ccgcctcctc ggcggacagc gatgctcagc 60
tggctgcggc cgagtcacgc cctagcgtg gcagggccgc tgaccgaccg acggaggcgc 120
cgattggccg attgtccact gcgcagaagg agcagctgct ccgcgccccg ccgcgcccgc 180
ctgaggccga ggtccgcagg gccgcgggga agccgagggc tgccggagaa ccctgcaggt 240
gtcactcggg acgcggaagt gcgcttgccg aggtttgttt tacaatacgc ttgagactcc 300
ccgacaagcg taatttggtc gagttcgacg ggaaagtact cteccccccc cagcgccggc 360
cgcgtagtcc gaggttactg tccccggcgc gtccctctgtt gcccagtcac agaggctgcc 420
cttgaacccg ggcgcgcacg agcgcagggc atccgaggcg acagcccctg gcacggcccc 480
acctgtaccc agcctggcag gaagactgta atcgtgggaa tacagctacc taccaggca 540
atatgaagat tttatttgta gaacctgcc ttttccttag tgcatttgc atgactttga 600
ccggtccact gacaacgcaa tatgtttatc ggagaatatg ggaagaaact ggcaactaca 660
ctttttcacc tgatagcaat atttctgagt gtgaaaaaaa caaaagcagc ccaatttttg 720
cattccagga ggaagtccag aaaaaagtgt cacgttttaa tctgcagatg gacataagtg 780
gattaattcc tggctctagt tctacattca tacttttgtc tattagtgat cactacggac 840
gaaaattccc tatgattttg tcttcgctg gtgctcttgc aaccagcgtt tggctctgtt 900
tgctttgcta ttttgccttt ccattccagc ttttgattgc atctaccttc attggtgcat 960
tttgtggcaa ttataccaca ttttggggag cttgctttgc ctatatagtt gatcagtgtg 1020
aagaacacaa acaaaaaaca attcgaatag ctatcattga ctttctactt ggacttgta 1080
ctggactaac aggactgtca tctggctatt ttattagaga gctagggttt gagtggctgt 1140
ttctaattat tgctgtgtct cttgctgtta atttgatcta tattttatct tttctcgag 1200
atccagtga agagtgttca tctcagaatg ttactatgtc atgtagtga ggettcaaaa 1260
acctatttta ccgaacttac atgcttttta agaatgcttc tggtaagaga cgatttttgc 1320
tctgtttgtt actttttaca gtaatcactt atttttttgt ggtaattggc attgccccaa 1380
tttttatcct ttatgaattg gattcaccac tctgctggaa tgaagttttt ataggttatg 1440
gatcagcttt gggtagtgcc tcttttttga ctagtctcct aggaatatgg cttttttctt 1500
attgtatgga agatattcat atggccttca ttgggatttt taccacgatg acaggaatgg 1560
ctatgaccgc gtttgccagt acaacactga tgatgttttt agccaggggtg ccgttccttt 1620
tcactattgt gccattctct gttctacggt ccatgttgtc aaaagtgggt cgttcgactg 1680
aacaaggtag cctgtttgct tgtattgctt tcttagaaac acttgaggga gtcactgcag 1740
tttctacttt taatggaatt tactcagcca ctgttgcttg gtaccctggc ttcactttcc 1800
tgctgtctgc tggctctgta ctacttcag ccatcagctc atgtgtgtgc aagtgtacca 1860
gctggaatga gggaaagctat gaacttctta tacaagaaga atccagtga gatgcttcag 1920
acagagcctg ttaagctgct attgatagtc ggagcttata tactgtgact tctgaagact 1980
atacatgaat tccacaatca gtgctttgtt gatacaaaat ccttaaaagg gaggcacttt 2040

```

-continued

```

aaagaatatg tatttttcac ttttcttaat atgtttcatc ggtgacaggc atgataatat 2100
ttctatatgt aatgggtaat tgggaaaaaa tagatgataa ataaaattgc tctaaagaag 2160
ttaaaaaact gaatgaacag ctaatactgg tataaagtaa ctaatgtttg gagccaacat 2220
ttgttccttg tgtcagcaaa aggatattca cattccatga tccttggtg agaattctgc 2280
ctctagtctt tcttaccag ctgttgtcta tccttggtca attataaata ctgctaaggg 2340
catttttaaa atacgatctt gtactcctta aatttgaatc cgtcagcacg gtcactcata 2400
ggaaaatgat caaacaagca agccagtcac gatttgactc cttcccatct catttcttac 2460
tgccttacgc tcatectgag gtccaccttg gtctctaaaa acaccatgtg ttctcatgcc 2520
tccatgtctt ttcacacact gtccatttg ctcttctctc cacattacat tgaaactttc 2580
aagcctcagt cgaaacattg cttctcttgg atagcagcct tcttgacatc cctcctcact 2640
ccccagtcct tacagggctt ccatagctct ttgtgtgcac ttcgatccca gcattttcca 2700
tcgacttgta attgtttctg ctacctgaca atcatcgctt tgagtactgg gacaaccttt 2760
gattactcat tatactctca ataaatattt gttgaactaa aaaaaaaaaa aaaaaaaaaa 2820
aaaaaaaaa 2828

```

<210> SEQ ID NO 22

<211> LENGTH: 2840

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: C14orf139 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 22

```

gtttttgtgc aggaacagcc cctcccgctt ttgtcctggc ggtgagcacc cagggctaag 60
cttttgaaca ctttctttgt gtttggtatc agccaggcca atgcatattt gctttcattt 120
cttcttgagc ttgaggagct cctgggtgca aatcttggaa aatgaggatc tctgagcctt 180
tccaggccag ctctttgttt tgtagcagac aattgaggct ttgaaaagga aagtgggtgg 240
gggcacccca cagggtggcc tcatacccca attgccagtg cctgcaggct gcttcagcag 300
aggccagag tcaaagagga cttaaaacca gctgtcgttt ctcccttagc ttctgtgtat 360
gagagaaaac acttctgttt ttcaaagtaa gaacaaggag gaatttgttt ctaaaagaac 420
attaaaacac aggcctgttg tctaaaagca aatggttcag caggatgttc agggccttaa 480
agcacagtca gcaggactca gcactcctca gcacctgctc tccggttgtc atggtaacat 540
catccccaac ccaaccacct tgtccagccg agagacagca atcataagga gggacctcgg 600
tttccccga ggatcctggg cttcctttct gaaacgcttg cttctgagct cagcaaccag 660
gaacaccagg ccagcccac cccagcacct ctgtggagat gagggacaaa gtcctacagt 720
ccctcttctt gttctgatga gaaagggagg gaagaaaaca taccctgagc gcttgaata 780
tggtcatgac actttcaaaa agcctgtgct atggagtcac gatcagaaac cagagtgtgg 840
agagggtcag cagcctgctt cagagcagcc agctaggcgg ggagtggtaa atttgggact 900
tgtaccagc catgactggc tccagaccca gtgctccact ctatggaatg ttccctgggc 960
ctcagttgct ttcctttcct ttgcaggccg cgggctgctg ccactctggc agctggtgag 1020
ttagctggag ggcaacattc caaagcaggg gcagcatgct gctttcctcc tgtgccact 1080
cctgcgggga agtccgttga ctcccaccgc tgaaggagc tggcaacacc aggatgaggt 1140
cccaggggac gggagcaggt acccactgtc tgtctacctt cccactggaa aagcacggac 1200

```

-continued

```

aggccagccc ttgcgggggc aggcagagga cagagttggc tttgcgcggt ctctgcctgc 1260
tgagcagttc caattcctct catgggagaa acaaggagge agtcgcttgt gcatgttcca 1320
gaagttttac tggggaggag gaagcggaca gaggaagctg tgtgtgcatg tgaaggggtg 1380
ggcaggggtg gagggatgca cgcgtatgtg agcatagcat gtgtgagtac tacacacatc 1440
tccatgcaga agcacaaactg ggcagccctg gcttccagct ctgggcttca gcacaacaga 1500
caccagcctg tggctctctca gaagccaggg agaccacatc gggctcagga cgttttacc 1560
aaagtccaga gtttttatgc ctctccctgg cattctccat aaagaaggga aggtcagatg 1620
acctcttaga tctgtgtcat ctgggaattt ccttgggctg gtttagacac gatgccctct 1680
ttttctcagg atagcagata acctgctttg aaagagggct taattctgtg ggctcctaat 1740
tttctccttt ctctctctct tctgtgtgt gtgtgttggg aaaatggcaa gttccaata 1800
ccagcttttg aggaacgatt acgttttccc tccaatttca agtcgaaag accagagccc 1860
tcattccaaa gccccccacc cagatggatt ttttcgttcc atttgcctac cgtcccatgg 1920
gagggcccca tgtctctca gaaccatcc tggaggcagc aggtcgggta gagtgtgtt 1980
ggcctgtcga tgacctccac ccctgagatt gtgaacaagg atgtctgggg cgatgtgag 2040
aatgtttttg aagctgtccc cagatgacgc tgatgatcac accagattga gtgctgcgat 2100
cgccttgagt ccaacctctg cataaacgag gttctcataa acaagttcac tctacctaa 2160
gctaagtcta tgtgagcaaa cccacttcat cctttgtacc tggagacctg gttactacta 2220
cctgatactg acctgttcat gtagctggaa tgggtgtgtt catgcagtgt ggaccaagca 2280
atggcatggg gtgtgtgtgt gtgtgtgtgt gtgtctgtgt gtgtgtgttt gtgtatgct 2340
tcacacttgt gtgtgtatat gtgcatgtag atgtgcataaat gatgtcaaag 2400
acaaacacat tccattgttt taaatattct attatgtaa caatacgag agggaccata 2460
tctactcttg tcatattatt tgtgatggtt aaacatgcat ttgcaataaa ttaagctttc 2520
tggaaggca agcagatttg gagccaaacg actgtctcgg aacatgtgtg tggtatctcg 2580
gttcatatca agtccaaagc taatggagcc ttcccccca tccagggagg aacaccagga 2640
ccccggagtt tcttcttagt gctatatatt aaagttgcat tgacgttttc ctcccttcc 2700
ttttgtgcaa gttggaagta gcagtgttct aaaagatggg ttgacgtttt tgctgttgtt 2760
ttatgttttt aaaaatgtat ctgctttgtg ttggaaata aaaatctcta ttttggtcta 2820
tgaaaaaaaa aaaaaaaaaa 2840

```

```

<210> SEQ ID NO 23
<211> LENGTH: 2309
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: PIAS1 glucocorticoid receptor-responsive gene
<400> SEQUENCE: 23

```

```

gggggggcgg gccggggcgg ggccaggcgg gctagagggg cgggtctagc ggcgccccc 60
ggcgaagttc actgcgcttg cgtgacaga cgcaagatgg cggacagtgc ggaactaaag 120
caaatggtta tgagccttag agtttctgaa ctccaagtac tgttgggcta cgccgggaga 180
aacaagcacg gacgcaaaca cgaacttctc acaaaagccc tgcatttgct aaaggctggc 240
tgtagtctg ctgtgcaaat gaaaattaag gaactctata ggcggcggtt cccacagaaa 300
atcatgacgc ctgcagactt gtccatcccc aacgtacatt caagtcctat gccagcaact 360

```

-continued

ttgtctccat ctaccattcc acaactcact tacgatggtc accctgcac atcgccatta	420
ctccctgttt ctcttctggg acctaaacat gaactggaac toccacatct tacatcagct	480
cttcaccag tccatccgga tataaaactt caaaaattac cattttatga tttactggat	540
gaactgataa aaccaccag tctagcatca gacaacagtc agcgttttcg agaaacctgt	600
tttgcatctg ccttgacacc acaacaagtg cagcaaatca gtagttccat ggatatttct	660
gggaccaa atgtacttcc agtacaggtc cagttaagggt tttgtttatc agaaaccagt	720
tgtccacaag aagatcactt cccacccaat ctttgtgtga aagtgaatac aaaaccttgc	780
agccttccag gttaccttcc acctacaaaa aatggcgtgg aaccaaagcg acccagccga	840
ccaattaata tcacctcact tgtccgactg tccacaacag taccaaacac gattgttgtt	900
tcttgactg cagaaattgg aagaaactat tccatggcag tatatcttgt aaaacagttg	960
tcctcaacag ttcttcttca gaggttacga gcaaagggaa taaggaatcc ggatcattct	1020
agagctttaa ttaagagaa gttgactgag gatccagaca gtgaaatagc tacaaccagc	1080
ctaagggttt ctctactatg tccacttgggt aaaatgcggc tgacaattcc gtgtcgggac	1140
cttacatggt ctcatctaca atgttttgac gcaactcttt acattcagat gaatgagaaa	1200
aaaccaacct gggtttgtcc tgtctgtgat aagaaggctc catatgaaca cettattatt	1260
gatggcttgt ttatggaaat cctaaagtac tgtacagact gtgatgaaat acaatttaag	1320
gaggatggca cttgggcacc gatgagatca aaaaagggaag tacaggaagt ttctgcctct	1380
tacaatggag tcgatggatg cttgagctcc acattggagc atcaggtagc gtctcaccac	1440
cagtcctcaa ataaaaacaa gaaagtagaa gtgattgacc taacctaga cagttcatct	1500
gatgaagagg aagaagagcc atctgccaag aggacctgtc cttccctatc tcccacatca	1560
ccactaaata ataaaggcat ttaagtctt ccacatcaag catctccagt atcccgacc	1620
ccaagccttc ctgctgtaga cacaagctac attaatcct cctcatcca agactatagg	1680
catcctttcc acatgacacc catgccttac gacttacaag gattagattt ctttcctttc	1740
ttatcaggag acaatcagca ttacaacacc tccttgcttg ccgctgcagc agcagcagtt	1800
tcagatgac aagacctcct acactcgtct cggtttttcc cgtatacctc ctacagatg	1860
tttcttgatc agttaagtgc aggaggcagt acttctctgc caaccaccaa tggaagcagt	1920
agtggcagta acagcagcct ggtttcttcc aacagcctaa gggaaagcca tagccacacc	1980
gtcacaacaa ggagcagcac ggacacggca tccatctttg gcacatacc agacattatt	2040
tcattggact gattcccagg cctgtgtgt cccatcccca cccagatcg aatgaacttg	2100
gcagaaagaa gagaactttg tgtctgttt taccttactc tgtttagaaa agtatacaag	2160
cgtgtttttt ttcctttttt tagggaaaaa attaaaagaa atgtacagag aacaaaacta	2220
tattttcagt tttacttttg tatataaatc taagactgcc tgtgtgataa aacacttggt	2280
taaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2309

<210> SEQ ID NO 24

<211> LENGTH: 1740

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: IDH2 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 24

ccagcgttag cccgcggcca ggcagccggg aggagcggcg cgcgtcggga cctctccgc	60
cctgctcgtt cgctctccag cttgggatgg ccggctacct gcgggtcgtg cgctcgtct	120

-continued

```

gcagagcctc aggcctcgcg cggcctggg cgcggcggc cctgacagcc cccacctcgc 180
aagagcagcc gcgcgccac tatgcccaca aaaggatcaa ggtggcgaag cccgtggtgg 240
agatggatgg tgatgagatg acccgattta tctggcagtt catcaaggag aagctcatcc 300
tgccccacgt ggacatccag ctaaagtatt ttgacctcgg gctcccaaac cgtgaccaga 360
ctgatgacca ggtcaccatt gactctgcac tggccacca gaagtacagt gtggctgtca 420
agtgtgccac catcaccctc gatgaggccc gtgtggaaga gttcaagctg aagaagatgt 480
ggaaaagtcc caatggaact atccggaaca tcttgggggg gactgtcttc cgggagccca 540
tcatctgcaa aaacatccca cgcctagtcc ctggctggac caagcccatc accattggca 600
ggcacgcccc tggcgaccag tacaaggcca cagactttgt ggcagaccgg gccggcactt 660
tcaaaatggt cttcaccoca aaagatggca gtggtgtcaa ggagtgggaa gtgtacaact 720
tccccgcagg cggcgtgggc atgggcatgt acaacaccga cgagtccatc tcaggttttg 780
cgcacagctg cttccagtat gccatccaga agaaatggcc gctgtacatg agcaccaaga 840
acaccatact gaaagcctac gatgggcggt tcaaggacat cttccaggag atctttgaca 900
agcactataa gaccgacttc gacaagaata agatctggta tgagcaccgg ctcatgatg 960
acatgggtgg tcaggctctc aagtcttcgg gtggctttgt gtgggcctgc aagaactatg 1020
acggagatgt gcagtcagac atcctggccc agggctttgg ctcccttggc ctgatgacgt 1080
ccgtcctggt ctgccctgat ggaagacga ttgaggctga ggcgctcat gggaccgtca 1140
cccgccacta tcgggagcac cagaagggcc ggcccaccag caccaacccc atcgccagca 1200
tctttgcctg gacacgtggc ctggagcacc gggggaagct ggatgggaaac caagacctca 1260
tcaggtttgc ccagatgctg gagaagggtg gcgtggagac ggtggagagt ggagccatga 1320
ccaaggacct ggcgggctgc attcacggcc tcagcaatgt gaagctgaac gagcacttcc 1380
tgaacaccac ggacttctc gacaccatca agagcaacct ggacagagcc ctgggcaggc 1440
agtaggggga ggcgccaccc atggctgcag tggaggggcc agggctgagc cggcgggtcc 1500
tcttgagcgc ggcagagggt gagcctcaca gcccctctct ggaggccttt ctaggggatg 1560
tttttttata agccagatgt ttttaaaagc atatgtgtgt ttccctcat ggtgacgtga 1620
ggcaggagca gtgcgtttta cctcagccag tcagtatgtt ttgcatactg taatttatat 1680
tgcccttggg acacatgggt ccatatttag ctactaaaaa gctcttcaca aaaaaaaaaa 1740

```

<210> SEQ ID NO 25

<211> LENGTH: 1552

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: SERPINF1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 25

```

ggtcgcttta agaaaggagt agctgtaatc tgaagcctgc tggacgctgg attagaaggc 60
agcaaaaaaa gctctgtgct ggctggagcc ccctcagtgt gcaggcttag agggactagg 120
ctgggtgtgg agctgcagcg tatccacagg cccaggatg caggccctgg tgctactcct 180
ctgcattgga gccctcctcg ggcacagcag ctgccagaac cctgccagcc ccccgaggga 240
gggctcccca gaccccgaca gcacaggggc gctggtggag gaggaggatc ctttcttcaa 300
agtccccgtg aacaagctgg cagcggctgt ctccaacttc ggctatgacc tgtaccgggt 360
gcgatccagc acgagcccca cgaccaacgt gctcctgtct cctctcagtg tggccacggc 420

```

-continued

```

cctctcggcc ctctcgctgg gagcggagca gcgaacagaa tccatcattc accgggctct 480
ctactatgac ttgatcagca gccagacat ccatgggtacc tataaggagc tccttgacac 540
ggtcactgcc cccagaaga acctcaagag tgcctcccg atcgtctttg agaagaagct 600
gcgcataaaa tccagctttg tggcacctct ggaaaagtca tatgggacca ggcccagagt 660
cctgacgggc aaccctcgct tggacctgca agagatcaac aactgggtgc aggccagat 720
gaaaggggaag ctgccaggt ccacaagga aattcccgat gagatcagca ttctccttct 780
cgggtgtggcg cacttcaagg ggcagtgggt aacaaagttt gactccagaa agacttcct 840
cgaggatttc tacttgatg aagagaggac cgtgagggtc cccatgatgt cggaccctaa 900
ggctgtttta cgctatggct tggattcaga tctcagctgc aagattgccc agctgccctt 960
gaccggaagc atgagtatca tcttcttct gccctgaaa gtgaccaga atttgacctt 1020
gatagaggag agcctcacct ccgagttcat tcatgacata gaccgagaac tgaagaccgt 1080
gcaggcggtc ctactgtcc ccaagctgaa gctgagttat gaaggcgaag tcaccaagtc 1140
cctgcaggag atgaagctgc aatccttgtt tgattcacca gactttagca agatcacagg 1200
caaaccatc aagctgactc aggtggaaca ccgggctggc tttgagtgga acgaggatgg 1260
ggcgggaacc acccccagcc cagggctgca gctgcccac ctcccttcc cgctggacta 1320
tcaccttaac cagcctttca tcttctgtact gagggacaca gacacagggg ccttctctt 1380
cattggcaag attctggacc ccaggggccc ctaatatccc agtttaatat tccaataccc 1440
tagaagaaaa ccgaggagc agcagattcc acaggacacg aaggctgccc ctgtaagggt 1500
tcaatgcata caataaaga gctttatccc taaaaaaaaa aaaaaaaaaa aa 1552

```

<210> SEQ ID NO 26

<211> LENGTH: 4816

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: ERBB2 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 26

```

gttccccgat ttttgtgggc gctgccccg cccctcgcc cctgctgtg tccatatatc 60
gaggcgatag ggttaaggga aggcggacgc ctgatgggtt aatgagcaa ctgaagtgtt 120
ttccatgatc ttttttgagt cgcaattgaa gtaccacctc ccgagggtga ttgcttcccc 180
atgcggggta gaacctttgc tgtcctgttc accactctac ctccagcaca gaatttggt 240
tatgcctact caatgtgaag atgatgagga tgaaaacctt tgtgatgatc cacttccact 300
taatgaatgg tggcaaagca aagctatatt caagaccaca tgcaaagcta ctccctgagc 360
aaagagtcac agataaaacg ggggcaccag tagaatggcc aggacaaacg cagtgcagca 420
cagagactca gacctggca gccatgcctg cgcaggcagt gatgagagtg acatgtactg 480
ttgtggacat gcacaaaagt gagtgtgcac cggcacagac atgaagctgc ggctccctgc 540
cagtcctcag acccacctgg acatgctccg ccacctctac cagggtgccc aggtggtgca 600
gggaaacctg gaactcacct acctgcccac caatgccagc ctgtccttcc tgcaggatat 660
ccaggaggtg cagggctacg tgctcatgc tcacaaccaa gtgaggcagg tcccactgca 720
gaggctgcgg attgtgcgag gcaccagct ctttgaggac aactatgcc tggccgtgct 780
agacaatgga gaccctgta acaataccac cctgtcaca ggggcctccc caggaggcct 840
gcgggagctg cagcttcgaa gcctcacaga gatcttgaag ggaggggtct tgatccagcg 900

```

-continued

gaacccccag	ctctgctacc	aggacacgat	tttgtggaag	gacatcttcc	acaagaacaa	960
ccagctggct	ctcacactga	tagacaccaa	ccgctctcgg	gcctgccacc	cctgttctcc	1020
gagtgtgaag	ggctcccgt	gctggggaga	gagttctgag	gattgtcaga	gcctgacgcg	1080
cactgtctgt	gccggctgg	gtgcccgtg	caaggggcca	ctgcccactg	actgctgcca	1140
tgagcagtgt	gctgccggct	gcacggggcc	caagcactct	gactgcctgg	cctgcctcca	1200
cttcaaccac	agtggcatct	gtgagctgca	ctgcccagcc	ctggtcacct	acaacacaga	1260
cacgtttgag	tccatgcccc	atcccagagg	ccggtataca	ttcggcgcca	gctgtgtgac	1320
tgcctgtccc	tacaactacc	tttctacgga	cgtggggtcc	tgcacctcgc	tctgccccct	1380
gcacaaccaa	gaggtgacag	cagaggatgg	aacacagcgg	tgtgagaagt	gcagcaagcc	1440
ctgtgcccga	gtgtgctatg	gtctgggcat	ggagcacttg	cgagaggtga	gggcagtta	1500
cagtgcgaat	atccaggagt	ttgctggctg	caagaagatc	tttgggagcc	tggcatttct	1560
gccggagagc	tttgatgggg	accagcctc	caacactgcc	ccgctccagc	cagagcagct	1620
ccaagtgttt	gagactctgg	aagagatcac	aggttaccta	tacatctcag	catggccgga	1680
cagcctgcct	gacctcagcg	tcttccagaa	cctgcaagta	atccggggac	gaattctgca	1740
caatggcgcc	tactcgctga	cctgcaagg	gctgggcac	agctggctgg	ggctgcgctc	1800
actgagggaa	ctgggcagtg	gactggcct	catccaccat	aacaccacc	tctgcttctg	1860
gcacacggtg	ccctgggacc	agctctttcg	gaacccgcac	caagctctgc	tccacactgc	1920
caaccggcca	gaggacgagt	gtgtggggca	gggcctggcc	tgcaccagc	tgtgcgccc	1980
agggcactgc	tggggctccag	ggcccaccca	gtgtgtcaac	tgcagccagt	tccttcgggg	2040
ccaggagtgc	gtggaggaat	gccgagtact	gcaggggctc	cccaggaggt	atgtgaatgc	2100
caggcactgt	ttgccgtgcc	accctgagtg	tcagccccag	aatggctcag	tgacctgttt	2160
tggaccggag	gctgaccagt	gtgtggcctg	tgccactat	aaggaccctc	ccttctgcgt	2220
ggcccgcctg	cccagcggtg	tgaaacctga	cctctcctac	atgcccatct	ggaagtcttc	2280
agatgaggag	ggcgcatgcc	agccttgccc	catcaactgc	accactcct	gtgtggacct	2340
ggatgacaag	ggctgccccg	ccgagcagag	agccagccct	ctgacgtcca	tcactctctg	2400
ggtggttggc	attctgtctg	tctgtgtctt	gggggtgtgc	tttgggatcc	tcataaagcg	2460
acggcagcag	aagatccgga	agtacacgat	gcggagactg	ctgcaggaaa	cggagctggt	2520
ggagccgctg	acacctagcg	gagcgatgcc	caaccaggcg	cagatgcgga	tcctgaaaga	2580
gacggagctg	aggaaggtga	aggtgcttgg	atctggcgct	tttggcacag	tctacaaggg	2640
catctggatc	cctgatgggg	agaatgtgaa	aattccagtg	gccatcaaag	tgttgaggga	2700
aaacacatcc	cccaaagcca	acaagaaat	cttagacgaa	gcatacgtga	tggtggtgt	2760
gggctcccca	tatgtctccc	gccttctggg	catctgcctg	acatccacgg	tgacgtggt	2820
gacacagctt	atgccctatg	gctgcctctt	agaccatgtc	cgggaaaacc	gcggacgcct	2880
gggctcccag	gacctgtctg	actggtgtat	gcagattgcc	aaggggatga	gctacctgga	2940
ggatgtgcgg	ctctacacac	gggacttggc	cgctcggaac	gtgctggtca	agagtcccaa	3000
ccatgtcaaa	attacagact	tccggctggc	tccgctgctg	gacattgacg	agacagagta	3060
ccatgcagat	gggggcaagg	tccccatcaa	gtggatggcg	ctggagtcca	ttctccggcg	3120
gcggttcacc	caccagagtg	atgtgtggag	ttatggtgtg	actgtgtggg	agctgatgac	3180
ttttggggcc	aaaccttacg	atgggatccc	agccggggag	atccctgacc	tgctggaaaa	3240
gggggagcgg	ctgccccagc	cccccatctg	caccattgat	gtctacatga	tcatggtcaa	3300

-continued

atgttgatg attgactctg aatgtcggcc aagattccgg gagttggtgt ctgaattctc	3360
ccgcattggcc agggaccccc agcgttttgt ggtcatccag aatgaggact tgggcccagc	3420
cagtcccttg gacagcacct tctaccgctc actgctggag gacgatgaca tgggggacct	3480
ggtggatgct gaggagtatc tggtagccca gcagggttc ttctgtccag accctgcccc	3540
gggcgtggg ggcattgtcc accacaggca ccgcagctca tctaccagga gtggcgggtg	3600
ggacctgaca ctagggtctg agccctctga agaggaggcc ccaggtctc cactggcacc	3660
ctccgaagg gctggctccg atgtatttga tggtagctg ggaatgggg cagccaagg	3720
gctgcaaagc cccccacac atgaccccag cctctacag cggtagctg aggacccac	3780
agtacccctg ccctctgaga ctgatggta cgttgcccc ctgacctga gccccagcc	3840
tgaatatgtg aaccagccag atgttcggcc ccagccccct tcgcccag agggccctct	3900
gctgctgcc cgacctgtg gtgccactct ggaaaggccc aagactctct ccccaggga	3960
gaatggggtc gtcaaagacg tttttgcctt tgggggtgcc gtggagaacc ccgagtactt	4020
gacacccag ggaggagctg cccctcagcc ccacccctc cctgcctca gcccagcctt	4080
cgacaacctc tattactggg accaggaccc accagagcgg ggggtccac ccagcacctt	4140
caaagggaca cctacggcag agaaccaga gtacctgggt ctggacgtgc cagtgtgaac	4200
cagaaggcca agtccgcaga agccctgatg tgtctcagg gagcaggga ggctgactt	4260
ctgctggcat caagaggtg gagggccctc cgaccactc caggggaacc tgccatgcca	4320
ggaacctgtc ctaaggaaac ttctctctc cttgagttcc cagatggctg gaaggggtcc	4380
agcctcgtt gaagaggaac agcactggg agtctttgtg gattctgagg cctgcccac	4440
tgagactcta ggggtcagtg gatgccacg cccagcttg cccttctct ccagatctg	4500
ggtactgaaa gccttaggga agctggcctg agaggggaag cggccctaag ggagtgtcta	4560
agaacaaaag cgaccattc agagactgtc cctgaaacct agtactgcc cccatgagga	4620
aggaacagca atggtgtcag tatccaggct ttgtacagag tgctttctg tttagttttt	4680
actttttttg tttgttttt ttaaatga aataaagacc cagggggaga atgggtgtt	4740
tatggggagg caagtgtggg gggctcttct ccacaccac tttgtccatt tgcaaatata	4800
ttttggaaaa cagcta	4816

<210> SEQ ID NO 27

<211> LENGTH: 6831

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: PECAM1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 27

ccaggcccca ttgtcccg tttccagcca tggctgcat tacctgacca gcgccacagc	60
cggctctctc gcaggcgccg ggagaagtga ccagagcaat ttctgctttt cacagggcgg	120
gtttctcaac ggtgacttgt gggcagtgcc ttctgtgag cgagtcattg ccgaaggca	180
gaactaactg tgctgcagt cttactctc aggatgcagc cgagggtggc ccaaggggcc	240
acgatgtggc ttggagtct gctgacctt ctgctctgtt caagcctga gggtaagaa	300
aactctttca caatcaacag tgtgacatg aagagcctgc cggactggac ggtgcaaat	360
gggaagaacc tgacctgca gtgcttcgc gatgtcagca ccacctctca cgtcaagcct	420
cagcaccaga tgctgttcta taaggatgac gtgctgtttt acaacatctc ctccatgaag	480

-continued

agcacagaga gttattttat tctgaagtc cggatctatg actcaggagc atataaatgt	540
actgtgattg tgaacaacaa agagaaaacc actgcagagt accaggtgtt ggtggaagga	600
gtgccagtc ccagggtgac actggacaag aaagaggcca tccaaggtgg gatcgtgagg	660
gtcaactgtt ctgtcccaga ggaaaaggcc ccaatacact tcacaattga aaaacttgaa	720
ctaaatgaaa aaatggtcaa gctgaaaaga gagaagaatt ctcgagacca gaattttgtg	780
atactggaat tccccgtga ggaacaggac cgcgttttat ccttcgatg tcaagctagg	840
atcattttctg ggatccatat gcagacctca gaatctacca agagtgaact ggtcacctg	900
acggaatcct tctctacacc caagttccac atcagcccca ccggaatgat catggaagga	960
gtcagctcc acattaagtg caccattcaa gtgactcacc tggcccagga gtttcagaa	1020
atcataattc agaaggacaa ggcgattgtg gcccaaca gacatggcaa caaggctgtg	1080
tactcagtc tggccatggt ggagcacagt ggcaactaca cgtgcaaagt ggagtcacg	1140
cgcataatcca aggtcagcag catcgtggtc aacataacag aactattttc caagcccgaa	1200
ctggaatctt ccttcacaca tctggaccaa ggtgaaagac tgaacctgtc ctgctccatc	1260
ccaggagcac ctccagccaa cttcaccatc cagaaggaag atacgattgt gtcacagact	1320
caagatttca ccaagatagc ctcaaagtcg gacagtggga cgtatatctg cactgcaggt	1380
attgacaaag tggtaagaa aagcaacaca gtccagatag tcgtatgtga aatgctctcc	1440
cagccagga tttcttatga tgcccagttt gaggtcataa aaggacagac catcgaaagt	1500
cgttgcgaaat cgatcagtg aactttgcct atttcttacc aactttttaa aacaagtaaa	1560
gttttgaga atagtaccaa gaactcaaat gatcctgcgg tattcaaaga caaccact	1620
gaagacgtcg aataccagtg tgttcagat aattgccatt cccatgccaa aatgttaagt	1680
gaggttctga gggtaaggt gatagcccg gtggatgagg tccagatttc tatectgtca	1740
agtaaggtgg tggagtctgg agaggacatt gtgctgcaat gtgctgtgaa tgaaggatct	1800
ggtccatca cctataagtt ttacagagaa aaagaggga aaccttcta tcaaatgacc	1860
tcaaatgcc cccaggcatt ttggaccaag cagaaggcta gcaaggaaca ggaggagag	1920
tattactgca cagcctcaa cagagccaac cagcctcca gtgtcccag aagcaaaata	1980
ctgacagtc gagtcattct tgcccattgg aagaaggac ttattgcagt ggttatcatc	2040
ggagtgatca ttgctctctt gatcattgag gccaaatgtt attttctgag gaaagccaag	2100
gccaaagcaga tgccagtga aatgtccagg ccagcagtac cacttctgaa ctccaacaac	2160
gagaaaatgt cagatcccaa tatggaagct aacagtcatt acggtcaca tgacgatgtc	2220
agaaaccatg caatgaaacc aataaatgat aataaagagc ctctgaactc agacgtgcag	2280
tacacggaag ttcaagtgtc ctacagtgag tctcacaag atctaggaaa gaaggacaca	2340
gagacagtgt acagtgaagt ccggaaagct gtccctgatg ccgtggaag cagatactct	2400
agaacggaag gctcccttga tggaacttag acagcaaggc cagatgcaca tccctggaag	2460
gacatccatg ttccgagaag aacagataat cctgtattt caagacctct gtgcacttat	2520
ttatgaacct gccctgtctc cacagaacac agcaattcct caggctaagc tgcgggttct	2580
taaatccatc ctgctaagtt aatgttgggt agaaagagat acagaggggc tgttgaattt	2640
cccacatacc ctccctccac caagttggaa catccttga aattggaaga gcacaagagg	2700
agatecaggg caaggccatt gggatattct gaaacttgaa tattttgttt tgtgcagaga	2760
taaagacctt ttccatgcac cctcatcac agaaaccaat tttctttttt atactcaatc	2820
atttctagcg catggcctgg tttagaggctg gttttttctc ttttctttg gtccttcaaa	2880

-continued

ggctttagt	tttggtagt	ccttggtctt	tggaaatata	cagtgtgac	cagacagcct	2940
ccccctgtcc	cctctatgac	ctcgccctcc	acaaatggga	aaaccagact	acttgggagc	3000
accgcctgtg	aaataccaac	ctgaagacac	cgttcattca	ggcaacgcac	aaaacagaaa	3060
atgaaggtag	aacaagcaca	gatgttcttc	aactgttttt	gtctacactc	tttctctttt	3120
cctctaccat	gctgaaggct	gaaagacagg	aagatgggtc	catcagcaaa	tattattctt	3180
aattgaaaa	ttgaaatgtg	tatgtttctt	actaattttt	aaaaatgtat	tccttgccag	3240
ggcaggcaag	gtggctcacg	cctgtaatcc	cagcacttca	ggaggctgag	gtgggcggat	3300
cacctgaggt	caggagttag	agaccagcct	gatgaaaccc	tgtctctact	aaaaatacaa	3360
gaattagccg	ggcgtggtag	cgcattccct	tagtatcagc	tactcaagag	gctgaggtag	3420
gattatcgct	tgaaccagg	aaacggaggt	tgtatgtgag	ggagatcgcg	ccactgcact	3480
ccagcctgag	tgacagagtg	agaatccatc	tcaaaaaaaa	caaaaaacaa	aattgcttgc	3540
taaagaagtg	gtctcctgag	gtcttaagac	attcctgaca	gtgtcttgag	tgggtgggag	3600
agaggctgct	gtcattgcgc	tgtggaattt	cacagatgag	aaccacgcct	agccaaaatc	3660
acttttctg	tttgctcag	tgacacagct	gcagggaccc	tcgtggatgt	tgtattaaat	3720
aaatttgacc	tttgctcttt	gcagatctgt	gaaatgtgt	cttctgaggg	gccacatgca	3780
tctatagtgc	tgaggactcc	ttgggcctct	gaagtcacag	agagaaccga	gcaggctctat	3840
gtttttgttt	tgttgttttg	agacggagat	tcgctcttgt	tgcccgggct	ggactgcagc	3900
ggcgcaacct	ctgctcactg	caacctccgc	ctcctgggtt	caagcagttc	tcctgtctca	3960
gcctcccag	tagctgggat	tacaggcaca	tgtcaccacg	cctggctaata	ttttgtattt	4020
ttagtagaga	tggggtttca	ccacgttgge	caggctgac	tcgaatgcct	gacctttggt	4080
gatctgcccg	ccttgtcttc	atgtgtgctc	cacaggcctt	tgggttggga	ttgcaggcgt	4140
gagccaccat	gcccagccta	gactcttttg	acaatatgat	gaaagctgtt	ggttcctttc	4200
cccaacacac	acacaccgag	ttgtatcacg	aaaatgtcat	acaatttcca	ggttttctga	4260
gtggtgggct	cagattgagg	tcaaggatc	agacgacctc	taacgacctt	catgtctctg	4320
ttgatgatct	ggggacagcc	agatccccct	tgctccaggga	gttccttagt	cccttgccac	4380
caccagagaa	gggcaattgc	cacgggagct	gcaaagaccc	tattcctact	cctggcgctt	4440
tacttatgca	gcacgactga	attttttgtt	ttgttttgtt	ttgttgagac	aggggcttgc	4500
tctgttgccc	aggctggagt	gcagtggcac	aacaatggct	caccgcagcc	tcgaaccctt	4560
gggctcaagc	gatcctccca	tctcagcttc	ctgggtagct	gggaccagag	gcgtgagccg	4620
ccatagctgg	ctaattttta	attttttttt	tgacagagatg	aggtttcacc	atggtgcccc	4680
ggctgggtctc	gaacttctgg	gctcaagtga	tcctccctcc	ttggcctcgc	aaagtgtctg	4740
gattgcaggc	atgagccacc	gcccccgcc	tgtggagcac	acatgagttt	aaaattactt	4800
tccttctctg	ctatatcttc	gaggaggaaa	cttcattcgc	agggatcttt	cttagtggtt	4860
ttaatggcta	aaaggctctg	ctgaatccag	gacgtgggtt	ttagccttcc	tcggcagctg	4920
ccgtaacccc	gggtgtctaaa	cctgaagcat	cccaggagca	cccactccag	gagttttctc	4980
ggcgcgggaa	ctcattagtt	agagcgccct	cttgtgttct	catgtggtaa	tcggtcactg	5040
aaggacttaa	aatggctcct	agccaacaca	cagtaaaact	tttccctctt	ctgaccccaa	5100
gaggtcagcc	acccatttca	tgagcatata	ctggtcgccc	catcagcgtt	ctctgattgg	5160
ctaactgaac	ccactccccg	acctagactc	aagacaggcg	aagtgacgct	taggtcaaca	5220

-continued

```

ttcactcact aaagcaacga ctgtcgggag attttgtctc ccgctggttt tggaatggtg 5280
tctggagaca tttttggttg tcacagctgg gtgggtgtgc tcccgccatc tggtaggtgtag 5340
aaaccaagca tgtcctctaaa catcctacag gcacagaacc gtctcccacg accaagcatg 5400
atcaagtccc aaatgccaat aatggccagg ttgagaaact ctgcacagaa gcatccagtt 5460
atttgtctgt ttgtctcaaca agcttgtgct catcatgctc tgtgttctctg acgctgtgct 5520
gggtgttggc ggtgggaaga ttacaagagt cacatggcag ctgtcctcct ggaaggtaca 5580
accagtaga gatgcagact aacagagagc caattacaaa gcagtgtgac aagcgtcatg 5640
gtggaaaatt aaaagctcaa acaaggcac atgggagggg cttccaacac agactttggg 5700
ggatccagga aggtctaaga ggaagtggg tctcaccaaa gccttgacca taggcagagg 5760
gtaccagtgg aaaaggtggg gtgaagaaca ttgaggacaa aaggaagaag tgcaggaagg 5820
ccctgaggca agggagtggg ggtgtccctg gagggatggc agcagggcag tctgtcagac 5880
ccaagtggcc tccagcccta gaagccaatt agtctctctc aaaaagctgt cactgtcccc 5940
taagaattgc tgccaggctc ccactggcct gactcagtct ttgagagtct taaggaggag 6000
gtctctgaaa ggtacacacc aagaactctc cccagcacag ctgtttttaa gactctccac 6060
cagcgtcatt ggcgtgttgg gaagaaaccc tctgccacag aggccagctt cagcctttgc 6120
ctaacaccgc aaggggcaat ggaaaggtaa acgggaagga gatgtctccc cagcaggcta 6180
tttgaggaca gtcttccctg cagaagatct caacctgggg tccacagagt ggaatgtta 6240
gagtaggagg ctaggcaaac atgagcagga caggtagggg cccccacagg aatgtcaggc 6300
taccatcagg tgatggtcag gtggttgta aactgtctct gtaaaataat aattggttgc 6360
agccagctcc aagcaaggac agtctctcaa tagatacaaa acacctgat ctggtgatca 6420
gccgttccc gataagatct caggagctgg gcaagcagcc tggagcatgc gcaccaagag 6480
gcaaaatggc ggaatttaac cagtatatga cctaccttcc tctgggaacg cagcactggt 6540
aaggggaaaa atgcctcaag tgagcatgcg cgcaacttca gtaatcacac tgtgcatgcg 6600
accccttcca agtctgtggc agtcaccaca tacgcgga gctgtgtgca agggaagaat 6660
caggggagat gagacgtaaa tcccagaact atgccaata cataaaaccc caagttaagg 6720
gtcaggcagg gcacttagat ctctcaagtt gcctgcctga cccaagtga gtgtacttcc 6780
ttttgttctc gctctaaaac tttttaataa actctcactc ctgctctaaa a 6831

```

<210> SEQ ID NO 28

<211> LENGTH: 2956

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: LBH glucocorticoid receptor-responsive gene

<400> SEQUENCE: 28

```

ggggctgagt gctcagtgga gagcggggag ttgtgtccac cttgccgacg tcgctagccg 60
tggggctgtc ctgggaaggc ggacggcgag cgcccggtgt ccgcactcgg ccgctgccc 120
tgcccgtctg cgcccgtgtc atcctcactc gggacgcagg gaccgttttt aaatcacagg 180
ggcgtgtgtc agcctgcctt aggaacttcat gtctatatat ttccccattc actgccccga 240
ctatctgaga tcggccaaga tgactgaggt gatgatgaac acccagccca tggaggagat 300
cggcctcagc ccccgcaagg atggccttcc ctaccagatc tcccagacc cgtcagattt 360
tgaccgtgtc tgcaaaactga aggacgtct gccctccata gtggtggaac ccacagaagg 420
ggaggtggag agcggggagc tccggtggcc ccctgaggag ttctgtgtcc aggagatga 480

```

-continued

gcaagataac	tgcgagaga	cagcgaaaga	aaataaagag	cagtagagtc	cctgtggact	540
cccatgggtc	ataccagcca	gcattctgtc	ctgaactgtg	tttttcccat	catgacggaa	600
gaagagagtg	agccgcaatt	gttctgaaaa	tgtaaaca	ggcttctgtt	ttgcacctgc	660
agatcaccca	gttggttttc	ttttcttttc	ttgecttttt	ttttttttga	aatttgccga	720
gcagtggagc	cctctgacaa	tttgcaaggc	cctctgagaa	aggaagctgc	ttagagccag	780
ggggttagtg	ggtgagggga	gcgagtgtc	tttttgagat	cattatctga	actcaggcag	840
cctagtagag	gcagtgtgtg	gattccaatg	ggtcttggtg	ggtgggaggt	ggggcatgtg	900
caaagcaagc	aaggaacatt	tggggtaaga	aaacaaacat	gaggcaaaag	aaaaaataca	960
tgtttttaag	aaaacattga	gcagagaact	gcagccagga	tgcgctcagc	agacattcac	1020
tctggctgct	gggacatcag	aaaacaaagt	cttcattctc	ctctccagtt	tcacccaccc	1080
caccctttgc	tttcatttca	ggtgtgttgg	tctatatgac	agggaggaga	gtaaaggaga	1140
gcaggagcaa	ttggctgcct	gcaaaagccag	ctggagggtga	agtgacagaa	aggaaaggtc	1200
accccatctc	actccatggc	ctctctgtc	ccagctgtgg	taggctcaca	tagccagttg	1260
gatcggtttt	taagaggcag	tgcttttcag	cttttctccc	tgatatatcc	attttgcttc	1320
ccagcacttt	ttaggagtag	tgagagcact	tctgcctctt	gttggaagcc	ccaggggtga	1380
cactcagcac	gaaggctctc	cccttaactg	ctgcccctcc	aagacttgct	cccgagatgg	1440
agtgggctgt	gtcttccagg	ctggcccttc	cttctcctca	ccgccacctt	ccctgcccga	1500
gccccagcag	ccatgggtac	atgggtccccc	agctcaccta	tggaattccc	ccagctctgc	1560
cagctgcagt	actcacgccc	catgggggat	cttggctctg	ttttcttggt	ggagcctagt	1620
ggagagcaga	cgtggctttt	tatgtgtctt	gttggggagg	tgacttgcat	ggtggggaca	1680
aggctgtcgt	ggcaaccttg	ggatcgagtt	tgagactaaa	ggatgtcatg	agatccctgg	1740
cttctcccca	tgttgttccc	ggacaagggc	agaaggagg	catggcaagg	gacctctgct	1800
gtccttactc	aacagtgggc	ctcatccctc	cccacctccc	actgcttctc	gcaagggcac	1860
cagttgtatg	agaaagtgtg	cctttggact	taggatttct	tattgtagct	aagagccatc	1920
tgaagcagca	gggtgcagga	caaagtcttc	agtcgcccga	gagcagtacc	gtgtggccaa	1980
gaggtggact	cagagccttc	cttgagctaa	actcggccaa	ccaaggcacg	cagcatgtcc	2040
cctcaggtct	ccagtcagtc	cagggtgacc	ctcagttctg	gacgtgtgta	tatagctgta	2100
tttaatacct	caaggtcatt	gtggctctgg	ggatgccggg	gcaggaggac	gaggggtgcg	2160
tgtggacaca	gcagtcgcg	gaattccgtt	ctgggaagcc	aatggctcgc	ggcaccctct	2220
gcttctctcc	tctgttgtct	gctgtgtga	cacacatcaa	tggaataaac	ttcttccaac	2280
tcctgcgaga	agtgaggag	gcgggcagcc	tgacccgaga	ggggcttttc	tctctcttgc	2340
tccccgcttc	gttctgtttt	ggctgcagag	agtggttcat	ccatactctc	attccctcgc	2400
ctccccctgt	ggacgggggt	cttgcctttt	caattcctgt	gttttggtgt	cttcccttat	2460
ctgctaccct	gaatcacctg	tctgtgtctt	gctgtgtgat	gggaacatgc	ttgtaaactg	2520
cgtaacaaat	ctactttgtg	tatgtgtctg	tttatggggg	tggtttatta	tttttgctgg	2580
tccttagacc	actttgtatg	accgtttgca	gtctgagcag	gccaggggct	gacagctaat	2640
gtcaggaccc	tcagcgttgg	agcctgctgg	ggggacccag	ctgctcttgg	acaagtggct	2700
gagctcctat	ctggcctcct	cttttttttt	ttttcaagta	atttgtgtgt	atttctaact	2760
gattgtattg	aaaaaatcc	tagtatattca	gtaaaaatgc	ctgttgtgag	atgaacctcc	2820

-continued

tgtaacttct atctgttctt ttttgaggct cagggagaaa ctageatttt tttttttcca	2880
aactactttt tgtcactgtg acagttgtaa ataaagtttg aaaatgcttt ccactctgaa	2940
aaaaaaaaaaaa aaaaaa	2956

<210> SEQ ID NO 29

<211> LENGTH: 2262

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: ST3GAL5 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 29

ctggggagta atagcatggg caaccattat cctgtctcgc cgccaccag gacatggctt	60
ctgttccaat gccaagttag tacacctatg tgaaactgag aagtgattgc tcgaggcctt	120
ccctgcaatg gtacaccga gctcaaagca agatgagaag gccagcttg ttattaaaag	180
acatcctcaa atgtacattg cttgtgtttg gagtgtggat cctttatata ctcaagttaa	240
attatactac tgaagaatgt gacatgaaaa aaatgcatta tgtggacctt gaccatgtaa	300
agagagctca gaaatatgct cagcaagtct tgcagaagga atgtcgcccc aagtttgcca	360
agacatcaat ggcgctgtta tttgagcaca ggtatagcgt ggacttactc ccttttgtgc	420
agaaggcccc caaagacagt gaagctgagt ccaagtacga tcctcctttt gggttccgga	480
agttctccag taaagtccag accctcttgg aactcttgcc agagcacgac ctccctgaac	540
acttgaaaagc caagacctgt cggcgctgtg tggttatttg aagcggagga atactgcacg	600
gattagaact gggccacacc ctgaaccagt tcgatgttgt gataaggtaa aacagtgcac	660
cagttgaggg atattcagaa catgttgga ataaaaactac tataaggatg acttatccag	720
agggcgacac actgtctgac cttgaatatt attccaatga cttatttgtt gctgttttat	780
ttaagagtgt tgatttcaac tggcttcaag caatggtaaa aaaggaaacc ctgccattct	840
gggtacgact cttcttttgg aagcaggtgg cagaaaaaat ccactgcag ccaaaacatt	900
tcaggatttt gaatccagtt atcatcaaag agactgcctt tgacatcctt cagtactcag	960
agcctcagtc aaggttcttg ggcgagata agaactgccc cacaatcggg gtcattgccg	1020
ttgtcttagc cacacatctg tcgcatgaag tcagtttggc gggttttgga tatgacctca	1080
atcaaccag aacacctttg cactactctg acagtcaatg catggctgct atgaactttc	1140
agaccatgca taatgtgaca acggaaacca agttcctctt aaagctggc aaagaggag	1200
tggtgaaaga tctcagtgga ggcattgac gtgaattttg aacacagaaa acctcagttg	1260
aaaatgcaac tctaactctg agagctggtt ttgacagcct tcttgatgta tttctccatc	1320
ctgcagatag tttgaagtgc agctcatggt tttaactttt aatttaaaaa cacaaaaaaa	1380
atttttagctc ttcccacttt ttttttctta tttatttgag gtcagtgttt gtttttgac	1440
accattttgt aaatgaaact taagaattga attggaaaga cttctcaaag agaattgtat	1500
gtaacgatgt tgtattgatt ttaagaaag taatttaatt tgtaaaactt ctgctcggtt	1560
acactgcaca ttgaatacag gtaactaatt ggaaggagag gggaggtcac tcttttgatg	1620
gtggccctga acctcattct ggttcctgc tgcgctgctt ggtgtgaccc acggaggatc	1680
cactcccagg atgacgtgct ccgtagctct gctgctgata ctgggtctgc gatgcagcgg	1740
cgtgaggcct gggctggttg gagaaggta caaccctct ctgttggtct gccttctgct	1800
gaaagactcg agaaccaacc agggaagctg tcctggagggt ccctggtcgg agaggacat	1860
agaatctgtg acctctgaca actgtgaagc caccctgggc tacagaaacc acagtcttcc	1920

-continued

cagcaattat tacaattcctt gaattccttg gggatttttt actgcccttt caaagcactt	1980
aagtgttaga tctaactgtt tccagtgtct gtctgaggtg acttaaaaaa tcagaacaaa	2040
acttctatta tccagagtca tgggagagta caccctttcc aggaataatg ttttgggaaa	2100
cactgaaatg aaatcttccc agtattataa attgtgtatt taaaaaaaag aaacttttct	2160
gaatgcctac ctggcgggtg ataccaggca gtgtgccagt taaaaaagat gaaaaagaat	2220
aaaaactttt gaggaaaaaa aaaaaaaaaa aaaaaaaaaa aa	2262

<210> SEQ ID NO 30

<211> LENGTH: 4909

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: IL1R1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 30

tagacgcacc ctctgaagat ggtgactccc tcttgagaag ctggaccctt tggtaaaaga	60
caaggccttc tccaagaaga atatgaaagt gttactcaga cttatttggt tcatagctct	120
actgatttct tctctggagg ctgataaatg caaggaacgt gaagaaaaaa taattttagt	180
gtcatctgca aatgaaattg atgttcgtcc ctgtcctctt aacccaaatg aacacaaagg	240
cactataact tggataaag atgacagcaa gacacctgta tctacagaac aagcctccag	300
gattcatcaa cacaagaga aactttggtt tgttcctgct aaggtggagg attcaggaca	360
ttactattgc gtggtaaaga attcatctta ctgcctcaga attaaaaaa gtgcaaaatt	420
tgtggagaat gagcctaact tatgttataa tgcacaagcc atatttaagc agaaactacc	480
cgttgcaagg gacggaggac ttgtgtgcc ttatatggag ttttttaaaa atgaaaaata	540
tgagttacct aaattacagt ggtataagga ttgcaaacct ctacttcttg acaatataca	600
ctttagtggg gtcaaagata ggctcatcgt gatgaatgtg gctgaaaagc atagagggaa	660
ctatacttgt catgcacct acacatactt gggcaagcaa tatcctatta cccgggtaat	720
agaattttatt actctagagg aaaacaaacc cacaaggcct gtgattgtga gccagctaa	780
tgagacaatg gaagtagact tgggatccca gatacaattg atctgtaatg tcaccggcca	840
gttgagtgc attgcttact ggaagtggaa tgggtcagta attgatgaag atgaccagct	900
gctaggggaa gactattaca gtgtggaaaa tcttgcaaac aaaagaagga gtaccctcat	960
cacagtgtct aatatatcgg aaattgaaag tagattttat aaacatccat ttacctgttt	1020
tgccagaat acacatggta tagatgcagc atatatccag ttaatatac cagtcactaa	1080
tttcagaag cacatgattg gtatatgtgt cacgttgaca gtcataattg tgtgttctgt	1140
tttcatctat aaaatcttca agattgacat tgtgttttgg tacagggatt cctgctatga	1200
ttttctccca ataaaagctt cagatggaaa gacctatgac gcatatatac tgtatccaaa	1260
gactgttggg gaagggtcta cctctgactg tgatattttt gtgtttaaag tcttgctga	1320
ggtcttgtaa aaacagtgtg gatataagct gttcatttat ggaagggatg actacgttgg	1380
ggaagacatt gttgaggtca ttaatgaaaa cgtaaagaaa agcagaagac tgattatcat	1440
tttagtcaga gaaacatcag gcttcagctg gctgggtggg tcatctgaag agcaaatagc	1500
catgtataat gctcttggtc aggatggaat taaagttgtc ctgcttgagc tggagaaaat	1560
ccaagactat gagaaaatgc cagaatcgat taaattcatt aagcagaaac atggggctat	1620
ccgctggtea ggggacttta cacagggacc acagtctgca aagacaaggt tctggaagaa	1680

-continued

tgtcaggtac	cacatgccag	tccagcgcag	gtcaccttca	tctaaacacc	agttactgtc	1740
accagccact	aaggagaaac	tgcaaagaga	ggctcacgtg	cctctcgggt	agcatggaga	1800
agttgccaa	agttctttag	gtgcctcctg	tcttatggcg	ttgcaggcca	ggttatgcct	1860
catgctgact	tgacaggttc	atggaatgta	actatatcat	cctttatccc	tgaggtcacc	1920
tggaatcaga	ttattaaggg	aataagccat	gacgtcaata	gcagcccagg	gcacttcaga	1980
gtagagggct	tggaagatc	ttttaaaaag	gcagtaggcc	cgggtgtggtg	gtcacgcct	2040
ataatcccag	cactttggga	ggctgaagtg	ggtggatcac	cagaggtcag	gagttcgaga	2100
ccagcccagc	caacatggca	aaaccccatc	tctactaaaa	atacaaaaat	gagctaggca	2160
tggtggcaca	cgctgtaat	cccagctaca	cctgaggctg	aggcaggaga	attgcttgaa	2220
ccggggagac	ggaggttgca	gtgagccgag	tttgggccac	tgactcttag	cctggcaaca	2280
gagcaagact	cgtctcmeta	aaaagggcaa	taaatgcctc	ctctgaatgt	ttgaactgcc	2340
aagaaaaggc	atggagacag	cgaactagaa	gaaagggcaa	gaaggaaata	gccaccgtct	2400
acagatggct	tagttaagtc	atccacagcc	caaggcgagg	gctatgcctt	gtctggggac	2460
cctgtagagt	cactgacctc	ggagcggctc	tctgagagg	tgctgcaggc	aaagtgagac	2520
tgacacctca	ctgaggaagg	gagacatatt	cttgagaaac	ttccatctct	cttgatattt	2580
ccatacacat	cccagccag	aagttagtgt	ccgaagaccg	aattttattt	tacagagctt	2640
gaaaactcac	ttcaatgaac	aaagggatcc	tccaggatcc	caaagttttg	aagtcatctt	2700
agctttccac	aggagggaga	gaacttaaaa	aagcaacagt	agcagggaat	tgatccactt	2760
cttaatgctt	tcctccctgg	catgaccatc	ctgtcctttg	ttattatcct	gcattttacg	2820
tctttggagg	aacagctccc	tagtggcttc	ctcgtctctc	aatgtccctt	gcacagccca	2880
cacatgaacc	atccttccca	tgatgcgctc	cttctgtcat	cccgtccttg	ctgaaacacc	2940
tcccaggggc	tccacctgtt	caggagctga	agcccatgct	ttcccaccag	catgtcactc	3000
ccagaccacc	tccttgccct	gtcctccagc	ttccctccgc	tgtcctgctg	tgtgaattcc	3060
caggttggcc	tggtggccat	gtgcctgccc	cccagcactc	ctctgtctct	gctcttgctt	3120
cgacctctcc	tcctcctttg	cctaggaggc	cttctcgcat	tttctctagc	tgatcagaat	3180
tttaccaaaa	ttcagaacat	cctccaatcc	cacagtctct	gggagacttt	ccctaagagg	3240
cgacttcctc	tccagccttc	tctctctggt	caggccactc	gcagagatgg	tggtgagcac	3300
atctggggag	ctggtctccc	tccagctgga	attgctgctc	tctgagggag	aggctgtggt	3360
ggctgtctct	gtccctcact	gccttccagg	agcaatttgc	acatgtaaca	tagatttatg	3420
taatgcttta	tgttttaaaa	cattccccaa	ttatcttatt	taatttttgc	aattattcta	3480
attttatata	tagagaaagt	gacctatttt	ttaaaaaat	cacactctaa	gttctattga	3540
acctaggact	tgagcctcca	tttctggctt	ctagtctggt	gttctgagta	cttgatttca	3600
ggtcaataac	gggtccccct	cactccacac	tggtcacgtt	gtgagaagaa	atgacatttt	3660
gctaggaagt	gaccgagtct	aggaatgctt	ttattcaaga	caccaaattc	caaacttcta	3720
aatgttgga	ttttcaaaaa	ttgtgttttag	attttatgaa	aaactctctc	actttcatct	3780
attctttccc	tagaggcaaa	catttcttaa	aatgtttcat	tttcattaaa	aatgaaagcc	3840
aaatttatat	gccaccgatt	gcaggacaca	agcacagt	taagagttgt	atgaacatgg	3900
agaggacttt	tggtttttat	atttctcgta	tttaatatgg	gtgaacacca	acttttattt	3960
ggaataataa	ttttcctcct	aaacaaaaac	acattgagtt	taagtctctg	actcttgctt	4020
ttccacctgc	tttctcctgg	gcccgctttg	cctgcttgaa	ggaacagtgc	tgttctggag	4080

-continued

```

ctgctgttcc aacagacagg gcttagcttt catttgacac acagactaca gccagaagcc 4140
catggagcag ggatgtcacg tcttgaaaag cctattagat gttttacaaa ttaattttg 4200
cagattatatt tagtctgtca tccagaaaat gtgtcagcat gcatagtgtc aagaaagcaa 4260
gccaatattgg aaacttaggt tagtgacaaa attggccaga gagtgggggt gatgatgacc 4320
aagaattaca agtagaatgg cagctggaat ttaaggaggg acaagaatca atggataagc 4380
gtgggtggag gaagatccaa acagaaaagt gcaaagttat tccccatctt ccaagggttg 4440
aattctggag gaagaagaca cattcctagt tccccgtgaa cttcctttga cttattgtcc 4500
ccactaaaac aaaacaaaaa acttttaatg ccttccacat taattagatt ttcttgacgt 4560
ttttttatgg cattttttta aagatgccct aagtgttgaa gaagagtgtg caaatgcaac 4620
aaaatattta attaccggtt gttaaaactg gtttagcaca atttatattt tccctctctt 4680
gcctttctta tttgcaataa aaggatttga gccatttttt aaatgacatt ttgataaat 4740
tatgtttgta ctagtgtgat aaggagtttt ttttaacctg tttatataat ttgcagcag 4800
aagccaaatt tttgtatat taaagcacca aattcatgta cagcatgcat cacggatcaa 4860
tagactgtac ttattttcca ataaaatttt caaactttgt actgttaaa 4909

```

<210> SEQ ID NO 31

<211> LENGTH: 2210

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: BIN1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 31

```

cgcgccctc cctcctcgcg gacctggcgg tgccggcgcc cggagtggcc ctttaaaagg 60
cagcttattg tccggagggg gcggggcggg ggcgcgcacc gcgcctgag gcccgcccc 120
tccctctccc ctccctctgt ccccgctcg ctgctgggt agctcgtgg ctgctcgcc 180
cgtccggcgc acgctccgcc tccgtcagtt ggctccgctg tcgggtgcgc ggcgtggagc 240
ggcagccggg ctggacgcgc ggcgggggct gggggctggg agcgcggcgc gcaagatctc 300
cccgcgcgag agcggccccc gccaccgggc gaggcctgcg ccgcgatggc agagatgggc 360
agtaaagggg tgacggcggg aaagatcgcc agcaacgtgc agaagaagct caccgcgcgc 420
caggagaagg ttctccagaa gctggggaag gcagatgaga ccaaggatga gcagtttgag 480
cagtgcgtcc agaatttcaa caagcagctg acggagggca cccggctgca gaaggatctc 540
cggacctacc tggcctccgt caaagccatg cacgaggctt ccaagaagct gaatgagtgt 600
ctgcaggagg tgtatgagcc cgattggccc ggcagggatg aggcacacaa gatcgagag 660
aacaacgacc tgctgtggat ggattaccac cagaagctgg tggaccaggc gctgctgacc 720
atggacacgt acctgggcca gttcccgac atcaagtcac gcattgcaa gcgggggcgc 780
aagctggtgg actacgacag tgcccgccac cactacgagt cccttcaaac tgccaaaaag 840
aaggatgaag ccaaaattgc caaggccgag gaggagctca tcaaagccca gaagggttt 900
gaggagatga atgtggatct gcaggaggag ctgccgtccc tgtggaacag ccgcgtaggt 960
ttctacgtca acacgttcca gagcatcgcg ggcctggagg aaaacttcca caaggagatg 1020
agcaagctca accagaacct caatgatgtg ctggtcggcc tggagaagca acacgggagc 1080
aacaccttca cggtaaacgc ccagcccaga aagaaaagta aactgttttc gcggctgcgc 1140
agaaagaaga acagtgacaa cgcgcctgca aaagggaaca agagcccttc gcctccagat 1200

```

-continued

```

ggctccccctg ccgccacccc cgagatcaga gtcaaccacg agccagagcc ggccggcggg 1260
gccacgcgccg gggccaccct ccccaagtcc ccatctcagc cagcagagcc ctccggaggtg 1320
gcgggtggga cccaaactgc ggctggagcc caggagccag gggagacggc ggcaagtga 1380
gcagcctcca gctctcttcc tgtgtctgtg gtggagacct tcccagcaac tgtgaatggc 1440
accgtggagg gcggcagtg ggccggggcg ttggacctgc cccaggttt catgttcaag 1500
gtacaggccc agcacgacta cacggccact gacacagacg agctgcagct caaggctggt 1560
gatgtggtgc tggatgaccc cttccagaac cctgaagagc aggatgaagg ctggctcatg 1620
ggcgtgaagg agacgcactg gaaccagcac aaggagctgg agaagtgcg tggcgtcttc 1680
cccgagaact tactgagag ggtcccatga cggcggggcc caggcagcct ccggcggtgt 1740
gaagaacacc tcctcccgaa aaatgtgtgg ttcttttttt tgttttgttt tcgtttttca 1800
tcttttgaag agcaaaggga aatcaagagg agacccccag gcagaggggc gttctcccaa 1860
agattaggtc gttttccaaa gagccgcgtc ccggcaagtc cggcggaatt caccagtgtt 1920
cctgaagctg ctgtgtcttc tagttgagtt tctggcgccc ctgcctgtgc ccgatgtgt 1980
gcctggccgc agggcggggc tgggggctgc cgagccacca tgcttgctg aagcttcggc 2040
cgccgccccc gggcaagggt cctcttttcc tggcagctgc tgtgggtggg gccagacac 2100
cagcctagcc tggctctgcc ccgcagacgg tctgtgtgct gtttgaatat aaatcttagt 2160
gttcaaaaca aaatgaaaca aaaaaaaaaaata gataaaaact ctcaaaaaaa 2210

```

<210> SEQ ID NO 32

<211> LENGTH: 4664

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: WIPF1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 32

```

gcagcctccc ggctgtgagc gcttttctctg cccgccccgc tcagccctgc ggaccccggg 60
agaagtttcc cagaaaaaat gccacgcgcg gcgcggggct gcggagtcgt ccggagccgc 120
tgcgcgattt atcagcaaga ctgttgaacg cataactgcc caagatgcct gtccctcccc 180
ctccagcacc cccgcgcgcc ccgacgtttg cactggccaa tacagagaag cctaccttga 240
ataagacaga gcaggctggg agaaatgtc tcctttctga tatcagcaaa gggaagaaac 300
taaagaagac ggtcaccaat gacagaagtg caccaatact ggacaaacct aaaggagctg 360
gtgctggagg cgggtggtgt ggctttggtg gagggcggcg atttgccgga ggaggtggtg 420
gcggaggcgg tggaaagttt ggagggggcg gacctccagg tctgggagga ttgttccagg 480
ctggaatgcc gaagctgaga tccacggcca acagggataa tgattctgga ggaagccgac 540
caccattgtt gccaccggga ggaagatcca catctgcgaa acccttttca cccccaagtg 600
gccacgggag gtttctctgt ccttctccag gccacagaag tgggtcccca gagcctcaga 660
ggaaccgaat gccgccccca agggccgacg tgggctcaaa gcctgatagc attcctctc 720
cagtacctag tactccaaga ccattcaat caagtccgca caaccggggg tccccaccag 780
tgcccgagg cccaggcag cccagccccg ggccccactc tcccccttc cctggaaacc 840
gcggcactgc tttgggagga ggtcacaatc gtcagtcctc cttgagctcc tctcgcctc 900
tctccaaacc gcctccccct cgcctaccc ccagcagggc cttggatgac aaacccctc 960
caccacctcc tccagtgggc aacaggccct ccatccacag ggaagcgggt cccctctctc 1020
ctcctcagaa caacaagcct ccagtgcctt ccactccgcg gccttcggcc tcctcacagg 1080

```

-continued

ccccacctcc	gccgccacct	cccagcaggc	ccgggccgcc	tcctctgect	ccaagttcca	1140
gcggcaatga	cgaaacccca	agaactccac	agcggaatct	gtccctcagt	tcgtccacgc	1200
ccccgttacc	ttcgccagga	cgttcaggtc	ctcttctccc	cccgccagtc	gagagacccc	1260
cacctccagt	gagggaccgc	ccaggccgat	caggccccct	cccaccacct	cctccagtaa	1320
gcagaaacgg	cagcacatct	cgggccctgc	ctgctacccc	tcagttgcca	tccaggagtg	1380
gagtagacag	tcccaggagt	ggccccaggc	ctccccctcc	tcctgatagg	cccagtgctg	1440
gggcacctcc	cccacctcca	ccatcaacat	ctattagaaa	tggttccaa	gactctccat	1500
gtgaagatga	gtgggaaagc	agattctact	tccatccgat	ttccgatttg	ccacctccag	1560
agccatatgt	acaaacgacc	aaaagttatc	ccagcaaaact	ggcaagaaac	gaaagccgga	1620
gtggatccaa	ccgaagagaa	aggggtgctc	caccactccc	tccatcccg	aggtgatctt	1680
tgcttctct	tctctaccca	agctcaagag	ctgcttctgt	tgctatctaa	gaactgcata	1740
ccctcctccc	tgcttctctc	cttgtgcctc	atgtatgggc	aggaggaaag	gtgggagggg	1800
gagtggaagt	atgcgtgtgt	gggtgggaat	cggtaagaaa	tgacactagc	ttttcatatt	1860
gtgtttattc	tccaggctat	tgcttgcttc	agctgcagcc	tgctgtgct	ggctgctggg	1920
gtcgataggc	ttttgtcgta	ataggcagag	atgacttgca	tcccagcttt	ccaccaacca	1980
aattcaaaaca	ttcactgctt	atttggtaca	gactgtaatt	attaaagtcc	ctgagagctg	2040
ttttctcccg	ttcctttttc	gcatgcttgg	cctcctctct	gtttctatga	accacagacc	2100
acctaagcaa	gctgctgagt	aagggctcac	tggaacttg	cagtcacagg	atgtccaatc	2160
tttggcagtc	cgaacttggc	tctaggacag	agctgtccaa	tagaaatata	atgtgagccc	2220
catatacaat	ttttacatct	ctaataatct	ttaaacaagt	gaagttaata	tgcatccaaa	2280
atatttcaac	ctgtaatcaa	cataaaatct	taatgagata	ttttatatta	ttttttggta	2340
ctgaatcttc	aaaatccaga	gtgtatttta	cacttacccg	acatctccat	tcagactagt	2400
cacattttta	agtgtcagtc	agccacatgt	ggctgggtggc	tactggatta	gacagcacga	2460
gtctggaaga	tggaagctag	tgcaaaaacc	tcttgtttaa	aaaacaaaaa	aggcaagatg	2520
ggcttgagcg	attcaagagg	caactaaaaa	taaaattagg	accagcacc	ttgtttgaca	2580
cacagtttga	ccttcgatct	tcctccctta	acttccctct	tccttaata	tctgtatata	2640
agtgttgctt	caaagtacca	aggtcagaaa	ttgattcagt	acggtttact	aaagtcatgt	2700
ggaataaagc	cattggaaac	aaatggaaag	cctgtcggga	cttctgggct	cagaaccagc	2760
tggtccacgc	actccacttg	tcagctggac	ttctgccttg	tgaatggaa	gcagccttg	2820
ttcctttctg	gctgagcaag	ctcctgaggc	tggaagagac	taggaaggct	tggtaggagg	2880
ggaaaaaagt	caggaaaaga	tatcaaatca	gaaacatgga	agaagaaggg	aaccgatctg	2940
agttgggtggg	caaaactcta	aaaatctaaa	tctgatgctt	atgtaagggt	tgagcgaatt	3000
agggagattg	ctagtggaaa	ttggagggaa	ttgtttttgc	atcatttgct	taggatctat	3060
gcaaatatag	ctccactaaa	ggaccatagg	gaagagccag	ccttgccctt	tcttatatga	3120
ttttgtttac	aaaattttac	tgggactttt	aaatctagct	atagagttgg	gaaaaaatat	3180
ttccacttag	atattttaca	tggtttttgt	taaaattacc	attacttggt	ttttaaaaac	3240
acatgaccac	atatgtatat	gtatatctac	ctaaacattg	tatcatgggt	tcagtatggt	3300
attcatgtat	tactgggaga	tgctaccaag	aaaccaaccc	aaagaaaatt	ctgaaaaata	3360
catttctatt	tatagaataa	atgttttcatt	tatataaaag	caaaagaact	tagagttcta	3420

-continued

ataaatggga tgtctaataa attatgaagt tactgatttg aatatattat atttttataa	3480
cttccttgcc aaagtcttga tttagtacat tagagaacct gtgtttcctc tctcctctac	3540
cattcatctc tcttcctac agtcatttgg gctttttact caaagagaat caagaaataa	3600
taaggtataa caagcttggc aaagtgttgg ctttttataa aaaaattttt ttaatctcta	3660
gcagtttggg aatttagcag catcatttat ttgggattct tttatctgat ttcaacagt	3720
aaaaacatcc ctatgataaa gctaatagac ccatttcaca aaagatggaa ttgcccctc	3780
ctagaaaata tgacggagaa aagtctgact cagagaaagt gagtctgaat ttataaggg	3840
gtagtaagaa ttggacaatt cctttgcata tctgaacttg gcaggtagcg ttctaactct	3900
gaaacagggt gatagctcaa agttgccatt catccagaat agattgtttt agaagttagt	3960
gtttaagtga ctgtttcatt aatacaccta caccctttct ttgaaagttt gcaacctaat	4020
tgcactctaaa actatgaata agttctgtgg taaaatctta aactatggaa aattacaaaa	4080
atgaattttt cttccctgaa atcagagctt acatgtgtgt ttttttataa cattttcaga	4140
taaatgtatt caacatgtaa tacagtattt taacattcac ctcttatttt atattgaaat	4200
gtattacagt attaaaactc agtgttcagt atttatttca ctatgcattt tatttagtaa	4260
aagccaggag aaatgtttta tccaatgggt ccttactttg tgatttataa gaaatcaact	4320
tttttttatg tctaagtagt agattatttg catatttgta aaaactgtta ggtctttata	4380
ttttaaagtg taataccagt tttgttattt tagtagcaga aatgggatga ttgttaaagt	4440
tccccaaaaa tgttggcatg aaattaattt ttccctcctt atagtcaagg accgtagagg	4500
aagaaaaact tttttttcat accatgcact atgtaaacag acacattttg ctatctgtgt	4560
catcaggata gtgtaagtgg tagggtagag actaccctag acatctgcat ctttgtaagt	4620
tagccagaca ataaagaaaa gcagaatgaa aaaaaaaaaa aaaa	4664

<210> SEQ ID NO 33

<211> LENGTH: 1166

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: TFPI glucocorticoid receptor-responsive gene

<400> SEQUENCE: 33

attcccaact gccagtgatc tctgaagccg actctgaggg tccctctttg ctctaacaga	60
cagcagcgac tttaggctgg ataatagtca aattcttacc tcgctctttc actgctagta	120
agatcagatt gcgtttcttt cagttactct tcaatcgcca gtttcttgat ctgcttctaa	180
aagaagaagt agagaagata aatcctgtct tcaatacctg gaaggaaaaa caaaataacc	240
tcaactccgt tttgaaaaaa acattccaag aactttcatc agagatttta cttagatgat	300
ttacacaatg aagaaagtac atgcactttg ggcttctgta tgctgtctgc ttaatcttgc	360
ccctgccctt cttaatgctg attctgagga agatgaagaa cacacaatta tcacagatac	420
ggagttgcc aactgaaac ttatgcattc attttgtgca ttcaaggcgg atgatggccc	480
atgtaaagca atcatgaaaa gatttttctt caatatcttc actcgacagt gcgaagaatt	540
tatatatggg ggatgtgaag gaaatcagaa tcgatttgaa agtctggaag agtgcaaaaa	600
aatgtgtaca agagataatg caaacaggat tataaagaca acattgcaac aagaaaagcc	660
agattttctg tttttggaag aagatcctgg aatatgtcga gggttatatta ccaggatttt	720
ttataacaat cagacaaaac agtgtgaacg tttcaagtat ggtggatgcc tgggcaatat	780
gaacaatttt gagacactgg aagaatgcaa gaacatttgt gaagatggtc cgaatggttt	840

-continued

```

ccagtggtat aattatggaa ccagctcaa tgcgtgtaat aactccctga ctcgcaatc   900
aaccaaggtt cccagccttt ttgttacaaa agaaggaaca atgatgggtt ggaagaatgc   960
ggctcatatt taccaagtct ttctgaacgc cttctgcatt catgcatcca tgttctttct 1020
aggattggat agcatttcat gctatgtta atatttgtgc ttttggcatt tccttaatat 1080
ttatatgtat acgtgatgcc ttgatagca tactgctaataaagtttttaa tatttacatg 1140
catagtaaaa aaaaaaaaaa aaaaaa                                     1166

```

```

<210> SEQ ID NO 34
<211> LENGTH: 8449
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: FN1 glucocorticoid receptor-responsive gene
<400> SEQUENCE: 34

```

```

gccccgcgcg gctgtgctgc acagggggag gagaggggaa cccaggcgcg agcgggaaga   60
ggggacctgc agccacaact tctctggtcc tctgcatccc ttctgtccct ccaccgtec   120
ccttccccac cctctggccc ccaccttctt ggagcgaca acccccggga ggcattagaa   180
gggatttttc ccgaggttg cgaagggaag caaacttggg ggcaacttgc ctcccgtgc   240
gggcgtctct cccccaccgt ctcaacatgc ttaggggtcc ggggcccggt ctgctgctgc   300
tgcccgctca gtgcctgggg acagcgggtgc cctccacggg agcctcgaag agcaagaggc   360
aggctcagca aatggttcag cccagtcctc cggtggtgtg cagtcaaagc aagccccggt   420
gttatgacaa tggaaaacac tatcagataa atcaacagtg ggagcggacc tacctaggca   480
atgcgttggt ttgtacttgt tatggaggaa gccgaggttt taactgcgag agtaaacctg   540
aagctgaaga gacttgcttt gacaagtaca ctgggaacac ttaccgagtg ggtgacactt   600
atgagcgtcc taaagactcc atgatctggg actgtacctg catcggggct gggcgaggga   660
gaataagctg taccatcgca aaccgctgcc atgaaggggg tcagtcctac aagattggtg   720
acacctggag gagaccacat gagactggtg gttacatgtt agagtgtgtg tgtcttggtg   780
atggaaaagg agaatggacc tgcaagccca tagctgagaa gtgttttgat catgctgctg   840
ggacttccta tgtggtcgga gaaacgtggg agaagcccta ccaaggctgg atgatggtag   900
attgtacttg cctgggagaa ggcagcggac gcatcacttg cacttctaga aatagatgca   960
acgatcagga cacaaggaca tcctatagaa ttggagacac ctggagcaag aaggataatc 1020
gaggaaacct gctccagtgc atctgcacag gcaacggccg aggagagtgg aagtgtgaga 1080
ggcacacctc tgtgcagacc acatcgagcg gatctggccc cttcacccgat gttcgtgcag 1140
ctgtttacca accgcagcct cccccccagc ctctcccta tggccactgt gtcacagaca 1200
gtggtgtggt ctactctgtg gggatgcagt ggctgaagac acaaggaaat aagcaaatgc 1260
tttgacgtg cctgggcaac ggagtcagct gccaaagagac agctgtaacc cagacttacg 1320
gtggcaactc aaatggagag ccatgtgtct taccattcac ctacaatggc aggacgttct 1380
actcctgcac cacagaaggg cgacaggacg gacatctttg gtgcagcaca acttcgaatt 1440
atgagcagga ccagaaatac tctttctgca cagaccacac tgttttgggt cagactcgag 1500
gaggaaatc caatggtgcc ttgtgccact tccccttcct atacaacaac cacaattaca 1560
ctgattgcac ttctgagggc agaagagaca acatgaagtg gtgtgggacc acacagaact 1620
atgatgccga ccagaagttt gggttctgcc ccatggctgc ccacgaggaa atctgcacaa 1680

```

-continued

c caatgaagg ggtcatgtac cgcattggag atcagtggga taagcagcat gacatgggtc	1740
a catgatgag gtgcacgtgt gttgggaatg gtctgggga atggacatgc attgcctact	1800
c gcagcttcg agatcagtgc attgttgatg acatcactta caatgtgaac gacacattcc	1860
a caagcgtca tgaagagggg cacatgctga actgtacatg ctctgggtcag ggtcggggca	1920
g gtggaagtg tgatcccgtc gaccaatgcc aggattcaga gactgggacg ttttatcaaa	1980
t tggagattc atgggagaag tatgtgcacg gtgtcagata ccagtgtac tgctatggcc	2040
g tggcattgg ggagtggcat tgccaacctt tacagaccta tccaagctca agtggctctg	2100
t cgaagtatt tatcactgag actccgagtc agcccaactc ccacccatc cagtggaatg	2160
c accacagcc atctcacatt tccaagtaca ttctcagggt gagacctaaa aattctgtag	2220
g ccgttgaa ggaagctacc ataccaggcc acttaactc ctacaccatc aaaggcctga	2280
a gcctggtgt ggtatacag ggcagctca tcagcatcca gcagtacggc caccaagaag	2340
t gactcgtt tgacttcacc accaccagca ccagcacacc tgtgaccagc aacacgtga	2400
c aggagagac gactcccttt tctcctcttg tggccacttc tgaatctgtg accgaaatca	2460
c agccagtag ctttgtggtc tcttggtct cagcttcga caccgtgtcg ggattccggg	2520
t ggaatatga gctgagttag gagggagatg agccacagta cctggatctt ccaagcacag	2580
c cacttctgt gaacatccct gacctgttc ctggccgaaa atacattgta aatgtctatc	2640
a gatatctga ggatggggag cagagtttga tctgtctac ttcacaaaca acagcgctg	2700
a tgccctcc tgaccgact gtggaccaag ttgatgacac ctcaattgtt gtctgctgga	2760
g cagaccca ggctccatc acaggttaca gaatagtcta ttcgccatca gtagaaggta	2820
g cagcacaga actcaacctt cctgaaactg caaactccgt caccctcagt gacttgcaac	2880
ctggtgttca gtataacatc actatctatg ctgtggaaga aaatcaagaa agtacacctg	2940
ttgtcattca acaagaaacc actggcacc cagctcaga tacagtgcc tctccagggt	3000
a cctgcagtt tgtggaagt acagacgtga aggtaccat catgtggaca ccgcctgaga	3060
gtgcagtga cggtaccgt gtggatgtga tcccgtcaa cctgcctggc gagcacgggc	3120
a gaggctgcc catcagcagg aacaccttg cagaagtcac cgggctgtcc cctggggcca	3180
c ctattactt caaagtctt gcagttagc atgggagga gagcaagcct ctgactgctc	3240
a acagacaac caaactggat gctccacta acctccagt tgtcaatgaa actgattcta	3300
ctgtcctggt gagatggact ccacctggg ccagataac aggataccga ctgacctgg	3360
gccttaccg aagaggacag ccaggcagt acaatgtgg tccctctgtc tccaagtacc	3420
c actgaggaa tctgcagcct gcatctgagt acaccgtatc cctcgtggc ataaaggga	3480
a ccaagagag ccccaaagcc actggagtct ttaccacact gcagcctggg agctctattc	3540
c accttaca caccgagggt actgagacca ccattgtgat cacatggacg cctgctccaa	3600
gaattggtt taagctgggt gtacgaccaa gccagggagg agaggacca cgagaagtga	3660
cttcagactc aggaagcatc gttgtgtcc gcttgactcc aggagtagaa tacgtctaca	3720
ccatccaagt cctgagagat ggacaggaaa gagatgcgc aattgtaaac aaagtgggta	3780
c accattgtc tccaccaaca aacttgcatc tggaggcaaa ccctgacact ggagtgtca	3840
c agtctcctg ggagaggagc accacccag acattactgg ttatagaatt accacaaccc	3900
ctacaaacgg ccagcaggga aattctttgg aagaagtgg ccatgctgat cagagctcct	3960
gcacttttga taacctgagt cccggcctgg agtacaatgt cagtgtttac actgtcaagg	4020
a tgacaagga aagtgtccct atctctgata ccatcatccc agctgttct cctcccactg	4080

-continued

acctgcgatt	caccaacatt	ggtccagaca	ccatgcgtgt	caectgggct	ccaccccat	4140
ccattgattt	aaccaacttc	ctggtgcgtt	actcacctgt	gaaaaatgag	gaagatgttg	4200
cagagttgtc	aatttctcct	tcagacaatg	cagtggctct	aacaaatctc	ctgcctggta	4260
cagaatatgt	agtgagtgtc	tccagtgtct	acgaacaaca	tgagagcaca	cctcttagag	4320
gaagacagaa	aacaggtctt	gattcccca	ctggcattga	cttttctgat	attactgcca	4380
actcttttac	tgtgcactgg	attgctctc	gagccaccat	cactggctac	aggatccgcc	4440
atcatcccg	gcacttcagt	gggagacctc	gagaagatcg	ggtgccccac	tctcggaatt	4500
ccatcacctc	caccaacctc	actccaggca	cagagtatgt	ggtcagcatc	gttgccttta	4560
atggcagaga	ggaaagtccc	ttattgattg	gccacaatc	aacagtttct	gatgttcga	4620
gggacctgga	agttgttgct	gcgaccccc	ccagcctact	gatcagctgg	gatgctctg	4680
ctgtcacagt	gagatattac	aggatcactt	acggagagac	aggaggaaat	agccctgtcc	4740
aggagtccac	tgtgcctggg	agcaagtcta	cagctaccat	cagcggcctt	aaacctggag	4800
ttgattatac	catcactgtg	tatgctgtca	ctggccgtgg	agacagcccc	gcaagcagca	4860
agccaatttc	cattaattac	cgaacagaaa	ttgacaaacc	atcccagatg	caagtgaccg	4920
atgttcagga	caacagcatt	agtgtcaagt	ggctgccttc	aagttccctt	gttactgggt	4980
acagagtaac	caccactccc	aaaaatggac	caggaccaac	aaaaactaaa	actgcaggtc	5040
cagatcaaac	agaaatgact	attgaaggct	tcagcccac	agtgagatg	gtggttagtg	5100
tctatgtcca	gaatccaagc	ggagagagtc	agcctctggt	tcagactgca	gtaaccaaca	5160
ttgatcgccc	taaaggactg	gcattcactg	atgtggatgt	cgattccatc	aaaattgctt	5220
gggaaagccc	acaggggcaa	gtttccaggt	acagggtgac	ctactcgagc	cctgaggatg	5280
gaatccatga	gctattccct	gcacctgatg	gtgaagaaga	cactgcagag	ctgcaaggcc	5340
tcagaccggg	ttctgagtac	acagtcagtg	tggttgccct	gcacgatgat	atggagagcc	5400
agccctgat	tggaaaccag	tccacagcta	ttcctgcacc	aactgacctg	aagttcactc	5460
aggtcacacc	cacaagcctg	agcgcaccag	ggacaccacc	caatgttcag	ctcactggat	5520
atcgagtgcg	ggtgaccccc	aaggagaaga	cgggaccaat	gaaagaaatc	aaccttgctc	5580
ctgacagctc	atccgtgggt	gtatcaggac	ttatgggtgg	caccaaatac	gaagtgagtg	5640
tctatgtctc	taaggacact	ttgacaagca	gaccagctca	gggagttgtc	accactctgg	5700
agaatgtcag	cccaccaaga	agggtcgtg	tgacagatgc	tactgagacc	accatcacca	5760
ttagctggag	aaccaagact	gagacgatca	ctggcttcca	agttgatgcc	gttccagcca	5820
atggccagac	tccaatccag	agaaccatca	agccagatgt	cagaagctac	accatcacag	5880
gtttacaacc	aggcactgac	tacaagatct	acctgtacac	cttgaatgac	aatgctcgga	5940
gctccctgt	ggtcatcgac	gcctccactg	ccattgatgc	accatccaac	ctgcgtttcc	6000
tggccaccac	acccaattcc	ttgctgggtat	catggcagcc	gccacgtgcc	aggattaccg	6060
gtacatcat	caagtatgag	aagcctgggt	ctcctcccag	agaagtggtc	cctcggtccc	6120
gccctgggtg	cacagaggct	actattactg	gcctggaacc	gggaaccgaa	tatacaattt	6180
atgtcattgc	cctgaagaat	aatcagaaga	gcgagcccct	gattggaagg	aaaaagacag	6240
acgagcttcc	ccaactggta	acccttccac	accccaatct	tcatggacca	gagatcttgg	6300
atgttccttc	cacagtccaa	aagaccctt	tcgtcaccca	ccctgggtat	gacactggaa	6360
atggtattca	gcttcctggc	acttctggtc	agcaaccacg	tggtgggcaa	caaatgatct	6420

-continued

ttgaggaaca tggtttttagg cggaccacac cgcccacaac ggccaccccc ataaggcata	6480
ggccaagacc ataccgcgcg aatgtaggac aagaagctct ctctcagaca accatctcat	6540
gggccccatt ccaggacact tctgagtaca tcatttcatg tcctcctgtt ggcactgatg	6600
aagaaccctt acagttcagg gttcctggaa cttctaccag tgccactctg acaggcctca	6660
ccagagggtgc cacctacaac atcatagtgg aggcactgaa agaccagcag aggcataagg	6720
ttcggaaga ggttgttacc gtgggcaact ctgtcaacga aggcttgaac caacctacgg	6780
atgactcgtg ctttgacccc tacacagttt cccattatgc cgttgagat gagtgggaac	6840
gaatgtctga atcaggcttt aaactgttgt gccagtgtt aggccttga agtggtcatt	6900
tcagatgtga ttcactaga tgggtccatg acaatgggt gaactacaag attggagaga	6960
agtgggacgc tcaggagaa aatggccaga tgatgagctg cacatgtctt gggaacggaa	7020
aaggagaatt caagtgtgac cctcatgagg caacgtgtta tgatgatggg aagacatacc	7080
acgtaggaga acagtggcag aaggaatgc tcgggtgccat ttgctcctgc acatgctttg	7140
gaggccacgc gggctggcgc tgtgacaact gccgcagacc tgggggtgaa cccagtccc	7200
aaggcactac tggccagtcc tacaaccagt attctcagag ataccatcag agaacaaca	7260
ctaagttaa ttgccaatt gagtgttca tgcctttaga tgtacaggct gacagagaag	7320
attcccgaga gtaaatcgc tttccaatcc agaggaacaa gcatgtctct ctgccaagat	7380
ccatctaac tggagtgatg ttgacagacc cagcttagag ttcttcttct tttcttaagc	7440
cctttgctct ggaggaaagt ctcacgttc agctcaactc acagcttctc caagcatcac	7500
cctgggagtt tcctgagggt tttctcataa atgagggtg cacattgcct gttctgcttc	7560
gaagtattca ataccgctca gtattttaa tgaagtgatt ctaagatttg gtttgggatc	7620
aataggaaag catatgcgc caaccaagat gcaaatgtt tgaatgata tgacaaaat	7680
tttaagtagg aaagtcaccc aaacacttct gctttcactt aagtgtctgg cccgcaatac	7740
tgtaggaaca agcatgatct tgttactgtg atattttaa tatccacagt actcactttt	7800
tccaaatgat cctagtaatt gcctagaaat atctttctct tacctgttat ttatcaattt	7860
ttcccagtat ttttatacgg aaaaaattgt attgaaaaca cttagtatgc agttgataag	7920
aggaatttgg tataattatg gtgggtgatt attttttata ctgtatgtgc caaagcttta	7980
ctactgtgga aagacaactg ttttaataaa agatttacat tccacaactt gaagttcatc	8040
tatttgatat aagacacctt cgggggaaat aattcctgtg aatattcttt ttcaattcag	8100
caaacatttg aaaatctatg atgtgcaagt ctaattgttg atttcagtac aagattttct	8160
aaatcagttg ctacaaaaac tgattgggtt ttgtcacttc atctcttcac taatggagat	8220
agctttacac tttctgcttt aatagattta agtggacccc aatatttatt aaaattgcta	8280
gtttaccggt cagaagtata atagaaataa tctttagtgt ctcttttcta accattgtaa	8340
ttcttccctt cttccctcca cctttccttc attgaataaa cctctgttca aagagattgc	8400
ctgcaaggga aataaaaatg actaagatat taaaaaaaaa aaaaaaaaaa	8449

<210> SEQ ID NO 35

<211> LENGTH: 4625

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: FAM134A glucocorticoid receptor-responsive gene

<400> SEQUENCE: 35

agcgtccgc agtcacgtga cgctcgtccg caacctctgc tgctctccgc ggccgcccct	60
--	----

-continued

tccgcctgac	gcgcccccg	cgcgccgc	gcagccctgg	ctctcgcgg	gctcgggcg	120
cggtgcggc	gggctatgg	cgagcgcg	tggcggggt	aacactggcg	cggtggggg	180
gccgggatg	ggcctgagc	tgggcctgg	tctgggtctg	agcctaggca	tgagtgaggc	240
caccagttag	gcagaggagg	aggcgccac	ggcgaggcg	gtgggacgc	tgccacgac	300
gctgtggctg	cggtccgcg	gctgggaggc	ggtgctggcg	gcggcgcagc	ggttgcctgt	360
gtgggagaag	ccgtgcaca	gcctggtcac	ggcgccgcg	ctcaacggcc	tcttctggtt	420
gctgtcttcc	tcgtccctcc	ggcccttctt	cctactcagc	gtctcacttt	tgccctattt	480
tctgctggat	ctctggcagc	ctcgctttct	ccctgacgtt	tcagcatcat	ccccagagga	540
gccacactct	gacagttagg	gtgcggggtc	aggcgcccg	ccgcacctgc	tgagtgtgcc	600
cgagttgtgc	agatacctgg	ctgagagctg	gctcaccttc	cagattcacc	tgaggagct	660
gctgcagtac	aagaggcaga	atccagctca	gttctgcgtt	cgagtctgct	ctggctgtgc	720
tgtgttggt	gtgttgggac	actatgttcc	agggattatg	atttcctaca	ttgtcttgtt	780
gagtatcctg	ctgtggcccc	tgggtgttta	tcattgagctg	atccagagga	tgtacactcg	840
cctggagccc	ctgctcatgc	agctggacta	cagcatgaag	gcagaagcca	atgccctgca	900
tcacaaacac	gacaagagga	agcgtcaggg	gaagaatgca	ccccaggag	gtgatgagcc	960
actggcagag	acagagagtg	aaagcgaggc	agagctggct	ggcttctccc	cagtgggtga	1020
tgtgaagaaa	acagcattgg	ccttgcccat	tacagactca	gagctgtcag	atgaggaggc	1080
ttctatcttg	gagagtgggt	gcttctccgt	atcccgggcc	acaactccgc	agctgactga	1140
tgtctccgag	gatttggaac	agcagagcct	cccaagtga	ccagaggaga	ccctaagccg	1200
ggacctaggg	gagggagagg	agggagagct	ggccctccc	gaagacctac	taggcgctcc	1260
tcaagctctg	tcaaggcaag	ccttggaactc	ggaggaagag	gaagaggatg	tggcagctaa	1320
ggaaaccttg	ttgcggctct	catcccccct	ccactttgtg	aacacgcact	tcaatggggc	1380
agggtcccc	ccagatggag	tgaatgctc	ccctggaggga	ccagtggaga	cactgagccc	1440
cgagacagtg	agtgggtggc	tcactgctct	ggccggcacc	ctgtcacctc	cactttgcct	1500
tgttggaagt	gacccagccc	cctcccccct	cattctccca	cctgttcccc	aggactcacc	1560
ccagcccctg	cctgcccctg	aggaagaaga	ggcactcacc	actgaggact	ttgagttgct	1620
ggatcagggg	gagctggagc	agctgaatgc	agagctgggc	ttggagccag	agacaccgcc	1680
aaaaacccct	gatgctccac	ccctggggcc	cgacatccat	tctctggtac	agtcagacca	1740
agaagctcag	gccgtggcag	agccatgagc	cagccgttga	ggaaggagct	gcaggcacag	1800
tagggcttcc	tggctaggag	tgttgctgtt	tctcctttg	cctaccactc	tgggggtggg	1860
cagtgtgtgg	ggaagctggc	tgtcggtatg	tagctattcc	accctctgcc	tgctgctctg	1920
cctgctgtcc	tgggcatggg	gcagtaacctg	tgccctaggat	tggttttaaa	tttgtaaata	1980
attttccatt	tgggttagtg	gatgtgaaca	gggctaggga	agtccttccc	acagcctgcg	2040
cttgccctcc	tgctcatct	ctattctcat	tccactatgc	cccaagccct	ggtggtctgg	2100
ccctttcttt	ttctctctat	cctcaggggac	ctgtgctgct	ctgcccctcat	gtcccacttg	2160
gttggttagt	tgaggcactt	tataattttt	ctcttgctct	gtgttctttt	ctgctttatt	2220
tccctgctgt	gtcctgtcct	tagcagctca	acccatccct	ttgccagctc	ctcctatccc	2280
gtgggcactg	gccaagcttt	agggagggtc	ctggtctggg	aagtaaagag	taaacctggg	2340
gcagtggtgc	aggccagtag	ttacactctt	aggtaactgt	agtcgtgtga	accttccactg	2400

-continued

catccttgcc ccattcagcc cggcctttca tgatgcagga gagcagggat cccgcagtac	2460
atggcgccag cactggagtt ggtgagcatg tgctctctct tgagattagg agcttcctta	2520
ctgctcctct gggatgacca agtgtagtgg gacccctac tagggtcagg aagtggacac	2580
taacatctgt gcagggttg acttgaaaa taaagtgtg attggctaga actgctgcct	2640
ccctgactgt gagctgcctt ccacaccctg cactgcactg tgtctctctc tcacccttaa	2700
cctgcttcac tccagtctgt tctggctgtt tattaccttg ttgcaaaaca gggccgaagc	2760
aaggattacc ttgacaacc tagcttctct ttagccatct tccttgacag tgtgatctgt	2820
ttagtgagat ttagcatgtg tgaataaagt atatgcagga ggaaattgct ttgtcttccc	2880
aatcggtaga aatcgggac cataaaaatt gtgttttacc atgtggccta caacctaac	2940
actgctttct taagaagtct tcaccatct acatgctaac aactcactca gcctggattt	3000
atccttactg gggagccaa acaagcaata gaggacctt acctgtgtta gaaatgagtt	3060
ggagccaagg aacctgaag aaatagtatc ttaacagtta ctgagtcctat tgtatgtgct	3120
tggctctgct ctgagtgatt tatatgtatt aagatttttc ctcacaggtc agatatatac	3180
tgttactaac ttcattttat agacagggtta agcttctga aggccacagg tcccagtaaa	3240
ttgtggagcc agaaccctaa ccaagaagt tttggcttca gcaaatgcat cagacagccc	3300
ctgtccatta atagggcaca ggtaggaaga tgcacaagga tgtgggaact atagagaacc	3360
aatctgatgc cttggcttaa caaagagtgg acatggcaag ccttctctct tggggaagaa	3420
aagcccgaaa ctgagcagat ggctctctt atgagttcat gtctctcgcc ttcagctgga	3480
ggtaccatat ggcgatgcta cctgtcttct tgctggaggt accatattgt aatgctgcct	3540
ggctgtctgc tggaggtaac atatggtaat gctgcctgtc tttctgaggt tgacttttat	3600
gcatgtctt tcttaagtgt gtaagaattt ttctgtttgc ttcacatttg actgagaatc	3660
attctagggt ttgattgagc cctgtctctg tgccactaaa ggaactcgaa cttttcatca	3720
cttagagatt tcagagggga atggaaaaac agttctaac aataagcaag caattcaaga	3780
aaaatagaat taatcaggca atgactgcaa catgtctat ctttaactca ttttcttatt	3840
aagcttgac attgacaata gaaccagaag cttgtagctg gatcaaaata ttctccatag	3900
gcctggagtt tcatgagggt ctattctttt gttgttgttg ttttggtttt ttgttttttg	3960
tgggtttttt tttttttttt ttgagacgg agtcttgttc tgggtgccag gctggagtgc	4020
aatggtgcag tcttggttca ctgcaacctc tgctcccgag gttcaacaa ttctcctgcc	4080
tcagccgtcc aagtagctgg gattacaggt gcatgccag atgcctggct attttttgta	4140
tttttagtag aggtggggtt tcaccatgtt ggcaggtctg gtctcgaaact cctgacctca	4200
ggtgattcac ccacctcgcc ctcccaaagt gctgggatta caggtgtgag ccacggcgcc	4260
cagcctcatg aggtctctatt ctttacattc accatggctc gatgggtgct acatgtttgt	4320
ctatgatttt ttttttctat tatcagggtg cttggccggt tcatgcccca cgatgaaagg	4380
gccagaggtt ttcatatgag taaaagaaaa aagcagaaat gtgaaacct caattaggct	4440
aaacaaaaat caactggaaa agtacaggct gaggggagaa gagttggcta catgtttatg	4500
ttaggggagg agggagtaca ttttagctat gtattcaaac agctaatagt ttaatgttgc	4560
tgcttataaa cttaatttta ggctgcatta ataaaagtg agtctccaaa acaaaaaaaaa	4620
aaaaa	4625

<210> SEQ ID NO 36

<211> LENGTH: 7556

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: NR1P1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 36

gcagcgccct tcgcggaacc agcctgacgg agccggaggc tgggagccgc ggcgccctgg      60
ggaagtgttt ggattgtgag ctatttcaga actgttctca ggactcatta ttttaacatt      120
tgggagaaac acagccagaa gatgcacact tgactgaagg aggacaggga atctgaagac      180
tccggatgac atcagagcta cttttcaaca gccttctcaa ttttctttct cagaaagcag      240
aggctcagag cttggagaca gacgaacact gatatttgca tttaatgggg aacaaaagat      300
gaagaaggaa aaggaatata ttactaagg attctatctg cttactgcta cagacctatg      360
tgtaagga   ttcttctctc cctccttgcg tagaagttga tcagcactgt ggtcagactg      420
catttatctt gtcattgcca gaagaaatct tggacagaat gtaacagtac gtctctctct      480
gattgcatg   gaaggtgata aactgatact cctttattaa agttacatcg cactcaccac      540
agaaaaccat tctttaaagt gaatagaaac caagcccttg tgaacacttc tattgaacat      600
gactcatgga gaagagcttg gctctgatgt gcaccaggat tctattgttt taacttacct      660
agaaggatta ctaatgcac   aggcagcagg gggatcagg   actgccgttg aaaaaagtc      720
tgctgggcat aatgaagagg atcagaactt taacatttct ggcagtgcac tccccacctg      780
tcaaagtaat ggtccagttc tcaatacaca tacatatcag gggctctggc tgctgcacct      840
caaaaaagcc agactgttgc agtcttctga ggactggaat gcagcaaagc ggaagaggct      900
gtctgattct atcatgaatt taaacgtaaa gaaggaagct ttgctagctg gcatggttga      960
cagtgtgcct aaaggcaaac aggatagcac attactggcc tctttgcttc agtcattcag      1020
ctctaggctg cagactgttg ctctgtcaca acaaatcagg cagagcctca aggagcaagg      1080
atatgccctc agtcatgatt ctttaaaagt ggagaaggat ttaagggtgt atgggtgttg      1140
atcaagtcac ttaaaaactt tgttgaagaa aagtaaagtt aaagatcaa agcctgatac      1200
gaatcttctc gatgtgacta aaaacctcat cagagatagg tttgcagagt ctctcatca      1260
tgttggacaa agtggaaaca aggtcatgag tgaaccgttg tcatgtgctg caagattaca      1320
ggctgttgca agcatggtgg aaaaaagggc tagtcctgcc acctcaccta aacctagtgt      1380
tgcttgtagc cagttagcat tacttctgtc aagcgaagcc catttgagc agtattctcg      1440
agaacacgct ttaaaaagc   aaaatgcaaa tcaagcagca agtgaaagac ttgctgctat      1500
ggccagattg caagaaaatg gccagaagga tgttggcagt taccagctcc caaaaggaat      1560
gtcaagccat cttaatggtc aggcagaagc atcatcaagc aaactgatgg ctagcaaaag      1620
tagtgctaca gtgtttcaaa atccaatggg tatcattcct tcttccccta aaaatgcagg      1680
ttataagaac tcaactgaaa gaaacaatat aaacaagct gctaacaata gtttgctttt      1740
acatcttctt aaaagccaga ctatacctaa gccaatgaat ggacacagtc acagtgaag      1800
aggaagcatt tttgaggaaa gtagtacacc tacaactatt gatgaatatt cagataacaa      1860
tcctagtttt acagatgaca gcagtgggtg tgaaagtctt tattccaact gtgttcccat      1920
agacttgctt tgcaaacacc gaactgaaaa atcagaatct gaccaacctg tttccctgga      1980
taacttcact caatccttgc taaacacttg ggatccaaaa gtcccagatg tagatatcaa      2040
agaagatcaa gatacctcaa agaattctaa gctaaactca caccagaaag taacacttct      2100
tcaattgcta cttggccata agaatgaaga aaatgtagaa aaaaacacca gccctcaggg      2160

```

-continued

agtacacaat gatgtgagca agttcaatac acaaaattat gcaaggactt ctgtgataga	2220
aagccccagt acaaatcgga ctactccagt gagcactcca cctttactta catcaagcaa	2280
agcagggctct cccatcaatc tctctcaaca ctctctggtc atcaaatgga attccccacc	2340
atatgtctgc agtactcagt ctgaaaagct aacaaatact gcatctaacc actcaatgga	2400
ccttacaaaa agcaaagacc caccaggaga gaaaccagcc caaatgaag gtgcacagaa	2460
ctctgcaacg tttagtgccg gtaagctgtt acaaaattta gcacaatgtg gaatgcagtc	2520
atccatgtca gtggaagagc agagaccag caaacagctg ttaactggaa acacagataa	2580
accgataggt atgattgata gattaaatag ccctttgctc tcaataaaa caaatgcagt	2640
tgaagaaaat aaagcattta gtagtcaacc aacaggctct gaaccagggc tttctggttc	2700
tgaaatagaa aatctgcttg aaagacgtac tgtcctccag ttgctcctgg ggaaccccaa	2760
caaaggggaag agtgaaaaaa aagagaaaac tcccttaaga gatgaaagta ctcaggaaca	2820
ctcagagaga gctttaagtg aacaaatact gatggtgaaa ataaatctg agccttgatga	2880
tgacttacaa attcctaaca caaatgtgca cttgagccat gatgctaaga gtgccccatt	2940
cttgggtatg gctcctgctg tgacagagaag cgcacctgcc ttaccagtgt ccgaagactt	3000
taaatcgagc cctgtttcac ctacagattt ttctttctcc aagaatggtc tgctaagtcg	3060
attgctaaga caaatcaag atagttacct ggcagatgat tcagacagga gtcacagaaa	3120
taatgaaatg gcacttctag aatcaagaa tctttgcatg gtccctaaga aaaggaagct	3180
ttatactgag ccattagaaa atccatttaa aaagatgaaa aacaacattg ttgatgctgc	3240
aaacaatcac agtgccccag aagtactgta tgggtccttg cttaaccagg aagagctgaa	3300
atttagcaga aatgatcttg aatttaata tcttctggtt catggctcag ccagcgaaaag	3360
tgaacacagg agttggggcca gagagagcaa aagctttaat gttctgaaac agctgcttct	3420
ctcagaaaac tgtgtgcgag atttgtccc gcacagaagt aactctgtgg ctgacagtaa	3480
aaagaaagga cacaaaaata atgtgaccaa cagcaaacct gaatttagca tttcttcttt	3540
aatgggactg atgtacagtt ccactcagcc cagcagttgc atggataaca ggacattttc	3600
ataccaggtg tagtaaaaa ctctgtgag tcctactttc cctgagcact tgggctgtgc	3660
agggctctaga ccagaatctg ggcttttgaa tgggtgttcc atgccagtg agaaaggacc	3720
cattaagtgg gttatcactg atgcggagaa gaatgagtat gaaaaagact ctccaagatt	3780
gacaaaaacc aacccaatac tatattacat gcttcaaaaa ggaggcaatt ctgttaccag	3840
tcgagaaaac caagacaagg acatttgag ggaggcttca tctgctgaaa gtgtctcaca	3900
ggtcacagcc aaagaagagt tacttctac tgcagaaacg aaagcttctt tctttaattt	3960
aagaagccct tacaatagcc atatgggaaa taatgcttct cgcacacaca gcgcaaatgg	4020
agaagtttat ggacttcttg gaagcgtgct aacgataaag aaagaatcag aataaaatgt	4080
acctgccatc cagtttttga tctttttaaa actaatgagt atgaacttga gatctgtata	4140
aataagagca tgatttgaaa aaaagcatgg tataattgaa acttttttca ttttgaaaag	4200
tattgggttac tgggtgatgtt gaaatatgca tactaatttt tgcttaacat tagatgtcat	4260
gaggaaaacta ctgaactagc aattgggtgt ttaacacttc tgtatgcac agataacaac	4320
tgtgagtagc ctatgaatga aattctttta taaatattag gcataaatta aaatgtaaaa	4380
ctccattcat agtggattaa tgcattttgc tgcctttatt agggtaacttt attttgcttt	4440
tcagaagtca gcctacataa cacattttta agtctaacc tgttaacaa ctctttaaag	4500
gataattatc caataaaaaa aaacctagtg ctgattcaca gcttattatc caattcaaaa	4560

-continued

ataaattaga	aaaatatatg	cttacatttt	tcactttttg	taaaaagaaa	aaaaaaagg	4620		
gtttattttt	aactcttgga	agaggttttg	tggttcccaa	tgtgtctgtc	ccaccctgat	4680		
ccttttcaat	atatatttct	ttaaaccctg	tgctacttag	taaaaattga	ttacaattga	4740		
gggaagtttg	atagatcctt	taaaaaaaag	gcagatttcc	atTTTTtGTA	ttttaactac	4800		
tttactaaat	taatactcct	cctttttacag	aattagaaaa	gttaacattt	atcttttaggt	4860		
ggtttcctga	aaagtTgaat	atttaagaaa	ttgtttttta	cagaagcaaa	atggcTTTTc	4920		
tttgacagt	tttaccatc	tcttgtaaaa	gttaattctc	accattcctg	tggtacctgc	4980		
gagtgttatg	accaggattc	cttaaacctg	aactcagacc	acttgcatta	gaaccatctg	5040		
gagcacttgt	tttaaaatgc	agattcatag	gcagcatctc	agatctacag	aacaagaatc	5100		
tctgctaagt	ggacctggaa	tcttccatct	gcactttaac	atgctctcta	ggtgtttctt	5160		
gtgtttgaga	accatgactt	atgactttcc	tcagaacatg	agactgtaaa	acaaaaacaa	5220		
aaaactatgt	gatgcctcta	ttttccccaa	tacagtcaca	catcagctca	aaatttgcaa	5280		
tattgtagtt	catatattac	cgttatgtct	ttggaaatcg	ggttcagaac	actttttatg	5340		
acaaaaattg	ggtggagggg	ataactttca	tatctggctc	aacatctcag	gaaaatctgt	5400		
gattatttgt	gtgttcta	aat	gagtaacatc	tacttagtta	gccttaggga	tggaacaa	5460	
gggcactta	ccaaactcag	gtgattccag	gatggtttgg	aaacttctcc	tgaatgcac	5520		
cttaaccttt	attaaaacca	ttgtcctaag	aacaatgcca	acaaagctta	caacatttag	5580		
tttaaaccca	agaagggcac	taaactcaga	ttgactaaat	aaaaagtaca	aagggcacat	5640		
atcgtgaca	gaattgtaca	caatcactcc	attggatctt	ttactttaaa	gtagtgatga	5700		
aaagtacatg	ttgatactgt	cttagaagaa	attaatatat	tagtgaagcc	acatgggggt	5760		
tcagttgcga	aacaggctcg	tttttatgtt	cagtttgtac	aatccacaat	tcattcacca	5820		
gatattttgt	tcttaattgt	gaaccagggt	agcaaatgac	ctatcaaaaa	ttattctata	5880		
atcactacta	gttaggatat	tgatttaaaa	ttgttctact	tgaagtgggt	tctaagattt	5940		
ttatattaaa	aatagggtgtg	atttccta	atgatctaaa	accctaaatg	gttatttttc	6000		
ctcagaatga	tttgtaaaata	gctactggaa	atattataca	gtaataggag	tggtgattat	6060		
gcaacatcat	ggagaagtga	aggcataggc	ttattctgac	ataaaattcc	actggccagt	6120		
tgaatatatt	ctattccatg	tccatactat	gacaatctta	ttgtcaaacac	tatataaata	6180		
agctttttaa	caagtcattt	ttcttgatcg	ttgtggaagg	tttggagcct	tagaggtagt	6240		
tcagaaaaaa	tatgttggtg	ttctcccttg	ggtaggggga	aatgaccttt	ttacaagaga	6300		
gtgaaattta	ggtcagggaa	aagaccaagg	gccagcattg	ctacttttgt	gtgtgtgtgt	6360		
gtgggttttg	ttttgttttt	ttgggtggct	ggttggtttc	gttggtgtta	acaaaggaat	6420		
gagaatatgt	aatacttaaa	taaacatgac	cacgaagaat	gctgttctga	tttactagag	6480		
aatgttccca	atttgaattt	agggtgattt	taaagaacag	tgagaaaggg	catacatcca	6540		
cagattcact	ttgtttatgc	atatgtagat	acaaggatgc	acataatac	attttcaagg	6600		
actatttttag	atatctagac	aattttcttct	aataaagtca	tttgtgaaag	ggtactacag	6660		
cttattgaca	tcagtaaggt	agcattcatt	acctgtttat	tctctgctgc	atcttacaga	6720		
agagtaaaact	ggtgagagta	tatatattttat	atatatatat	atatatatat	atataatatg	6780		
tatatatata	tatatgtact	tgttacatga	agatgttaaa	atcggttttt	aaagggtgatg	6840		
taaaatagtg	tttctta	aat	gaaaaataca	tattttgtat	tggtcta	aatg	caacagaaaa	6900

-continued

```

gccttttaat ctctttgggt cctgtatatt ccatgtataa gtgtaaatat aatcagacag 6960
gtttaaaagt tgtgcatgta tgtatacagt tgcaagtctg gacaaatgta tagaataaac 7020
cttttattta agttgtgatt acctgctgca tgaaaagtgc atgggggacc ctgtgcatct 7080
gtgcatttgg caaaatgtct taacaaatca gatcagatgt tcatectaac atgacagtat 7140
tccatttctg gacatgacgt ctgtgggtta agctttgtga aagaatgtgc tttgattcga 7200
agggtcttaa agaatttttt taatcgtcaa ccacttttaa acataaagaa ttcacacaac 7260
tactttcatg aattttttta tcccattgca aacattattc caagagtatc ccagtattag 7320
caatactgga atataggcac attaccattc atagtaagaa ttctgggtgt tacacaacca 7380
aatttgatgc gatctgctca gtaataataat ttgccatttt tattagaaat ttaatttctt 7440
catgtgatgt catgaaactg tacatactgc agtgtgaatt tttttgtttt gttttttaat 7500
cttttagtgt ttacttctcg cagtgaattt gaataaatga gaaaaaatgc attgtc 7556

```

<210> SEQ ID NO 37

<211> LENGTH: 1516

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: RAC2 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 37

```

tgccccacca ccgtgtctcc tcagcaggcg cctcaccagc ctccacaccc ctgcgcccc 60
cagaaacgcg cctggccctg agctgtcacc accgacactc tccaggtccc ggacacgatg 120
caggccatca agtgtgtggt ggtgggagat ggggcccgtg gcaagacctg ccttctcatc 180
agctacacca ccaacgcctt tcccggagag tacatcccca ccgtgtttga caactattca 240
gccaatgtga tgggtggacag caagccagtg aacctggggc tgtggggcac tgtggggcag 300
gaggactacg accgtctccg gccgtctctc tatccacaga cggacgtctt cctcatctgc 360
ttctccctcg tcagcccagc ctcttatgag aacgtcccgc ccaagtgggt ccagaagtg 420
cggcaccact gcccagcac acccatcacc ctgggtggga ccaagctgga cctgcgggac 480
gacaaggaca ccacgagaa actgaaggag aagaagctgg ctcccatcac ctaccgcag 540
ggcctggcac tggccaagga gattgactcg gtgaaatacc tggagtgtct agctctcacc 600
cagagaggcc tgaaaaccgt gttcgacgag gccatccggg ccgtgtgtgt ccctcagccc 660
acgcggcagc agaagcgcgc ctgcagcctc ctctaggggt tgcaccccag cgctcccacc 720
tagatgggtc tgatcctcca ggatccccc ccaaagcctg atggcacccc ggctggccat 780
gctgtccctc cctgtggcg tttcttagca gatggctgca gagcttcggt gatggtcttt 840
tctgtactgg aggctcctg aggccaggaa cgtgcaaatt tgcagggtgt gcatcccaag 900
cccctcatgc tcctgccttc ctgagggcca gaggggagcc ccaggaccca ttaagccacc 960
cccgtgttcc tgccgtcagt gccaaactgc gcatgtggaa gcatctaccc gttcactcca 1020
gtccaccccc acgcctgact cccctctgga aactgcaggc cagatggttg ctgccacaac 1080
ttgtgtacct tcagggatgg ggctcttact ccctcctgag gccagctgct ctaatatcga 1140
tggctctgct tgccagagag ttctcttacc cagcaaaaat gagtgtctca gaagtgtgct 1200
cctctggcct cagttctcct cttttggaac aacataaaac aaatttaatt ttctacgcct 1260
ctggggatat ctgctcagcc aatggaaaat ctgggttcaa ccagcccctg ccattttctta 1320
agactttctg ctgcactcac aggatcctga gctgcactta cctgtgagag tcttcaaact 1380
tttaaacctt gccagtcagg acttttgcta ttgcaaatag aaaaccaaac tcaacctgct 1440

```

-continued

```

taagcagaaa ataaatttat tgattcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaaaaaaa aaaaaa 1516

```

```

<210> SEQ ID NO 38
<211> LENGTH: 1641
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: SPP1 glucocorticoid receptor-responsive gene

```

```

<400> SEQUENCE: 38
ctccctgtgt tgggtggagga tgtctgcagc agcatTTaaa ttctgggagg gcttggttgt 60
cagcagcagc aggaggaggc agagcacagc atcgtcgga ccagactcgt ctgaggccag 120
ttgcagcctt ctgagccaaa cgcgcaccaa ggaaaactca ctaccatgag aattgcagtg 180
atttgctttt gcctcctagg catcacctgt gccataccag ttaaacaggc tgattctgga 240
agtcttgagg aaaagcagct ttacaacaaa taccagatg ctgtggccac atgggtaaac 300
cctgacccat ctcaagaaca gaattctcta gcccacaga atgctgtgtc ctctgaagaa 360
accaatgact ttaacaaga gaccttcca agtaagtcca acgaaagcca tgaccacatg 420
gatgatatgg atgatgaaga tgatgatgac catgtggaca gccaggactc cattgactcg 480
aacgactctg atgatgtaga tgacactgat gattctcacc agtctgatga gtctcaccat 540
tctgatgaat ctgatgaact ggtcactgat tttcccacgg acctgccagc aaccgaagtt 600
ttcactccag ttgtccccac agtagacaca tatgatggcc gaggtgatag tgtggtttat 660
ggactgaggt caaaatctaa gaagtcttcg agacctgaca tccagtacct tgatgctaca 720
gacgaggaca tcacctcaca catggaaagc gaggagtga atggtgcata caaggccatc 780
cccgttgccc aggacctgaa cgcgccttct gattgggaca gccgtgggaa ggacagttat 840
gaaaagagtc agctggatga ccagagtgtc gaaaccaca gccacaagca gtccagatta 900
tataagcgga aagccaatga tgagagcaat gagcattccg atgtgattga tagtcaggaa 960
ctttccaaag tcagccgtga attccacagc catgaatttc acagccatga agatatgctg 1020
gtttagtagc ccaaaagtaa ggaagaagat aaacacctga aatttcgtat ttctcatgaa 1080
ttagatagtg catcttctga ggtcaattaa aaggagaaaa aatacaattt ctactttgc 1140
atttagtcaa aagaaaaaat gctttatagc aaatgaaag agaacatgaa atgcttcttt 1200
ctcagtttat tgggtgaatg tgtatctatt tgagtctgga aataactaat gtgtttgata 1260
attagtttag tttgtggett catggaaact ccctgtaaac taaaagcttc agggttatgt 1320
ctatgttcat tctatagaag aaatgcaaac tatcactgta ttttaattat tgttattctc 1380
tcatgaatag aaatttatgt agaagcaaac aaaatacttt taccactta aaaagagaat 1440
ataacatttt atgtcactat aatcttttgt tttttaagtt agtgtatatt ttgttgtgat 1500
tatctttttg tggtgtgaat aaatctttta tcttgaatgt aataagaatt tgggtgtgtc 1560
aattgcttat ttgttttccc acggttgtcc agcaattaat aaaacataac cttttttact 1620
gcctaaaaaa aaaaaaaaaa a 1641

```

```

<210> SEQ ID NO 39
<211> LENGTH: 6463
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: PHF15 glucocorticoid receptor-responsive gene

```

-continued

<400> SEQUENCE: 39

ctctcttctgct cgctcgctcc ctctctctcc tgctggctgc ctgttctagg aagccagcgc	60
ggagagggggg gggatgcaca gcacagggga gagagattgc gcatgttggt cagtcgtgtt	120
ttaaagagta cagtgcgggg aggctgagag gggcgcctgc aacaacaact ttggaagga	180
tggaagagaa gaggcgaaaa tactccatca gcagtgacaa ctctgacacc actgacagtc	240
atgcgacatc tacatccgca tcaagatgct ccaaactgcc cagcagcacc aagtcgggct	300
ggccccgaca gaacgaaaag aagccctccg aggttttccg gacagacttg atcacagcca	360
tgaagatccc ggactcatc cagctcagcc cggatgacta ctacatcctg gcagacccat	420
ggcgacagga atgggagaaa ggtgtgcagg tgctgcccgg ggcagaggcc atcccagagc	480
ccgtgggtgag gatcctccca ccactggaag gccccctgc ccaggcatcc ccgagcagca	540
ccatgcttgg tgagggtcc cagcctgatt ggccaggggg cagccgctat gacttgagc	600
agattgatgc ctactggctg gagctcatca actcggagct taaggagatg gagaggccgg	660
agctggacga gctgacatta gagcgtgtgc tggaggagct ggagaccctg tgccaccaga	720
atatggccag ggccattgag acgcaggagg ggctgggcat cgagtacgac gaggatgttg	780
tctgcgagct gtgtcgtctc cctgagggcg aggatggcaa cgagatggtc ttctgtgaca	840
agtgaacgt ctgtgtgcat caggcatgct acgggaccc ctcaagtgccc acgggcagct	900
ggctgtgccc gacgtgtgcc ctgggtgtcc agccaaagtg cctgctctgc cccaagcgag	960
gaggagcctt gaagcccact agaagtggga ccaagtgggt gcatgtcagc tgtgccctat	1020
ggattcctga ggtcagcatc ggctgcccag agaagatgga gcccatcacc aagatctcgc	1080
atatccacgc cagccgtggt gctctgtcct gcagcctctg caaggaatgc acaggcacct	1140
gcaccagatg ttccatgctt tctgctgca cagcgttcca tgtcacatgc gcctttgacc	1200
acggcctgga aatgcggact atattagcag acaacgatga ggtcaagtgc aagtcattct	1260
gccaggagca cagtgcgggg ggcccacgta atgagcccac atctgagccc acggaaccca	1320
gccaggctgg cgaggacctg gaaaagggtga ccttgcgcaa gcagcggctg cagcagctag	1380
aggaggactt ctacgagctg gtggagccgg ctgaggtggc tgagcggctg gacctggctg	1440
aggcactggt cgacttcac taccagtact ggaagctgaa gaggaaagcc aatgcccaacc	1500
agccgctgct gacccccaa accgacgagg tggacaacct ggcccagcag gagcaggacg	1560
tcctctaccg ccgcctgaag ctcttcaccc atctgcggca ggacctagag agggttagaa	1620
atctgtgcta catggtgaca aggcgcgaga gaacgaaaca cgccatctgc aaactccagg	1680
agcagatatt ccacctgcag atgaaactta ttgaacagga tctgtgtcga ggccctgtcca	1740
cctcattccc catcgatggc accttcttca acagctggct ggcacagtcg gtgcagatca	1800
cagcagagaa catggccatg agcgagtggc cactgaacaa tgggcaccgc gaggaccctg	1860
ctccagggct gctgtcagag gaactgctgc aggacgagga gacactgctc agcttcatgc	1920
gggacccctc gctgcgacct ggtgacctg ctaggaaggc ccgaggccgc acccgctgc	1980
ctgccaagaa gaaaccacca ccaccaccac cgcaggacgg gcctgggtca cggacgactc	2040
cagacaaagc cccaagaag acctggggcc aggatgcagg cagtggcaag gggggcaag	2100
ggccacctac caggaaagca ccacgtcgga catcttctca cttgccgtcc agccctgcag	2160
ccggggactg tcccatccta gccacccctg aaagccccc gccactggcc cctgagaccc	2220
cggacgaggc agcctcagta gctgctgact cagatgtcca agtgccctggc cctgcagcaa	2280
gccctaagcc tttgggcggc ctccggccac cccgcgagag caaggaacc cggagattgc	2340

-continued

cggtgcccag	gcctgatgct	gggatgggac	caccttcagc	tgtggctgag	aggcccaagg	2400
tcagcctgca	ttttgacact	gagactgatg	gctacttctc	tgatggggag	atgagcgact	2460
cagatgtaga	ggccgaggac	ggtgggggtgc	agcgggggtcc	ccgggaggca	ggggcagagg	2520
aggtgggtccg	catgggcgta	ctggcctcct	aactcaccct	cttccctgtc	ccaggccctg	2580
ccctgggtccc	cccacaaggc	ctcagcccag	tcacaactgc	catttccagt	ctctgctgag	2640
tgtcccagac	cctcgaggct	gccactccgt	cgtgggttta	tttttaatat	agagagagtt	2700
ttgaattcta	cactgttgtc	tttctctgt	gctggcctag	gacattagga	ttccttcac	2760
ggctccggcc	gctaggaccc	tgccagggtcc	cgcgcacat	ccctgccctg	cccacgtggt	2820
attgtcgggc	tcctggctag	atgcaagcaa	ggtggacaag	agctcaggac	tcagcccac	2880
tgccactggg	tgacacagac	tgtcgtttgg	gcattatttc	atggcagatg	ggccagtcca	2940
gggcctaccc	cgcttgccc	ccagatccca	ctgggggtcca	tttgggggt	cctgctacac	3000
tccaccgatc	cccaggaag	tataataaac	gatacccagc	cagagtctac	tcactgtcac	3060
aagcacacag	agtttatatg	agaaagcact	gaggggggtgc	agagggcccg	ctagtccag	3120
gggaactgaa	agctgttctc	gatcagcccg	tatcatctga	ggcctgcctg	cccaccctgc	3180
cacctcctcc	tccttctgtg	ctctgcccct	gccagtgcct	agcccagcgg	ctctgggaag	3240
gggttcccag	aatccctcct	gagctgtgcc	atttactcag	gggactccca	aacagccagc	3300
tgccagtgca	ggtggagggc	tgtaggggag	ggccagtgcc	cagacagggt	catggggctc	3360
agaccagccc	actgtagaga	atcactctga	ggctccaact	tccttccttc	cttcggggcc	3420
agtctcggcc	gaagtctggt	cacgctcaga	cagagctgac	cagaccagac	cgtttgcctt	3480
ttcaagtttc	ctagtctctg	tacaagatga	gcttcttccg	tggtttcctt	ttggaaactc	3540
ctccttccaa	caagcagtgg	gatcccgggg	cccagggcgg	gccgggtgtg	gccgctgggg	3600
ctgttgtaag	tcttgetgga	tgttcccctg	ttcctgagcc	ttaacccttc	gcacagccat	3660
ccccccccc	gtcctgccc	ccccccccc	cgtcctgcct	ttcccacccc	acccttaggt	3720
cccaggtagt	tgctctgaag	agtttcagta	gagtggcccc	aggtgatag	ctcagggaac	3780
aacaaaaaag	gaattccgtg	aaaacatttt	tttttctttg	atgaattact	cctgggtcac	3840
ttccaccact	ggtaaagcca	gaacttctcc	aaaaagaacc	ttgcaaaaag	tccagtgaat	3900
cagtgcgaac	attctgtgga	tgccaaagaa	tattttgacc	ataatacagc	acagcctgga	3960
cctgacaact	tgtcatttgg	actttttttt	aaatggagtt	ctttagcaac	aaagtataga	4020
aacatgttca	ttgcacacac	ccaaggagaa	gagctcaagc	gcttgaaga	ggatgctttg	4080
ctgctgctga	agtgtaacctg	ggtgttagat	ttcagatcct	gggctgagcc	cactgtgagc	4140
tttctctaac	tgtgagactc	acagagggga	aagatactga	cggtgaaacc	agcatggaaa	4200
acgtctttac	catgtggttc	cctcctcccc	aaatacataa	agcaaataag	caggatgggg	4260
aacagcttga	ccttcaccca	cccctaactc	caaaactatc	aaggtacgac	agtggcattg	4320
tcacgcagac	tcaatttcat	gtgaatttta	gcaaaacagg	aaacaaagat	aatgactcag	4380
ttcagaggat	cggacaaaatg	tgtctagtcc	gggtggactc	ggagggagtg	gggtgggctt	4440
caaggattct	gggcgttggg	atggcatgag	ctaccctgta	gagtttagtc	tgctgccccg	4500
ccttggtagt	agtgaccagt	cagtgtcagc	atcagtgtcc	caaccccagt	ctctgtttac	4560
tgcccttgaa	cagaacttct	tccttcccca	tgctttgggt	cacctcgggc	tgcaaccctg	4620
tctgtgccag	attgcccggt	ctgaccctgc	aggaagcaaa	gaggtgagct	taaagaacaa	4680

-continued

```

ccaaactctg ccaggggtcc cagaaagccc aggggtccagc agtctcagca cttggcccct 4740
tgccccttca caccatctctg gggcaggggc tgggcctccc tgggtggcagg ggtgggtgga 4800
gaattaggga gaggggtgcaa cgagtctggc cccttgccctc gggctggctg gtgttcttcc 4860
aagagcctct gctcacattg ttggcctctg gattctggcc cttcttcatt ggctgttget 4920
ttggactgga ctgttctgta gctgtgtgcc tgcagaacct agatgtctgt taggtggct 4980
ggctgctcgc aggggagggg ggtggccttt catttggggg gccctttcac tcccaggcca 5040
agccctggag caatcttctt caggcagctg tctccacctc caggatgtcc agcaggtgc 5100
aaggagaagg atgccagcca cccatcctcc ccagttccc agcctttccc ctgttggtca 5160
cagccgtctc tgtcttttct cgtctactg tcccagtggt agagggtttt gctgtccctg 5220
agactgaggc aggttccttt tccaggtcag aggtggaggt agatctttct ctcaaccaca 5280
tctgcctcca cacacagctc ctccgcaggg aaggagaagc tgctctgtaa ctcatctggt 5340
ctatcgtccc ccttctcact gacctgaccg cccaccacct ccttcccct catcacatga 5400
caaaggataa tgtgcaagaa aagtattttt atgtatcata aatgtatttt gaaacaaatg 5460
agaagaagaa aggtagaagg gtttatttta ttaaatgagc ctgacttagt gacagtgtgt 5520
gagcatttgc aatgtaaggg cctcagcttc cttggagaag ccaccccagg tttccagaca 5580
tagatgttga attgtttgtg ggggggtgtc caggccacgt ctctgtgtgc cgtatgcagg 5640
catgcctgtg tatactgtgt atgggcacac tgggactagc tgggacaatt cctagagatt 5700
caactgcccc attctaacca acattggcag cggtgaact tggcatttcc ttgctaactg 5760
ccagatgtgg ccaacctttg tccatatgca aacctgaa aaatgatctg gatttctata 5820
gcaaggccct tggggagggc actctcccat gcccttgcc tcgctggcca cattggccaa 5880
tgagccaggg ctggagtctg agacctttgg ttgttcttta aggcacctcc tggcacttcc 5940
tccctcagag gcacaaacac tttgtgttcc acgtcagttt gaggggacgg tggggggatg 6000
atatgaatgt cacaggagga gacaccttct gtctttgttt caaagaaagt gatgtgccat 6060
ttgttaatat acaagagaaa tattgaaaat atattgaaa gagcaatttt aaattatttt 6120
tggcttatgt tgcaatatat attttcttgt attagaaaag attcctttgt agagaaaaaa 6180
tgtatttttc attaacgcaa agacctattt ctcttttttg tacattgtcc atgtgcgcaa 6240
cccttaacga gcaatagaat gtatggtcac ctgggtgtgg ccagtgcctg ctgtgcctg 6300
catgattctg tgttgcctgct gctgcatagt tcccagcccc atcctgtcct gctcactcat 6360
gggggcttcc agaccccgcc cccaccaggg cttgtgtcat agggagccct ttgcactcct 6420
cgtgtgttgg caaacgcagt taataaagca gtgttttctg tgc 6463

```

```

<210> SEQ ID NO 40
<211> LENGTH: 2828
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BTN3A2 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 40

```

```

catagatgaa aatggcaagt tcctggcctt tccttctgct caactttcat gtctccctcc 60
tcttgggtcca gctgctcact ccttgtctcag ctcaagtttct tgtgcttgga ccctctgggc 120
ccatectggc catgggtggg gaagacgctg atctgccctg tcacctgttc ccgacctga 180
gtgcagagac catggagctg aagtgggtaa gttccagcct aaggcagggt gtgaacgtgt 240
atgcagatgg aaaggaagtg gaagacaggc agagtgcacc gtatcgaggg agaacttcga 300

```

-continued

ttctgcggga	tggcatcact	gcagggaagg	ctgctctccg	aatacacaac	gtcacagcct	360
ctgacagtgg	aaagtacttg	tgttatttcc	aagatggtga	cttctatgaa	aaagccctgg	420
tggagctgaa	ggttgcagca	ctgggttcta	atcttcacgt	cgaagtgaag	ggttatgagg	480
atggagggat	ccatctggag	tgcaggcca	cggctggta	cccccaacce	caaatacagt	540
ggagcaacgc	caagggagag	aacatcccag	ctgtggaagc	acctgtgggt	gcagatggag	600
tgggcctata	tgaagtagca	gcactctgtga	tcatgagagg	cggctccggg	gaggggtgat	660
cctgcatcat	cagaaattcc	ctctcgggcc	tggaaaagac	agccagcatt	tccatcgag	720
accccttctt	caggagcgcc	cagccctgga	tcgcagccct	ggcagggacc	ctgcctatct	780
tgctgctgct	tctcgccgga	gccagttact	tcttgaggag	acaacagaag	gaaataactg	840
ctctgtccag	tgagatagaa	agtgcacaag	agatgaaaga	aatgggatat	gctgcaacag	900
agcgggaaat	aagcctaaga	gagagcctcc	aggaggaact	caagaggaaa	aaaatccagt	960
acttgactcg	tggagaggag	tcttcgtccg	ataccaataa	gtcagcctga	tgctctaattg	1020
gaaaaaatggc	cctcttcaag	cctggaaaaa	tggtgacccc	catggacacc	tctctaaact	1080
ctctgcagca	gatgtaattc	tgtatccaga	catggcaaat	gccatcctcc	ttgtttctga	1140
ggaccagagg	agtgtagcgc	gtgctgagga	gccccatgac	ctaccagaca	accctgagag	1200
atttgaatgg	cgttactgtg	tgcttggtg	tgaaagcttc	atgtcagaga	gacactactg	1260
ggaggtggaa	gtgggggaca	gaaaagagtg	gcataattggg	gtatgtagta	agaacgtgga	1320
gaggaaaaaa	gtttgggtca	aaatgacacc	ggagaacgga	tactggacta	tgggcctgac	1380
tgatgggaat	aagtatcggg	ctctcactga	gcccagaacc	aacctgaaac	ttcctgagcc	1440
tcctaggaaa	gtgggggtca	tcctggacta	tgagactgga	catatctcgt	tctacaatgc	1500
cacggatgga	tctcatatct	acacatttct	gcacgcctct	tcctctgagc	ctctgtatcc	1560
tgtattcaga	attttgaact	tggagccac	tgccctgacc	gtttgcccaa	tacccaaaagt	1620
agagagttec	cccgatcccg	acctagtgcc	tgatcattcc	ctggagatac	caactgacccc	1680
aggcttagct	aatgaaagtg	gggagcctca	ggctgaagta	acatctctgc	ttctccctgc	1740
ccagcctgga	gctaagggtc	tcaccctcca	caacagccag	tcagaaccat	aaagctacag	1800
gcacacactg	aagcacttta	ctgatattca	ttcaattatt	ccataggaca	gttggttgag	1860
tttggtgcc	ccttattggc	ccctttatac	agataaggaa	actggggtgt	agaaaagtgt	1920
attgacttta	caaagcagac	aggaatagt	aacaacagag	ctgggatctg	aacaacaatg	1980
actaacatta	atggagaatt	taaaacgttc	tgagtgtgt	gttatgagct	ttggtgggtg	2040
tcactccttt	aatcctcaca	accccctgtc	aggtagtctc	atttggcaag	tatggaagca	2100
gaggcagggc	aacattaagt	agcttacata	actcacacgg	taatttgtgc	agttgggaga	2160
tgttcagctt	cagtccttgg	ccaattgccc	gttcttttcc	agcctgattt	ttcctgcattg	2220
ggaagagccc	acatgtagcc	ctgagggttc	cttcccagga	cagctccagg	atcgagatca	2280
ctgtgagtgg	ttgtggagtt	aagaccccta	tggactcctt	cccagctgat	tatcagagcc	2340
ttagaccacg	cactccttgg	attggtctctg	cagagtgtct	tggttgagag	aataacgttg	2400
cagttccac	agggcatgtg	actttgaaag	agactagagg	ccacactcag	ttaataatgg	2460
ggcacagatg	tgttccaccc	caacaaatgt	gataagtgat	cgtgcagcca	gagccagcct	2520
tccttcagtc	aaggtttcca	ggcagagcaa	ataccctaga	gattctctgt	aatattggta	2580
atttggatga	aggaagctag	aagaattaca	gggatgtttt	taatccact	atggactcag	2640

-continued

tctcctggaa aaggatctgt ccactcctgg tcattggtgg atgttaaacc catattcctt	2700
tcaactgctg cctgctaggg aaaactgctc ctcattatca tcaactattat tgcaccacac	2760
tgtatccctt ctactgggca agtgcttgct aagttctagt tgttcaataa atttgtaaat	2820
aatgctga	2828

<210> SEQ ID NO 41

<211> LENGTH: 2698

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: SESN1 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 41

gccgtccgtg ctgactgagg cgctgcagcc aggagccgcg gccggctgcc cagcgctcgc	60
cgcctccgcg cgctccgagc cgccccgcg ccgacatgcg cttggccgccc gccgccaacg	120
aggcgtagac ggcccccttg gcgggtctcg ggctgctggg ctgcaagcag tgcggcgggg	180
gccgcgacca ggacgaggaa cttggcatta gaattcctcg accactagga cagggaccaa	240
gcagattcat ccagaaaag gagatcctcc aagtggggag tgaagacgca cagatgcatg	300
ctttatttgc agattctttt gctgcttttg gccgtttgga taacattacg ttagtgatgg	360
ttttccccc acaatattta gaaagtttct taaaaactca gcaatctcta ctgcaaatgg	420
atgggcccgtt acccctacat tatcgtaact acattggaat aatggctgcg gcaagacatc	480
agtgtccta cttagtgaac ctgcatgtaa atgatttctt tcatgttggt ggggacccca	540
agtggctcaa tggtttagag aatgtctctc aaaaactaca gaatttagga gaacttaaca	600
aagtgttagc ccatagacct tggccttatta ccaaagaaca cattgaggga cttttaaaag	660
ctgaagagca cagctggtcc cttgcggaat tggtagatgc agtagtttta ctacacact	720
atcattctct tgcctcattc acattcggct gtggaatcag tccagaaatt cattgtgatg	780
gtggccacac attcagacct ccttctgtta gcaactactg catctgtgac attacaaatg	840
gcaatcacag tgtggatgag atgccggtca actcagcaga aaatgtttct gtaagtgatt	900
ctttctttga ggttgaagcc ctcatggaaa agatgaggca gttacaggaa tgcgagatg	960
aagaagaggc aagtcaggaa gagatggctt cacgttttga aatagaaaaa agagagagta	1020
tgtttgtctt ctcttcagat gatgaagaag ttacaccagc aagagctgta tctcgtcatt	1080
ttgaggatag tagttatggc tataaagatt tctctagaca tgggatgcat gttccaacat	1140
ttcgtgtcca ggactattgc tgggaagatc atggttatct tttggtaaat cgcctttatc	1200
cagatgtggg acagttgatt gatgaaaaat ttcacattgc ttacaatctt acttataata	1260
caatggcaat gcacaaagat gttgatacct caatgcttag acgggcaatt tggaactata	1320
ttcactgcat gtttgaata agatatgatg attatgacta tgggtgaaat aaccagctat	1380
tggatcgtag ctttaaagtt tatatcaaaa ctgttggttg cactcctgaa aaggttacca	1440
aaagaatgta tgatagcttc tggaggcagt tcaagcactc tgagaagggt catgttaatc	1500
tgtctcttat agaagctagg atgcaagcag aactccttta tgctctgaga gccattaccc	1560
gctatatgac ctgatgcctt tccttcatta aagatgattc tggaatgatc agcagatata	1620
gtctacaagg ggggaaggta taagccccag gaccaatggt agacaaaata attcagaaat	1680
ccattgtgcc atgattcctt tagtttctgc tatttttctg tggaaaacca ctgctggcac	1740
aagcagtgac tgtttggcag cttcaagttt agagctgtga agacaggctg ccattcacag	1800
tattttgctt ttgacagta caagatgctg tgtaactggt ttaatacagc aaatagtaac	1860

-continued

```

tctccaaatc ctgttgcttt tatgttaaata aagataacaa gaattggagc atgcaaagaa 1920
tggaacttgg ataatactt aagctttata tgtaaagaat tttagaagat cttggtgctg 1980
ctattcctgc tggaggaaatg aatagatggc tgtttcagtt aagctattag taataaaaagt 2040
gaacattgct actatctgag cctacataca taacttgtgt gatttcaaata taaacttgca 2100
ttatgtgtta attttcttgc atctaaaaaa gcatagaatt cctactcaca cagctcagca 2160
acaaccattt tgatggtaac agttaatttc tttcattagt tttttaaat cagggttctg 2220
gatattaaat taaaatggca ttcttaaaga ttttcttcaa aaagcaatcc taaatgaaag 2280
tgtgtaaatt ataagaagct ggcgatcttt tgatatgctg tttcacagga tcctgacact 2340
ggagggcagc tgtcttgctg attacttggt tttccagcac caaagttgtg ggacatgttg 2400
ctgtagactg ctgcgcagtc ctgggtgcat tcagtctctc tgctctgccc tgctctctgg 2460
tccccacttt aaaggctgtg cagctcctta aataataaag ctggaaaata tttttagtcg 2520
ggttatcaaa tttgatttac aaaaacgcta actttgtttg aaatgcaaac aggtttgaaa 2580
atatgtatta agtactttgt attctggaag cgtgaattgc ttttgaagtc tgcagtatt 2640
actggtattt ttaataaag aagaattttt ctccaatttt aaaaaaaaa aaaaaaaaa 2698

```

<210> SEQ ID NO 42

<211> LENGTH: 5215

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: MAP3K5 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 42

```

cgagcgcggc gcccttgagc tgcaccgcgg cgcaggtttg cgagccgact tgcagccgg 60
ccaagaaaag gaagctccgt ccttccccgc tcaccggctt tccccacccc ttgtactcta 120
aactctgcag agggcgcagc gcgcggccac ggaggcgcgg agggaggagc agccgcgcgc 180
gggcagcggc gtgccctcgg gggagagggc gccggagagg aggcggcggc gcggcggcga 240
gggcgcggcg cgcgatggca gctgcttagc ccggcggggc cggagcagcc ccgagctgtg 300
gctggccagg cgggtgcggc gggcggggga cgcgcgcgc gttgctgccc ggcccgagga 360
gatgagcacg gaggcgagc agggcatcac tttctctgtg ccacccttcg cccctcggg 420
cttctgcacc atccccgagg gcggcatctg caggagggga ggagcggcgg cgggtggcga 480
gggcgaggag caccagctgc caccgcgcgc gccgggcagc ttctggaacg tggagagcgc 540
cgctgccctt ggcacgcggt gtccggcggc caccctctcg agcagtgcc cccgaggccg 600
gggcagctct gttggcgggg gcagccgagc gaccacggtg gcatatgtga tcaacgaagc 660
gagccaaggg caactggtgg tggccgagag cgaggccctg cagagcttgc gggaggcgtg 720
cgagacagtg ggcgccaccc tggaaaccct gcattttggg aaactcgact ttggagaaac 780
caccgtgctg gaccgctttt acaatgcaga tattgcggtg gtggagatga gcgatgcctt 840
ccggcagcgg tccttggttt accaccttgg ggtgagagaa agtttcagca tggccaacaa 900
catcatcttc tactgtgata ctaactcgga ctctctgcag tcaactgaag aaataatttg 960
ccagaagaat actatgtgca ctgggaacta cacttttggt ccttacatga taactccaca 1020
taacaaagtc tactgctgtg acagcagctt catgaagggg ttgacagagc tcatgcaacc 1080
gaacttcgag ctgcttcttg gaccatctg cttacctctt gtggatcgtt ttattcaact 1140
tttgaagggt gcacaagcaa gttctagcca gtacttcggg gaatctatac tcaatgacat 1200

```

-continued

caggaaagct	cgtaatttat	acactggtaa	agaattggca	gctgagttgg	caagaattcg	1260
gcagcgagta	gataatatcg	aagtcttgac	agcagatatt	gtcataaatc	tgttactttc	1320
ctacagagat	atccaggact	atgattctat	tgtgaagctg	gtagagactt	tagaaaaact	1380
gccaaccttt	gatttggcct	cccatcacca	tgtgaagttt	cattatgcat	ttgcaactgaa	1440
taggagaaat	ctccctgggtg	acagagcaaa	agctcttgat	attatgattc	ccatgggtgca	1500
aagcgaagga	caagttgctt	cagatatgta	ttgcctagtt	ggtcgaatct	acaaagatat	1560
gtttttggac	tctaatttca	cggacactga	aagcagagac	catggagctt	cttgggtcaa	1620
aaaggcattt	gaatctgagc	caacactaca	gtcaggaatt	aattatgcgg	tcctcctcct	1680
ggcagctgga	caccagtttg	aatcttctt	tgagctccgg	aaagttgggg	tgaagctaag	1740
tagtcttctt	ggtaaaaagg	gaaacttgga	aaaactccag	agctactggg	aagttggatt	1800
ttttctgggg	gccagcgctc	tagccaatga	ccacatgaga	gtcattcaag	catctgaaaa	1860
gcttttttaa	ctgaagacac	cagcatggta	cctcaagtct	attgtagaga	caattttaat	1920
atataagcat	tttgtgaaac	tgaccacaga	acagcctgtg	gccaaagcaag	aacttgtgga	1980
cttttggaatg	gatttctctg	tcgaggccac	aaagacagat	gttactgtgg	ttaggtttcc	2040
agtattaata	ttagaaccaa	ccaaaatcta	tcaaccttct	tatttgtcta	tcaacaatga	2100
agttgaggaa	aagacaatct	ctatttgga	cgtgcttct	gatgacaaga	aaggtataca	2160
tgagtggaat	tttagtgctt	cttctgtcag	gggagtgagt	atttctaaat	ttgaagaaag	2220
atgctgcttt	ctttatgtgc	ttcacaaatc	tgatgatctt	caaactctatt	tctgtacaga	2280
acttcattgt	aaaaagtttt	ttgagatgg	gaacaccatt	accgaagaga	aggggagaag	2340
cacagaggaa	ggagactgtg	aaagtgactt	gctggagtat	gactatgaat	atgatgaaaa	2400
tggtgacaga	gtcgttttag	gaaaaggcac	ttatgggata	gtctacgcag	gtcgggactt	2460
gagcaaccaa	gtcagaattg	ctattaagga	aatcccagag	agagacagca	gatactctca	2520
gccccgtcat	gaagaaatag	cattgcataa	acacctgaag	cacaaaaata	ttgtccagta	2580
tctgggctct	ttcagtgaga	atggtttcat	taaaatcttc	atggagcagg	tccttgagg	2640
aagtctttct	gctctccttc	gttccaaatg	gggtccatta	aaagacaatg	agcaacaat	2700
tggcttttat	acaaagcaaa	tactggaagg	attaaaaat	ctccatgaca	atcagatagt	2760
tcaccgggac	ataaagggtg	acaatgtgtt	gattaatacc	tacagtgggtg	ttctcaagat	2820
ctctgacttc	ggaacatcaa	agaggcttgc	tggcataaac	ccctgtactg	aaacttttac	2880
tggtaccctc	cagtatatgg	caccagaaat	aatagataaa	ggaccaagag	gctacggaaa	2940
agcagcagac	atctggtctc	tgggctgtac	aatcattgaa	atggccacag	gaaaaccccc	3000
attttatgaa	ctgggagaac	cacaagcagc	tatgttcaag	gtgggaatgt	ttaaagtcca	3060
ccctgagatc	ccagagtcca	tgtctgcaga	ggccaaggca	ttcatactga	aatgttttga	3120
accagatcct	gacaagagag	cctgtgctaa	cgacttgctt	gttgatgagt	ttttaaaagt	3180
ttcaagcaaa	aagaaaaaga	cacaacctaa	gctttcagct	cttccagctg	gatcaaatga	3240
atatctcagg	agtatatcct	tgccggtacc	tgtgctgggtg	gaggacacca	gcagcagcag	3300
tgagtacggc	tcagtttcac	ccgacacgga	gttgaaagtg	gaccccttct	ctttcaaaac	3360
aagagccaag	tcctgcggag	aaagagatgt	caagggaatt	cggacactct	ttttgggcat	3420
tcagatgag	aattttgaag	atcacagtgc	tctctcttcc	cctgaagaaa	aagattctgg	3480
attcttcatg	ctgaggaagg	acagtgagag	gcgagctacc	cttcacagga	tcctgacgga	3540
agaccaagac	aaaattgtga	gaaacctaat	ggaatcttta	gctcaggggg	ctgaagaacc	3600

-continued

```

gaaactaaaa tgggaacaca tcacaaccct cattgcaagc ctcagagaat ttgtgagatc 3660
cactgaccga aaaatcatag ccaccacact gtcaaagctg aaactggagc tggacttcga 3720
cagccatggc attagccaag tccaggtggt actctttggt tttcaagatg ctgtcaataa 3780
agttcttcgg aatcataaca tcaagccgca ctggatgttt gccttagaca gtatcattcg 3840
gaaggcggta cagacagcca ttaccatcct ggttccagaa ctaaggccac atttcagcct 3900
tgcatctgag agtgatactg ctgatcaaga agacttggat gtagaagatg accatgagga 3960
acagccttca aatcaaaactg tccgaagacc tcaggctgtc attgaagatg ctgtggctac 4020
ctcaggcgtg agcacgctca gttctactgt gtctcatgat tcccagagtg ctcaccggtc 4080
actgaatgta cagcttgga ggatgaaaat agaaaccaat agattactgg aagaattggt 4140
tcggaaagag aaagaattac aagcactcct tcctcgagct attgaagaaa aagaccaaga 4200
aattaaacac ctgaagctta agtccaacc catagaaatt cctgaattgc ctgtatttca 4260
tctaaattct tctggcacia atactgaaga ttctgaactt accgactggc tgagagtga 4320
tggagctgat gaagacacta taagccggtt ttgggtgaa gattatacac tattggatgt 4380
tctctactat gttacacgtg atgacttaaa atgcttgaga ctaaggggag ggatgctgtg 4440
cacactgtgg aaggctatca ttgactttcg aaacaaacag acttgactgt tgctcaatct 4500
aatcttcgat ggaaattcta aaaattaata cagagctgat cttcttgggg gtgggaaaat 4560
cgaagggaga ggagaaaggc gctgcacttt aaatccagta tttgtttact catgttaaaa 4620
aaaaaaaaa cagacaaaac acactgaaat ttcctaacta catctatttc tataattttt 4680
aaggactctt cataaggact cttaaaataa tcctgaacat tagaaccta atgttcagga 4740
agattttaat ctaagcattt ttatggaaat atttttaatg cagcagctat tgcacttcag 4800
ccaaatgttt atttcacaca aaacggatgt aacatttcat gtgatcgtgc accactggaa 4860
caaaacaaaa atgtgacct aactgtttag gcttctgtgt gtttgaata tgccttaata 4920
atctgagtag aaatgcgtaa tttcaattac tgtataaagt ttatgtttt ttaagtgtgc 4980
agaatctgag agcaatgggt tttacttctc tgtgttaatt gtaatatga ctctattttg 5040
taacttaagt ttctgacctg tcgtacattt gtttgagtcg tttatgtact actgaactgt 5100
accagttgca catgcttgaa ctgtagtaat gttagcttgt tctaaagcta tccattgtgt 5160
catatttact ctaaaaatta aagagactct caacaaaaa aaaaaaaaa aaaaa 5215

```

<210> SEQ ID NO 43

<211> LENGTH: 4655

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: DPYSL2 glucocorticoid receptor-responsive gene

<400> SEQUENCE: 43

```

tctgtgcacc ttgcgggtgg cgcgcaacgg cagccgcggc agcagctagg gggcttgtgc 60
acacagcgag ggagacttag ggactggcag acggacggac ggacggcgag gaccctaccc 120
gagccccga gccatggcgg agagaaagca atccgggaag gcggcagagg acgaagaggt 180
ccctgctttt tttaaaaacc tgggctccgg cagccccaag ccccggcaga aattctgtgg 240
catgttctgc ccggtggaag ggtcctcgga gaacaagacc atcgacttcg actcgtgtgc 300
ggtgggccgg ggctcggggc aggtggtggc tcagcagcgg gacgtcgccc acttggggcc 360
ggacccgcag ccgccgtact cgcggcaggg ccggcgcgcc ggcgagagc catctgttga 420

```

-continued

atcgggccgg aaggtggaga tccggagggc ctcgggcaaa gaagccctgc agaacaatcaa	480
cgaccagagc gatcgtcttc tgatcaaagg aggtaaaatt gttaatgatg accagtcgtt	540
ctatgcagac atatacatgg aagatgggtt gatcaagcaa ataggagaaa atctgattgt	600
gccaggagga gtgaagacca tcgaggccca ctcccggatg gtgatcccc gaggaattga	660
cgtccacact cgtttccaga tgccctgatca gggaaatgacg tctgctgatg atttcttcca	720
aggaaccaag gcggccctgg ctgggggaac cactatgacg attgaccacg ttgttcctga	780
gcctgggaca agcctgctcg ctgcctttga ccagtggagg gaatgggccc acagcaagtc	840
ctgctgtgac tactctctgc atgtggacat cagcgagtgg cataagggca tccaggagga	900
gatggaagcg cttgtgaagg atcacggggt aaattccttc ctctgttaca tggctttcaa	960
agatcgcttc cagctaacgg attgccagat ttatgaagta ctgagtgtga tccgggatat	1020
tggcgccata gcccaagtcc acgcagaaaa tggcgacatc attgcagagg agcagcagag	1080
gatcctggat ctgggcatca cgggccccga gggacatgtg ctgagccgac ctgaggagggt	1140
cgaggccgaa gccgtgaatc gtgccatcac catcgccaac cagaccaact gcccgctgta	1200
tatcaccaag gtgatgagca aaagctctgc tgaggtcatc gcccaggcac ggaagaaggg	1260
aactgtggtg tatggcgagc ccatcactgc cagcttggga acggacggct cccattactg	1320
gagcaagaac tgggccaagg ctgctgcctt tgtcacctcc ccaccttga gccctgatcc	1380
aaccactcca gactttctca actccttgct gtctgtgga gacctccagg tcacgggcag	1440
tgccattgc acgtttaaca ctgcccagaa ggctgtagga aaggacaact tcacctgat	1500
tccggagggc accaatggca ctgaggagcg gatgtccgtc atctgggaca aggotgtggt	1560
cactgggaag atggatgaga accagtttgt ggctgtgacc agcaccaatg cagccaaagt	1620
cttcaacctt tacccccgga aaggccgcat tgctgtggga tccgatgccg acctggtcat	1680
ctgggacccc gacagcgta aaaccatctc tgccaagaca cacaacagct ctctcgagta	1740
caacatcttt gaaggcatgg agtgccgccc ctccccactg gtggtcatca gccaggggaa	1800
gattgtcctg gaggacggca cctgcatgt caccgaaggc tctggacgct acattccccg	1860
gaagcccttc cctgattttg ttacaagcg tatcaaggca aggagcaggc tggtgagct	1920
gagagggggt cctcgtaggc tgtatgacgg acctgtgtgt gaagtgtctg tgacgcccga	1980
gacagtcact ccagcctcct cggccaagac gtctcctgcc aagcagcagg ccccacctgt	2040
ccggaacctg caccagtctg gattcagttt gtctgggtgct cagattgatg acaacattcc	2100
ccgcccgcacc acccagcgta tcgtggcgcc ccccggtggc cgtgccaca tcaccgcct	2160
gggctagagc tcttgggctg tgccgtccac tggggactgg ggatgggaca cctgaggaca	2220
ttctgagact tctttcttcc ttctttttt tttttttgtt tttttttta agagcctgtg	2280
atagttactg tggagcagcc agttcatggg gtcccccttg gggccccaca ccccgctctc	2340
caccaagagt tactgatttt gctcatccac ttccctacac atctatgggt atcacacca	2400
agactacca ccaagctcat acagggaacc acaccaaca cttagacatg cgaacaagca	2460
gccccagcg agggctctct tcgccttcaa cctcctagtg tctgttagca tcttcctttt	2520
catgggggga ggggaagataa agtgaattgc ccagagctgc ctttttcttt tctttttaaa	2580
aattttaaga agttttcttt gtggggctgg ggaggggccc gggtcaggga gagtcttttt	2640
tttttttttt ttttaatact aaattggaac atttaattcc atattaatac aaggggtttg	2700
aactggacat cctaattgat caattacgtc atcaccacgc tgattccggg tggttgga	2760
actcatcgtg tctgtctga gaggtccac aatgccacc cgcacgcca ttctgtagtc	2820

-continued

```

ttcagggtca gctgttgata aaggggcagg cttgcgttat tggcctagat tttgctgcag 2880
attaaatcct ttgaggattc tcttctcttt taccattttt ctgcgtgctc tcactctctc 2940
tttctctctc tagcttttta attcatgaat attttcgtgt ctgtctctct ctctctctgt 3000
gtttectcca gcccttgctc cggagacggg gttttctctc cttgccccat tatcttttca 3060
cctcccaggc ctaccatttc atgggtggcg ttgggtccgc ctaaaggatt tgagcgtttg 3120
ccattgcaag catagtgtcg tgtcatcctg gtocatgtag gactgggtgt aaccacctgc 3180
catcatgagg atgtgtgcta gagtgtggga ccttggccaa gtgcaggaat gggccatgcc 3240
gtctcacca cagtatcaca cgtggaaccg cagacagggc ccagaagctt tagaggtatg 3300
aggctgcaga accggagaga ttttctctct tgcagtgtct tctggctaaa gtcacgggtca 3360
aacctaaaca ccgagcctca ttaacccaag tgaaccaacc aaagtcacca gttcagaagt 3420
gctaagctaa taggagtctg acccgagggc ctgctgcttc ctggttaagt atcttttgag 3480
attctagaac acatgggagc tttttatttt cggggaaaaa ccgtattttt ttcttggtcca 3540
attattttcta aagacacact acatagaaag aggcctata aactcaaaaa gtcattggga 3600
aacttaaagt ctattctact ttgcaagagg agaaatgtgt tttatgaacg atagatcaca 3660
tcagaactcc tgtggggagg aaaccttata aattaaacac atggccccct tagagaccac 3720
agggtgatgtc tgtctccatc ctctctctc cttttctgtc acctttcccc ctagtgggt 3780
cctttggacc taccctgtc cttgctgact tgtgttgcac tgtattccaa acgtgtttac 3840
aggttctctt aagcaatggt gtatttgcag gcttttctga atacaaaac tgctttttgt 3900
aaagcgtaaa aacatcacaa agtaggtcat tccatcacca ccctgtctc tctacacatt 3960
ttgcctttgg gcatctggtt ggggttttgg gttttttgtt gttgtgtttt atttgttatt 4020
ttaaaggtaa attgcacttt taaaaaata attggttgac ttaatattt tgcttttttt 4080
ctcacctgca cttagaggaa atttgaacaa gttggaaaaa aacaattttt gtttcaattc 4140
taagaaacac ttgcagctct agtatcact tgagtcttcc tgtttttcct gtaccgggtc 4200
atggtaattt ttggtgtgtt tgggtgtttt cttaaaaaac aagttaaaac ctgacgattt 4260
ctgcaggctg tgtaagcatg tttacctgtt ggcttgcctt gtgtgtctgt taaatgaatg 4320
tcatatgtaa atgctaaaat aaatcgacag tgtctcagaa ctgaataact gcagtgactt 4380
gatgtcttaa aacagtgtag gatttaagaa tagatggttt ttaatcctgg aaattgtgat 4440
tgtgacctat gagtggagga actttcagtt ctaaagctga taaagtgtgt agccagaaga 4500
gtactttttt ttttgaacc actgtcttga tggcaaaata attatggtaa aaaacaagtc 4560
tcgtgtttat tattccttaa gaactctgtg ttatattacc atggaacgcc taataaagca 4620
aaatgtggtt gtttcaggaa aaaaaaaaaa aaaaa 4655

```

<210> SEQ ID NO 44

<211> LENGTH: 4417

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: SEMA4D glucocorticoid receptor-responsive gene

<400> SEQUENCE: 44

```

gctgtaacac tcaccgtgaa ggtctgcagc ttcactcccc agccagcgag accacgaacc 60
caccagaagg aagaaactct gaacacatct gaacatcaga agggacagac tccagacgcg 120
ccaccactct gctaacacca gatagtggaa agaaaccatg tgctgaaatg tttgacgaca 180

```

-continued

ctgatggttt gactctgcta actggaatgg cttattgtgc aagaaagtac acctggtcgg	240
gtcctggggc tcactctctag caccagcaaa gatttcttga gacgtcttcc tagaaatgac	300
tggaaagtgt caagaggcat aagatacagc atttcttctg aggccttgaa gaagtatcaa	360
gtgggctttg acattgcggg ggtgagagcg acccctctcc acctggagaa ctgggaaatg	420
tggattctca gggaccgcgc tgttcacgag ctccaggctg tgetgctggc cctggctctg	480
gggcgctgag cgcactctgc aatagcacac ttgccgggcc acctgctgcc gtgagccttt	540
gctgctgaag cccttggggg cgcctctacc tgatgaggat gtgcaccccc attagggggc	600
tgctcatggc ccttgcaagt atgtttggga cagcgatggc atttgacccc ataccccgga	660
tcacctggga gcacagagag gtgcacctgg tgcagtctca tgagccagac atctacaact	720
actcagcctt gctgctgagc gaggacaagg acaccttgta cataggtgcc cgggaggcgg	780
tcttcgctgt gaacgcactc aacatctccg agaagcagca tgagggtgat tggagggtct	840
cagaagacaa aaaagcaaaa tgtgcagaaa aggggaaatc aaaacagaca gagtgcctca	900
actacatccg ggtgctgcag ccactcagcg ccacttcctt ttacgtgtgt gggaccaacg	960
cattccagcc ggctgtgac cacctgaact taacatcctt taagtctctg gggaaaaatg	1020
aagatggcaa aggaagatgt ccttttgacc cagcacacag ctacacatcc gtcattggtg	1080
atggagaact ttattcgggg acgtcgtata attttttggg aagtgaacct atcatctccc	1140
gaaattcttc ccacagtcct ctgaggacag aatatgcaat cccttgctg aacgagccta	1200
gtttcgtgtt tgctgacgtg atccgaaaaa gccagacag ccccgacggc gaggatgaca	1260
gggtctactt cttcttcacg gaggtgtctg tggagtatga gtttgtgttc aggggtctga	1320
tcccacggat agcaagagtg tgcaaggggg accagggcgg cctgaggacc ttgcagaaga	1380
aatggacctc cttcctgaaa gcccgaactc tctgctcccg gccagacagc ggettggtct	1440
tcaatgtgct gcgggatgtc ttcgtgctca ggtccccggg cctgaagggt cctgtgttct	1500
atgcactctt caccaccagc ctgaacaacg tggggctgtc ggcagtgtgc gcctacaacc	1560
tgccacagc cgaggaggtc ttctccacg ggaagtacat gcagagcacc acagtggagc	1620
agtccacac caagtgggtg cgtatataatg gcccggtacc caagccgcgg cctggagcgt	1680
gcatcgacag cgaggcacgg gccgccaaact acaccagctc cttgaatttg ccagacaaga	1740
cgtctcagtt cgttaaagac caccctttga tggatgactc ggtaacccca atagacaaca	1800
ggcccaggtt aatcaagaaa gatgtgaact acaccagat cgtggtggac cggacccagg	1860
ccctggatgg gactgtctat gatgtcatgt ttgtcagcac agaccgggga gctctgcaca	1920
aagccatcag cctcgagcac gctgttcaca tcatcgagga gaccagctc ttccaggact	1980
ttgagccagt ccagaccctg ctgctgtctt caaagaaggg caacaggttt gtctatgctg	2040
gctctaactc gggcggtgtc caggcccccgc tggccttctg tgggaagcac ggcacctgcg	2100
aggactgtgt gctggcgagg gaccctact gcgcctggag cccgcccaaca gcgacctgcg	2160
tggctctgca ccagaccgag agccccagca ggggtttgat tcaggagatg agcggcgatg	2220
cttctgtgtg cccggcctcg tctcctaagc ccctccctcc tcttggtccc tcttccctgt	2280
cctgtctggg ccatgtgggg gacaggaggc ttctctctcc ctggaccccc tggccagcct	2340
cgggtgcggg gcccgacagc agctcgaggg tctccttgct gccgcccttc ctgagtgacc	2400
aggcacagca cgtgcacgcc ctggggaaact tctacctctt ctgccaggcc acaggctctg	2460
cagacattcg ctttgtctgg gagaagaatg ggcgagctct ggagacctgt gtccctgtgc	2520
agacccatgc actgccgat ggcagggccc atgcactcag ctggctgcag gacgccatca	2580

-continued

```

gggaaagcgc tgaagtatgc tgcctgtgcc tctctcagc agggaaacaag acttcgaagg 2640
tgcaggttgc tgtgatgaga cctgaagtga cccaccagga gaggtggacc agagagctct 2700
ctgcctggag ggctgtggct ggggagcacg accggatgat gcagagctgg aggaaggcgt 2760
gggaaagctg tagcaaggac accctgtagc caccaggaag gagtccctga caccgacctc 2820
aaccccaaca agaccctgct gccactgacc acagccaccc ccggagaagg cctggteccc 2880
cacaactgtg aactgtcttg cccaagcctg ctctgaacac agccattggg ccaccacctg 2940
atgggcagag gcgggacagt ggagaagcct ggaacccaag tgggcctgtg acaggaacta 3000
agacttaaaa aattaggtgc ttacctggga cagtaagttc tgtctggcac aagcaggtaa 3060
ccaggatggc taacaggctt tgatagctgc tcgtgaacta aaacagcagg gtgtgtgcag 3120
gttctctctc tacggtcagg cagcaggctc tgaaggctga tctacaccg tcccagtgc 3180
tccccttgac agagtgcgcc caccacctaa tagccaacag ggtagcatg gccagcacag 3240
atcgctgctt ttattgatgc aaatcaagcc tgcgtcttct cctccctgca gacttagcca 3300
aggaactcca agatgcata ctgggacaag aaaagggtgag actccacatg gaaatgcctt 3360
gccctaaacc ttgaatgact gtgagatgcg atctgggagt gcactctgtc agtctttgtg 3420
ttttcttcac taacctcaga atactgggct ctattttatc aagcgtgca gtttatgcct 3480
ctgtcccgtc aatgctcagc ttctgcaaca ggacacaaa cttgatgcag aaagccaaat 3540
aggtaatta tgcaaatctc ctgggtgccat attaaatttc ttgacgatgg aatgagtctc 3600
atgagtgttt tgttctacct gctttcaagt ctctaattat taaagctgta tctctgaaga 3660
ctgtgtcact gtgtgtgtga acttgtcta aagctactca gcctttaatc ttacacacac 3720
gtctcttctt gtctgttgaa tgacagtttt catgtctatc ataaaacaa agcctctgtt 3780
aaaagtcaag ccgcaccctc ctgggtgatcc tagcaaatac tgagtgtctt cccagcagtg 3840
tgacaatgac ctgttttgca tccccctctt ctggagctgg acaaatctc taccagcctt 3900
tgtgtgggat cagcatacat cgctgctaa ttccttcagg atccatcaca acaggtgtcc 3960
tgaagatgct ggagacaccc tggttgtctc cacacgttcc ccctccgcac cccaagtcca 4020
gaggcccgag tgctgtgtgag gtgtgtgctt gccatccag ccaaggatgc cagtcttgct 4080
cacggaacca tcacatactc ataacctgaa gttttcctgt aaaatatcca tcagctcact 4140
gtggttcttg ctttgggtgt ggcttcaacc actacaaact gatgagtcaa atgctatggg 4200
ctttaggctt atattcttgg tgcgttttct tgtctcttct cctgaagtct ggatttcaag 4260
cactttcaca cttaacaaaa taattacata cttgaagttt tcgtaatgtg gagtgttcta 4320
ctgggaaatg gagttatgag gatgaatttc tgagtcttct tttgctctgc tggaaaaaat 4380
aaaaatagag ttgtacattg aaaaaaaaaa aaaaaaa 4417

```

<210> SEQ ID NO 45

<211> LENGTH: 3108

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: STOM glucocorticoid receptor-responsive gene

<400> SEQUENCE: 45

```

gcctctggct cctcagggca ttcccgccgg ctccgggttt ggcaacgagg acgggggagt 60
gcgactgcgt ctccggcagc atggccgaga agcggcacac acgggactcc gaagcccagc 120
ggctccccga ctcttcaag gacagcccca gtaagggcct tggacctgc ggatggattt 180

```

-continued

tggtggcggt	ctcattctta	ttcaccggtta	taactttccc	aatctcaata	tgatgtgca	240
taaagattat	aaaagagtat	gaaagagcca	tcatctttag	attgggtcgc	attttacaag	300
gaggagccaa	aggacctggt	ttgtttttta	ttctgccatg	cactgacagc	ttcatcaaag	360
tggacatgag	aactatttca	tttgatattc	ctcctcagga	gatcctcaca	aaggattcag	420
tgacaattag	cgtggatggt	gtgggtctatt	accgcgttca	gaatgcaacc	ctggctgtgg	480
caaatatcac	caacgtgac	tcagcaaccc	gtcttttggc	acaaactact	ctgaggaatg	540
ttctgggcac	caagaatctt	tctcagatcc	tctctgacag	agaagaaatt	gcacacaaca	600
tgcagtctac	tctggatgat	gccactgatg	cctggggaat	aaaggtggag	cgtgtggaaa	660
ttaaggatgt	gaaactacct	gtgcagctcc	agagagctat	ggctgcagaa	gcagaagcgt	720
cccgcgaggc	ccgcgccaa	gttattgcag	ccgaaggaga	aatgaatgca	tccagggctc	780
tgaaagaagc	ctccatggtc	atcactgaat	ctcctgcagc	ccttcagctc	cgatacctgc	840
agacactgac	caccattgct	gctgagaaaa	actcaacaat	tgtcttccct	ctgcccatag	900
atatgctgca	aggaatcata	ggggcaaaac	acagccatct	aggctagtgt	agagatgagc	960
gctagccttc	caagcatgaa	gtcggggacc	aaattagcct	ttaactcata	aagagaggggt	1020
agggcttttc	tttttccata	tgtcaattgt	ggtgttccca	gaatgtatag	cagttataaa	1080
aataggtgaa	agaattgtta	gcttgtaaat	actgagagat	tggtgattta	tataaggtaa	1140
tctgttagtc	ttaaaatagt	taaaagtgtg	tattttttaga	ttattatgta	gtagggttaga	1200
tccctcttgt	tttgaacttc	actgactcat	tctgaacccc	ctaagcacc	aggccagagg	1260
caagaacctg	ggctgtaact	gccacctgac	accgctgact	ggctaaatgc	tttgacagaa	1320
gtgatgacct	tacaccacaa	ccagcttctc	caggctcatat	gtgccttacc	tccagagagt	1380
cttttttttt	ttttttctga	gatggagttt	cactcttgtt	gccagggctg	gagtgcataa	1440
gcatgatctc	ggctcactgc	aacctccgcc	tcctgggttc	aagagattct	cctgcctcag	1500
cctccccagt	agctgggatt	acaggctcat	gccaccatgc	ccagctaatt	ttgtatttat	1560
tattattgtt	ttttagtaga	gacgggggtt	caccatgttg	gccaggctag	tcacgaactc	1620
ctaacctcag	gtgatccacc	cacctctgcc	tcccaaagt	ctgggattac	agcoatgagc	1680
taccacacct	ggtttgagga	gtcttaatta	aggaaatttc	cctaattgtc	atttattttc	1740
taaatccaga	ccgtgtttca	gaataatcct	tacttgagag	tagccatttt	cttgctgtga	1800
cttgtcagaa	ctagaggaaa	tagccaagac	taatgaaaaa	gattactcta	acccttaaaa	1860
gactttttaa	ttcactacta	gagtggtcac	tttaaaaata	catccatggt	ttaacttatt	1920
tgagccttct	ttatgagtaa	atgattcttc	cttgttctgt	ctttcaaacc	agctaaatat	1980
ttgtcacaaa	agtgtttttt	tctcactgtt	gcctattttc	atatatcagg	ttttaaatag	2040
ttttaatttt	ttaataaaat	tttctctacg	ttctatatgc	aattgttata	tatctatttg	2100
aatagctgaa	ggactaaaat	acttttttaa	gagataactt	caggaaacca	ttatatttta	2160
ctatctgcat	gctgttaact	gtggtacact	gtgaaatatg	ttgattacaa	acccattcat	2220
tacatagtat	aaggaattca	cagtatattg	actatatagt	gtctaagtat	cttgggcaga	2280
tactgtcaaa	cttacaatat	ctatatagat	gtaggctctt	ttaaatttac	ctagtcattc	2340
ttctatcatg	tatattgatg	ctgaaagagg	aactgggtcag	ctcctctgga	caacaaattc	2400
ttagtctata	atattaggag	acatcttctg	ttttgcaaat	gtctgtgaat	ctgagcaacc	2460
tggcattctg	cttactggcc	agaaagctgg	cgggtgacat	ttgtaacatt	tcctctttga	2520
gactctgagt	tcacctagag	aagtctaagc	ataacagctt	tccttcccag	cacgagcctt	2580

-continued

tatagctctc tttagctcaa ccactctgtc catccagcca atggatgtcc cttccctgt	2640
acccaattt caagcttatt ttaggaagcc ttgaactacc atgtatcctg gctcctagct	2700
gagtttatta gaggtatgga gcagtgcac ttaaactcaa gttgactta cattttgaat	2760
tttaaaatga tggttttatc tgttgtgtga agtgggtcac ccttgaggac caggagcctc	2820
catatcctga ctgaaaacct tttctgagac ttagagtaac agtgcctttg gttccttgag	2880
ttctcctgtc tccagatacc aaatgacctt gacttttctg ccttgtgaat tcgtagtcca	2940
atcagctgaa attaatcac ttgggaggga cgcatagaag gagctctagg aacacagtgc	3000
cagtgcagaa gtttctccag gtggcctccc tttccaacaa tgtacataat aaagtgtatg	3060
cactttcact aataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa	3108

<210> SEQ ID NO 46

<211> LENGTH: 4090

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: MAOA glucocorticoid receptor-responsive gene

<400> SEQUENCE: 46

gggcgctccc ggagtatcag caaaaggggt cgcgccgcc acagtgcgcc gctccccccg	60
ggtatcaaaa gaaggatcgg ctccgcccc gggtccccc ggggagttga tagaagggtc	120
cttcccacc tttgccgtcc ccactcctgt gcctacgacc caggagcgtg tcagccaaag	180
catggagaat caagagaagg cgagtatgc gggccacatg ttcgacgtag tcgtgatcgg	240
aggtggcatt tcaggactat ctgctgccaa actcttgact gaatatggcg ttagtgtttt	300
ggttttagaa gctcgggaca gggttggagg aagaacatat actataagga atgagcatgt	360
tgattacgta gatgttggtg gagcttatgt gggaccaacc caaacagaa tcttacgctt	420
gtctaaggag ctgggcatag agacttaca agtgaatgtc agtgagcgtc tcgttcaata	480
tgtcaagggg aaaacatata catttcgggg cgccctttcca ccagtatgga atccattgc	540
atatttgat tacaataatc tgtggaggac aatagataac atggggaagg agattccaac	600
tgatgcaccc tgggaggctc aacatgctga caaatgggac aaaatgacca tgaaagagct	660
cattgacaaa atctgctgga caaagactgc taggcgggtt gcttatcttt ttgtgaatat	720
caatgtgacc tctgagcctc acgaagtgtc tgccctgtgg ttcttgtggt atgtgaagca	780
gtgcgggggc accactcgga tattctctgt caccaatggt ggccaggaa ggaagtttgt	840
aggtggatct ggtcaagtga gcgaacggat aatggacctc ctccgagacc aagtgaagct	900
gaaccatcct gtcactcacg ttgaccagtc aagtgaacac atcatcatag agacgctgaa	960
ccatgaacat tatgagtga aatacgtaat taatgcgata cctccgacct tgactgccaa	1020
gattcacttc agaccagagc ttccagcaga gagaaccag ttaattcagc ggcttccaat	1080
gggagctgtc attaatgca tgatgtatta caaggaggcc ttctggaaga agaaggatta	1140
ctgtggctgc atgatcattg aagatgaaga tgctccaatt tcaataacct tggatgacac	1200
caagccagat gggtcactgc ctgccatcat gggttcatt cttgcccgga aagctgatcg	1260
acttgctaag ctacataagg aaataaggaa gaagaaaatc tgtgagctct atgccaaagt	1320
gctgggatcc caagaagctt tacatccagt gcattatgaa gagaagaact ggtgtgagga	1380
gcagtactct gggggctgct acacggccta ctccctcct gggatcatga ctcaatatgg	1440
aagggtgatt cgtcaacccg tgggcaggat tttctttgcg ggcacagaga ctgccacaaa	1500

-continued

gtggagcggc	tacatggaag	gggcagttga	ggctggagaa	cgagcagcta	gggaggtctt	1560
aatggtctc	gggaaggtga	ccgagaaaga	tatctgggta	caagaacctg	aatcaaagga	1620
cgttcacg	gtagaaatca	cccacacctt	ctgggaaagg	aacctgccct	ctgtttctgg	1680
cctgctgaag	atcattggat	ttccacatc	agtaactgcc	ctggggtttg	tgctgtacaa	1740
atacaagctc	ctgccacggg	cttgaagttc	tgttcttatg	ctctctgctc	actgggtttc	1800
aataccacca	agaggaaaat	attgacaagt	ttaaaggctg	tgtcattggg	ccatgtttaa	1860
gtgtactgga	tttaactacc	tttggttaa	ttccaatcat	tgttaaagta	aaaacaattc	1920
aaagaatcac	ctaattaatt	tcagtaagat	caagctccat	cttatttgtc	agtgtagatc	1980
aactcatggt	aattgataga	ataaagcctt	gtgatcactt	tctgaaatc	acaaagttaa	2040
acgtgatgtg	ctcatcagaa	acaatttctg	tgctctgttt	ttattccctt	caatgcaaaa	2100
tacatgatga	tttcagaaac	aaagcatttg	actttctgtc	tgtaggagtg	gagtaggtga	2160
aggcccagcc	tgtaactgtc	ctttttcttc	ccttaggcaa	tggtgaactg	tcattacaga	2220
gcctagaggc	tcacagcctc	ctggaggaag	cagcctccac	tttggatcag	gaaatagtaa	2280
aggaaagcag	tggtgggggt	agcggcatgc	agaccctcag	accagaatgg	ggacatcttg	2340
tggtctgctg	cctcaggaat	ctcctgacca	cttgtagtcc	ctccgacttc	tctagacatc	2400
tagtctcagt	gctagcttat	ttgtattttt	cctctttcac	ttcttatgga	ggagagtgtt	2460
taactgagtt	agaatgttga	aactgacttg	ctgtgactta	tgtagcagctt	tccagttgag	2520
cagaggaaaa	tagtggcagg	actgtcccc	aggaggactc	cctgcttagc	tctgtgggag	2580
accaactacg	actggcatct	tctcttcccc	ctggaaggca	gctagacacc	aatggatcct	2640
tgtaggttgt	aacattctat	ttcaacttca	ggaaagcagc	agttttcttt	taatttttcc	2700
tatgaccata	aaattagaca	tacctctcaa	cttacatatg	tcttcaacat	ggttacctct	2760
gcataaatat	tagcaaagca	tgccaatttc	tcttaagtac	tgaaatacat	atgataaatt	2820
tgactgttat	ttgttgagac	tatcaaacag	aaaagaaatt	agggctctaa	tttccttaaa	2880
gcaagctcac	ttgctttagt	tgtaagttt	tataaaagac	atgaaattga	gtcattttat	2940
atatgaaaac	taagttctct	atcttaggag	taatgtcggc	ccacaagggt	gccacctct	3000
tgttttcccc	ttttaaaaac	tcagattttt	aaaagccctt	tccaaagggt	tcaactgtaa	3060
aatacttctt	tttacaatgt	atcaacatat	ttttatttaa	ggggaattaa	caattgccag	3120
ggaaaccagc	caacccaagt	ttattatata	attaacctta	tcataaatc	aaacctaat	3180
tgctggagcc	tggtgtgagg	acataaatct	tccaaagttt	tgctatccct	aagagctgca	3240
ttttctact	gctctttacc	ttgcatttta	gctaatttag	gagttttgag	aatgtattgg	3300
atacgtcca	gtacataagg	agttgcgcga	tattatatca	gactgctttg	agaaatctca	3360
tccctagtct	attgcagttg	tttctattag	cttactgatt	aactcagtc	tgacacacct	3420
tttgggaaat	gctgatttaa	acttcttaac	tggaacagct	tggaacagta	atcagtttgc	3480
taacatattt	aaagtcttga	atgttgaaga	actcatgtga	tttacccttt	tcaacttttt	3540
ggaaaacgat	ttaatttatt	ctaattagat	taacctatt	aatctatgga	ttgggtatca	3600
aatgaatgc	cagtcagat	gtgcctagac	acgaaattgg	agctgaggac	tctcacgata	3660
tgcaagttca	tccaacgtga	agataccata	agctttttct	ctgaaccaga	gaaatgaaag	3720
tcagtttaag	aggctgatag	atcttgccc	tgtaaggca	tccacttcac	agttctgaag	3780
gctgagtcag	ccccactcca	cagttaggcc	aagaattaga	ttttaaaact	tcactgtct	3840
gtcccagtta	actgttaaat	aaggcctcat	cctccactga	agagtatgga	ttgaaggatt	3900

-continued

```

gtgaactatg tttagtgtga ttgtgaactt ggtgcctaata gttccatgtc tgaagtttgc 3960
cccagtgtcta cacgttggag tatacctatg tgttgtgttt gccactgaag taagattttg 4020
cctgtatggt actgttttgt ttgttaataa agtgcactgc caccaccaat gcaaaaaaaaa 4080
aaaaaaaaaa 4090

```

```

<210> SEQ ID NO 47
<211> LENGTH: 6784
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: glucocorticoid receptor (GR) alpha

```

```

<400> SEQUENCE: 47

```

```

ggcgccgcct ccaccgcgc cccgctcggc cccgctcgcg cgcccaggcc gggctgccct 60
ttcgcgtgtc cgcgctctct tccctccgcc gccgcctcct ccattttgcg agctcgtgtc 120
tgtgacggga gcccgagtc cgcctgccg gtcggggacg gattctgtgg gtggaaggag 180
acgccgcagc cggagcggcc gaagcagctg ggaccgggac ggggcacgcg cgcccggaac 240
ctcgaccgcg ggagcccgcc gcggggcgga gggctggctt gtcagctggg caatgggaga 300
ctttcttaaa taggggtct cccccaccc atggagaaa gggcggtgt ttacttcctt 360
tttttagaaa aaaaaatat atttcctcc tgctcctct gcgttcacaa gctaagttgt 420
ttatctcggc tgcggcgga actgcggac gtggcgggcg agcggctcct ctgccagagt 480
tgatattcac tgatggactc caaagaatca ttaactcctg gtagagaaga aaacccagc 540
agtgtgcttg ctcaggagag gggagatgtg atggacttct ataaaccct aagaggagga 600
gctactgtga aggtttctgc gtcttcaccc tcaactggctg tcgcttctca atcagactcc 660
aagcagcgaa gacttttggg tgattttcca aaaggctcag taagcaatgc gcagcagcca 720
gatctgtcca aagcagtttc actctcaatg ggactgtata tgggagagac agaaacaaaa 780
gtgatgggaa atgacctggg attccacag cagggccaaa tcagcctttc ctcgggggaa 840
acagacttaa agcttttggg agaagcatt gcaaacctca ataggctcac cagtgttcca 900
gagaaccccc agagttcagc atccactgct gtgtctgctg ccccccacaga gaaggagttt 960
ccaaaaactc actctgatgt atcttcagaa cagcaacatt tgaagggcca gactggcacc 1020
aacggtggca atgtgaaatt gtataccaca gaccaaagca cctttgacat ttgcaggat 1080
ttggagtgtt cttctgggtc ccaggtaaa gagacgaatg agagtcttg gagatcagac 1140
ctgttgatag atgaaaactg tttgctttct cctctggcgg gagaagacga ttcattcctt 1200
ttggaaggaa actcgaatga ggactgcaag cctctcattt taccggacac taaacccaaa 1260
attaaggata atggagatct ggttttgtca agccccagta atgtaacact gcccgaagt 1320
aaaacagaaa aagaagattt catcgaaact tgcacccctg gggtaattaa gcaagagaaa 1380
ctgggcacag tttactgtca ggcaagcttt cctggagcaa atataattgg taataaaatg 1440
tctgccattt ctgttcattg tgtgagtacc tctggaggac agatgtacca ctatgacatg 1500
aatacagcat ccttttctca acagcaggat cagaagccta tttttaatgt cattccacca 1560
attcccggtg gttccgaaaa ttggaatagg tgccaaggat ctggagatga caacttgact 1620
tctctgggga ctctgaactt cctgggtcga acagtttttt ctaatggcta ttcaagcccc 1680
agcatgagac cagatgtaag ctctcctcca tccagctcct caacagcaac aacaggacca 1740
cctcccaaac tctgcctggg gtgctctgat gaagcttcag gatgtcatta tggagtotta 1800

```

-continued

acttgtggaa	gctgtaaagt	tttcttcaaa	agagcagtgg	aaggacagca	caattaccta	1860
tgtgctggaa	ggaatgattg	catcatcgat	aaaattcgaa	gaaaaaactg	cccagcatgc	1920
cgctatcgaa	aatgtcttca	ggctggaatg	aacctggaag	ctcgaaaaac	aaagaaaaaa	1980
ataaaaggaa	ttcagcaggc	cactacagga	gtctcacaag	aaacctctga	aaatcctggg	2040
aacaaaacaa	tagttcctgc	aacgttacca	caactcacc	ctaccctggg	gtcactgttg	2100
gagggttattg	aacctgaagt	gttatatgca	ggatatgata	gctctgttcc	agactcaact	2160
tggaggatca	tgactacgct	caacatgtta	ggaggcgggc	aagtgtattgc	agcagtgaaa	2220
tgggcaaaag	caataccagg	tttcaggaac	ttacacctgg	atgaccaa	gaccctactg	2280
cagtactcct	ggatgtttct	tatggcattt	gctctggggg	ggagatcata	tagacaatca	2340
agtgcaaac	tgctgtgttt	tgctcctgat	ctgattatta	atgagcagag	aatgactcta	2400
ccctgcatgt	acgaccaatg	taaacacatg	ctgtatgttt	cctctgagtt	acacaggcct	2460
cagggtatctt	atgaagagta	tctctgtatg	aaaaccttac	tgtttctctc	ttcagttcct	2520
aaggacggtc	tgaagagcca	agagctat	gatgaaatta	gaatgaccta	catcaaagag	2580
ctaggaaaag	ccattgtcaa	gaggggaagg	aactccagcc	agaactggca	gcgggtttat	2640
caactgacaa	aactcttggg	ttctatgcat	gaagtgggtg	aaaatctcct	taactattgc	2700
ttccaaacat	ttttggataa	gacctagagt	attgaattcc	ccgagatgtt	agctgaaatc	2760
atcaccaatc	agataccaaa	atattcaaat	ggaaatatca	aaaaacttct	gtttcatcaa	2820
aagtgtactgc	cttaataaga	atgggtgcct	taaagaaagt	cgaattaata	gcttttattg	2880
tataaactat	cagtttgtcc	tgtagagggt	ttgttgtttt	attttttatt	gttttcactc	2940
gttggtttgt	tttaaatcag	cactacatgt	ggtttataga	gggccaagac	ttggcaacag	3000
aagcagttga	gtcgtcatca	cttttcagtg	atgggagagt	agatggtgaa	atttattagt	3060
taatatatcc	cagaaattag	aaaccttaat	atgtggacgt	aatctccaca	gtcaaagaag	3120
gatggcacct	aaaccaccag	tgcccaaagt	ctgtgtgatg	aactttctct	tcatactttt	3180
tttcacagtt	ggctggatga	aattttctag	actttctggt	ggtgtatccc	ccccctgtat	3240
agttaggata	gcatttttga	tttatgcctg	gaaacctgaa	aaaaagttaa	caagtgtata	3300
tcagaaaagg	gaagtgtgct	cttttatagc	tattactgtc	tggttttaac	aatttccttt	3360
atatttagtg	aactacgctt	gctcattttt	tcttacataa	ttttttattc	aagtatttgt	3420
acagctgttt	aagatgggca	gctagtctgt	agctttccca	aataaactct	aaacattaat	3480
caatcatctg	tgtgaaaatg	ggttggtgct	tctaacctga	tggcacttag	ctatcagaag	3540
accacaaaaa	ttgactcaaa	tctccagtat	tcttgtcaaa	aaaaaaaaaa	aaaaagctca	3600
tattttgtat	atatctgctt	cagtggagaa	ttatataggt	tgtgcaaatt	aacagtccta	3660
actggtatag	agcacctagt	ccagtgcctt	gctgggtaaa	ctgtggatga	tggttgcaaa	3720
agactaat	aaaaataaac	taccaagagg	ccctgtctgt	acctaacg	ctatttttgc	3780
aatggctata	tggcaagaaa	gctggtaaac	tatttgcctt	tcaggacctt	ttgaagtagt	3840
ttgtataact	tcttaaaagt	tgtgattcca	gataaccagc	tgtaacacag	ctgagagact	3900
tttaatcaga	caaagtaatt	cctctcacta	aactttaccc	aaaaactaaa	tctctaatat	3960
ggcaaaaatg	gctagacacc	cattttcaca	ttcccatctg	tcaccaattg	gttaatcttt	4020
cctgatggta	caggaaagct	cagctactga	tttttgtgat	ttagaactgt	atgtcagaca	4080
tccatgtttg	taaaactaca	catcccta	gtgtgccata	gagtttaaca	caagtcctgt	4140
gaatttcttc	actgttgaaa	attattttaa	acaaaataga	agctgtagta	gccctttctg	4200

-continued

tgtgcacctt	accaactttc	tgtaaactca	aaacttaaca	tatttactaa	gccacaagaa	4260
atttgatttc	tattcaaggt	ggccaaatta	tttgtgtaat	agaaaactga	aaatctaata	4320
ttaaaaatat	ggaacttcta	atatatTTTT	atatttagtt	atagtttcag	atatatatca	4380
tattggtatt	cactaatctg	ggaagggaag	ggctactgca	gctttacatg	caattttatta	4440
aaatgattgt	aaaatagctt	gtatagtgtg	aaataagaat	gattttttaga	tgagattgtt	4500
ttatcatgac	atgttatata	TTTTTgtag	gggtcaaaga	aatgctgatg	gataacctat	4560
atgatttata	gtttgtacat	gcattcatat	aggcagcgat	ggtctcagaa	accaaacagt	4620
ttgctctagg	ggaagaggga	gatggagact	ggtcctgtgt	gcagtgaagg	ttgctgaggc	4680
tctgaccag	tgagattaca	gaggaagtta	tcctctgcct	cccattctga	ccacccttct	4740
cattccaaca	gtgagtctgt	cagcgcaggt	ttagtttact	caatctcccc	ttgcactaaa	4800
gtatgtaaag	tatgtaaaca	ggagacagga	aggtggtgct	tacatcctta	aaggcaccat	4860
ctaatagcgg	gttactttca	catacagccc	tccccagca	gttgaatgac	aacagaagct	4920
tcagaagttt	ggcaatagtt	tgcatagagg	taccagcaat	atgtaaatag	tcagaatctt	4980
cataggttgc	caataatata	ctaattcctt	tctatcctac	aacaagagtt	tatttccaaa	5040
taaaatgagg	acatgttttt	gttttctttg	aatgcttttt	gaatgttatt	tgttattttt	5100
agtatttttg	agaaattatt	taataaaaaa	acaatcattt	gctttttgaa	tgctctctaa	5160
aagggaatgt	aatatTTTaa	gatggtgtgt	aaccggctg	gataaatttt	tggtgcctaa	5220
gaaaactgct	tgaatatctt	tatcaatgac	agtgttaagt	ttcaaaaaga	gcttctaaaa	5280
cgtagattat	cattccttta	tagaatgtta	tgtggttaaa	accagaaagc	acatctcaca	5340
cattaatctg	attttcatcc	caacaatctt	ggcgtcaaaa	aaatagaact	caatgagaaa	5400
aagaagatta	tgtgcacttc	gttgtcaata	ataagtcaac	tgatgctcat	cgacaactat	5460
aggaggcttt	tcattaaatg	ggaaaagaag	ctgtgccctt	ttaggatacg	tgggggaaaa	5520
gaaagtcac	ttaattatgt	ttaattgtgg	atttaagtgc	tatatggtgg	tgctgtttga	5580
aagcagattt	atttcctatg	tatgtgttat	ctggccatcc	caaccctaac	tggtgaagtt	5640
tgtagtaact	tcagttagag	ttggttactc	acaacaaatc	ctgaaaagta	tttttagtgt	5700
ttgtagggtat	tctgtgggat	actatacaag	cagaactgag	gcacttagga	cataacactt	5760
ttgggggtata	tatatccaaa	tgccctaaaac	tatggggagga	aaccttggcc	accccaaaaag	5820
gaaaactaac	atgatttgtg	tctatgaagt	gctggataat	tagcatggga	tgagctctgg	5880
gcatgccatg	aaggaaagcc	acgctccctt	cagaattcag	aggcaggag	caattccagt	5940
ttcacctaag	tctcataatt	ttagttccct	tttaaaaacc	ctgaaaacta	catcaccatg	6000
gaatgaaaaa	tattgttata	caatacattg	atctgtcaaa	cttcagaac	catggtagcc	6060
ttcagtgaga	tttccatctt	ggctggtcac	tcctgactg	tagctgtagg	tgaatgtgtt	6120
tttgtgtgtg	tgtgtctggt	tttagtgtca	gaagggaat	aaaagtgtaa	ggaggacact	6180
ttaaaccctt	tggttgaggt	ttcgtaattt	cccagactat	tttcaagcaa	cctgggtccac	6240
ccaggatttag	tgaccaggtt	ttcaggaaaag	gatttgcttc	tctctagaaa	atgtctgaaa	6300
ggatttttatt	ttctgatgaa	aggctgtatg	aaaataccct	cctcaaataa	cttgcttaac	6360
tacatataga	ttcaagtgtg	tcaatattct	attttgtata	ttaaatgcta	tataatgggg	6420
acaaatctat	attatactgt	gtatggcatt	attaagaagc	tttttcatta	ttttttatca	6480
cagtaatttt	aaaatgtgta	aaaattaaaa	ccagtgactc	ctgttttaaaa	ataaaagtgtg	6540

-continued

tagtttttta ttcattgctga ataataatct gtagttaaaa aaaaagtgtc tttttaccta	6600
cgcagtgtaaa tgtcagactg taaaaccttg tgtggaaatg ttttaactttt attttttcat	6660
ttaaatttgc tgtttctgga ttaccaaac acacatttgt accgaattgg cagtaaatgt	6720
tagccattta cagcaatgcc aaatatggag aaacatcata ataaaaaat ctgctttttc	6780
atta	6784

<210> SEQ ID NO 48

<211> LENGTH: 4154

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: glucocorticoid receptor (GR) beta

<400> SEQUENCE: 48

ggcgccgcct ccacccgctc cccgctcggg cccgctcgtc cgcccaggcc gggctgccct	60
ttcgctgtgc cgcgctctct tccctccgcc gccgcctcct ccattttgctg agctcgtgtc	120
tgtgacggga gcccgagtca ccgcttgcgc gtcggggacg gattctgtgg gtggaaggag	180
acgccgcagc cggagccggc gaagcagctg ggaccgggac ggggcacgcg cgcccgaac	240
ctcgaccgcg ggagcccgcc gcggggcgga gggctggctt gtcagctggg caatgggaga	300
ctttcttaaa taggggctct cccccaccc atggagaaa gggcggtgtt ttacttctt	360
tttttagaaa aaaaaatat atttcctcc tgcctctctt gcgttcacaa gctaagtgt	420
ttatctcgcc tgcggcgga actgcggacg gtggcgggcg agcggtcct ctgccagagt	480
tgatattcac tgatggactc caaagaatca ttaactcctg gtagagaaga aaacccagc	540
agtgtgcttg ctcaggagag gggagatgtg atggacttct ataaaacct aagaggagga	600
gctactgtga aggttttgc gtcttcaccc tcaactggctg tcgcttctca atcagactcc	660
aagcagcgaa gacttttggg tgattttcca aaaggctcag taagcaatgc gcagcagcca	720
gatctgtcca aagcagtttc actctcaatg ggactgtata tgggagagac agaaacaaaa	780
gtgatgggaa atgacctggg attccacag caggggccaa tcagccttcc ctcgggggaa	840
acagacttaa agcttttggg agaaagcatt gcaaacctca ataggctcag cagtgttcca	900
gagaacccca agagttcagc atccactgct gtgtctgctg cccccacaga gaaggagttt	960
ccaaaaactc actctgatgt atcttcagaa cagcaacatt tgaagggcca gactggcacc	1020
aacggtggca atgtgaaatt gtataccaca gaccaaagca cctttgacat tttgcaggat	1080
ttggagtgtt cttctgggtc cccaggtaaa gagacgaatg agagtccttg gagatcagac	1140
ctgttgatag atgaaaactg tttgctttct cctctggcgg gagaagcga ttcatctctt	1200
ttggaaggaa actcgaatga ggactgcaag cctctcattt taccggacac taaacccaaa	1260
attaaggata atggagatct ggttttgtca agccccagta atgtaacct gccccagtg	1320
aaaacagaaa aagaagattt catcgaaact tgcacccctg gggtaattaa gcaagagaaa	1380
ctgggcacag tttactgtca ggcaagcttt cctggagcaa atataattgg taataaaatg	1440
tctgccattt ctgttcatgg tgtgagtacc tctggaggac agatgtacca ctatgacatg	1500
aatacagcat ccttttctca acagcaggat cagaagccta tttttaatgt cattccacca	1560
attcccgttg gttccgaaaa ttggaatagg tgccaaggat ctggagatga caacttgact	1620
tctctgggga ctctgaaact cctcgttcga acagtttttt ctaatggcta ttcaagcccc	1680
agcatgagac cagatgtaag ctctctcca tccagctcct caacagcaac aacaggacca	1740
cctcccaaac tctgcctggt gtgctctgat gaagcttcag gatgtcatta tggagtctta	1800

-continued

acttggtgaa gctgtaaagt tttcttcaaa agagcagtgg aaggacagca caattaccta	1860
tgtgctggaa ggaatgattg catcatcgat aaaattcgaa gaaaaaactg cccagcatgc	1920
cgctatcgaa aatgtcttca ggctggaatg aacctggaag ctcgaaaaac aaagaaaaaa	1980
ataaaaggaa ttcagcaggc cactacagga gtctcacaag aaacctctga aaatcctggt	2040
aacaaaacaa tagttcctgc aacgttacca caactacccc ctacctggt gtcactgttg	2100
gaggttattg aacctgaagt gttatatgca ggatatgata gctctgttcc agactcaact	2160
tggaggatca tgactacgct caacatgta ggagggcggc aagtgattgc agcagtgaag	2220
tgggcaaagg caataccagg ttccaggaac ttacacctgg atgaccaaat gaccctactg	2280
cagtactcct ggatgtttct tatggcattt gctctggggt ggagatcata tagacaatca	2340
agtgcaaac tgcgtgtttt tgcctcgat ctgattatta atgagcagag aatgactcta	2400
ccctgcatgt acgaccaatg taaacacatg ctgtatgttt cctctgagtt acacaggctt	2460
caggatatct atgaagagta tctctgtatg aaaaccttac tgcttctctc ttcagttcct	2520
aaggacggtc tgaagagcca agagctattt gatgaaatta gaatgaccta catcaaagag	2580
ctaggaaaag ccattgtcaa gaggaagga aactccagcc agaactggca gcggttttat	2640
caactgacaa aactcttgga ttctatgcat gaaaatgta tgtgggttaa accagaaagc	2700
acatctcaca cattaatctg attttcatcc caacaatctt ggcgctcaaa aaatagaact	2760
caatgagaaa aagaagatta tgtgcacttc gttgtcaata ataagtcaac tgatgctcat	2820
cgacaactat aggaggcttt tcattaatg ggaagaag ctgtgccctt ttaggatacg	2880
tgggggaaaa gaaagtcatc ttaattatgt ttaattgtgg atttaagtgc tatatgggtg	2940
tgctgtttga aagcagattt atttctatg tatgtgttat ctggccatcc caaccacaa	3000
tgttgaagtt tgtagtaact tcagtgaag ttggttactc acaacaaatc ctgaaaagta	3060
tttttagtgt ttgtaggtat tctgtgggat actatacaag cagaactgag gcacttagga	3120
cataacactt ttggggtata tatatccaaa tgcctaaaac tatgggagga aacctgggc	3180
accccaaaag gaaaactaac atgatttgtg tctatgaagt gctggataat tagcatggga	3240
tgagctctgg gcatgccatg aaggaaagcc acgctccctt cagaattcag aggcagggag	3300
caattccagt ttcacctaa gttcataatt ttagttccct tttaaaaacc ctgaaaacta	3360
catcaccatg gaatgaaaaa tattgttata caatacattg atctgtcaaa cttccagaac	3420
catggtagcc ttcagtgaga ttccatctt ggctgggtcac tccctgactg tagctgtagg	3480
tgaatgtgtt tttgtgtgtg tgtgtctggt tttagtgtca gaagggaat aaaagtgtaa	3540
ggaggacact ttaaacctt tgggtggagt ttcgtaattt cccagactat tttcaagcaa	3600
cctggtccac ccaggattag tgaccaggtt ttcaggaaag gatttgcttc tctctagaaa	3660
atgtctgaaa ggattttatt ttctgatgaa aggctgtatg aaaataccct cctcaaataa	3720
cttgcttaac tacatataga ttcaagtgtg tcaatattct attttgtata ttaaatgcta	3780
tataatgggg acaaatctat attatactgt gtatggcatt attaagaagc tttttcatta	3840
ttttttatca cagtaatttt aaaatgtgta aaaattaaaa ccagtgactc ctgtttaaaa	3900
ataaaagttg tagtttttta ttcattctga ataataatct gtagttaaaa aaaaagtgtc	3960
tttttaccta cgcagtgaag tgcagactg taaaacctg tgtggaaatg tttactttt	4020
attttttcat ttaaatgtgc tgttctggta ttaccaaacc acacatttgt accgaattgg	4080
cagtaaatgt tagccattta cagcaatgcc aaatatggag aaacatcata ataaaaaaat	4140

-continued

ctgctttttc atta 4154

<210> SEQ ID NO 49

<211> LENGTH: 6330

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<223> OTHER INFORMATION: nuclear receptor subfamily 3, group A, member
1, transcript variant 4 (NR3A1), estrogen receptor
(ESR1, ER, ESR, ESRA, ESTR) cDNA (complete)

<400> SEQUENCE: 49

```

aggagctggc ggagggcggt cgtcctggga ctgcacttgc tcccgtcggg tcgcccggct    60
tcaccggacc cgcaggctcc cggggcaggg cgggggccag agctcgcgtg tcggcgggac    120
atgcgtgcg tcgcctctaa cctcgggctg tgctcttttt ccagggtggc cgccgggttc    180
tgagccttct gccctgcggg gacacggtct gcaccctgcc cgcggccacg gacctgacc    240
atgacctccc acaccaaagc atctgggatg gccctactgc atcagatcca agggaacgag    300
ctggagcccc tgaaccgtcc gcagctcaag atccccctgg agcggccctt gggcgagggtg    360
tacctggaca gcagcaagcc cgcctgttac aactaccccg agggcgccgc ctacgagttc    420
aacgccgcgg ccgccgcca cgcgcaggtc tacggtcaga ccggcctccc ctacggcccc    480
gggtctgagg ctgcggcggt cggtccaac ggcctggggg gtttcccccc actcaacagc    540
gtgtctccga gcccgctgat gctactgcac ccgccgcgc agctgtcgc tttcctgcag    600
ccccacggcc agcagggtcc ctactacctg gagaacgagc ccagcggcta caccgtgcgc    660
gaggccggcc ccgccgcatt ctacaggcca aattcagata atcgacgcca gggtagcaga    720
gaaagattgg ccagtaccaa tgacaaggga agtatggcta tggaatctgc caaggagact    780
cgtactgtg cagtgtgcaa tgactatgct tcaggctacc attatggagt ctggctcgtg    840
gagggtgcca aggccttctt caagagaagt attcaaggac ataacgacta tatgtgtcca    900
gccaccaacc agtgaccatc tgataaaaac aggaggaaga gctgccaggc ctgccggctc    960
cgcaaatgct acgaagtggg aatgatgaaa ggtgggatac gaaaagaccg aagaggaggg    1020
agaatgttga aacacaagcg ccagagagat gatggggagg gcaggggtga agtgggtct    1080
gctggagaca tgagagctgc caacctttgg ccaagcccg ccatgatcaa acgctctaag    1140
aagaacagcc tggccttgtc cctgacggcc gaccagatgg tcagtgcctt gttggatgct    1200
gagcccccca tactctattc cgagtatgat cctaccagac cttcagtgga agcttcgatg    1260
atgggcttac tgaccaacct ggcagacagg gagctgggtc acatgatcaa ctgggcgaag    1320
agggtgccag gctttgtgga ttgacctc catgatcagg tccacctctt agaatgtgcc    1380
tggctagaga tcctgatgat tggctctgtc tggcgctcca tggagcacc agggaagcta    1440
ctgtttgctc ctaacttgct cttggacagg aaccagggaa aatgtgtaga gggcatgggtg    1500
gagatcttcg acatgctgct ggctacatca tctcggttcc gcatgatgaa tctgcaggga    1560
gaggagtgtg tgtgcctcaa atctattatt ttgcttaatt ctggagtgtg cacatttctg    1620
tccagcacc cgaagtctct ggaagagaag gaccatatcc accgagtcct ggacaagatc    1680
acagacactt tgatccacct gatggccaag gcaggcctga ccctgcagca gcagcaccag    1740
cggctggccc agctcctcct catcctctcc cacatcaggc acatgagtaa caaaggcatg    1800
gagcatctgt acagcatgaa gtgcaagaac gtgggtgccc tctatgacct gctgctggag    1860
atgctggacg cccaccgcct acatgcgcc actagccgtg gaggggcac cgtggaggag    1920
acggacaaaa gccacttggc cactgcgggc tctacttcac cgcattcctt gcaaaagtat    1980

```

-continued

tacatcacgg	gggaggcaga	gggtttccct	gccacgggtct	gagagctccc	tggtccccc	2040
acgggttcaga	taateccctgc	tgcattttac	cctcatcatg	caccacttta	gccaaattct	2100
gtctcctgca	tacactccgg	catgcatcca	acaccaatgg	ctttctagat	gagtggccat	2160
tcatttgctt	gctcagttct	tagtggcaca	tcttctgtct	tctgttggga	acagccaaag	2220
ggattccaag	gctaaatctt	tgtaacagct	ctctttcccc	cttgetatgt	tactaagcgt	2280
gaggattccc	gtagctcttc	acagctgaac	tcagtctatg	ggttggggct	cagataactc	2340
tgtgcattta	agctacttgt	agagaccag	gcctggagag	tagacatttt	gcctctgata	2400
agcacttttt	aaatggctct	aagaataagc	cacagcaaag	aatttaaagt	ggctccttta	2460
attggtgact	tggagaaagc	taggtcaagg	gtttattata	gcacctctt	gtattcctat	2520
ggcaatgcat	ccttttatga	aagtgttaca	ccttaaagct	tttatatgac	tgtagcagag	2580
tatctggtga	ttgtcaattc	attcccccta	taggaataca	aggggcacac	aggaaggca	2640
gatccccag	ttggcaagac	tattttaact	tgatacactg	cagattcaga	tgtgctgaaa	2700
gctctgcctc	tggtttcccg	gtcatgggtt	ccagttaatt	catgcctccc	atggacctat	2760
ggagagcagc	aagttgatct	tagttaagtc	tccttatatg	agggataagt	tcctgatttt	2820
tgtttttatt	tttgtgttac	aaaagaaagc	cctccctccc	tgaacttgca	gtaaggtcag	2880
cttcaggacc	tggtccagtg	ggcactgtac	ttggatcttc	ccggcgtgtg	tgtgccttac	2940
acaggggtga	actgttcact	gtggtgatgc	atgatgaggg	taaatggtag	ttgaaaggag	3000
caggggcctc	ggtgttgcac	ttagccctgg	ggcatggagc	tgaacagtac	ttgtgcagga	3060
ttgttgtggc	tactagagaa	caagagggaa	agtagggcag	aaactggata	cagttctgag	3120
gcacagccag	acttgctcag	ggtggccctg	ccacaggctg	cagctaccta	ggaacattcc	3180
ttgcagaccc	cgcattgccc	tttgggggtg	ccctgggata	cctggggtag	tcagactctt	3240
cttcatttcc	cagcgtggcc	ctgggttgaa	gaagcagctg	tcacagctgc	tgtagacagc	3300
tgtgttccta	caattggccc	agcaccctgg	ggcacgggag	aagggtgggg	accgttgctg	3360
tcactactca	ggctgactgg	ggcctggtca	gattacgtat	gcccttgggtg	gtttagagat	3420
aatccaaaat	caggggttgg	tttggggaag	aaaatcctcc	cccttccctc	cccgccccgt	3480
tccttaccgc	ctccactcct	gccagctcat	ttccttcaat	ttcctttgac	ctataggcta	3540
aaaaagaaag	gctcattcca	gccacagggc	agccttccct	gggcctttgc	ttctctagca	3600
caattatggg	ttacttcctt	tttcttaaca	aaaaagaatg	tttgatttcc	tctgggtgac	3660
cttattgtct	gtaattgaaa	ccctattgag	aggtgatgtc	tgtgttagcc	aatgaccag	3720
gtgagctgct	cgggcttctc	ttggatgtgc	ttgtttggaa	aagtggattt	cattcatttc	3780
tgattgtcca	gttaagtgat	caccaaagga	ctgagaatct	gggagggcaa	aaaaaaaaaa	3840
aaagttttta	tgtgcactta	aatttgggga	caattttatg	tatctgtgtt	aaggatatgt	3900
ttaagaacat	aattcttttg	ttgctgtttg	tttaagaagc	accttagttt	gtttaagaag	3960
caccttatat	agtataatat	atattttttt	gaaattacat	tgcttgttta	tcagacaatt	4020
gaatgtagta	attctgttct	ggatttaatt	tgactgggtt	aacatgcaaa	aaccaaggaa	4080
aaatatattag	tttttttttt	tttttttgta	tacttttcaa	gctaccttgt	catgtataca	4140
gtcatttatg	cctaaagcct	ggtgattatt	catttaaatg	aagatcacat	ttcatatcaa	4200
cttttgtatc	cacagtagac	aaaatagcac	taatccagat	gcctattggt	ggatactgaa	4260
tgacagacaa	tcttatgtag	caaagattat	gcctgaaaag	gaaaattatt	cagggcagct	4320

-continued

aattttgctt ttacaaaaat atcagtagta atatttttgg acagtagcta atgggtcagt	4380
gggttctttt taatgtttat acttagattt tcttttaaaa aaattaaaaa aaaacaaaaa	4440
aaaatttcta ggactagacg atgtaatacc agctaaagcc aaacaattat acagtggaag	4500
gttttacatt attcatccaa tgtgtttcta ttcattgtta gatactacta catttgaagt	4560
gggcagagaa catcagatga ttgaaatgtt cgcccagggg tctccagcaa ctttggaat	4620
ctctttgtat ttttacttga agtgccacta atggacagca gatattttct ggctgatgtt	4680
ggtattgggt gtaggaacat gatttaaaaa aaaactcttg cctctgcttt cccccactct	4740
gaggcaagtt aaaatgtaaa agatgtgatt tatctggggg gctcaggat ggtggggaag	4800
tggattcagg aatctgggga atggcaaaata tattaagaag agtattgaaa gtatttgga	4860
gaaaatggtt aattctgggt gtgcaccagg gttcagtaga gtccacttct gccctggaga	4920
ccacaaatca actagctcca tttacagcca tttctaaaaa ggcagcttca gttctagaga	4980
agaaagaaca acatcagcag taaagtccat ggaatagcta gtggtctgtg tttcttttcg	5040
ccattgccta gcttgccgta atgattctat aatgccatca tgcagcaatt atgagaggct	5100
aggcatcca aagagaagac cctatcaatg taggttgcaa aatctaacc ctaaggaagt	5160
gcagtctttg atttgatttc cctagtaacc ttgcagatat gtttaaccaa gccatagccc	5220
atgccttttg agggctgaac aaataaggga cttactgata atttactttt gatcacatta	5280
agggtgtctc accttgaat cttatacact gaaatggcca ttgatttagg ccactggctt	5340
agagtactcc tccccetgca tgacactgat tacaataact ttctattca tactttccaa	5400
ttatgagatg gactgtgggt actgggagtg atcactaaca ccatagtaat gtctaattt	5460
cacaggcaga tctgcttggg gaagctagtt atgtgaaagg caaatagagt catacagtag	5520
ctcaaaaggc aaccataatt ctctttgggt caggctcttg gagcgtgatc tagattacac	5580
tgcaccattc ccaagttaat ccctgaaaa cttactctca actggagcaa atgaactttg	5640
gtcccaaata tccatctttt cagtagcgtt aattatgctc tgtttccaac tgcatttcct	5700
ttccaattga attaaagtgt ggctctgtt ttagtcattt aaaattgttt tctaagtaat	5760
tgtgcctct attatggcac ttcaattttg cactgtcttt tgagattcaa gaaaaatttc	5820
tattcttttt tttgcatcca attgtgcctg aactttttaa atatgtaaat gctgccatgt	5880
tccaaaacca tgcctagtg gtgtgttttag agctgtgcac cctagaaaca acatattgtc	5940
ccatgagcag gtgcctgaga cacagacccc tttgcattca cagagaggtc attggttata	6000
gagacttgaa ttaataagtg acattatgcc agttctctgt ctctcacagg tgataacaa	6060
tgttttttgt gcactacata ctcttcagtg tagagctctt gttttatggg aaaaggctca	6120
aatgccaaat tgtgtttgat ggattaatat gcccttttgc cgatgcatac tattactgat	6180
gtgactcggg tttgtcgag ctttgctttg tttaatgaaa cacacttgta aacctctttt	6240
gcactttgaa aaagaatcca gcgggatgct cgagcacctg taaacaattt tctcaacct	6300
tttgatgttc aaataaagaa ttaactaaa	6330

What is claimed is:

1. A method for treating estrogen receptor alpha-negative breast cancer in a patient, the method comprising: determining that the breast cancer does not express detectable levels of estrogen receptor alpha; and a) administering radiation or at least a first chemotherapeutic agent to said patient; then b) administering an effective amount of a glucocorticoid receptor antagonist (GRA) to the patient; then c) administering radiation again or at least a second chemotherapeutic agent

to the patient after the glucocorticoid receptor antagonist is administered to the patient, whereby said estrogen receptor alpha-negative breast cancer is treated in the patient.

2. The method of claim 1, wherein the breast cancer comprises cancer cells that are glucocorticoid receptor-positive (GR+).

3. The method of claim 1, wherein the glucocorticoid receptor antagonist (GRA) has an undetectable or a lower

219

level of activity as a progesterone receptor antagonist as compared to its level of activity as a glucocorticoid receptor antagonist.

4. The method of claim 1 wherein the first or the second chemotherapeutic agent is a platinum based agent selected from carboplatin and cisplatin.

5. The method of claim 1 wherein the first or the second chemotherapeutic agent is a taxane.

6. The method of claim 1 wherein the first or the second chemotherapy agent is selected from the group consisting of a serine/threonine kinase inhibitor, a tyrosine kinase inhibitor, an angiogenesis inhibitor, an anti-epidermal growth factor receptor antibody, and trastuzumab.

7. The method of claim 1 wherein the GRA comprises an azadecalin moiety.

8. The method of claim 1 wherein the GRA comprises a pyrimidinedione moiety.

9. The method of claim 1 wherein the GRA comprises a dihydropyridine moiety.

10. The method of claim 1 wherein the GRA comprises an octahydrophenanthrene moiety.

11. The method of claim 1 wherein the GRA is mifepristone.

12. The method of claim 1, wherein said first chemotherapeutic agent, said second chemotherapeutic agent, or both, comprises an apoptosis-inducing agent.

220

13. The method of claim 12, wherein said apoptosis inducing-agent is radiation, a chemotherapeutic, or an immunotherapy.

14. The method of claim 12 wherein the GRA is in a class of compounds selected from the group of classes of compounds consisting of steroids, octahydrophenanthrenes, pyrimidinediones, dihydropyridines, dihydroisoquinolines and azadecalins.

15. The method of claim 14 wherein the GRA is an aryl pyrazolo azadecalin.

16. The method of claim 12 wherein the GRA is a selective GRA having an undetectable or a lower level of activity as a progesterone receptor antagonist as compared to its level of activity as a glucocorticoid receptor antagonist.

17. The method of claim 12 wherein the GRA is a non-selective GRA.

18. The method of claim 17 wherein the GRA is mifepristone.

19. The method of claim 1 wherein the GRA comprises a dihydroisoquinoline moiety.

20. The method of claim 1 wherein the first or the second chemotherapeutic agent is a camptothecin.

* * * * *